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ABSTRACT 
The modern age faces a progressive lengthening of life span, which is often associated 
with the onset of degenerative disorders such as Parkinson’s, Alzheimer’s and cancer. 
These diseases do not yet have a cure. The Hedgehog/Gli signalling pathway is one of the 
most promising pathways of cellular communication. Pharmacological modulation of this 
pathway would provide a remarkable approach for new potential therapeutics in 
regenerative medicine and cancer (Chapter 1).  
Attention was focussed on coagulin L I and withanolide F II, two natural steroidal 
lactones featuring interesting reactive functionalities. The aims of this project (Chapter 
2) were to investigate the chemical modifications of these natural products to prepare 
novel analogues for a structure-activity relationship study. 
 
Leads compounds coagulin L I and withanolide F II. 
3β-Methoxy-pregnenolone III is known as able to treat degenerative pathologies of the 
nervous system which could be implicated in Parkinson’s and Alzheimer’s diseases. The 
3β-methoxy group also provides metabolic stability in vivo. Therefore, a library of 
steroidal analogues decorated differently on the right-hand side (IV and V) has been 
prepared by organometallic additions of heterocycles to the side-chain of this 
commercially-available steroid (III, Chapter 3).  
 
Chapter 3. Towards steroids with heterocyclic side-chains. 
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The 14β-hydroxyl group is rarely found amongst withanolides, and no syntheses of 
withanolides with the cis-C/D ring rearrangement have been reported to date. Thus, the 
total synthesis of unnatural withanolide analogues X based on the Hajos and Parrish 
ketone derivative IX was investigated starting with readily available materials VI, VII 
and VIII (Chapter 4).  
 
Chapter 4. Studies towards novel withanolide analogues. 
Coagulin L I is the major metabolite extracted at AnalytiCon Discovery from plant 
material. Hence, its conversion into the more active withanolide F II via intermediate XI 
was explored (Chapter 5). Further elaboration of the left-hand side to provide additional 
novel compounds for our library of small molecules was also investigated.  
 
Chapter 5. Elaboration of coagulin L I. 
 
.
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CHAPTER 1.  
INTRODUCTION: THE HEDGEHOG/GIi SIGNALLING 
The progress of medical sciences and the widespread wealth in the developed world has 
had a major impact in lengthening of life expectancy. This has led to an increased number 
of age-associated loss of functionalities and diseases, including Parkinson’s and 
Alzheimer’s diseases, neurodegeneration and tumours. Although medical advances have 
provided improved knowledge on symptom management and palliative treatments, 
research into finding definitive cures for many of these patients remains an unmet need. 
1.1. STEM CELLS: A CONCISE OVERVIEW 
1.1.1. Embryonic and adult stem cells 
In the last three decades attention has been given to understand the biology of stem cells 
and their crucial implications in organ formation, size, regeneration and homeostasis. 
Stem cells are unspecialised cells characterised by a long-term self-renewal capacity and 
an extensive differentiation potential, that is, to make copies of themselves and to develop 
into specialised cells.1 Basically, two types of stem cells can be distinguished: embryonic 
stem cells (ESC) and adult stem cells. ESC and adult stem cells are both able to  
self-renew, but there is a difference. In fact, ESC are responsible for the very early stage 
of organ development and growth, and they can differentiate in all the cell lines within an 
organism, even under cultured conditions or after transplantation in vivo. On the contrary, 
adult stem cells can generate only specialised cells and are dedicated to mantain the 
homeostasis of their own tissues by replacing dead cells throughout life and/or to repair 
damages after injuries.2 
1.1.2. Cancer stem cells 
Genetic, age-related or inherited alterations of stem cells during life span may lead to loss 
of their functionalities and to the onset of degenerative diseases and cancer.3 It is well 
known that solid tumours are made of clusters of different cells. Amongst them, a new 
type of cell has been recently identified: cancer stem cells (CSCs). These cells have the 
same properties of stem cells, self-renewal and plasticity, but they are able to regenerate 
primary tumours after inoculation in vivo and to give rise to a progeny of more specialised 
cancer cells. CSCs are believed to be responsible for initiating and maintaining cancer 
growth, and to be the common precursor from which all other cancer cells can arise.4 
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1.1.3. Induced pluripotent stem cells  
The interest in stem cell research increased remarkably in 2006, when the Nobel laureate 
Shinya Yamanaka discovered the genetic factors essential to converting back mature 
specialised cells into the pluripotent embryonic state. The newly formed cells, called 
induced pluripotent stem cells (iPSCs), possess both features typical of embryonic stem 
cells, i.e. the infinite self-renewal property and very high plasticity.5 These findings 
completely changed the understanding of human biology. In fact, using iPSCs it became 
possible to make all the cell types existing in the human body directly from mature cells 
without destruction of the early embryos and so allowed ethical issues related to 
embryonic stem cell research to be sidestepped.6  
1.2. APPLICABILITY OF STEM CELLS IN NEURODEGENERATION AND 
CANCER 
The extraordinary advances in stem cell research is having a huge impact in regenerative 
medicine, cellular and genetic therapies and drug discovery. Their applications have 
helped, amongst others, to gain an understanding of the transformations of a fertilized egg 
into an organism, to achieve insights into molecular and genetic mechanisms of inherited 
diseases and cancer, to replace damaged or dead cells in disorders such as type II diabetes, 
stroke and neurodegeneration, to create models for drug testing, and to find out side 
effects in earlier stage of experimentation.7 As a further advantage, iPS cells generated 
directly from an individual patient should be genetically identical to that patient, thus they 
could be transplanted with potentially no risk of rejection (Figure 1.1).7, 8 
 
Figure 1.1. Yamanaka’s representation of the possible applications of iPS cell technology (Figure 
reproduced from Cell, 2009, 137, p. 13).7 
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1.2.1. Parkinson’s disease  
Parkinson’s disease (PD) is a debilitating neurodegenerative condition common amongst 
people aged over 65. It is reported that in the United Kingdom in 2012 more than 127000 
people suffered from PD.9 PD is caused by the progressive loss of the neurons producing 
dopamine in the substantia nigra, a deficit that leads to tremors, bradikinesia, rigidity and 
other neuropsychiatric symptoms such as depression, anxiety and sleep disturbances.9 
Current treatments of PD include pharmacological replacement with levodopa, brain 
stimulation and palliative care, with poor results especially in long-term therapy (along 
with additional side effects). Recently, cell-replacement by administration of 
dopaminergic cells derived from embryonic stem cells on in vivo PD animal models gave 
positive results in preclinical experiments. Nevertheless, continued research to elucidate 
the underlying mechanism of stem cell therapy is still needed before applications of PD 
cellular therapy are tested in clinical trials.10  
1.2.2. Alzheimer’s disease  
Alzheimer’s disease (AD) is a form of dementia characterised by a progressive decline of 
cognitive abilities which can lead to severe loss of memory, immobility and death. The 
Alzheimer’s Society reports that in the UK 496000 people are affected by AD, and 
amongst them 17000 are under the age of 65.11 There is currently no cure for AD, except 
for occupational and symptomatic therapies. Although the widespread degeneration of 
neurons and synaptic connectivity seemed to prevent the application of a cell-based 
replacement therapy, recent progress has been made in treating AD using stem cells. 
Transplantation of neural stem cells resulted in an increased synaptic density, suppression 
of inflammation and improvement of neurogenesis in a mouse model of AD. Furthermore, 
human AD modelling for genetic studies and drug testing have been realised using 
iPSCs.12 The hope is that in the future iPSC technology will help to understand the basis 
of AD and resolve the numerous issues still related to this complex disease, hopefully 
providing personalised therapy to the patients.12  
1.2.3. Cancer 
Cancer is an aggressive disease in which a heterogeneous mass of cells acquires aberrant 
proliferative activity, does not respond to growth suppressors and apoptotic signals, and 
can spread to other tissues and organs by invasion and metastasis.13 Despite many 
advances in tumour treatments, there are still a considerable number of patients not 
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responsive to chemo- and radiation therapy. This seems to be due to the presence of CSC, 
a population of cells that can acquire treatment-resistance and can be involved in 
metastasis.14 Thus, targeting CSC would provide a good possibility to fully eradicate 
cancer. Moreover, iPSC technology could help to understand the oncogenic molecular 
mechanisms, to design new drugs for selective tumour targeting and/or to replace blood 
cells and damaged organs and tissue in leukaemia or after chemotherapy.15 
1.3. ABOUT CELL-TO-CELL INTERACTIONS: EMBRYONIC SIGNALLING 
PATHWAYS 
During development and specialisation, intercellular cross-talk is of prime importance to 
channel stem cell differentiation into a selected cell lineage. Several mechanisms lie 
behind stem cell fate. Amongst others, developmental signalling pathways such as 
Hedgehog (Hh)/Gli, Wnt/β-catenin and Notch have been identified as key factors in the 
regulation of the two unique characteristics of stem cells: self-renewal and differentiation 
(Figure 1.2).3, 16-18  
These three pathways are evolutionarily conserved, and strictly cooperate in the 
regulation of embryonic development, cell proliferation, migration and differentiation. 
Their aberrances have been related to the onset of several degenerative diseases and 
cancer.17 Therefore, understanding the processes that regulate cell division, maturation 
and dissemination, and being able to manipulate them with selective small molecule 
modulators would help to develop new treatments and overcome the many issues still 
unresolved in the stem cell field. 
1.3.1. Hh/Gli signalling pathway 
The Hh/Gli signalling pathway was first identified in the fruit fly Drosophila 
melanogaster and takes the name from the evidence that mutation of the gene encoding 
for its biological agonist gave rise to a phenotype of larvae with particular hair similar to 
hedgehog spines.19 In mammals, this pathway is activated after binding of Hh functional 
glycoproteins, termed Sonic (Shh), Indian (Ihh), and Desert (Dhh), to the  
12-transmembrane receptor Patched1 (Ptch1, Figure 1.2, C). This entails the release of 
the 7-transmembrane receptor-like Smoothened (Smo), which in turn activates the 
intracellular complex of Costal2 (Cos2), Fused (Fu) and suppressor of Fused (Su(Fu)), 
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and turns on the cascade of intracellular events ending with the translocation in the 
nucleus of the Gli-transcription factors.20-22 
 
Figure 1.2. Overview of Notch (a), Wnt (b) and Hh/Gli (c) signalling pathways.21 (Reproduced from 
Biochim. Biophys. Acta, 2013, 1830, p. 2483). 
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NANOG, the gene that encodes for the protein regulating the embryonic stem cells 
renewal and the re-programming of adult somatic cells to iPS cells, is one of the most 
important transcription factors controlled by the Hh/Gli signalling pathways.23 
Misregulation of the Hh/Gli cascade has been related to the generation and progression 
of several cancer types including medulloblastoma, leukemia, lung, pancreas, breast and 
colon cancer.24 Moreover, a higher Hh signalling activity has recently been detected in 
CSCs than in normal adult cells, thus strengthening the hypothesis of its contribution to 
cancer maintenance and resistance (Figure 1.2, c).16 
1.3.2. Wnt signalling pathway 
The Wnt signalling pathway derives its name from the contraction of wingless, a gene 
responsible for segment polarity in Drosophila, and Int-1, its murine homologue.25 The 
protein β-catenin is the major intracellular signal transducer in the Wnt cascade (Figure 
1.2, b). When the pathway is not active, β-catenin undergoes a series of processes leading 
to its final proteosomal degradation. On the other hand, activation of the pathways by 
binding of Wnt glycoproteins to a 7-membered transmembrane G-protein-coupled 
receptor Frizzled (Fzd) results in the release of the downstream signal mediator Disheveld 
(Dvl), and in the final disassembling of the β-catenin destruction complex. The stabilised 
β-catenin is then accumulated in the cytoplasm, and eventually it can translocate into the 
nucleus to regulate gene expression in cooperation with other transcription factors.21, 25 
It has been demonstrated that the Wnt/β-catenin signalling pathway is involved in  
self-renewal of ESC and adult stem cells and in the maintenance of their pluri- and 
multipotency.26 Deregulated Wnt pathways after mutations of its elements and/or hyper-
activation have been found in several types of cancer, and are associated with CSCs 
activity.16, 17 Moreover, Wnt signalling also seems to be involved in the reprogramming 
of iPSCs, but its role in this regard needs to be further clarified.27 
1.3.3. Notch signalling pathway 
The Notch signalling pathway takes its name from the evidence that a genetic defect in 
the flies Drosophila melanogaster caused little notches at the end of their wings.28 Unlike 
Hh/Gli and Wnt pathways, the Notch single transmembrane receptor is not activated by 
secreted glycoproteins, but by interaction with Delta, Serrate, Delta-like (Dll) or Jagged 
(Jag) ligands, which are transmembrane proteins in juxtaposed cells (Figure 1.2, a). 
Downstream events lead to the release of the Nicd transcription factor, its translocation 
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into the nucleus and further activation of targeted genes.28, 29 The Notch pathway has a 
crucial implication in the control and survival of adult stem cells and its aberrant 
regulation has an oncogenic effect,16, 17 although less is known about its role in ESC and 
iPSCs.  
1.4. Hh/Gli MODULATORS: THE STATE OF THE ART 
In 2010 Mas and Ruiz i Altaba reported in a comprehensive review the known small 
molecule modulators of the Hh/Gli signalling pathway, and classified them according to 
whether they were from a natural or synthetic source, and their mode of action.24 More 
recently Trinh et al. published an updated review of Hh inhibitors.30 A summary of the 
most representative modulators of the Hh/Gli cascade is provided below. 
1.4.1. Natural Hh/Gli antagonists  
Given the significant role of Hh/Gli in tissue patterning and cell number maintenance, 
and its implications in tumour formation and development, small molecule inhibitors of 
this growth-factor pathway have proven valuable in providing leads for anticancer 
therapies, and they are still an active area of research.  
1.4.1.1. The first Hh/Gli antagonists: jervine 1.1 and cyclopamine 1.2 
Jervine 1.1 and cyclopamine 1.2 are C-nor-D-homo steroids, otherwise called 
[14(13→12)]-abeo-steroids, extracted from the plants of Veratrum genus, and are 
recognised as the first naturally occurring inhibitors of Hh/Gli expression (Figure 1.3).31 
They act as Smo receptor antagonists, and they prevent the downstream cascade of 
intracellular events by blocking Smo in an inactive form. Compounds 1.1 and 1.2 feature 
an interesting 6-6-5-6 ring pattern, which differs from the standard steroidal 6-6-6-5 
skeleton. Ring D is spirocyclic attached to a tetrahydrofuran, which is, in turn, fused to a 
substituted piperidine. 
 
Figure 1.3. Structures of jervine 1.1 and its 11-deoxy derivative cyclopamine 1.2. 
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1.4.1.2. Potent modulators from cyclopamine 1.2 derivatisation  
The potential of cyclopamine 1.2 as an anti-cancer drug has been confirmed by several 
experiments in vitro and in vivo.24 However, its poor solubility and instability under acidic 
conditions along with a range of associated side effects drove scientists to synthesise 
novel cyclopamine prodrugs, with improved bioavailability and pharmacokinetics, and 
selective tumour targeting properties (Figure 1.4). KAAD-Cyclopamine 1.3, the prostate-
specific antigen peptide-cyclopamine conjugate 1.4,32 the water soluble carbohydrate-
cyclopamine derivative 1.533 and carboxylate cyclopamine tartrate 1.634 are some 
representative examples (Figure 1.4). IPI-926 otherwise called saridegib (Infinity) 1.7 is 
a sulfonamide with improved potency and plasma half-life. Compound 1.7 is currently in 
phase II trials.35 
 
Figure 1.4. Representative examples of anticancer prodrugs based on cyclopamine 1.2. 
1.4.1.3. Additional natural Hh inhibitors from screening libraries  
A wide range of other natural products have shown inhibitory activity by targeting the 
pathway at different sites (1.8-1.19, Figure 1.5). Curcumin 1.8 is a diferuloylmethane 
derivative extracted from Curcuma longa36 which is able to downregulate Shh protein 
and the downstream expression of Gli1 in Hh/Gli, and to decrease the levels of β-catenin 
in Wnt signalling pathway. The cytotoxic effects in medulloblastoma cells are 
encouraging.37  
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Figure 1.5. Examples of natural product inhibitors of Hh/Gli signalling. 
The screening of a library of 94 natural products and 102 plant extracts on a cell-based 
assay allowed the identification of bisindole alkaloids staurosporinone 1.9,  
6-hydroxystaurosporinone 1.10, 5,6-dihydroxyarcyriaflavin A 1.11, sesquiterpene 
zerumbone 1.12, withanolides physalin F 1.13 and physalin B 1.14 as potent inhibitors of 
the transcription activity of Gli1 with IC50 values of 1.8, 3.6, 6.9, 7.1, 0.66 and  
0.62 µM, respectively (Figure 1.5). Compounds 1.9, 1.12, 1.13 and 1.14 also showed 
inhibitory activity on Gli2-mediated transcription (IC50 values of 7.1, 2.7, 1.4 and 1.5 µM, 
respectively) and reduction of the expression of anti-apoptotic protein Bcl2. Moreover,  
13,14-seco-16,24-cyclosteroids 1.13 and 1.14 were remarkably cytotoxic in human 
pancreatic cancer cell lines PANC1, with IC50 values of 2.7 and 5.3 µM vs the standard 
cyclopamine 1.2 with IC50 value of 8.0 µM.
38  
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The triazole piperazine itraconazole 1.15 displayed Hh inhibitory activity in vitro even in 
the presence of Smo mutations that confer resistance, whereas, when used in combination 
with arsenic trioxide, it blocked the growth of medulloblastoma and basal cell carcinoma 
in a mouse cancer model.39 Colecalciferol 1.16 and other vitamin D derivatives have also 
been reported as Hh pathways antagonists (Figure 1.5).40  
Finally, cytotoxic natural product inhibitors of Gli1 mediated transcription in cell lines 
overexpressing Hh signalling have been extracted from Excoecaria agallocha, such as 
quercetine derivative 1.17,41 from Acacia pennata, such as taepeenin D 1.1842 and from 
Adenium obesum, such as cardiac glycoside 1.19 (Figure 1.5).43  
1.4.2. Synthetic Hh/Gli antagonists  
1.4.2.1. Synthetic Gli-mediated transcription inhibitors from compound library screening 
It is well known that the combination of high-throughput chemistry (HTC) and  
high-throughput screening (HTS) can produce a range of bioactive lead compounds. In 
biological research and drug discovery, cell based assays are widely used to search for 
new bioactive compounds in a rapid manner, to evaluate drug toxicity and to study key 
molecular events in single cells. Amongst others, the luciferase assay system is a reporter 
gene assay that monitors cellular response at the transcription level by detecting emission 
of bioluminescence associated with increased activity of the enzyme firefly luciferase. A 
construction in which protein Gli binding sites have been coupled upstream to the gene 
encoding luciferase has been applied to compound libraries for primary screening and 
target validation of some of the most potent Hh/Gli pathway antagonists with activity 
downstream of Smo and Su(Fu). 44, 45 
Examples of such compounds are the symmetric hexahydro-pyrimidine GANT-61 1.20 
and the substituted thiophene GANT-58 1.21, two potent Gli1 antagonists (G =Gli and 
ANT = antagonist) identified from a library diversity set of 1990 compounds supplied by 
the USA National Cancer Institute;46 HPI1 1.22, HPI2 1.23, HPI3 1.24 and HPI4 1.25 
(HPI = Hh Pathway Inhibitors), which arose from the screening of 122755 small 
molecules;47 and the 2,4-disubstuted thiazole derivative JK184 1.26, identified from a 
screen of 20000 heterocycles as a promising inhibitor of the Gli1 transcription activity 
(Figure 1.6). 48 
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Figure 1.6. Synthetic inhibitors of Gli-mediated transcription from compound library screening. 
1.4.2.2. Synthetic Smo inhibitors from compound library screening 
Smo inhibitors currently represent the largest class of Hh antagonist. Structurally diverse 
compounds SANT1 1.27, SANT2 1.28, SANT3 1.29 and SANT4 1.30 (S = Smo and  
ANT = antagonist) were the first synthetic Smo antagonists identified when Beachy and  
co-workers screened a library of 10000 compounds during their mechanistic studies on 
the modulation of Smo activity (Figure 1.7).49  
 
Figure 1.7. Some Smo inhibitors from compound library screening. 
The aminoproline CUR61414 1.31 (Curis) emerged from a HTS against 100000 small 
molecules on a Hh-responsive reported cell line (Figure 1.7). It is the first Smo antagonist 
to enter clinical trials. However, these studies were stopped because of undesirable 
pharmacokinetic issues 19, 50 
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1.4.2.3. Synthetic Smo inhibitors in clinical trials 
Smo inhibitors are giving promising results in clinic trials. GDC-0449 1.32 (Curis, 
Evotec, and Genentech), also known as vismodegib, is the first Hh pathway inhibitor 
approved by the Food and Drug Administration (FDA) and is currently in phase II for 
treatment of the medulloblastoma, basal cell carcinoma and a number of other solid 
advanced tumours (Figure 1.8). It was developed from lead compound 1.33. 
Replacement of the benzimidazyl group with a pyridyl group and modification of the 
aromatic functionality attached to the amide group resulted in a compound with excellent 
potency, improved metabolic stability, low clearance and high absorption.51, 52  
 
Figure 1.8. Synthetic Smo inhibitors in clinical phase I and II trials. 
The potent and selective Smo antagonist NVP-LDE225 1.34, also known as erismodegib 
(Novartis), was discovered through a HTS of compound libraries generated by solid phase 
combinatorial chemistry (Figure 1.8).53 This biphenyl-3-carboxamide led to dose-related 
tumour growth inhibition in a medulloblastoma allograft mouse model, and it is currently 
being evaluated in clinical development as a treatment for basal cell carcinoma, Gorlin’s 
syndrome and pancreatic cancer.52  
Quinazoline 1.35 (XL-139, Bristol-Myers Squibb and Exelixis) was disclosed as an oral 
Smo antagonist, and it is still progressing in clinical trials as a well-tolerated 
antineoplastic in medulloblastoma, basal cell carcinoma and chronic myeloid leukemia 
(Figure 1.8).30, 52 
Based upon the evidence that benzimidazole derivatives gave promising results in 
inhibiting the activity of Gli/luciferase in a related assay, researchers have undertaken 
synthetic efforts to design a lead with improved pharmacokinetic properties. The resulting 
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urea PF-04449913 1.36 (Pfizer)54 is currently being tested in humans as a 
chemotherapeutic agent for advanced solid tumours as well as for haematologic 
malignancies (Figure 1.8).52 
1.4.2.4. Robotnikinin 1.37: joint target-based screening and combinatorial chemistry 
Robotnikinin 1.37 (Figure 1.9) is the first reported Hh/Gli antagonist active upstream of 
Smo, identified at Harvard University during a target-based screening against a library of 
10000 structurally diverse compounds including 12-, 13- and 14-membered macrocycles. 
Its discovery stemmed from a novel investigative approach in the field of Hh pathway 
modulators, that is, the identification of compounds able to bind the known protein target 
of interest Shh/N-terminal peptide (ShhN) in small molecule microarrays (SMM), 
followed by library deconvolution.30, 55, 56 
 
Figure 1.9. The direct Shh-binder robotnikinin 1.37, the hit compound 1.38 and the Smo antagonist 1.39. 
A library of macrocycles was synthesised via a diversity-oriented synthesis (DOS) in the 
solid phase using the encoded one macrobead/one stock solution approach, and Evans’ 
chiral auxiliaries, chiral 1,2-aminoalcohols, and unsaturated acids as readily available 
building blocks. Macrocycle 1.38 was identified as the best binder of ShhN in a 
concentration dependent manner.55 Afterwards, a number of additional analogues were 
synthesised in liquid phase, and subjected to a secondary screening in cellular assays and 
structure-activity relationship (SAR) study. As the result, two novel Hh/Gli inhibitors 
with diverse mode of action were identified, i.e. the Hh ligand inhibitor robotnikinin 
1.37,55 and the potent Smo antagonist BRD-6851 1.39 (IC50 value of 0.4 µM vs 0.6 µM 
of cyclopamine 1.2).56 The authors pointed out that the presence of the inverted amino-
alcohol was enough to diversify the bioactivity of analogues 1.37 and 1.39, in spite of the 
retention of the 12-membered scaffold, the ene functionality and the lipophilic 
substituents with (R)-configuration (Figure 1.9).56 
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In addition to the number of Hh antagonists descrived above, several other inhibitors have 
been identified. They include pyrrolopyridines, phthalazines, piperidines, piperazines,  
N-acylthioureas, N-acylureas, N-acylguanidines, triazoles, indazoles, estrone derivatives 
and many others arising from HTS of chemical libraries, rational design, chemical 
complexity or simplification of earlier hits. Some of these compounds are currently under 
investigation as potential anticancer drugs.19, 24, 30  
1.4.3. Hh/Gli agonists  
1.4.3.1. Synthetic Hh/Gli agonists from HTS 
Despite the extensive findings concerning the Hh/Gli signalling pathway inhibitors, only 
a little is known about the related agonists. The first compound classified as a Smo agonist 
and named Hh-Ag 1.1 1.40 was identified at Curis in 2002, and it emerged from the HTS 
of 140000 synthetic compounds in a mammalian cell based assay (Figure 1.10).57  
 
Figure 1.10. Hh/Gli agonists. 
Structure-activity studies on hit 1.40 led to the synthesis of analogue Hh-Ag 1.2 1.41 with 
better stability in vitro and in vivo and with less toxicity (Figure 1.10).57 
Chlorobenzothiophene 1.42 (named SAG, S = Smo and AG = AGonist) was studied in 
Beachy’s group, during experiments to elucidate the biochemical mechanisms of Smo. It 
was shown that binding of SAG to Smo at low doses (about 3 nM) resulted in the 
activation of the pathways. By contrast, when the concentration was increased it acted as 
an inhibitor, maybe because of dual binding to both Smo and to a downstream effector 
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that prevented the starting of the cascade. A few years later, a patent was placed on the 
prophylactic and therapeutic use of 1.40, 1.41 and 1.42 to treat anxiety, depression, and 
cognitive and degenerative disorders because of the ability of such compounds to increase 
brain cell division.58  
Purmorphamine 1.43, a 2,6,9-trisubstituted purine containing a 4-morpholinoaniline is an 
agonist of Shh receptor Smo (Figure 1.10). It was discovered when researchers from The 
Scripps Research Institute and Novartis screened a library of 50000 heterocycles to search 
for compounds with osteogenesis-inducing activity.59 In this assay, Smo agonist 1.43 
induced differentiation in multipotent stem cells from fibroblast to osteocyte after 6 days 
of treatment at 2 µM.59 Moreover, in a recent experiment it increased up to eight-fold the 
differentiation rate of mammalian dopamine-producing cells PC12 by activation of the 
oncogene SCL/TAL 1 interrupting locus.60 Together, these results give value to the role 
of Hh/Gli agonists as promoters of stem cell differentiation, and indicate their use as 
possible therapeutics for Parkinson’s and other degenerative diseases.  
1.4.3.2. Natural Hh/Gli agonists: oxysterols 
Oxysterols are oxidised derivatives of cholesterol, an endogenous steroid involved in Shh 
pathway activation and transduction. It is known that cholesterol participates in the 
autocatalytic activation process of Shh morphogen before its binding to Patch.61 
However, in the case of genetic mutations leading to deficiencies in sterol synthesis, Shh 
protein can still activate its pathways, although aberrancies in downstream events could 
be seen. Therefore, it appears that oxysterols play a central role in the Hh/Gli signalling 
transduction.62 The most active steroid, 20(S)-hydroxycholesterol 1.44 exerts an 
osteoinductive effect in pluripotent mesenchymal cells by stimulation of Hh/Gli,63 and 
activates Wnt and Notch target genes in bone marrow stromal cells.64 The mechanism of 
action of oxysterols remains unclear, although recent experiments carried out using 
unnatural oxysterols supports the hypothesis of an allosteric interaction with Smo at a 
different site to the one used by cyclopamine 1.2 and other Smo regulators  
(Figure 1.10).65, 66 
1.5. SUMMARY 
Signalling pathways such as Hh/Gli, Wnt and Notch are being actively studied to find 
cures for debilitating degenerative diseases, non-healing wounds and cancer.17 However, 
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in spite of the encouraging results achieved, examples of drug resistance have been 
displayed during clinical trials of Hh/Gli antagonists, several side effects have been 
identified, and a clear correlation between kinds of tumours and dependence from Hh/Gli 
signalling is still not available, thus preventing personalised cures.30, 52 Furthermore, the 
number of known Hh/Gli agonists is limited to few examples, and none of them have 
been progressed into clinical trials, although Curis are believed to be exploring 
applications of Hh agonists in Parkinson’s, Alzheimer’s and other diseases.67 Hence, it 
appears that resaerch into the discovery of selective modulators of these signalling 
pathways is still a valuable research area. 
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CHAPTER 2.  
RESEARCH OBJECTIVES 
The structural variety of Hh/Gli modulators and their potential medical applications have 
spurred our interest in the identification and synthesis of novel small molecule Hh/Gli 
agonists or antagonists to provide leads for anticancer drugs or regenerative therapies.  
The objectives of this project are two-fold: 
1. Identification of active lead compounds. 
2. Conversion of the active lead compounds into drug candidates.  
2.1. LEAD COMPOUNDS 
Though synthetic small molecules provide an enormous contribution to the generation 
and identification of new drug candidates, one very successful drug discovery strategy is 
based on the exploitation of the potential diversity of active natural products.68, 69  
Thus, we first sought novel potential Hh/Gli modulators amongst natural products via 
cell-based HTS. This was carried out at AnalytiCon Discovery GmbH (Postdam, 
Germany), one of the world’s largest manufacture of pure natural product screening 
compounds, in cooperation with Prof. Altaba group (University of Geneva), a pioneer in 
developmental genetics with particular focus on the role of Gli proteins in embryo 
formation and diseases.  
Amongst a number of natural products screened, attention has been focussed on two 
compounds isolated from Withania adpressa, coagulin L 2.1 and withanolide F 2.2 
(Figure 2.1), which showed interesting activity in the modulation of embryonic signalling 
pathways. The detailed results of this collaboration are confidential.  
 
Figure 2.1. Coagulin L 2.1 and withanolide F 2.2. 
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Interestingly, these compounds have an oxygenated steroidal framework, which is also 
present in jervine 1.1 and cyclopamine 1.2 (Figure 1.3) and oxysterols such as compound 
1.44 (Figure 1.10). Moreover, withanolide F 2.2 features an α,β-unsaturated carbonyl 
functionality, typical also of physalins F 1.13 and B 1.14 (Figure 1.5), and known to be 
an important anticancer pharmacophore.70  
2.2. LEAD OPTIMISATION 
In drug discovery it is important to structurally modify the lead compound in order to 
identify the pharmacophoric features. This is especially true for natural products, as they 
often bear functionalities that do not contribute to their biological activity and may lead 
to toxic side effects or compromise the metabolic stability.  
Thus, with regards to withanolide F 2.2, we aimed to synthesise a number of derivatives 
for SAR studies, as shown in Figure 2.2. 
 
Figure 2.2 Intended modification in the hit to lead generation for withanolide F 2.2. 
There were three main aims: 
1. We wanted first to investigate the influence of the right-hand side and the 
importance of the lactone ring in the modulation of the Hh/Gli signalling pathway. 
For that, we decided to elaborate the side-chain of a commercially available 
steroid with a number of heterocycles via organometallic additions or ring-closing 
metathesis reactions, in a diversity-driven approach (Figure 2.3). Details of this 
work are presented in Chapter 3.  
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Figure 2.3. Elaborations of the side chain of a readily available steroid. 
2. Changes in the configuration of the steroidal framework from a trans-C/D-ring 
fusion (common in sterols, the bile acids and nearly all types of steroids) to a  
cis-C/D-ring fusion (typical of the cardiac glycosides and related aglycones) could 
entail changes in bioactivity. Thus, we planned the asymmetric total synthesis of 
the unnatural withanolide F 2.5, featuring the methyl group at C-13 and the 
hydroxyl group at C-14 cis to each other, starting from cheap commercially 
available materials (Figure 2.4). This research is outlined in Chapter 4.  
 
Figure 2.4. Modification of the lead compound 2.2 into its epimer 2.5. 
3. Finally, we wanted to investigate the importance of the 1-oxo-2,5-diene pattern in 
rings A and B towards the bioactivity. Therefore, we aimed to evaluate the 
reactivity of a series of withanolide derivatives 2.6 (Figure 2.5). This will be 
described in Chapter 5.  
 
Figure 2.5. Modifications of rings A and B. W, X, Y, Z = H, C, O, S, N, halogen. 
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CHAPTER 3.  
TOWARDS STEROIDS WITH HETEROCYCLIC SIDE-CHAINS 
3.1. THE SIDE-CHAIN OF STEROIDS 
The female and male sex hormones such as estrone 3.1 and testosterone 3.2 lack a  
side-chain, and C-17 is oxidised to the ketone or alcohol level respectively, whilst 
progesterone 3.3 and corticosteroids such as cortisone 3.4 have a two carbon side-chain 
containing a keto group (Figure 3.1). Aliphatic side-chains are more common in bile 
acids such as cholic acid 3.5, sterols such as cholesterol 3.6 and phytosterols such as 
stigmasterol 3.7. Polyhydroxylated aliphatic side-chains decorate the more exotic plant 
hormones such as brassinolide 3.8 and cucurbitacine B 3.9, which possess important 
effects in plant growth71 and antitumour activity,72 respectively, and in the insect 
hormones73 such as ecdysone 3.10.  
 
Figure 3.1. Selected examples of open-chain steroids. 
Nature has also provided a number of steroids decorated with cyclic appendages in the 
form of oxygenated and, less commonly, nitrogen-containing heterocycles (Figure 3.2). 
Cardiac glycosides and aglycones such as digitoxigenin 3.11 and bufalin 3.12 possess an 
unsaturated γ- or δ-lactone, respectively, which is directly linked to C-17. Similar 
functionalities are present amongst withanolides such as withanolide B 3.13 and 
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ixocarpalactone A 3.14, although a one or two carbon linker distances the heterocycle 
from the tetracyclic steroidal core. A unique spiro group consisting of two oxygenated 
rings fused at C-22 forms the side-chain of the sapogenins such as sarsasapogenin 3.15. 
Finally, cyclic side-chains containing nitrogen are present in some steroidal alkaloids: 
tomatidine 3.16 and veratramine 3.17 are two examples of these compounds with 
‘normal’ (6-6-6-5 tetracyclic) and ‘modified’ (6-6-5-6 tetracyclic) skeletons, respectively. 
 
Figure 3.2. Selected steroids with cyclic side-chains. 
3.1.1. The side-chain of steroidal modulators of Hh/Gli signalling pathway 
As described in Chapter 1, steroidal compounds play a critical role in the modulation of 
the embryonic signalling pathways, particularly the Hh/Gli, but also the Wnt and  
Notch.38, 43, 63, 66 
3.1.1.1. Steroidal Smo modulators 
Cyclopamine 1.2 and its derivatives, featuring an alkaloid heterobicyclic side-chain, are 
Hh/Gli antagonists binding Smo in a narrow pocket between the 7-membered  
trans-membrane region and the extracellular domain.66, 74 Oxysterols such as 20(S)-
hydroxycholesterol 1.44 also bind Smo, and their binding site has been identified at a 
different place to cyclopamine 1.2 and mimics, i.e. at an extracellular domain rich in 
cysteines. Oxysterols are characterised by an aliphatic hydroxylated side-chain, and they 
are the only naturally occurring Hh/Gli activators known.65, 66 Recently, researchers at the 
Harvard Medical School have developed the sterol 3.18 bearing a nitrogen-containing 
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aliphatic side-chain. Interestingly, this compound showed inhibition of Hh/Gli in mouse 
embryo fibroblast cells (NIH-3T3) with an IC50 value of 5 µM, by binding to Smo at the 
same site as oxysterols (Figure 3.3).75 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Spatial representations of cyclopamine 1.2, 20(S)-hydroxycholesterol 1.44 and  
22-azacholesterol 3.18. 
The Smo modulators 1.2, 1.44 and 3.18 possess a common steroidal framework with 
trans-junctions between rings B and C, and C and D, and a 3β-hydroxyl-5-ene pattern in 
rings A and B (Figure 3.3). However, these compounds possess remarkably different 
mechanisms of action.62, 75 Therefore, we could speculate that the orientation and the 
presence of heteroatoms in the side-chain rather than the steroidal skeleton could be the 
pharmacophore responsible for their different activities.  
3.1.1.2. Steroidal Gli transcription factors modulators 
Steroids are also found amongst the compounds which modulate the Gli transcription 
factor. In fact, two compounds belonging to the withanolide and the cardenolide class, 
physalin B 1.13 and β-D-glucosyl-(1→4)-β-D-thevetoside 1.19 (Figure 3.4), have shown 
interesting Gli transcription factor inhibition, with IC50 values of 1.4 and 0.11 µM, 
respectively.38, 43 However, their binding site remains unclear.  
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Physalin 1.13 and cardenolide 1.19 are structurally very different. The 1-oxo-2-ene 
system and the 5β,6β-epoxide present in the left-hand side of compound 1.13 are absent 
in compound 1.19, while the 3β-hydroxyl group ether-linked to the sugar appendage in 
compound 1.19 is missing in withanolide 1.13. (Figure 3.4). Thus, we imagined that the 
pharmacophore of the compounds involved in the inhibition of the Hh/Gli signalling 
might be the right-hand side side-chain containg a lactone-ring which is present in both 
compounds, although included in a complex cage-shaped structure in physalin 1.13 whilst 
easily accessible in cardenolide 1.19. 
 
 
 
  
 
Figure 3.4. Spatial representations of the Gli transcription factors inhibitors 1.13 and 1.19. 
3.1.1.3. Structure-activity relationship studies of oxysterols 
Preliminary SAR studies by Nachtergaele et al. on oxysterols showed that the 
stereochemistry at the chiral centres was crucial for the activation of the Hh/Gli pathway 
in Shh-responsive mouse embryonic fibroblast cell line (NIH-3T3 cells).  
20(S)-Hydroxycholesterol 1.44 proved to be the most active compound (EC50 value of 3 
µM), while the 20(R)-diastereoisomer 3.19 and the enantiomer 3.20 were inactive. 
Compounds 3.21-3.27 lacking the C-20 hydroxyl were also inactive, even in the presence 
of hydroxyls distributed along the side-chain or in the tetracyclic scaffold (Figure 3.5).65  
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Figure 3.5. SAR of oxysterols as Hh/Gli activators in NIH-3T3 cells.65 
A number of studies have highlighted the importance of oxysterols in Hh/Gli signalling,61-
66, 76, 77 and this class of steroids has also been recently evaluated for their selectivity 
towards the liver X receptor (LXR), a nuclear receptor implied in the homeostasis of 
cholesterol and identified as an inhibitor of Hh/Gli signalling.78 20(S)-
Hydroxycholesterol 1.44, 20(S),25-dihydroxycholesterol 3.28 and 23(S)-
hydroxycholesterol 3.29 (Figure 3.6) demonstrated the best activation of the Hh/Gli 
signalling in the osteogenic pluripotent stem cell line (C3H10T1/2) with 91.8, 107.8 and 
87.1 fold mRNA induction respectively over DMSO control, and 6.8, 4.1 and 17.8 fold 
Hh selectivity against LXR. Moreover, oxysterol 3.29 upregulated Gli1 and Patch 
expression in both C3H10T1/2 and murine bone stromal cell line (M2-10B4) with Ec50 
values ranging between 0.54-0.65 µM, and 3 fold selectivity relative to LXR.78 
Compound 3.29 lacks the 20(S)-hydroxyl, thus the question whether this functionality is 
crucial seems to remain unanswered. 
 
Figure 3.6. Oxysterols inducing osteogenic differentiation with highly Hh/Gli selective agonism relative 
to liver X receptor.78 
After this PhD project began, Nedelcu et al. published SAR studies on the side-chains of 
oxysterols and azasterols.75 With regard to oxysterols, it was noted that the 
stereochemistry at C-20 and the length of the side-chain had influence in the Hh/Gli 
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activation (Figure 3.7). Compounds 3.30-3.32 and 3.35-3.37 which possess linear side-
chains of two, three or four carbon in length were not active in the luciferase assay on a 
cell line derived from mouse embryo fibroblast (Shh Light cells II), whether the C-20 
hydroxyl was in the β- (3.30-3.32) or α-configuration (3.35-3.37). Compounds with linear 
side-chains of five (3.33 and 3.34) or six (3.38 and 3.39) carbons in length preserved the 
activity as long as the 20(S)-stereochemistry was maintained. For example steroids 3.33 
and 3.34 were active, while the 20(R)-diastereoisomers 3.38 and 3.39 were inactive. 
Saturation of the C-5,C-6 double bond did not affect the bioactivity, and 20(S)- and 20(R)-
steroids 3.40 and 3.41 were active and inactive, respectively, against the Hh/Gli 
signalling, as were the parent unsaturated 20(S)- and 20(R)-compounds 3.34 and 3.39. 
Finally, it was shown that a free hydroxyl group at C-3 was required, since the 3β-
methoxy-derivatives 3.42 and 3.43 exhibited reduced bioactivity.75 
 
Figure 3.7. Oxysterol SAR for Hh/signalling activation by Nedelcu et al.75 
For azasterols, the length of the side-chain and the stereochemistry at C-20 appear to be 
less important (Figure 3.8).75 In fact, azasterols 3.44, 3.45, 3.48 and 3.49 retain the 
inhibitory activity of the lead 22-azasterol 3.18, irrespective of the stereochemistry at C-
20. Instead, hydroxylation at the terminal carbon such as in compounds 3.46, 3.47, 3.50 
and 3.51 resulted in reduced activity 75  
 
Figure 3.8. Azasterol SAR for Hh/signalling inhibition by Nedelcu et al.75 
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3.2 PROJECT AIM: TOWARDS Hh/Gli MODULATORS WITH 
HETEROCYCLIC SIDE-CHAINS 
The chemical variety of steroidal Hh/Gli modulators reflects the diversity of their modes 
of action and, up to date, a comprehensive correlation of these structures with their 
activities is not available. In the light of the results shown in Figures 3.3-3.8, we first 
focussed our attention on an investigation of side-chain variations. To the best of our 
knowledge, no examples of heterocyclic analogues of steroids, in particular oxa-, thia- 
and aza- analogues, have been evaluated in embryonic signalling pathways. Thus, our 
aim was to synthesise a number of steroids bearing diverse side-chains and to test them 
in Hh/Gli signalling pathway in order to identify the structural features enhancing the 
biological activity. 
Our interest in the preparation of a small library of heterocyclic steroids in a diversity-
oriented manner drove a need for a flexible strategy in which a variety of side-chains 
could be attached to a common intermediate (Scheme 3.1).  
 
Scheme 3.1: General approach to the construction of heterocyclic side-chains. R = H or protecting group, 
R1 = heterocycle or aliphatic chain. 
It was envisaged that nucleophilic addition of organometallic reagents 3.53 to the C-20 
ketone of readily available steroid 3.52 would be a feasible way to synthesise a number 
of novel compounds 3.54 featuring the C-20 β-hydroxyl group, which seems to be 
required for the bioactivity of oxysterols (Scheme 3.1, a).  
Also of interest was the synthesis of potential steroidal Gli transcription inhibitors 
containing a lactone ring in the side-chain (generalised in compounds 3.55), which could 
mimic members of the cardenolide, bufadienolide and withanolide classes. These 
compounds could be generated by further elaboration of compound 3.54 as described later 
(Scheme 3.1, b).  
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3.3. RESULTS AND DISCUSSION 
3.3.1. The scaffold: 3β-methoxy-pregnenolone 3.60 
Commercially available pregnenolone 3.56 was chosen as a suitable building block as it 
possesses a cholesterol-like core and a ketone at C-20 for elaboration. We realised that 
the 3β-hydroxyl-5-ene pattern can be converted into progesterone 3.57 (a compound with 
strong hormonal activity)79 by means of the enzyme 3β-hydroxysteroid dehydrogenase 
(HSD3B) in the presence of NAD+. Moreover, 3β-hydroxysteroid sulfotransferases 
(HST), in the presence of 3’-phosphoadenosine-5’-phosphosulfate (PAPS), can give  
3β-pregnenolone sulfate 3.58, which is also biologically active (Scheme 3.2).80  
 
Scheme 3.2: Enzymatic transformation of pregnenolone 3.56. 
Although it is has recently be noted that a methoxy group at C-3 might be detrimental to 
activity against the Hh/Gli signalling,75 Baulieu et al.81 have shown that of 3β-methoxy-
pregnenolone 3.60 might be useful to treat neurodegenerative lesions, thus providing a 
potential treatment for Parkinson’s and Alzheimer’s deseases. Therefore, we decided to 
convert the 3β-hydroxyl group of pregnenolone 3.56 into its 3β-methyl ether 3.60 before 
constructing the side-chain (Scheme 3.3).81-84  
 
Scheme 3.3. Synthesis of 3β-methoxy-pregnenolone 3.60. 
 
Chapter 3. Towards steroids with heterocyclic side-chains 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 28 - 
3.3.1.1. Neighbouring group participation in the synthesis of 3β-methoxy-pregnenolone 
3.60  
The conversion of alcohol 3.56 into the 3β-methyl ether 3.60 with retention of 
configuration is a well-known reaction in the steroid field which occurs in two steps and 
requires the participation of the C-5,C-6 double bond as a neighbouring group (Scheme 
3.3).81-84 Thus, homoallylic alcohol 3.56 was first converted into tosylate 3.59  
(Table 3.1).  
 
Entry Conditions Yield / Comments 
1 p-TsCl (3.3 eq), py, rt 3.59 94%a 
2 p-TsCl (5 eq), py, rt 3.59 79%b 
3 p-TsCl (5 eq), DMAP (0.01 eq), py, rt 3.59 92%a 
4 p-TsCl (5 eq), DMAP (0.01 eq), py, 30 °C 3.59 67%a 
5 p-TsCl (5 eq), DMAP (0.1 eq), py, rt 3.59 64%,a 3.61 7%b 
6 p-TsCl (2 eq), DMAP (1 eq), Et3N (3 eq), CH2Cl2, rt 3.59 99% 
 
Table 3.1. Diverse reaction conditions for the synthesis of 3β-tosyl pregnenolone 3.59. Reactions were 
performed on 500 mg – 5 g scale. Reaction time: 18 h. aPurification via crystallisation from water. bAfter 
extraction of the mother liquor with CH2Cl2, then column chromatography on silica gel. 
Early attempts following published procedures led to tosylate 3.59 in yield up to 94% by 
exposure of pregnenolone 3.56 to an excess of p-toluenesulfonyl chloride in pyridine 
(entries 1 and 2),81 and catalytic amounts of 4-dimethylaminopyridine (entry 3).84 The 
yield dropped to 67% when the reaction mixture was stirred at 30 °C (entry 4). When the 
amount of 4-dimethylaminopyridine was increased to 10 mol% cyclic alcohol 3.61 was 
also isolated in 7% yield (entry 5).83, 85 In order to avoid the vast amount of pyridine used 
and simplify the work-up, we tried to carry out the reaction using p-toluenesulfonyl 
chloride, triethylamine and 4-dimethylaminopyridine in dichloromethane as previously 
reported for the tosylation of an unhindered primary alcohol (entry 6).86 Pleasingly, when 
these conditions were applied to our substrate, tosylate 3.59 was obtained in  
near-quantitative yield.  
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3.3.1.2. i-Steroid formation 
As mentioned above, in one example the i-steroid 3.61 was obtained in 7% yield (entry 
5, Table 3.1). Compound 3.61 is known in the literature83, 85 but the incomplete and 
conflicting published assignments of 1H- and 13C-NMR signals recorded at 200 MHz did 
not match our results. Therefore compound 3.61 was synthesised following published 
procedures for full characterisation and structural confirmation (Scheme 3.4).83  
 
Scheme 3.4. Synthesis of cyclo-alcohol 3.61. 
Compound 3.61 prepared via the literature method was identical to the sample obtained 
from the tosylation procedure. On inspection of 1H-, 13C-, DEPT-NMR and 2D 1H,13C-
HSQC, 1H,13C-HMBC and 1H,1H-COSY NMR spectra recorded at 500 MHz the signals 
of the C-4 cyclopropylic protons were identified at 0.28 and 0.51 ppm, while the proton 
at C-3 was observed at 1.07 ppm. These data are in contrast to the published values, which 
showed the three cyclopropylic protons as a multiplet between 0.24 and 0.49 ppm. A 
discrepancy was also found for the chemical shift of the C-19 methyl group at 1.03 ppm, 
against the published value of 1.18 ppm. On the other hand, the chemical shifts of the  
C-6 proton (3.24 ppm) and of the C-18 and C-21 methyl groups (0.65 and 2.09 ppm, 
respectively) matched the literature.83 
The mechanism leading to i-steroids was studied first by Shoppee87 and Winstein et al.88-
91 The reaction occurs in two steps, that is, first conversion of the 3β-hydroxyl group 3.6 
into a leaving group such as a chloride or tosylate (compounds 3.62 and 3.63), followed 
by alcoholysis or acetolysis to give steroids 3.64-3.66. However, in the presence of a base, 
the 3β-alkyl ethers 3.64-3.66 were not produced, but 3,5-cyclosteroids also called  
i-steroids 3.67-3.70 were formed (Scheme 3.5). 
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Scheme 3.5. Neighbouring group participation in the nucleophilic substitution at C-3 of cholesterol  
3.6.88, 90 
Looking at the mechanism (Scheme 3.6), the first step is the unimolecular displacement 
of the leaving group to give the cyclopropylic cation 3.71, which is in equilibrium with 
the unsaturated form 3.72. In the presence of nucleophiles such as methanol, the more 
reactive carbocation 3.71 readily gives the kinetic product 3.68. However, the instability 
of the i-steroids under slightly acidic conditions enables the reverse reaction, thus leading 
to the formation of the thermodynamic product 3.64. On the contrary, when a buffer such 
as potassium acetate is added to the reaction mixture, cyclosteroid 3.68 is formed. 88, 91 
 
Scheme 3.6. Neighbouring group participation in homoallylic steroids. 
3.3.1.3. Synthesis of 3β-methoxy-pregnenolone 3.60 from tosyl pregnenolone 3.59 
With 3β-tosyl pregnenolone 3.59 in hand, we were in a position to carry out its 
stereoselective conversion to the 3β-methoxy-derivative 3.60 (Table 3.2).  
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Entry Conditions Results  
1 3.59 0.1 M, reflux, 4 h 3.60/3.73 = 81/19, 99%  
2 3.59 0.01 M, reflux, 18 h 3.60/3.73 = 76/24a 
3 3.59 0.1 M reflux, 18 h 3.60/3.73 = 80/20a 
4 3.59 0.01 M, rt, 18 h Sm 3.59a 
5 3.59 0.1 M, rt, 18 h Sm 3.59a 
6 3.59 0.01 M, 30 °C, 18 h Mainly sm 3.59, trace of 3.60a 
7 3.59 0.1 M, 30 °C, 18 h Sm 3.59 and 3.60 = 1/1a 
8 3.59 0.03 M, reflux, 1.5 h 3.60/3.73 = 89/11, 100%  
 
Table 3.2. Diverse reaction conditions for the synthesis of 3β-methoxy-pregnenolone 3.60. All the reactions 
were performed in MeOH as reagent and solvent, on a 50 mg scale. aRatio determined by NMR analysis of 
the crude product. 
In spite of the stereospecificity and excellent yields published,81, 82, 84 we found that 
methyl ether 3.60 was not isolated as a single diastereoisomer, but with its 17α-epimer 
3.73 in an 81/19 ratio as determined by NMR analysis (entry 1). Attempts to minimise 
the formation of the undesired isomer by changing the reaction time, temperature, 
molarity and purification methods proved ineffective (entries 2-8).  
However, the major and desired isomer 3.60 could be isolated by recrystallisation from 
methanol leaving the filtrate enriched up to 47/53 in favour to the 17α-isomer 3.73. 
Crystallographic studies confirmed the structure of compound 3.60 (Figure 3.9). 
 
Figure 3.9. X-Ray crystallography of 3β-methoxy-pregnenolone 3.60 (CCDC 1021885, Appendix VII). 
The 17α-isomer 3.73 is known in the literature, although it has never been fully 
characterised. Rodig et al.92 described it as a secondary product of the synthesis of  
3β-methoxy-pregnenolone 3.60 from tosylate 3.59. Its structure was proposed after a 
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process of elimination which involved the comparison of infrared, optical rotation, optical 
rotatory dispersion and elemental analysis data with previously reported compounds 3α-
methoxy-pregnenolone 3.74 and 6β-methoxy-cyclo-steroid 3.75 (Figure 3.10).92  
 
Figure 3.10. Structures of 17α,3β-methoxy-pregnenolone 3.73, 3α-methoxy-pregnenolone 3.74 and 6β-
methoxy-cyclo-pregnenolone 3.75. 
We were therefore interested in obtaining a pure sample of the 17α-isomer 3.73. Since its 
isolation by recrystallisation was unsuccessful,92 we tried to epimerise the C-17 position 
of the 17β-isomer 3.60 by treatment with acid (entries 1-4, Table 3.3) or base (entries 5 
and 6).93  
 
Entry Conditions Results 
1 AcOH, THF, rt, 20 h Sm 3.60 
2 AcOH, THF, reflux, 20 h Sm 3.60 
3 AcOH, MeOH, reflux, 20 h Sm 3.60 
4 PTSA, MeOH, reflux, 18 h Sm 3.60 and decomposition 
5 LiHMDS, -78 °C, 2h Sm 3.60 
6 KOH, MeOH, reflux, 18 h Mixture 3.60/3.73 = 4/1 
 
Table 3.3. Attempted isomerization of 3β-methoxy-pregnenolone 3.60 to the 17α-epimer 3.73. 
Unfortunately, the only success was achieved when the β-isomer 3.60 was exposed to 
refluxing methanol containing potassium hydroxide followed by a quench with acetic 
acid (entry 6). This provided a 4/1 ratio of compound 3.60 to 3.73, but the 
diastereoisomers could not be separated and no further work was carried out.  
3.3.1.4. Alternative routes to 3β-methoxy-pregnenolone 3.60 
Alternative conditions to obtain 3β-methoxy-pregnenolone 3.60 in one step from 
pregnenolone 3.56 were also explored (Table 3.4).  
Chapter 3. Towards steroids with heterocyclic side-chains 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 33 - 
 
Entry Conditions Yield 
1 MeI (20 eq), Ag2O (1.5 eq), MS 4 Å, Et2O/THF, 40 °C, 18 h 3.60 70% 
2 MeI (5 eq), NaH (1.2 eq), Et2O/THF, rt, 18 h 3.60 80% 
3 MeI (5 eq), NaH (1.5 eq), Et2O/THF, rt, 3 d 3.60 63%  
3.76 5% 
 
Table 3.4. Alternative routes to 3β-methoxy-pregnenolone 3.60. 
Treatment of pregnenolone 3.56 with freshly prepared silver(I) oxide and an excess of 
methyl iodide led to diasteromerically pure methyl ether 3.60 in 70% yield compared with 
the 57% published yield (entry 1).94 Methylation using sodium hydride and methyl 
iodide, conditions applied in the synthesis of a 3β-methoxy derivative of cholesterol with 
a saturated aliphatic side-chain,95 was also successful (entry 2). The major secondary 
product of the reaction was identified as the ethyl derivative 3.76 (entry 3),96 formed via 
an α-carbonyl alkylation of the 3β-methyl ether 3.60 with excess methyl iodide. 
Compound 3.76 is known in the literature although it has never been fully characterised.96 
Its complete structural assignment is provided in the experimental section.  
Finally, we synthesised i-pregnenolone-methyl-ether 3.75 by refluxing tosyl 
pregnenolone 3.59 in methanol containing potassium acetate.82, 97 As expected, cyclo-
steroid 3.75 was exclusively obtained in 79% yield (Scheme 3.7).  
 
Scheme 3.7. Synthesis of i-pregnenolon-methyl ether 3.75. 
3.3.1.5. 1H- and 13C-NMR analysis  
Although 3β-methoxy-pregnenolone 3.60, 17α,3β-methoxy-pregnenolone 3.73, tosyl 
pregnenolone 3.59, ethyl ketone 3.76, cyclo-3β-hydroxy-steroid 3.61 and  
cyclo-3β-methoxy-steroid 3.75 (Figure 3.11) are reported in several papers, no detailed 
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NMR data are available. Therefore, we ran 1D- and 2D-NMR experiments for the full 
assignment of these compounds using a 500 MHz spectrometer. In particular, we found 
it convenient to narrow the spectral window from 5.5 to 0 ppm to obtain a better resolution 
of the overlapping low field signals in COSY, HSQC and HMBC techniques. The 
chemical shifts and spectra for these compounds are reported in Appendices I-III. 
 
Figure 3.11. Compounds discussed in Appendices I-III. 
3.3.2. Stereoselective addition of organolithium reagents to the side-chain of steroids 
The reaction of organometallic reagents with C-20-keto steroids is known as a valuable 
method to build side-chains with aliphatic or aromatic appendages whose diversity is 
reflected in a wide range of biological activities.98, 99  
3.3.2.1. Thiazolyl-steroids 
Encouraged by earlier work confirming that addition of lithiated thiazole and pyridine to  
C-20 ketones would give preferably the corresponding β-tertiary alcohols,99 we wanted 
to evaluate the outcome of these reactions on 3β-methoxy-pregnenolone 3.60. 
Although metallation at C-2 of thiazole is often carried by lithium halogen exchange of 
2-bromothiazole,99, 100 examples of direct lithiation can be also found. 100-102 Thus,  
2-lithiothiazole was prepared in situ by the reaction of thiazole 3.78 with n-butyllithium 
at –30 °C, and3β-methoxy-pregnenolone 3.60 was added (Table 3.5).  
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Entry Conditions Yield 
1 i) 3.78 (1.1 eq), n-BuLi (1.1 eq), -30 °C, 30 min 
ii) 3.60, -20 °C to rt, 4 h 
3.79/3.80 = 9/1: 35%  
Sm 3.60: 51% 
2 i) 3.78 (2.5 eq), n-BuLi (2.5 eq), -30 °C, 30 min 
ii) 3.60, -20 °C to rt, 2 h 
3.79/3.80 = 9/1: 84%  
 
Table 3.5. Synthesis of thiazolyl derivative 3.79. 
We found that when a stoichiometric amount of organolithium was used, thiazolyl steroid 
3.79 was obtained in poor yield along with recovered starting material (entry 1). In the 
presence of an excess of lithiothiazole, the yield could be increased up to 84% and in a 
shorter reaction time (entry 2). In both cases, analysis by NMR spectroscopy showed the 
presence of an inseparable compound identified as the C-20 epimer 3.80 (3.79/3.80 = 
9/1). However, pure 20(R)-thiazole 3.79 could be obtained in 48% yield by 
recrystallisation of the epimeric mixture from methanol, leaving the filtrate as a 77/23 
mixture of diastereoisomers 3.79 and 3.80. 
The proton NMR spectrum of thiazolyl steroid 3.79 showed three singlets at 0.86, 0.99 
and 1.70 ppm corresponding to the methyl groups at C-18, C-19 and C-21 respectively, 
which are in accordance to the data described by Shingata et al. for an analogous 
compound.99 An exhaustive structural assignment was obtained by combining 1D- and 
2D-NMR experiments (Appendices IV-VI). 
Indicative signals for the minor isomer 3.80 were determined from the 3.79/3.80 mixture. 
The differences were the aromatic doublets at 7.69 and 7.24 ppm shifted downfield with 
respect to the (R)-isomer 3.79, and the chemical shifts of methyl groups at C-18, C-19 
and C-21, which slightly decreased to 0.84, 0.91 and 1.58 ppm, respectively. In the carbon 
NMR spectrum the atoms in ring D and the side-chain also showed differences. Of 
particular relevance was the decrease in the chemical shift of C-22 from 180.6 to 179.4 
ppm and of C-13 from 43.3 to 42.8 ppm in the 20(R)- 3.79 and 20(S)-isomers 3.80, 
respectively. Full NMR data for compounds 3.79 and 3.80 are reported in Appendices 
IV-VI. 
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Conclusive evidence for the structure of thiazole 3.79 was obtained by X-ray diffraction, 
which confirmed the β-configuration of the C-20 hydroxyl group. In the solid state, 
thiazole-steroid 3.79 was observed as a dimer linked by hydrogen bonds between the 
tertiary hydroxyl group in the side-chain as donor and the heterocyclic nitrogen as 
acceptor. Two additional hydrogen bonds between the hydroxyl and two molecules of 
methanol used for recrystallisation were also observed (Figure 3.12).  
 
Figure 3.12. X-ray structure of thiazolyl-steroid 3.79 (CCDC 1019833, Appendix VIII). 
3.3.2.2. Stereochemical rationale 
It is precedented that organometallic additions to the C-20 ketone of pregnenolone 
analogues are highly stereoselective, providing predominantly the β-hydroxyl products.98, 
99, 103-105 It has also been shown that the carbonyl group in the side-chain adopts the 
preferred conformation as shown in compound 3.82 because of three factors: the presence 
of a chiral centre α to the ketone in which the small substituent is a proton, and the medium 
and large-sized groups are the ring D (as represented in 3.81); the C-18 methyl group, 
whose steric hindrance pushes the ketone towards the outside of the molecule; the C-21 
methyl group, which must be also staggered to avoid the bulky ring C  
(Scheme 3.8).98, 105  
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Scheme 3.8. Nucleophilic additions to the C-20 ketone: Felkin-Anh and anti-Felkin-Anh products. 
With this in mind, it is easy to picture that the attack of a nucleophile occurs from the 
external side of the molecule according the Bürgi-Dunitz angle, thus giving compound 
3.83 as the major compound, as predicted from the Felkin-Anh model. Therefore, the 
newly formed hydroxyl group would have predominantly a β-configuration and it would 
be in syn-relationship with the methyl group at C-18, as shown in 3.84.106 On the other 
hand, the addition of a nucleophile to the most hindered face of the carbonyl as in 3.85 
would lead to the sterically unfavoured compound 3.86, in which the C-20 hydroxyl group 
and the C-18 methyl group would be in anti-relationship and the C-20 chiral centre would 
have (S)-configuration as in the minor anti-Felkin-Anh product 3.87. 
These findings were in accordance with our results, and pleasingly the stereochemistry of 
the major compound isolated was in agreement with the 20β-configuration desired for 
our target molecules. 
3.3.2.3. Addition to the 17α-analogue 
We next explored addition to the 17α-epimer of 3β-methoxy-pregnenolone 3.73. As 
expected, treatment of the epimeric mixture 3.60/3.73 (in 42/58 and 78/22 ratio) with 
lithiothiazole gave a corresponding mixture of diastereomeric products 3.79/3.88 (in 
37/63 and 72/28 ratio, respectively) (entries 1 and 2, Table 3.6). 
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Entry Conditions Yield 
1 i) 3.78 (1.1 eq), n-BuLi (1.1 eq), -30 °C, 30 min 
ii) 3.60/3.73 = 42/58, -20 °C to rt, 3 h 
3.79/3.88 = 37/63: 60% 
2 i) 3.78 (2.5 eq), n-BuLi (2.5 eq), -30 °C, 20 min;  
ii) 3.60/3.73 = 78/22, -20 °C to -10 °C, 30 min 
3.79/3.88 = 72/28, 73% 
 
Table 3.6. Synthesis of C-17 epimeric thiazolyl steroids 3.79 and 3.88. THF was used as solvent. 
The formation of diasteroisomer 3.88 was proven by NMR spectroscopic analysis of the 
complicated diastereomeric mixture 3.79/3.88 (Appendices IV-VI). However, it was 
possible to isolate 3.88 cleanly by recrystallisation of the diastereomeric mixture 
3.79/3.88 (in a 72/28 ratio) from methanol. Indisputable evidence for the formation of 
diastereoisomer 3.88 was obtained by X-ray diffraction analysis (Figure 3.13).  
 
Figure 3.13. X-ray structure of thiazolyl-steroid 3.88 (CCDC 1019834, Appendix IX). 
3.3.2.4. The preparation of 2-pyridyl analogues  
The idea to prepare a steroid bearing a pyridyl group arose from the intention to insert a 
basic centre in the side-chain. Nitrogen-containing side-chains are a feature of 
cyclopamine 1.2 and azacholesterol 3.18, two potent Hh/Gli which interact with different 
binding sites on the Smo receptor (Figure 3.3). 
The stereoselective addition of 2-lithio-pyridine 3.90 to 17-keto and 20-keto steroids was 
described first by Heer and Hoffmann to occur with high stereoselectivity in favour of the  
20(R)-isomer 3.91 (Scheme 3.9),107 results recently confirmed by Shingate et al. 99 
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Scheme 3.9. Heer and Hoffmann’s reaction of 2-lithio-pyridine 3.90 with a 20-keto steroid 3.89.107 
We aimed to achieve a similar conversion by reacting 3β-methoxy-pregnenolone 3.60 
with 2-lithio-pyridine, which was freshly prepared by bromo-lithium exchange of  
2-bromo-pyridine 3.93 and n-butyllithium.108 As expected, the reaction resulted in a 
mixture of diastereoisomers 3.94/3.95 in a 9/1 ratio as determined by NMR spectroscopy, 
which after recrystallisation from methanol and dichloromethane gave pure 20(R)-isomer 
3.94 in 53% yield, leaving the filtrate enriched 3/2 in favour of the minor isomer 3.95 
(Scheme 3.10).  
 
Scheme 3.10. Synthesis of pyridyl-steroid 3.94. 
NMR analysis of pyridyl steroid 3.94 showed three singlets at 0.95, 1.02 and 1.60 ppm 
corresponding to the protons at C-18, C-19 and C-21 respectively, as previously reported 
by Shingate et al.99 for a similar compound. Indicative signals for the minor isomer 3.95 
were found at 8.48 and 7.18 ppm for the aromatic protons, and at 3.31, 1.45, 0.87 and 
0.73 ppm for the methyl groups. In accordance with the results of Heer and Hoffmann,107 
the newly formed hydroxyl of the major compound 3.94 was found in β-orientation (20R), 
and this was confirmed by crystallographic studies (Figure 3.14). 
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Figure 3.14. X-ray structure of pyridyl-steroid 3.94 (CCDC 1019835, Appendix X). 
3.3.2.5. Thiophene analogue 
We also wanted to synthesise a steroid featuring a thiophene group in the side-chain. This 
aromatic sulfur-containing heterocycle is bioisosteric with benzene. Thiophene-modified 
steroids are known in the literature (3.96-3.98, Figure 3.15).109, 110  
 
Figure 3.15. Selected steroids containing a thiophenyl group.109, 110 
Nevertheless, to the best of our knowledge, no nucleophilic additions of  
2-thiophenyllithium to C-20 steroidal ketones have been reported to date (Table 3.7).  
 
Entry Conditions Yield 
1 i) 3.99 (2.2 eq), n-BuLi (2.5 eq), -40 to -10 °C, 20 min 
ii) 3.60, 0 °C to rt, 2.5 h 
3.100/3.101 = 57/43: 
48%  
2 i) 3.99 (1.1 eq), n-BuLi (1.1 eq), TMEDA (1.1 eq),  
0 °C to rt, 50 min 
ii) 3.60, 0 °C to rt, 3 h 
3.100: 51%  
 
Table 3.7. Synthesis of thiophenyl-steroid 3.100. 
Chapter 3. Towards steroids with heterocyclic side-chains 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 41 - 
Treatment of ketone 3.60 with an excess of lithiothiophene led to a complex mixture of 
compounds. After column chromatography, thiophene-steroid 3.100 was detected. 
However, an inseparable compound was also found, which was assigned as the novel  
n-butyl derivative 3.101 (on the basis of a similar compound described by Shingate et 
al.)111 resulting from addition of n-butyllithium to 3β-methoxy-pregnenolone 3.60 (entry 
1). However, compond 3.101 was not fully characterised  
We thought the use N,N,N’,N’,-tetramethylethylenediamine112 might increase the 
reactivity of the stoichiometric lithiothiophene, and avoid the formation of 3.101 (entry 
2). Under these conditions, after column chromatography and recrystallisation from 
methanol, thiophene-steroid 3.100 was obtained diastereomerically pure in 51% yield. It 
should be noted that 3.100 readily undergoes dehydration (CD2Cl2 had to be employed 
for NMR studies as CDCl3 caused dehydration). 
The structure and stereochemistry of steroid 3.100 was elucidated by 1D- and 2D-NMR 
spectroscopy. The chemical shifts of C-14, C-17, C-18, C-19 and C-21 were in 
accordance to those above described for thiazolyl- and pyridyl-steroids 3.79 and 3.94. 
The assignment of the 20(R)-stereochemistry therefore seems secure.  
3.3.2.6. Oxa-heterocycles: furyl-steroids 
Having validated this approach, we wanted to use furans to build oxygenated heterocyclic  
side-chains. Nucleophilic additions of lithiofurans to 17-keto steroids have precedent in 
the literature, and they have been extensively used by Kametani et al. during their studies 
towards the synthesis of the ecdysones and brassinolides.113-118  
Of relevance in this regard, Kametani’s group developed a novel strategy to introduce a 
lactone in the side-chain using an Achmatowicz rearrangement of furan 3.104 to 
dihydropyran 3.105 (Scheme 3.11).115, 116 Stereoselective addition of lithiofuran 3.103 
gave the tertiary alcohol 3.104, which was treated with m-chloroperbenzoic acid to afford 
hemiacetal 3.105 in high yield. It was noted that the furyl derivative 3.104 was unstable, 
thus it was used without any further purification in the following oxidation to pyranone 
3.106. Hydrogenation of the side-chain resulted in a mixture of products 3.107-3.109, 
whose distributions varied according to the hydrogenation conditions.116  
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Scheme 3.11. Kametani’s rearrangement of furan 3.104.116 
In order to investigate an Achmatowicz reaction and introduce a lactone functionality, we 
first had to add a furyl group to the C-20 ketone. Hence, our next challenge was the 
isolation of pure furyl steroid 3.111 (Table 3.8).  
 
Entry Conditions Yield 
1 i) 3.110 (2 eq), n-BuLi (2 eq), -10 °C, 30 min 
ii) 3.60, -10 °C to rt, 2.5 h  
3.112: 33 % 
2 i) 3.110 (2 eq), TMEDA (2.5 eq), n-BuLi (2.1 eq),  
-50 °C, 40 min 
ii) 3.60, -50 °C to -30 °C, 30 min 
3.111: 84%  
 
Table 3.8. Synthesis of furyl-steroid 3.111. Reactions were performed in THF. 
An initial attempt was carried out following a slightly modified procedure of Kametani114, 
116 but this failed and the novel styrene 3.112 was obtained (entry 1). We therefore began 
a screening of different reaction temperatures, quenches, work-ups, purifications and 
deuterated NMR solvents, informed by the findings for the thiophene steroid study 
described above. We discovered that the reaction works best when furan 3.110 is lithiated 
at –50 °C and the starting material 3.60 is added at the same temperature in the presence 
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of N,N,N’,N’,-tetramethylethylenediamine. Thin layer chromatography and column 
chromatography were performed on silica gel basified by adding 1% of triethylamine to 
the eluting system. Moreover, NMR experiments were run in deuterobenzene. These 
conditions proved sucessful in suppressing the formation of 3.112 and furyl steroid 3.111 
was obtained in 84% yield along with traces of side-products which were not identified 
(entry 2). The stereochemistry of the 20(R)-hydroxyl in compound 3.111 was proved by 
NMR spectroscopy by comparison of the chemical shifts of the protons and carbons at 
C-11, C-12, C-13, C-15, C-16, C-20 and C-21 with those described above for thiazolyl- 
and pyridyl-steroids 3.79 and 3.94, and further confirmed by crystallographic studies on 
derivative 3.124 as described below. 
3.3.2.7. The Achmatowicz rearrangement of furans 
With the furyl group successfully added, the Achmatowicz rearrangement could be 
investigated. The proposed mechanism119 involved bromination of a furan (e.g. 3.113, 
Scheme 3.12) which leads to bromonium ion 3.114. Formation of oxonium ion 3.115 is 
followed by the addition of methanol which gives 3.116. Displacement of bromide leads 
to a second oxonium ion 3.117 which is trapped by methanol to give dimethoxyacetal 
3.118. Finally, in the presence of acidic media, dimethoxyacetal 3.118 is readily 
hydrolysed to un unstable acyclic 1,4-dicarbonyl intermediate 3.119, which in turn 
undergoes an intramolecular rearrangement to form the six-membered lactol 3.120.  
Scheme 3.12. Proposed mechanism for the Achmatowicz rearrangement.  
Chapter 3. Towards steroids with heterocyclic side-chains 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 44 - 
A number of reagents for the ring opening-cyclisation sequence have been published, 
including peroxyacids such as 3.121 (which lead to diketone 3.119 via the formation of 
epoxide 3.122 and further ring-opening, Scheme 3.12),120-122 also in the presence of 
vanadium acetylacetonate catalyst,123 dimethyldioxirane,124 N-bromosuccinimide,121, 125, 
126 pyridinium chlorochromate.122 More recently an example of Achmatowicz 
rearrangement by means of the enzyme laccase in the presence of oxygen and  
4-acetamido-(2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (4-acetamido-TEMPO) as the 
mediator have been also reported.127 
Amongst the number of methods available, we decided to use the milder  
N-bromosuccinimide for the furan ring opening-ring closure,121 because of the C-5,C-6 
double bond in 3.11 which might react with peroxyacids or bromine, and 
tetrapropylammonium perruthenate in the presence of N-methylmorpholine N-oxide128 
for the following oxidation of lactol 3.123 to lactone 3.124 (Scheme 3.13). These 
conditions proved successful, and 2-methyl-pyran-3,6-one 3.124 was obtained 
exclusively in two steps as a single diastereoisomer in 41% yield.  
Scheme 3.13. Achmatowicz rearrangement of furyl-steroid 3.124. 
The structure and stereochemistry of compound 3.124 was confirmed by X-ray 
crystallography (Figure 3.16).  
 
Figure 3.16. X-ray crystallography of lactone 3.124 (CCDC 1019836, Appendix XI). 
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Having demonstrated the viability of the Achmatowicz rearrangement on furyl derivative 
3.111 we speculated that a similar protocol could be applied to convert furfuryl steroid 
3.125 into hemiacetal 3.126, i.e. a steroid with a side-chain similar to withanolides 3.128, 
featuring an oxygenated heterocycle at C-22 and retention of the β-hydroxyl group at  
C-20 (Scheme 3.14). In theory, two possible products 3.126 and 3.127 could result. We 
suspected that by using suitable protecting groups the reaction could be selectively driven 
to form the desired isomer 3.126. 
 
Scheme 3.14. Potential strategy to withanolide analogue 3.126. 
The attempted synthesis of steroid 3.125 started with the preparation of the tert-
butyldimethylsilyl ether 3.131 in 75% yield (Schemes 3.15 and 3.16). Addition of the 
lithiated 5-hydroxymethyl-tert-butyldimethylsislyl ether 3.130129 to 3β-methoxy-
pregnenolone 3.60 gave a single diastereoisomer which was assigned as 20(R) based on 
NMR comparison of the chemical shifts of the protons and carbons at C-11, C-12, C-13, 
C-14, C-15, C-16, C-17, C-18, C-20 and C-21 with those previously described for furyl-
steroid 3.111. 
 
Scheme 3.15. TBS protection of furfuryl alcohol 3.130. 
 
Scheme 3.16. Synthesis of adduct 3.131 
Next, protection of the secondary hydroxyl group of steroid 3.131 as an acetate was 
attempted using acetic anhydride (entries 1-3, Table 3.9) or acetyl chloride (entries 4 
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and 5). Unfortunately, acetate 3.132 could not be obtained and alkene 3.133 was isolated 
as a side-product (entries 2, 3, and 4).  
 
Entry Conditions Results/Yield 
1 Ac2O/py = 1/3, rt, 2 d By-products 
2 Ac2O/py = 1/3, rt, 2 h By-products, 3.131 and 8% of 3.133 
3 Ac2O/py = 1/1, DMAP (cat), rt, 2 d  By-products and 3.133
a 
4 AcCl (15 eq), py, rt, overnight By-products and 3.133a 
5 AcCl (1.3 eq), CH2Cl2, rt, 30 min Decomposition 
 
Table 3.9. Attempted acetylation of tertiary alcohol 3.131. aDetected by NMR spectroscopy of the crude 
product. 
We next looked at the removal of the tert-butyldimethylsilyl ether (Scheme 3.17). On 
subjecting ether 3.131 to tetrabutylammonium fluoride129 the formation of a single 
product was apparent by thin layer chromatography and confirmed by high resolution 
mass spectroscopy. However, the appearance of additional signals in the proton and 
carbon NMR spectra did not allow secure characterisation of this compound as alcohol 
3.125, therefore this study was abandoned.  
 
Scheme 3.17. Attempted deprotection of silyl ether 3.131. 
3.3.2.8. Benzo-fused heterocycles: benzofuranyl-, benzothianyl- and N-methyl-indolyl 
steroids 
Based on the observation that aryl groups are common amongst Hh/Gli modulators, we 
next examined oxa-, thio- and aza-benzofused rings. We started our investigation on 
benzofuran, benzothiophene and N-methyl protected indole, commercially available 
heterocycles also identified in natural Hh/Gli antagonist taepeenin D 1.18 and 
staurosporinone 1.9, and in the synthetic Hh/Gli agonist SAG 1.41 (Figure 3.17). 
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Figure 3.17. Examples of Hh/Gli modulator with benzo-fused heterocycles. 
7-Benzofuranyl and 17-benzothianyl steroids have been previously synthesised by Suzuki 
coupling of 17-iodo steroids with the corresponding boronic acids in poor yields.130 
However, to the best of our knowledge no examples of organometallic addition of such 
heterocycles to 20-keto steroids have been reported.  
Following modified literature procedures, benzofuran 3.134131 and benzothiophene 
3.136132 were successfully lithiated and, upon reaction with ketone 3.60, benzofuranyl 
and benzothianyl steroids 3.135 and 3.137 were obtained as single diastereoisomers in 
56% and 47% yield, respectively (Scheme 3.18). 
 
Scheme 3.18. Synthesis of benzofuranyl- and benzothianyl-steroids 3.135 and 3.137. 
Metallation of N-methyl indole 3.138 is known to require a strong base such as  
tert-butyllithium133 or to occur at high temperature.134 Thus, we performed the lithiation 
at reflux, whilst the subsequent addition was carried out at room temperature. Under these 
conditions indolyl derivative 3.139 was obtained, albeit in an unoptimised 12% yield 
(Scheme 3.19).  
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Scheme 3.19. Synthesis of N-methyl-indolyl steroid 3.139. 
In all these cases only one diastereoisomer was seen, which was assumed to be 20(R) 
based on NMR comparison with the adducts previously prepared. 
3.3.2.9. Heterocyclic i-steroids: thiazolyl- and furanyl-derivatives 
To expand the small library of heterocyclic steroids, we chose to synthesise thiazolyl  
cyclo-steroid 3.140 and furanyl cyclo-steroid 3.141 to establish the importance of whether 
the steroid is in an open or cyclic form, and of a substituent at C-3 and at C-6 in SAR 
studies (Scheme 3.20). Based on the results previously achieved, lithiation of thiazole 
3.78 was carried out at -30°C, and after addition of ketone 3.75, thiazolyl cyclo-steroid 
3.140 was obtained in 58% yield. Lithiation of furan 3.110 worked better at lower 
temperature, and, in the presence of N,N,N’,N’,-tetramethylethylenediamine, furyl cyclo-
steroid 3.141 was obtained in 47% yield.  
 
Scheme 3.20. Synthesis of thiazyl 3.140 and furyl 3.141 derivatives of i-pregnenolon-methyl ether 3.75. 
In both cases, a secondary product likely to be the 20(S)-diasteroisomer could be seen in 
the proton and carbon NMR spectra. However, the small amount detected did not allow 
their identification to be confirmed. According with the Felkin-Anh prediction, the newly 
formed stereocentre at C-20 was assigned as 20(R) for the major product, by comparison 
to the NMR spectra of the analogous compounds 3.79 and 3.111, respectively. 
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3.3.2.10. Towards lactone side-chains via ring-closing metathesis 
Previously we reported that an Achmatowicz rearrangement of furyl and furfuryl 
functionalities could lead to compounds featuring oxygenated side-chain such as 3.124 
that resemble the withanolides 3.128 or the bufadienolides 3.142 (Figure 3.18). We 
thought it would be interesting to mimic these naturally occurring cyclic side-chains by 
synthesising α,β-unsaturated lactones such as 3.143. These steroids could be further 
functionalised at the double bond for SAR studies  
 
Figure 3.18. Similarities between diketopyranone 3.123, withanolides 3.128, bufadienolides 3.142, and 
fuctionalised α,β-unsaturated lactones with general structure 3.143. 
We proposed that the lactone ring in 3.143 could be closed via an olefin metathesis of 
compound 3.144 (Scheme 3.21). One of the two terminal vinyl groups could be inserted 
via esterification of the tertiary alcohol 3.146 with the acyl chloride 3.145. Grignard 
reaction of allylmagnesium bromide 3.147 to 3β-methoxy-pregnenolone 3.60 would lead 
to the installation of the first olefinic branch and give adduct 3.146 in which the newly 
formed hydroxyl group would have the desired β-configuration according to the Felkin-
Ahn model (see Scheme 3.8). 
 
Scheme 3.21. Retrosynthetic plan to α,β-unsaturated lactones. 
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Alkene metathesis has emerged as a potent tool in the steroid field, and all the ring-closing 
transformations, i.e. cross, enyne, ring-closing enyne, ring-closing dienyne and ring-
opening metathesis, have found interesting applications in the total synthesis, 
hemisynthesis, dimerisation and side-chain modification of steroids.135 
Despite this, to the best of our knowledge, the only example of ring-closing metathesis 
applied to the formation of withanolides has been published by Matsuya et al. during 
studies towards the synthesis of sorminone 3.157 and its analogues as novel  
anti-Alzheimer’s disease candidates (Scheme 3.22).136 The preparation of the substrate 
for the ring-closing metathesis started with the construction of the C-17 side-chain of 
commercially available 1α-hydroxy dehydroepiandrosterone 3.148 by Wittig olefination 
of the protected tert-butyldimethylsilyl ether 3.149, followed by ene reaction with 
paraformaldehyde, reduction of the alkene 3.150 and further oxidation of the side-chain 
with pyridinium dichromate to obtain the C-20 aldehyde 3.151.  
 
Scheme 3.22. Ring-closing metathesis approach of Matsuya et al. to sominone 3.157.136 
The first olefinic branch was inserted via a Barbier reaction involving 2-methylallyl 
bromide 3.152 and magnesium powder. The reaction resulted in poor stereoselectivity 
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and the (R)-isomer 3.153 was obtained in 42% yield. The second olefinic branch was 
installed by esterification of alcohol 3.153 with 2-hydroxymethylacryloyl chloride 
protected as para-methoxyphenyl ether 3.154, which was afterward released on treatment 
with cerium ammonium nitrate to give compound 3.155 in 50% yield over two steps. The 
o-tolyl variant of the second-generation Hoveyda-Grubbs’ catalyst 3.156 was found to be 
the best reagent for the ring-closing metathesis. The use of this catalyst for the conversion 
of 3.155 to the hindered lactone 3.157 gave only 22% yield, but the unreacted starting 
material could be recovered and reused.  
In 2012, Matsuya’s group patented the synthesis and the therapeutic use of steroid 3.162, 
characterised by an aromatic ring A and a δ-lactone in the side-chain monosubstituted 
with a hydroxymethyl group (Scheme 3.23). This compound was defined as ‘compound 
having neurite-outgrowing activity’ with applicability in the prevention and treatment of 
neurodegenerative diseases.137 Its synthesis was also based on a ring-closing metathesis 
approach. Notably, the less hindered olefin 3.161, which was prepared by oxidation of 
alcohol 3.158 with pyridinium dichromate followed by asymmetric allylboration and 
esterification of the resulting compound 3.159 with acryloyl chloride 3.160, showed a 
better reactivity towards catalyst 3.156 compared to compound 3.155, and the 
corresponding lactone 3.162 was obtained in 57% yield.  
 
Scheme 3.23. Patented synthesis of steroid 3.162 by Matsuya et al.137 
Inspired by these results, we targeted the simple unsubstituted C-20 lactone 3.168 
(Scheme 3.24). The first step was the stereoselective addition of allylmagnesium bromide 
3.163 to ketone 3.60138 which afforded exclusively the 20(S)-alcohol 3.164 in 72% yield. 
The following esterification of the sterically hindered tertiary alcohol 3.164 with 
commercially available acryloyl chloride 3.165138 was difficult and ester 3.166 was 
isolated in 33% yield, albeit along with recovered starting material. Afterwards, the use 
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of second-generation Hoveyda-Grubbs catalyst 3.167 led to the formation of the  
α,β-unsaturated lactone 3.168 in excellent yield  
Scheme 3.24. Synthesis of the C-20 steroidal lactone 3.168. 
Structural confirmation of steroid 3.168 was obtained by X-ray diffraction, and it once 
again confirmed that the addition of the organometallic reagent to the C-20 keto group 
occurred under Felkin-Anh control, thus leading to a β-tertiary alcohol in a stereoselective 
fashion (Figure 3.19). 
 
Figure 3.19. Crystal structure of steroidal lactone 3.168 (CCDC 1019837, Appendix XII). 
Finally, we wanted to see whether similar reaction conditions could be applied to the 
synthesis of an α,β-dimethyl-α,β-unsaturated C-20-δ-lactone 3.173, functionality typical 
of the withanolides (Scheme 3.25).  
The addition of 2-methylallylmagnesium chloride 3.169 to ketone 3.60 at 0 °C gave 
steroid 3.170 in a mixture along with inseparable side-products. Therefore, a switch to a 
lower temperature was made, and this resulted in β-alcohol 3.170 which was obtained in 
75% yield. Esterification in the presence of the bulky methyl-acryloyl chloride 3.171 gave 
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diene 3.172 in 12% yield along with recovered starting material. Nonetheless, the steric 
hindrance did not prevent the intramolecular ring-closure, and, on treatment with the 
second-generation Hoveyda-Grubbs catalyst 3.167, dimethyl-α,β-unsaturated lactone 
3.173 was obtained in 24% yield. 
 
Scheme 3.25. Synthesis of the C-20 dimethyl lactone 3.173. 
The structure of steroid 3.173 was elucidated by NMR spectroscopy and the 
stereochemistry was secured by comparison of the chemical shift of C-17, C-20 and  
C-21 with those of the unsubstituted lactone 3.168.  
With regards to the lactone ring, the 1H- and 13C-NMR spectra of compound 3.173 were 
in reasonable agreement with those of withanolide F 2.2 (Figure 3.20).139 Indeed, the 1H-
NMR spectrum showed singlets for the methyls C-6 and C-7 at 1.85 and 1.72 ppm, 
respectively, in withanolide 2.2, while they were a unique singlet at 1.88 ppm in steroid 
3.173. Methylenic protons at C-2 appeared as a multiplet between 2.35 and 2.50 ppm in 
withanolide 2.2, whereas they were spilt in a doublet at 2.71 ppm (J = 17.8 Hz) and in a 
multiplet between 2.05 and 1.69 ppm in steroid 3.173. The 13C-NMR showed a closer 
correspondence between the chemical shifts of C-1, C-3, C-4, C-5, C-6 and C-7 at 81.0, 
150.7, 120.1, 165.9, 20.2 and 12.1 ppm for withanolide 2.2 and at 82.6, 146.5, 121.4, 
165.9, 20.8 and 12.5 ppm for steroid 3.173, respectively. However, the signals of C-8 and 
C-2 were shifted downfield from 19.1 and 34.3 ppm in compound 2.2 to 24.6 and 41.1 
ppm in compound 3.173, respectively. This result was expected, considering the positions 
C-8 and C-2 as the most affected by of proximity of the steroidal framework  
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Figure 3.20. Structures of novel steroid 3.173 and withanolide F 2.2. 
3.4. SUMMARY 
A number of novel steroids have been prepared as potential modulators of the Hh/Gli 
signalling pathway (Figures 3.21-3.24). The majority of these compounds feature a 
cholesterol-like skeleton and a heterocylic side-chain containing a 20(R)-hydroxyl group 
(3.79, 3.94, 3.100, 3.111, 3.131, 3.135, 3.137, 3.139), or are C-20 vinylic analogues 
(3.112 and 3.133, Figure 3.21). 
 
Figure 3.21. Novel 3β-methoxy-pregnenolone derivatives featuring a heterocylic side-chain and a  
20(R)-hydroxyl or a C-20 vinyl group. 
Isomeric compounds featuring a 20(S)-hydroxyl group (3.80 and 3.95), an α-oriented 
side-chain (3.88) or a cyclic ring A (3.140 and 3.141) have been also prepared  
(Figure 3.22). 
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Figure 3.22. Novel isomeric 3β-methoxy-pregnenolone derivatives. 
Novel intermediates with aliphatic linear and branched side-chains containing a free 
20(S)-hydroxyl (3.164 and 3.170) or a C-20 ester (3.166 and 3.172) provide a wider 
chemical diversity to our small molecule library (Figure 3.23). 
 
Figure 3.23. Novel steroids with acyclic side-chains 
Finally, we successfully synthesised novel compounds with a δ-lactol (3.123) or δ-lactone 
(3.124, 3.168 and 3.173) in the side-chain (Figure 3.24) 
 
Figure 3.24. Novel lactonic steroids with a withanolide-like side-chain. 
Lactonic side-chains are a typical feature of withanolides. An overview of the main 
characteristics of these natural products and our efforts towards the synthesis of an 
unnatural withanolide are provided in Chapter 4.  
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CHAPTER 4.  
STUDIES TOWARDS NOVEL WITHANOLIDE ANALOGUES 
4.1. INTRODUCTION TO WITHANOLIDES 
In the history of medicine nature has always been a rich source of therapeutic agents, and 
many drugs that are now in commercial use are derived from plants, microbes or marine  
organisms.140, 141 
Traditional medicine pre-dated Western medicine and its origins are earlier than recorded 
human history. Ayurveda is one of the oldest and most diffused forms of popular medicine 
born in India more than 4000 years ago. Studies on the folklore claim Ayurvedic 
practitioners have provided useful leads in drug discovery and they have inspired the 
development of important therapeutics currently used to treat several chronic diseases.142 
Withania somnifera, also named Ashwagandha, Winter cherry or Indian ginseng, is an 
important plant in Ayurvedic healing that has been used since ancient times to enhance 
longevity and rejuvenation (Figure 4.1). It belongs to Rasayana, a group of treatments 
traditionally known to improve physical and mental abilities, to strengthen and give 
vigour to the body, to increase memory and acquire intelligence, to stimulate the defence 
system and to retard and arrest cell degeneration.143  
 
 
 
 
 
 
Figure 4.1. Representations of Withania somnifera. 
The chemical constitution of Aswagandha has been extensively investigated. 
Withanolides are the main bioactive components, localised in the leaves, where the 
concentration ranges between 0.001-0.5% of the dry weight, but are also present in the 
roots and fruits. These secondary metabolites are not directly involved in the normal 
growth, development or reproduction of the plants, but usually act as a defence system 
against animals, microorganisms or interspecies attacks.144-146 Withaferin A 4.1 was the 
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first withanolide isolated and it was found in the leaves of Withania somnifera by Lavie 
et al. in 1965 (Figure 4.2). It has been described as a white crystalline powder and its 
structure has been elucidated by spectroscopic methods and supported by chemical 
modifications.147 
 
Figure 4.2. Withaferin A 4.1  
A number of additional withanolides were subsequently purified and characterised. 
Recent reviews report more than 650 withanolides, more than half of which have been 
isolated over the last 14 years.148-150 
4.1.1. Natural occurrence of withanolides 
The Solanaceae are a family of dicotyledonous flowering plants, herbs and shrubs present 
in every continent and consisting of nearly 100 genera and more than 3000 species, many 
of which are edible or with medicinal properties.143, 150 Amongst them, plants belonging 
to Withania, Jaborosa, Datura and Physalis genera are the major source of 
withanolides.150 The genus Withania contains 23 species distributed in the dry parts of 
the temperate and tropical zones of the Mediterranean area, spreading from the Canary 
Islands to Southwest Asia. Jaborosa, Datura and Physalis genera are endemic to the 
North and South America continents.143 
As comprehensively reported by Misico et al.,150 after their first appearance in Withania 
somnifera, withanolides have been extracted from many other species of plants belonging 
to the Withania, Physalis, Jaborosa and Datura genera.150 Moreover, biologically 
interesting withanolides have been more recently extracted from other plants including 
Leguminosae, Labiatae, and Taccaceae and from marine microorganisms.150-152 
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4.1.2. Structural features of withanolides 
Withanolides are natural steroids characterised by a 28-carbon ergostane skeleton in 
which C-22 and C-26 or C-23 and C-26 are oxidised to form δ- or γ-lactone (such as in 
compounds 4.2 and 4.3, respectively, Figure 4.3), or, less common, lactols.149 The 
backbone consisting of the steroidal ABCD ring system and the oxygenated side-chain is 
generally designated the “withanolide skeleton”.153 Hydroxyls groups can typically 
decorate the framework at nearly every carbons, and they can be present as the free 
hydroxy or as epoxides, ethers, esters or more complex heterocycles.148-150 
 
Figure 4.3: Basic structures of δ-lactone and γ-lactone withanolides. 
In light of the plethora of structures, a classification of withanolides have been proposed 
(Figure 4.4).148-150  
According to the size of the side-chain, withanolides can be divided in: 
 Withanolides with δ-lactone or δ-lactol side-chains. 
 Withanolides with γ-lactone or γ-lactol side-chains.  
Within each group, a second classification divides withanolides into subclasses 
depending on the similarities between their skeletons:  
 Withanolides with unmodified skeleton, which are characterised by the parent 
skeleton of withaferin A 4.1 (general structure 4.4). 
 Withanolides with modified skeleton, which arise from different rearrangements 
of the side-chain and ring D mainly promoted by the hyperoxygenation (general 
structures 4.5-4.23).  
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Figure 4.4. Classification of withanolides. R = H, OH; O. 
4.1.3. Biosynthesis of withanolides 
Although the biosynthetic route is not well established, it is commonly acknowledged 
that withanolides are likely to be naturally synthesised according to the same isoprene-
pathway of natural triterpenes and sterols.143, 154 In plants, the synthesis of isoprene occurs 
via two different routes both starting with D-glucose: the mavalonate pathway in cytosol 
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and the non-mevalonate pathway in plastids. By administration of [13C1]-D-glucose to in 
vitro producing withanolide shoots of Withania somnifera, Chaurasiya et al.154 have 
recently demonstrated that both mevalonate and non-mevalonate pathways participate for 
the synthesis of withanolides, with a contribution of 75:25 in favour of the cytosolic route. 
An overview of the latter route leading to withaferin A 4.1 is shown in Scheme 4.1. 
Scheme 4.1. Overview of biosynthesis of withaferin A 4.1.143, 154 Labelled intermediates relate to the work 
of Chaurasiya et al.154
 
The biosynthetic pathway starts with the enzymatic conversion of [13C1]-D-glucose 4.24 
into pyruvate 4.26 in several steps including D-fructose-1,6-biphosphate 4.25 as 
intermediate. Two enzymatic transformations convert pyruvate 4.26 into acetyl Co-
enzyme A 4.27 and acetoacetyl CoA 4.28. Combination of metabolites 4.27 and 4.28 
gives 3-hydroxy-3-methyl-glutaryl-Co-enzyme A 4.29, which is in turn enzymatically 
metabolised to mevalonic acid 4.30. Only the (R)-form of this acid proceeds along the 
route via first phosphorylation to mevalonate-5-pyrophosphate 4.31 followed by 
decarboxylation to isopentenyl-5-pyrophosphate 4.32. Head-to-tail and head-to-head 
condensations of 6 units of pyrophosphate 4.32 lead to squalene 4.33, which undergoes 
epoxidation to 4.34 in the presence of NADPH and mytochondrial oxygen. Subsequent 
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cyclisation leads to compound 4.35, which can undergo methylenation by  
S-adenosylmethionine to 24-methylenecholesterol 4.36, a well known intermediate in the 
synthesis of cholesterol and related steroids.143, 154  
The relationship between 24-methylene cholesterol 4.36 and withanolides was first 
reported by Lockley in the 1970s, who showed that administration of [28-3H]-24-
methylenecholesterol to young leaves or the stem of Withania somnifera produced 
radioactive withanolides.155, 156 Additional proof was found when Velde et al., during 
studies on the constituents of W. somnifera157 and W. coagulans,158 isolated the novel 
steroids 4.37,157 4.38158 and 4.39,158 which were identified as biogenetic precursors of 
withanolides (Figure 4.5).  
 
Figure 4.5. Potential intermediates of the withanolides’ biosynthesis.157, 158 
Valde proposed that the biosynthetic pathway could start with the oxidation of  
24-methylene cholesterol 4.36 to sterol 4.39, followed by C-22 hydroxylation to 4.40 
(Scheme 4.2). Lactol 4.44 could be obtained in two ways. One way entailed the 
cyclisation of diol 4.40 to pyran 4.41 followed by hydroxylation. Otherwise, an allylic 
isomerisation of alcohol 4.40 to diol 4.42, followed by oxidation to aldehyde 4.43 and 
subsequent ring-closure could be also considered. Final oxidation of lactol 4.44 led 
afterwards to the typical withanolide side-chain 4.45.158 
Chapter 4. Studies towards novel withanolide analogues 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 62 - 
 
Scheme 4.2. Proposed biosynthesis of the withanolide side-chain.158 
Velde suggested also that the biochemical elaboration of rings A and B leading to the 
recurrent 1-oxo-2,5-diene pattern could occur after the formation of the side-chain.157 The 
simple sequence of C-1 hydroxylation to diol 4.46, selective oxidation to 1-keto-3β-
alcohol 4.47 and elimination to enone 4.48 has been confirmed by the isolation of the 
intermediates 4.45-4.48, which were afterwards subjected to biomimetic reactions 
(Scheme 4.3).158  
 
Scheme 4.3. Proposed biogenetical modifications of withanolides’ ring-A.157, 158  
The huge diversity of withanolide structures is reflected in the array of suggested 
biosyntheses. Particular attention has been given to the biosynthesis of withanolides with 
modified skeletons, including physalins, withametelins, acnistins, withajardins and 
withanolides with an aromatic ring D. These biogenetic pathways have in common the 
elaboration of hyperoxygenated precursor compounds in which the lactonic side-chain 
and the steroidal framework have been already preformed.148-150 However, an in-depth 
analysis of these routes is beyond the scope of this work.  
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4.1.4. Biological activities of withanolides 
The pharmacological properties of withanolides have aroused the interest of the scientific 
community, especially in recent years. The list of their biological activities is wide and 
includes: phytotoxic, antifeedant, insecticidal, antimicrobial, antiparasitic, trypanocidal, 
leishmanicidal, anti-inflammatory, antistress, immunosuppressive, immunomodulatory 
effects; CNS-related activities on synaptogenesis, neurite outgrowth and inhibition of 
cholinesterase; and anticancer activities including cytotoxic, cancer chemopreventive, 
antiangiogenic and microtubule stabilisator agents.148, 150 
4.1.4.1. Anticancer withanolides 
With regard to cancer, in the last decades the cytotoxicity of withanolides has been widely 
investigated against a number of cancer cells lines, and several compounds have been 
considered as potential anticancer therapeutics. In recent work Zhang et al.159 reported 
interesting antiproliferative activity of 15 withanolides with unmodified skeletons (IC50 
values in the range of 0.067-17.4 μM), either extracted from plant material or obtained 
via hemisyntheses, against 7 cancer cell lines including melanoma cell lines (murine 
B16F10 and human SKMEL28), human head and neck squamous cell carcinomas 
(HNSCC) cell lines (JMAR, MDA1986, DR081-1), human breast cancer cell lines 
(Hs578T) and non-malignant human renal epithelial cell line (MRC5), using cisplatin as 
a positive control. Combination of these results with precedent data allowed the authors 
to draw a SAR table for anticancer withanolides as follows (Figure 4.6):  
 Δ2-1-Oxo functionality is required in ring A. 
 Hydroxylation of C-4 slightly reduces the potency; acetylation increases it. 
 Replacement of the 5β,6β-epoxy group with the 4α-chloro-5β-hydroxy 
functionality does not decrease the cytotoxicity. 
 Substitution at C-7 has essentially no effect on anti-cancer activity. 
 Hydroxylation at C-11 and C-12 decreases the activity. 
 14α,15α-Epoxidation reduces the anticancer activity. 
 Hydroxylation, acetylation and epoxidation at C-16 and C-17 slightly reduces the 
potential of withanolides. 
 Hydroxylation or acetylation at C-18 and C-19 does not decrease the potency. 
 Hydroxylation at C-20, C-23, C-24 and C-27 of the side-chain decreases the 
anticancer potential. 
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 The δ-lactone is important in order to retain the antiproliferative activity. 
 Glycosylation of withanolides decreases the cytotoxic effect. 
 Withanolides with unmodified skeletons generally show the highest activity as 
antitumour agents compared to physalin, trechonolides and acnistine. 
 
Figure 4.6: SAR of cytotoxic withanolides based on witaferin A 4.1.159 
Additionally, the necessary contribution of the 5β,6β-epoxide to the anticancer activity 
has been recently confirmed by Joshi et al. by replacement of this functionality with 
alcohols, thiirane and amino alcohols (see Scheme 5.2 for synthetic details). In fact, the 
cytotoxicity of the resulting compounds appeared significantly reduced in tests against 
colon cancer (CACO-2), prostate cancer (PC-3), liver cancer (WRL-68) and breast cancer 
(MCF-7) cell lines (IC50  values > 85 µM), whilst the IC50  values of withaferin A 4.1 
ranged between 3.8 and 5.4 µM.160 
4.1.4.2. Withanolides with neurite outgrowth activity 
Withanolide A 4.49 is a highly oxygenated steroidal lactone isolated first from the roots 
of Withania somnifera, which is known to possess interesting neuropharmacological 
activities in promoting neurite outgrowth, reversing neurite atrophy and aiding synapse 
reconstruction. After its successful total synthesis from pregnenolone,161 Gademann and 
co-workers have recently investigated the influence of the 1-oxo-2-ene system towards 
the neurite outgrowth activity through the elaboration of ring A of withanolide A 4.49 
and evaluation in human medulloblastoma cells (see Schemes 5.3 and 5.4 for synthetic 
details).162 The quantitative results of the biological screening were uncertain, however 
some conclusions could be drawn (Figure 4.7): 
 1α-2,3-allylic alcohol, 3α-1,2-allylic alcohol and 3β-1,2-allylic alcohols retain the 
activity of withanolide A 4.49. 
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 C-1 hydroxylamine derivative does not change the activity. 
 A 2α,3α-epoxide or a 3α-1,2-allylic acetate showed less the activity then 
withanolide A 4.49. 
 C-1 methyl, allyl or benzyl oximes significantly decrease the activity. 
 
Figure 4.7: SAR of neurite-outgrowth withanolides based on withanolide A 4.49.162 
The authors assumed that the enone pattern in ring A might not be required for the 
bioactivity, and that the size of the substituents had more influence than the kind of 
functionality itself.162  
4.1.4.3. Withanolides active in the Hh/Gli signalling pathway 
Withanolides have also shown activity as inhibitors of the Hh/Gli signalling pathways. In 
2008 Hosoya and coworkers screened 94 natural products, including terpenoids, 
flavonoids, phenylpropanoids, glycosides and bisindole alkaloids, and 192 tropical plant 
extracts in a cell-based reporter assay to identify potential Hh/Gli inhibitors. Amongst 
them, two withanolides extracted from Physalia minima, physalin F 1.13 and physalin B 
1.14 (Figure 4.8), exhibited the highest inhibitory activity of the Gli-mediated 
transcription (IC50 = 0.66 and 0.62 μM, respectively) compared to cyclopamine 1.2 (IC50 
> 40 μM). Additionally, physalins 1.13 and 1.14 showed potent cytotoxicity in human 
cancer pancreatic cell lines (PANC-1) expressing Hh/Gli components (IC50 = 2.7 and 5.3 
μM, respectively). Again, cyclopamine gave weaker activity (IC50 8.0. μM).38 
 
Figure 4.8. Withanolide inhibitors of the Hh/Gli signalling pathway. 
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4.1.5. Chemical synthesis of withanolides 
The large number of withanolides and their biological activities have motivated many 
researchers to embark on the synthesis of this class of natural products. Generally two 
strategies have been chosen: first, the transformation of a commercially available steroid 
into the target withanolide; secondly, a stereocontrolled total synthesis when no suitable 
starting material was readily available. In the first case, cholesterol 3.6 and pregnenolone 
3.56 have been often used in model studies towards the synthesis of withanolides, as they 
bear a 3β-hydroxyl group and a C-5,C-6 double bond suitable for modification, and, in 
the case of pregnenolone 3.56, a C-20 ketone on which the withanolide side-chain could 
be easily installed (Figure 4.9).163  
 
Figure 4.9. Cholesterol 3.6 and pregnenolone 3.56 as commercially available materials for studies on the 
right- and left-hand side elaboration of withanolides. 
4.1.5.1. Earlier studies towards withanolide rings A and B 
Amongst a wide number of possible patterns which can decorate rings A and B, the 
synthesis of the epoxide and quinoid-like moieties typical of withaferin A 4.1 have been 
widely investigated, both because it was the first withanolide isolated and it possesses a 
wide range of bioactivities, and because the decoration is quite recurrent amongst 
withanolides.163-166 
In the mid seventies two independent groups, Ikekawa’s group164, 165 and Weissemberg 
at al.,166 studied concurrently the synthesis of the 1-oxo-2-en-5β,6β-epoxy-4β-hydroxy 
pattern (i.e. pattern of rings A and B) using cholesterol derivatives as starting materials.  
Ikekawa’s route proceeded through the synthesis of the key intermediate 4.54 (whose  
1-oxo-2,5-diene system is also present in rings A and B of withanolide F 2.2). Elaboration 
of ring A began with the reduction of epoxide 4.50 with hydrazine, followed by C-1 
oxidation to obtain the α,β-unsaturated ketone 4.52 (Scheme 4.4, pathway a). Afterwards 
the alkene in ring B was installed by alkaline hydrolysis of the acetate 4.52, and 
subsequent dehydration with phosphoryl chloride. The second strategy used 1α,2β-
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hydroxycholesterol 4.55 as starting material, and led to intermediate 4.54 in three steps, 
that is the selective acetylation of its less hindered 3β-hydroxyl group, followed by Jones 
oxidation of 1α-hydroxyl group in compound 4.56 and, finally, alkaline α,β-elimination 
of keto ester 4.57 (Scheme 4.4, pathway b).164, 165 
 
Scheme 4.4. Ikekawa’s synthesis of the the 1-oxo-2,5-diene system 4.54.164, 165 
Once dienone 4.56 was in hand, further functionalisation was carried out by its 
epoxidation to compounds 4.58 and 4.59 with m-chloroperbenzoic acid, followed by a 
nearly quantitative ring opening-elimination sequence to allylic alcohol 4.60 (Scheme 
4.5). The required 4β-hydroxyl group was installed as a glycol on treatment of α-mesylate 
4.61 with osmium tetroxide, thus allowing the stereoselective epoxide formation to give 
5β,6β-epoxy-4β-hydroxy-5β-cholest-2-en-1-one 4.63.164, 165 
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Scheme 4.5. Ikekawa’s synthesis of the 5β,6β-epoxy-4β-hydroxy system 4.63. 
The procedure designed by Weissenberg et al.166 has the advantage that it also give the  
1-oxo-2,5-dien-4β-hydroxy system 4.74, which is another of the most common 
substitution patterns of withanolide rings A and B (Scheme 4.6).  
 
Scheme 4.6. Weissenberg’s synthesis of the 5β,6β-epoxy-4β-hydroxy system 4.63.166 
The C-6,C-7 double bond in 1α,2α-epoxycholesta-4,6-dien-3-one 4.64 was selectively 
hydrogenated first. The formation of the 1-oxo-2-ene system began with the reduction of 
the 1α,2α-epoxide and 3-ketone in compound 4.65, then epoxidation of the C-4,C-5 
double bond in compound 4.66 followed by regioselective C-3 acetylation of 4.67 and 
C-1 oxidation of 4.68 to give ketone 4.69. After alkaline α,β-elimination epoxyenone 4.70 
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was obtained in good yield. Acid-catalysed opening of epoxide 4.70 gave 4β-alcohol 4.71. 
Finally the 4β,5β-epoxide was introduced smoothly by first dehydration of acetate 4.72 
with thionyl chloride to dienone 4.73, followed by a barium methoxide catalysed 
transesterification to allylic alcohol 4.74 and epoxidation in the presence of perbenzoic 
acid.166 
4.1.5.2. Rings A and B elaboration: towards the synthesis of withanolide D 4.86 
Ten years later, Ikekawa’s group described the first synthesis of withanolide D 4.86, a 
compound with the same A and B ring functionality, starting from a pregnenolone 3.56, 
through a different sequence of events (Scheme 4.7).167 
 
Scheme 4.7. Ikekawa’s synthesis of withanolide D 4.86.167  
Elaboration of rings A and B of pregnenolone 3.56 started with the oxidation of its  
3β-hydroxy-5-ene system to trienone 4.75 on treatment with 2,3-dichloro-5,6-dicyano-
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1,4-benzoquinone, followed by selective 1α,2α-epoxidation with alkaline hydrogen 
peroxide to intermediate 4.76. Using lithium reduction in liquid ammonia, epoxydienone 
4.76 was converted into 1α,3β-diol-5-ene 4.77. After having installed the side-chain, the 
more accessible hydroxyl of diol 4.78 was protected as the silyl ether 4.79, and the C,5-
C,6 double bond selectively epoxidised to 4.80 before oxidation of the  
1α-hydroxyl group to obtain ketone 4.81. Epoxide ring opening with thiophenol and 
aluminium oxide furnished thioether 4.82, which was dehydrated to dienone 4.83, 
oxidised to allylic sulfoxide 4.84 and finally subjected to a 2,3-sigmatropic rearrangement 
to introduce the 4β-hydroxyl in compound 4.85. Epoxidation with m-chloroperbenzoic 
acid afforded stereoselectively 5β,6β-epoxide 4.86 in good yield.167 
4.1.5.3. Earlier studies towards the synthesis of withanolide δ-lactone 
The first stereoselective construction of a 22(R)-δ-lactone in the steroid side-chain was 
achieved by Weihe and McMorris, during studies towards the synthesis of the fungi 
sexual hormone 23-deoxyantheridiol 4.96 (Scheme 4.8).168  
Scheme 4.8. Weihe and McMorris’s synthesis of 23-deoxyantheridiol 4.96.168 
To obtain the natural 22(R)-configuration, aldehyde 4.87 was first converted into vinyl 
ketone 4.89 by Wittig reaction with ylide 4.88, and afterwards stereoselectively 
epoxidised to the 22α,23α-epoxide 4.90. Ring-opening of epoxide 4.90 on treatment with 
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aluminium amalgam yielded exclusively the desired 22(R)-hydroxy ketone 4.91 in 86% 
yield. Ketol 4.91 was acetylated with α-bromoacetyl bromide 4.92 to compound 4.93, 
which was in turn subjected to an Arbuzov reaction with triethyl phosphite to obtain 
phosphonate 4.94. Ring-closure via an intramolecular Horner-Wadsworth-Emmons 
reaction gave finally δ-lactone 4.95 which featured the same 22(R)-configuration of the 
natural withanolide δ-lactone. 168 
4.1.5.4. Functionalisation of the withanolide δ-lactone  
Amongst a number of studies towards the synthesis of withanolide, Ikekawa and co-
workers also developed a strategy to functionalise the withanolide δ-lactone, e.g. by 
inserting a 27-hydroxyl group which is also a feature of withaferin A 4.1 (Scheme 4.9).169  
Prior to its decoration, the six-membered lactone was installed following the procedure 
previously developed by McMorris,168 altough the substrate 4.106 was prepared via a 
different route (Scheme 4.9).169 
Ikekawa’s synthesis started with the conversion of commercially available compound 
4.97 into olefin 4.100. Reduction of acid 4.97 with lithium aluminium hydride furnished 
alcohol 4.98, whose rings A and B were converted into acetate 4.99 before further 
elaboration of the side-chain. The C-20 hydroxyl group was oxidased with pyridinium 
chlorochromate, and afterwards subjected to a Wittig reaction with 
methylenetriphenylphosphorane to give olefin 4.100. Osmium tetraoxide oxidation of 
4.101 resulted in a mixture of 22(S)- and 22(R)-diols in 5/2 ratio. Only the desired  
22(S)-isomer was progressed in the synthesis, and, after its tosylation to compound 4.102, 
it was selectively epoxidised to compound 4.103 on treatment with potassium carbonate. 
An additional carbon was inserted in the side-chain via a Corey-Seebach umpolung 
reaction using 2-methyl dithiane 4.104, and the dithioether 4.105 was released to ketone 
4.106 by means of mercuric oxide and boron trifluoride etherate. On ketol 4.106, the 
unsaturated δ-lactone 4.107 was then built in three steps in 79% yield following 
McMorris’ procedure described in Scheme 4.8. 
With the δ-lactone in hand, its functionalisation was achieved by first stereospecific 
hydrogenation of the unsaturated ring to give compound 4.108, followed by α-alkylation  
with lithium N-isopropylcyclohexylamide and diphenyl sulfide to give a mixture of  
25(S)- 4.109 and 25(R)-thioethers in 3/2 ratio. Alkylation of the desired isomer 4.109 by 
means of lithium N-isopropylcyclohexylamide and formaldehyde was highly 
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stereoselective, and gave the intended 25(R)-isomer 4.110 in 68% yield. Finally, after 
elaboration of rings A and B to give compound 4.111, thermal elimination of the 
corresponding sulfoxide 4.112 furnished α,β-unsaturated δ-lactone 4.113, which featured 
the 22(R)-δ-lactone and the 27-hydroxyl group typical of withanolides and, in particular, 
of withaferin A 4.1.169 
Scheme 4.9. Ikekawa’s synthesis and C-25 functionalization of withanolide δ-lactone. aYield not given for 
the specific reaction.169 
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4.1.5.5. Synthesis of δ-lactone in 20(R)-hydroxyl withanolides 
It was known that the reaction of 22-aldehyde 4.114 with the anion of the substituted ethyl 
crotonate 4.115 was stereoselective, and furnished exclusively the six-membered lactone 
with the unnatural 22(S)-configuration 4.116 (Scheme 4.10).168, 170, 171 
 
Scheme 4.10. Stereoselective aldol condensation towards unsaturated lactone 4.116.170, 171 
However, during the synthesis of withanolide D 4.86, Ikekawa’s group discovered that, 
in the presence of a hydroxyl group in α-position to the aldehyde, this reaction conversely 
resulted in a lactone ring with 22(R)-configuration (Scheme 4.11).167  
 
Scheme 4.11. Ikekawa’s lactone ring formation during studies towards withanolide D 4.86.167 
To synthesise withanolide D 4.86, pregnenolone 3.56 was chosen as starting material and 
firstly elaborated in ring A to give compound 4.117. Construction of side-chain started 
with homologation via a Corey-Seebach umpolung reaction in the presence of dithiane 
4.118, giving a mixture of 20(R)-alcohol 4.119 and its 20(S)-isomer in 6/1 ratio.The 
aldehyde in compound 4.119 was released by treatment with mercuric oxide and boron 
trifluoride etherate and afterwards protected as its methoxymethyl derivative 4.120. 
Finally, reaction of aldehyde 4.120 with the lithium enolate of α,β-dimethyl ethyl 
crotonoate 4.121 afforded lactone 4.78, which was subsequently converted in eight steps 
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into withanolide D 4.86 (see Scheme 4.7). In contrast with literature precedent (Scheme 
4.10), the newly formed C-22 chiral centre was found in the natural (R)-configuration. 
The author assumed this was due to the steric hindrance of the 20β-methoxymethyl group, 
which selectively drove the attack of the enolate from the backside of the molecule and 
gave a 22(R)-lactone according to the Cram’s cyclic model.167 
4.1.5.6. The α-orientated withanolide side-chain: total synthesis of withanolide E 4.137 
Although the side-chain can be either α or β-orientated, the number of withanolides 
bearing an α-orientated side-chain is slightly smaller and this pattern always occurs with 
a 17β-hydroxyl or, more rarely, a 17β-methyl group.148-150 A typical example of 
withanolide featuring the 17α-side-chain and a 17β-hydroxyl group is withanolide E 
4.137, whose synthesis was accomplished by Perez-Medrano and Grieco starting from 
17-keto steroid 4.122 (Schemes 4.12 and 4.13).172 
Before starting the construction of the side-chain, ketone 4.122 was converted into diene 
4.124 in good yield by a Seagusa reaction followed by acetylation with isopropenyl 
acetate 4.123 (Scheme 4.12). A 14α-hydroxyl was afterwards inserted via a hetero Deals-
Alder reaction using benzyl nitrosoformate 4.125 as the dienophile, which in turn was 
generated in situ by oxidation of benzyl N-hydroxycarbamate with tetrabutylammonium 
periodate. The [4+2]-cycloaddition resulted in a mixture of isomers 4.126/4.127 in 1/2 
ratio. However, the unwanted β-isomer 4.126 isomerised by boiling in toluene, thus 
giving cycloadduct 4.127 in 85% overall yield. Hydrogenation of steroid 4.127 and 
subsequent reaction with copper(II) chloride were used to release the C-14 hydroxyl 
group. Deacetylation of C-1 and C-3 under basic conditions led finally to triol 4.128 in 
79% yield.172 
 
Scheme 4.12. C-14 α-hydroxylation in the synthesis of withanolide E 4.137.172 
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In contrast to the precedented results that organometallics react with C-20 keto steroids 
to give 20β-alcohols, addition of nucleophiles to C-17 keto steroids proved unsuccessful 
and led to the 17α-isomers. To achieve the particular stereochemistry, the authors 
converted the C-17 ketone of compound 4.129 (whose ring A was converted into a cyclic 
form as protection) into alkene 4.130, which was in turn di-hydroxylated on treatment 
with osmium tetraoxide in pyridine to obtain 17(S),20(R)-diol 4.131 and its 17(R),20(S)-
diastereisomer in 1.4/1 ratio (Scheme 4.13). The desired α-isomer 4.131 was oxidised to 
20-ketone 4.132 and then selectively alkylated with vinyllithium to the expected 20β-
alcohol 4.133. After protection of the hydroxyl groups as methoxymethyl ethers, 
ozonolysis of the vinyl group in compound 4.134 provided the 22-aldehyde 4.135 which 
was exclusively transformed into the 22(R)-lactone 4.136 on treatment with ethyl α,β-
dimethylcrotonate 4.121. The last steps were focused on the elaboration of rings A and 
B, and, after C-3 acetylation, C-1 Swern oxidation, elimination of the acetate and C-5,C-
6 epoxidation, withanolide E 4.137 was obtained in good yield from pentaol 4.136.172 
 
Scheme 4.13. Synthesis of the 17α-side-chain of withanolide E 4.137.172 
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4.1.5.7. A modern approach to withanolides: total synthesis of withanolide A 4.49 
The synthesis of withanolide A 4.49 carried out by Gademann and co-workers in 2011 
represents a modern approach to the total synthesis of withanolides, which occurred in 
fewer steps and was kept nearly free from protecting groups by using mild conditions and 
a well-designed order for installation of functionalities (Scheme 4.14). 161, 162  
 
Scheme 4.14. Gademann’s Total synthesis of Withanolide A 4.49.161, 162 
After protection of the hydroxyl group of pregnenolone 3.56, construction of the side-
chain was carried out followed classic conditions, i.e. Corey and Seebach umpolung 
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homologation by means of 1,3-dithiane 4.118 to intermediate 4.138 followed by the 
stereoselective vinylogous reaction of aldehyde 4.139 with ethyl 2,3-dimethylbut-2-
enoate 4.121 and lithium hexamethyldisilazide, thus leading to lactone 4.140 in 87% yield 
and good stereoselectivity. 
Attention was afterwards focussed on elaboration of rings A and B. On ring B, allylic 
alcohol 4.141 was prepared by a singlet-oxygen-mediated photooxygenative olefin 
migration in the presence of meso-tetraphenylporphyrin, and afterwards selectively 
epoxidised on treatment with m-cloroperbenzoic acid to compound 4.142.161, 162  
Acidic deprotection of the hydroxyl groups gave epoxy alcohol 4.143, and then 
elaboration of ring A to the common 1-oxo-2,5-diene pattern was successfully achieved 
without the use of protecting groups. The 3-hydroxyl group was first converted into 
unsaturated ketone 4.144 by treatment with tetrapropylammonium perruthenate and  
N-methyl morpholine N-oxide, followed by 2-iodobenzoic acid oxidation. After a  
Triton B-catalysed 1,2-epoxidation using hydrogen peroxide, epoxide 4.145 was 
subjected to a Wharton carbonyl transposition in the presence of hydrazine hydrochloride 
and triethylamine. Final oxidation of the resulting alcohol yielded withanolide A 4.49 in 
good overall yield.161, 162 
4.2. PROJECT AIM: STUDIES TOWARDS AN UNNATURAL WITHANOLIDE 
Withanolide F 2.2 is natural steroid characterised by the 1-oxo-2,5-diene system, which 
is present in withanolides with cytotoxic acvitity and/or inhibitors of the the Hh/Gli 
signalling pathway. Withanolide F 2.2 also contains the less common α-orientated 
lactonic side-chain, along with the 17β-, the 20β- and the 14α-hydroxyl groups (Figure 
4.10). 
 
Figure 4.10. Structural features of withanolide F 2.2. 
With the aim of assessing the SAR of this class of compound towards the Hh/Gli 
signalling pathway, we wanted to first evaluate the influence of the 14-hydroxyl group. 
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A 14β-hydroxyl is a common feature of Hh/Gli inhibitors physalin F 1.13, physalin 1.14 
and cardiac glycoside 1.19 (Figure 4.11), and it is rare substitution amongst withanolides.  
 
Figure 4.11. Natural Hh/Gli inhibitors. 
Therefore, our first goal was the synthesis of the 14β-hydroxyl withanolide F analogue 
2.5 with the C-13 methyl group and the C-14 hydroxyl group cis to each other, starting 
from cheap commercially available materials. The isolation or the total synthesis of the 
14β-withanolide F 2.5 have no literature precedent. The key steps of the planned route 
are shown in Scheme 4.15. 
 
Scheme 4.15. Retrosynthesis of 14β-hydroxy withanolide F 2.5.  
We believed that the side-chain could be installed from intermediate 4.146 via a 
modification of Medrano’s procedure for the synthesis of withanolide E 4.137172 by 
means of two consecutive Corey-Seebach umpolung reactions173, 174 followed by a 
vinylogous aldol reaction with the lithium enolate of α,β-dimethylcrotonate. The aromatic 
ring A and ring B could be converted into the 1-oxo-2,5-diene pattern by first Birch 
reduction175 followed by oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone,176 
thus setting the basis for further elaboration under Ikekawa’s conditions.167 
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Steroid 4.146 was envisioned to come from an intramolecular Friedel-Crafts alkylation 
of the aromatic ring A with the proximal keto group, followed by reduction of the resulting 
benzylic alcohol, or the styrene double bond in case of dehydration. 
The intramolecular asymmetric cyclisation of triketone 4.148 to diketoalcohol 4.147 is 
based on the Hajos-Parrish procedure.177, 178 Triketone 4.148 has been prepared via a 
Mannich-Robinson extension of cyclopentanedione 4.149 with vinyl ketone 4.150 
according to the procedure developed by Wang et al.179 and, previously, by Smith et al.180 
Bromide 4.151, ethyl acetoacetate 4.152 and cyclopentanedione 4.149 have been chosen 
as readily available materials for our planned synthesis. 
Except for the reactions described in Scheme 4.56, all the reactions described in this 
Chapter were run at AnalytiCon Discovery GmbH (Potsdam, Germany).  
4.3. RESULTS AND DISCUSSION 
4.3.1. Ring A: synthesis of vinyl ketone 4.150 
The first key intermediate vinyl ketone 4.150 is known in the literature as a useful 
intermediate for the synthesis of estrone and related steroids.179-181 The first synthesis of 
vinyl ketone 4.150 was achieved by Hughes and co-workers in the 1960s (Scheme 
4.16).180, 182  
 
Scheme 4.16. Early steps of Hughes and Smith’s synthesis of steroids.180, 182  
The synthesis began with treatment of bromide 4.153 with sodium acetylide in liquid 
ammonia to give alkyne 4.154, which was in turn elongated via a Mannich reaction to 
diethylamine 4.155 in good yield. To insert the keto group, the acetylenic bond was 
hydrated using mercuric sulfate in sulfuric acid and water, followed by purification by 
distillation. Under these conditions, ketoamine 4.156 underwent partial elimination, and 
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it was isolated as a mixture along with vinyl ketone 4.150 (in a ratio depending on the 
degree of fractionation). The mixture of compounds 4.156 and 4.150 was not separated, 
but was used directly in the following condensation.180 
Years later, Wang et al. described a different strategy to the synthsis of vinyl ketone 4.150 
(Scheme 4.17). The procedure started with bromide 4.151 which reacted in the presence 
of the dianion of ethyl acetoaceate 4.152 to give, via a selective γ-alkylation, ketoester 
4.157. After protection of the keto group, ester 4.158 was reduced to alcohol 4.159, and 
afterwards exposed to acidic conditions to promote dehydration and deprotection of the 
ketone. Thus, vinyl ketone 4.150 was easily obtained in 4 steps and 62% overall yield.179 
 
Scheme 4.17. Wang’s synthesis of vinyl ketone 4.150.179 
The route of Wang et al.179 seemed a straightforward way to prepare vinyl ketone 4.150. 
Nevertheless, we were obliged to revise this strategy in order to achieve a satisfactory 
yield and a better reproducibility (Scheme 4.18). 
 
Scheme 4.18. Synthesis of vinyl ketone 4.150. 
4.3.1.1. Step 1. γ-Alkylation of β-ketoester 4.152 with 3-methoxyphenetyl bromide 4.151 
The starting step of the planned synthesis was the γ-alkylation of the dianion of ethyl 
acetoacetate 4.152 by means of phenethyl bromide 4.151 (Table 4.1). Early efforts were 
carried out following the procedure of Wang et al.,179 i.e. first formation of the dianion 
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with sodium hydride and n-butyllithium followed by addition of bromide 4.151 (entries 
1-4). The first formation of monoanion was required because n-butyllithium is known to 
add also to the ester group of β-ketoesters, therefore protection of the carbonyl group from 
further nucleophilc attack was recommended.183 
 
Entry Conditions Yield (4.157) 
1 i) 4.152 (1.1 eq), NaH (1.3 eq), 0 °C, 5 min  
ii) n-BuLi (1.8 eq), -0 °C, 5 min 
iii) 4.151 (300 mg), 0 °C to rt, 30 min 
49%  
2 i) 4.152 (2.4 eq), NaH (2.8 eq), 0 °C, 10 min  
ii) n-BuLi (2.4 eq), -0 °C, 15 min 
iii) 4.151 (400 mg), 0 °C to rt, 30 min 
90% 
3 i) 4.152 (1.5 eq), NaH (1.6 eq), 0 °C, 10 min 
ii) n-BuLi (1.6 eq), -0 °C, 30 min 
iii) 4.151 (2.5 g), 0 °C to rt, 2h 
77% 
4 i) 4.152 (1.5 eq), NaH (1.6 eq), 0 °C, 15 min 
ii) n-BuLi (1.6 eq), -0 °C, 15 min 
iii) 4.151 (2.5 mg), 0 °C to rt, 30 min 
48% 
5 i) 4.152 (1.5 eq), LDA (3.2 eq), 0 °C to rt, 1 h 
ii) 4.151 (960 mg), 0 °C to rt, overnight 
60% 
 
Table 4.1. Synthesis of ketoester 4.157. Styrene 4.162 was detected by NMR spectroscopy as the side-
product in variable yield depending on the reaction conditions, but no efforts were made for its isolation. 
However, the reaction did not give the expected results and ketoester 4.157 was obtained 
in lower yield than the published (entry 1). An excess of dianion compared to the 
alkylating agent gave the best yield (entry 2), altough this outcome could not be 
reproduced. Different equivalents of base, temperatures, reaction times and quenching 
conditions were therefore screened (entries 3 and 4), but the yield remained low. Good 
reproducible results were obtained when two equivalents of the non-nucleophilic lithium 
diisopropylamide184 were used in the deprotonation step, thus leading to ketoester 4.157 
in 60% yield (entry 5). Unfortunately, all attempts to improve the yield by increasing 
reaction times and temperatures led mainly to the formation of a compound which was 
likely to be methoxystyrene 4.162, along with other by-products which were not fully 
characterised, whilst the use of lower temperatures and shorter reaction times did not 
allow the alkylation to take place.  
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4.3.1.2. Step 2. Protection of ketone 4.157 as its acetal 4.158 
The protection of ketone 4.157 as its acetal was required (Table 4.2). We again followed 
the procedure of Wang et al.,179 and, on treatment with an excess of ethylene glycol and 
catalytic amounts of p-toluenesulfonic acid, acetal 4.158 was obtained in 75% yield, 
against the 90% yield published (entry 1)  
  
Entry Conditions Yield 
1 (CH2OH)2 (5 eq), PTSA (0.01 eq), benzene, 90 °C,
a 18 h 4.158 75%  
2 (CH2OH)2 (5 eq), PTSA (0.01 eq), benzene, 95 °C,
a 3 d 4.163 48%b 
 
Table 4.2. Protection of ketone 4.158 as its acetal 4.159. aOil bath temperature. bEster 4.158 was not 
observed.  
Efforts aimed to improve the yield were carried out by using more than 0.01 equivalents 
of p-toluenesulfonic acid, 3 Å molecular sieves as dehydrating agent and/or the less toxic 
toluene as solvent. However, these conditions led only to more by-products, the major 
one of which was identified as the glycolic ester 4.163 (entry 2) arising from an acid-
catalysed transesterification of ethyl ester 4.157 with ethylene glycol. Compound 4.163 
is novel and it was fully characterised.  
4.3.1.3. Step 3. Synthesis of alcohol 4.159 
The reduction of ester 4.158 to the alcohol 4.159 is described by Wang et al. to occur in 
95% yield using stoichiometric lithium aluminium hydride in refluxing 
tetrahydrofuran.179 We prefered to use milder reaction conditions carrying out the 
reduction at lower temperature, which led to alcohol 4.159 in 88% yield (Scheme 4.19). 
Ketol 4.160 was the only by-product of the reaction. Therefore, the crude 4.159 could be 
used in the next step without any purification. 
 
Scheme 4.19. Reduction of ester 4.158. 
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In order to improve the overall yield, glycolic ester 4.163 was converted into alcohol 
4.159 on exposure to the same reaction conditions applied to ester 4.158 (Scheme 4.20). 
Thus, after protection of the ketone 4.163 as the acetal, ester 4.164 was reduced to alcohol 
4.159 on treatment with lithium aluminium hydride in satisfactory yield.  
 
Scheme 4.20. Conversion of glycolic ester 4.163 into alcohol 4.159. 
4.3.1.4. Step 4. Deprotection of acetal 4.159 
Wang’s group also reported the direct conversion of alcohol 4.159 into vinyl ketone 4.150 
on treatment with an excess of 12 M aqueous hydrochloric acid.179 Indeed, this reaction 
allowed the removal of the acetal (Scheme 4.21). However, at the same time, the hydroxyl 
group was substituted for a chlorine atom and compound 4.165 was exclusively obtained.  
 
Scheme 4.21. Synthesis of chloro derivative 4.165. 
Nevertheless, when the concentration of hydrochloric acid was lowered to 1 M, the ketone 
4.159 was exclusively deprotected, and ketoalcohol 4.160 was obtained in nearly 
quantitative yield (Scheme 4.22), although without elimination to alkene 4.150. 
 
Scheme 4.22. Synthesis of keto alcohol 4.160. 
Chloride 4.165 is known in the literature185 but no analytical data were published. Ketol 
4.160 is novel. Both compounds were fully characterised.  
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4.3.1.5. Step 5. Preparation of acetate 4.161 
With alcohol 4.160 in hand, the preparation of olefin 4.150 by first conversion of the 
primary alcohol into acetate 4.161, followed by a base-catalysed elimination was 
investigated. Indeed, novel acetate 4.161 was obtained in 61% on treatment with acetic 
anhydride and triethylamine (Scheme 4.23). 
 
Scheme 4.23. Synthesis of acetate 4.161. 
We noticed that compound 4.150 was a by-product of the reaction, and so the crude 
product was used in the next step without further purification. All attempts to prepare 
vinyl ketone in one step from alcohol 4.160 failed when using a different base, higher 
temperatures or longer reaction times.  
4.3.1.6. Step 6. Synthesis of vinyl ketone 4.150 
The last step to the key intermediate 4.150 was the elimination of the acetate promoted 
by base, which procedeed rapidly and in nearly quantitative yield by stirring the crude 
acetate 4.161 in the presence of of 1,8-diazabicyclo[5.4.0]undec-7-ene (Scheme 4.24).  
 
Scheme 4.24. Synthesis of vinyl ketone 4.150 from acetate 4.161. 
Under the same reaction conditions, also chloride 4.165 could be converted into vinyl 
ketone 4.150 (Scheme 4.25).  
 
Scheme 4.25. Synthesis of vinyl ketone 4.150 from chloride 4.165. 
Once vinyl ketone 4.150 was in hand, its reaction with cyclopentanedione 4.149 was 
investigated.  
Chapter 4. Studies towards novel withanolide analogues 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 85 - 
4.3.2. Rings C and D: synthesis of triketone 4.148 and its cyclisation to indanedione 
4.147 
4.3.2.1. Step 7. Synthesis of triketone 4.148 
In the 1970s, Hajos and Parrish from Hoffman-La Roche synthesised triketone 4.167 via 
an acid-catalysed Michael addition of cyclopentanedione 4.149 to methyl vinyl ketone 
4.166 (Scheme 4.26). The following intramolecular asymmetric cyclisation carried out in 
the presence of catalytic amounts of (S)-proline 4.168 as chiral inductor led exclusively 
to cis-diketoalcohol 4.169, which in turn was exposed to acidic conditions and dehydrated 
to indenedione 4.170.177, 178, 186 
 
Scheme 4.26. Hajos and Parrish’s asymmetric synthesis of indenedione 4.170.177, 178 
Concurrent studies by Eder, Sauer and Wiechert from Schering showed that the chiral 
homologue 4.172 could be obtained directly from triketone 4.171 by exposure to catalytic 
amounts of (S)-proline 4.168 containing a solution of organic or aqueous inorganic acids 
(Scheme 4.27).186-188 
 
Scheme 4.27. Eder, Sauer and Wiechert’s asymmetric synthesis of diketone 4.174.187 
The chiral bicycles 4.170 and 4.172 can be seen as the steroidal rings C and D, and A and 
B, respectively, and therefore have been extensively used in the preparation of diverse 
steroids.186  
In light of these results, the synthesis of triketone 4.148 was first carried out under  
the Hajos and Parrish conditions178 via an acid catalysed Michael addition of  
2-methyl-1,3-cyclopentandione 4.149 to vinyl ketone 4.150. Compound 4.148 was 
isolated, although in a low yield (entry 1, Table 4.3). 
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Entry Conditions Yield 
1 4.149 (1.7 eq), glacial AcOH/H2O = 2/98, 70 °C, 18 h 25%  
2 4.149 (1.2 eq), glacial AcOH/H2O = 6/1, 80 °C, 18 h 43%
 
3 4.149 (3 eq), Et3N (3.2 eq), THF, 40 °C, 1 d 90% 
 
Table 4.3. Acid- and base-catalysed Michael additions for the synthesis of triketone 4.148. 
In the presence of an excess of acetic acid compared to water (6/1 ratio), the yield of 
triketone 4.148 was increased, probably with the increasing degree of solubility of the  
1,3-cyclopentanedione 4.149 in the solvent mixture (entry 2). 
It was described that the Hajos-Parrish ketone 4.170 could be also obtained by subjecting 
vinyl ketone 4.166 and cyclopentanedione 4.149 to basic conditions.189 Moreover, Wang 
et al.179 and Kurosawa et al.190 reported that the prochiral triketone 4.148 could be 
synthesised in 75% and 80% yield, respectively, by stirring 4.150 and 4.149 in the 
presence of triethylamine for five days. The base-catalysed Michael addition was 
therefore addressed (entry 3). Pleasingly, and after a screening of reaction conditions, 
adduct 4.148 was obtained in 90% yield and in a considerably shorter reaction time 
compared to the literature procedures.179, 190 
4.3.2.2. Step 8. Intramolecular cyclisation of triketone 4.145  
During their studies, Clemente and Houk188, 191 reported that the conversion of prochiral 
triketone 4.148 into (S)-enedione 4.174 ([α]D at rt = +181°)187 occurred in 60% yield and 
92% enantiomeric excess (under the conditions of Eder, Sauer and Wiechert) using  
(S)-phenylalanine 4.173 (Scheme 4.28, a), and in 76% yield and 45% enantiomeric 
excess using (S)-proline 4.168 (under the neutral conditions of Hajos and Parrish) 
(Scheme 4.28, b).  
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Scheme 4.28. Asymmetric ring-closure of triketone 4.148 to (S)-enedione 4.174 as described by Clemente 
and Houk.188 
However, Hajos and Parrish reported in a patent that the compound isolated by heating 
triketone 4.148 in dimethylformamide in the presence of (S)-proline 4.168 was the  
“(+)-3aα-hydroxy-4β-(2-m-methoxyphenethyl)-7-aα-methyl-perhydroindan-1,5-dione” 
4.175 (oil, [α]D at 25 °C = +30°) (Scheme 4.29), 191 which in turn in the presence of p-
toluenesulfonic acid cyclised to compound (R)-4.176 (oil, [α]D at 25 °C = +45.3°)191 
described as “den optischen Antipoden des bekannten (-)-3-methoxyestra-1,3,5(10),8,14-
pentaen-17-one”, i.e. the optical antipode of the known dienone (S)-4.176 ([α]D at 23 °C 
= -105.3°) (Figure 4.12).192 
 
Scheme 4.29. Patented Hajos and Parrish’s intramolecular asymmetric cyclo-dehydration of triketone 
4.148.191 
 
Figure 4.12. Structure of dienone (S)-4.176. 
In light of these unclear results, and since no additional literature precedent was found for 
the amino acid-catalysed asymmetric intramolecular cyclisation of triketone 4.148, the 
synthesis of the desired 13β-methyl-14β-hydroxy steroid 4.147 was attempted by treating 
prochiral triketone 4.148 at room temperature with catalytic amounts of (S)-proline 4.168 
in dimethylformamide (entry 1, Table 4.4).178, 191 However, in spite of the high yields 
reported in the literature, no traces of product 4.147 were seen, but only unreacted starting 
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material was recovered even when different catalysts, solvents or temperature were 
screened (entries 2 and 3). 
 
Entry Conditions Yield 
1 (S)-proline 4.168 (0.03 eq), DMF, rt, 7 d Sm 4.148 
2 (S)-proline 4.168 (0.03 eq), MeCN, rt to 70 °C, 8 d Sm 4.148 
3 (S)-phenylalanine 4.173 (0.5 eq), MeCN, rt, 7 d Sm 4.148 
4 Et3N (1.2 eq), THF, rt to 70 °C, 5 d 7% 4.147 and 4.177  
(3/1 ratio)a 
5 DBU (0.5 eq), THF, rt, 5 d 37% 4.147 and 4.177  
(3/1 ratio)a 
6 DBU (0.3 eq), THF, 40 °C, 6 d 74% 4.147 and 4.177 
(3/1 ratio)a 
 
Table 4.4. The formation of ring C. Reactions were carried out on ca. 50 mg of triketone 4.148 as a 0.1-0.2 
M solution in THF, except for entry 6, where ca. 2.5 g of starting material were used. aRatio of keto alcohols 
4.147 and 4.177 are approximately calculated by proton NMR spectroscopy. 
In their studies towards the synthesis of estrone derivatives, Korosawa et al.190 prepared 
the 11α,13β-dimethyl-carbinol 4.179 by stirring vinyl ketone 4.178 and 
cyclopentanedione 4.149 with triethylamine for seven days (Scheme 4.30). Triketone 
4.180 was obtained as a side product. The trans-configuration of the C-11 and C-13 
methyl groups in 4.179 was preferred to prevent 1,3-diaxial interactions. However, no 
consideration about the stereochemistry of the C-14 hydroxyl group was reported.  
 
Scheme 4.30. Kurosawa’s synthesis of 11α,13β-dimethyl-carbinol 4.179.190 
The intramolecular aldol reaction of 4.148 was therefore attempted in the presence of 
triethylamine (entry 4, Table 4.3), and, as an alternative, 1,8-diazabicyclo[5.4.0]undec-
7-ene (entries 5 and 6). Pleasingly, the formation of racemic cis-ketoalcohol 4.147 was 
seen in both cases, although it was isolated as an inseparable mixture with the  
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trans-isomer 4.177 in about 3/1 ratio as detected by NMR spectroscopy. Efforts to achieve 
stereoselectivity were also carried out by adding (S)-proline 4.168 in a screening of bases, 
solvents and temperature. However, no stereochemical control was achieved, thus, the 
diastereomeric mixture of racemates 4.147 and 4.177 was carried through the next steps 
of the synthesis, leaving their potential chiral separation to a later stage. 
Ketoacohols 4.147193 and 4.177194 are known in the literature, although little analytical 
data were provided. With the purpose of full characterisation, analytical amounts of the 
3/1 mixture of carbinols 4.147 and 4.177, were subjected to HPLC. The less polar peak 
corresponded to the cis-diastereoisomer 4.147 which was isolated as a white powder, 
followed by the trans-diasteroisomer 4.177 as an amorphous solid. In the NMR spectra, 
relevant signals were those of the C-18 methyl group, which was seen in the 1H-NMR 
spectrum at 1.28 ppm in the cis-carbinol 4.147 and at 1.08 ppm in the trans-isomer 4.177, 
in accordance with the literature values.193, 194 In the 13C-NMR spectra, the methyl group 
was shown at 12.7 ppm and at 18.1 ppm in compound 4.147 and 4.177, respectively. 
Complete chemical shift assignment was supported by COSY, HMBC and HSQC 
experiments. 
During attempts to obtain the stereoselective intramolecular aldol cyclisation, it was 
noticed that in the presence of stoichiometric base and proline triketone 4.148 was 
consumed after 18 h of stirring. However, carbinols 4.147 and 4.177 were not isolated 
(longer times being needed to complete the reaction). The major product obtained was 
identified as bicycle 4.182 (Scheme 4.31). 
 
Scheme 4.31. Isolation of the kinetic product 4.182. aIn spite of the presence of (S)-proline 4.168 in the 
reaction mixture, compound 4.182 was assumend to be racemic based on the results shown in Table 4.4. 
Bicyclic system 4.182 is novel, and its structure was elucidated by 1H- and 2D-NMR 
spectroscopy. In the carbon NMR spectrum typical signals were found at 212.0 and 209.1 
ppm for the two carbonyl groups, and at 83.8 ppm for the C-8 alcohol. In the 1H-NMR 
spectrum the methyl group was seen at 1.06 ppm, while the C-15 axial and equatorial 
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protons were found at 2.36 and 2.50 ppm, respectively, as assigned on the basis of the 
Hajos and Parrish investigation described below.195  
In fact, Hajos and Parrish described the formation of the related bridged ketol 4.184 upon 
treatment of triketone 4.167 with piperidinium acetate 4.183 (Scheme 4.32).195 Treatment 
of bicycle 4.184 with piperidine 4.185 followed by acetic acid gave the epimerised C-4 
isomer 4.186. The authors assigned the stereochemistry at C-4 on the basis of the 
chemical shift of the axial H-6, which was found to be particularly shielded in compound 
4.186 (2.63 ppm) compared to isomer 4.184 (3.1 ppm) due to the syn-axial effect of the 
electronegative C-4 hydroxyl group. Comparison of these spectra with those of bicyclic 
compound 4.182 supported the assignment of its stereochemistry and connectivity. 
 
Scheme 4.32. Hajos and Parrish’s synthesis of bridged ketols 4.184and 4.186.195 
The bicyclic system 4.182 was imagined as the kinetic product of the reaction, which was 
formed first by nucleophilic attack of the enolate of the five-membered ring to the 
aliphatic ketone in intermediate 4.181 under basic conditions (Scheme 4.31). Indeed, 
when compound 4.182 was stirred with base for a longer time, a retro-aldol reaction on 
anion 4.187 to enolates 4.181 and 4.188 could occur, and led, after cyclisation of the 
latter, to the more stable keto alcohols 4.147 and 4.177 which were isolated in 40% yield 
and about 4/1 ratio (Scheme 4.33). 
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Scheme 4.33. Conversion of bridged ketol 4.182 into alcohols 4.147 and 4.177. 
4.3.3. Rings B: intramolecular Friedel-Crafts alkylation 
The next step of the planned synthesis was the intramolecular Friedel-Crafts alkylation to 
give the tetracyclic steroidal framework (scheme 4.34). All the expected products 4.189, 
4.190 and 4.191 would be suitable intermediates, considering that the removal of the 
newly formed hydroxyl group in compounds 4.189 and 4.190 or the reduction of the 
double bond in compound 4.191 should be feasible.  
 
Scheme 4.34. Intended sequence to the steroidal ABCD-ring framework. 
4.3.3.1. Intramolecular Friedel-Craft cyclisation with the unprotected 14-hydroxyl group 
The cyclisation of carbinols 4.147 and 4.177 bearing the free 14-hydroxyl group was 
addressed first. Daniewski et al.193 described that cis-carbinol 4.147 could be converted 
into dienone 4.176 via dihydroxy-ketone 4.189 on treatment with p-toluenesulfonic acid 
and acetic anhydride (Scheme 4.35). However, the supposed intermediate alcohol 4.189 
was not isolated, due to its rapid dehydration to dienone 4.176  
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Scheme 4.35: Daniewski and Koćor’s intramolecular cyclisation of diketoalcohol 4.147.193 
On the other hand, when steroid 4.192 with a substituent at C-11 was subjected to the 
same cyclisation, the triacetate 4.193 could be isolated in good yield  
(Scheme 4.36).193, 196  
 
Scheme 4.36: Daniewski’s intramolecular cyclisation of 11-acetyl-steroid 4.192.193, 196 
Daniewski supposed that the intramolecular cycloalkylation of carbinol 4.147 took place 
preferentially on the top face of molecule, thus leading to compound 4.194 with a trans-
junction between rings B and C, which is common amongst steroids (Scheme 4.37).193 
Under acidic conditions, a trans-diaxial elimination to form the C-8,C-9 alkene 4.195 
could occur. Finally, the newly formed unsaturation might take part in the acidic 
displacement of the C-14 acetate, leading to dienone 4.176 via cation 4.196. 
 
Scheme 4.37. 3D-model diagrams and possible explanation of Daniewski’s intramolecular cyclisation of 
steroid 4.147.193 
On the other hand, the steric hindrance due to the 11β-acetyl group in compound 4.192 
could drive the nucleophilic attack of the aromatic ring to occur from the bottom face of 
the molecule, thus forming acetate 4.193 with a cis-junction between rings B and C, which 
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in turn might prevent the subsequent elimination (Scheme 4.38). In the absence of the 
C,8-C,9 unsaturation, dienone 4.176 might not has been formed directly.193  
Scheme 4.38. 3D-model diagrams and possible explanation of Daniewski’s intramolecular cyclisation in 
the presence of a C-11 substitution.193 
cis-Alcohol 4.147 has no substitutent at C-11. However, it might be imagined that, by 
carrying out the cylisation under the Friedel-Crafts conditions, the Lewis acid might form 
a complex with the carbonyl group on the less hindered top face of the molecule (Scheme 
4.39). As a consequence, nucleophilic attack of the aromatic ring might occur from below, 
and lead to the cis-junction between rings B and C and to the equatorial 9-hydroxyl group, 
such as in 4.190, thus preventing elimination. However, to the best of our knowledge no 
precedent literature for this reaction was found. 
 
Scheme 4.39. 3D-model diagrams of the intended intramolecular Friedel-Crafts cycloalkylation. 
Aluminium trichloride, boron trifluoride and iron trichloride were tried first (Table 4.5). 
Treatment of a 3/1 mixture of carbinols 4.147 and 4.177 with a slight excess of aluminium 
trichloride at 0 °C led solely to dehydration and the known open enone 4.174 was isolated 
in 37% yield (entry 1). In the presence of boron trifluoride (entry 2) and iron trichloride 
(entry 3) cyclisation occurred along with elimination, and led to the dienone 4.176 as the 
major product.  
It is described that in a Friedel-Craft acylation the proton released during the  
re-aromatisation step might promote the elimination of water, an event that could be 
prevented by adding aluminium oxide as proton scavenger.197 The Lewis acids tin 
tetrachloride (entry 4) and titanium tetrachloride (entry 5) were therefore tried in the 
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presence of an excess of aluminium oxide. In both cases mainly dienone 4.176 and some 
decomposition were detected.  
 
Entry Conditions Yield 
1 AlCl3 (1.1 eq), 0 °C to rt, 10 h 4.174 37% 
2 BF3
.OEt2 (1 eq), rt, 2 h 4.176 90%
 
3 FeCl3 (1 eq), rt, 30 min 4.176
a 
4 1 M SnCl4 (1.2 eq), Al2O3 (5 eq), -10 °C to rt, 2 h 4.176 50%
 
5 1 M TiCl4 (1.1 eq), Al2O3 (5 eq), -15 °C to rt, 10 h 4.176
a 
6 1 M TiCl4 (1.0 eq), -40 °C, 30 min 4.176
a 
7 1 M (i-PrO)3TiCl (1.0 eq), 0 °C to rt, 18 h 4.174 50% 
8 1 M (i-PrO)4Ti (1.0 eq), rt, 18 h Sm 4.147 and 4.177 
9 Sc(OTf)3 (0.2 eq), -40 °C to rt, 18 h Sm 4.147 and 4.177 
10 Sc(OTf)3 (1 eq), -40 °C to 40 °C, 3 d 4.174
a 
11 PTSA (0.2 eq), 0 °C to rt, 1 d Sm 4.147 and 4.177, 
4.174 and 4.176a  
12 MeOH (solvent), rt to 60 °C, 1 d Sm 4.147 and 4.177 
13 MeOH (solvent), 140 °C, microwave, 2 h Sm 4.147 and 4.177,  
4.176, 4.148a 
 
Table 4.5: Attempted intramolecular cycloalkylation. Reactions performed in CH2Cl2, on ca. 10-50 mg of 
compounds 4.147 and 4.177 in approximately 3/1 ratio. aAs detected by proton NMR spectroscopy and  
LC-MS spectrometry of the unpurified reaction mixture. 
Next, titanium chloride and titanium isopropoxide were used (entries 6-8). Again, the 
cyclisation proved unsuccessful, and gave dienones 4.176 and 4.174, and unreacted 
starting material, in accordance to the strength of the acid. Similar results were obtained 
in the presence of scandium trifluoromethanesulfonate.198 In fact, under mild conditions 
the starting material did not react (entry 9), whereas by heating the reaction mixture to 
40 °C, diketone 4.174 was the major product formed (entry 10). 
The effects of a Brønsted acid and of a protic solvent were also evaluated, the latter chosen 
assuming that a hydrogen bond between the solvent and the ketone could promote the 
cyclisation. However, when catalytic amounts of p-toluenesulfonic acid were used 
dienone 4.176 was formed quickly at room temperature (entry 11). On the other hand, 
the starting material was found unreacted when it was heated in methanol (entry 12), 
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whilst it was converted either into dienone 4.176 and into the open triketone 4.148 under 
microwave irradiation at high temperature (entry 13). 
Two conclusions can be drawn. Under mild conditions, the cyclisation of 4.147 to form 
the steroidal framework is unlikely to occur. On the other hand, under harsh conditions 
the conjugated enedione 4.174 forms first. Afterwards, cyclisation can occur, but the 
unsaturation appears to promote the ready dehydration of the newly formed alcohol 4.197 
thus giving dienone 4.176 (Scheme 4.40). These results are contrary to Daniewski’s 
suggestions, which proposed the cyclisation to occur first, followed by dehydration (see 
Section 4.3.3.6. and Table 4.8 for further evidence of the initial formation of diketone 
4.174). 
 
Scheme 4.40. Outcome of the intramolecular Friedel-Craft cycloalkylation. 
Since the cyclisation with the retention of the free 14-hydroxyl group seemed difficult to 
achieve, its protection was considered to avoid the ready dehydration. In addition, 
chemical modification of the tertiary alocohol should provide a viable method to separate 
the C-13,C-14-cis- and trans- diastereoisomers.  
4.3.3.2. Towards the 14-trimethylsilyl ether  
The screening of the potential protecting groups started with the trimethylsilyl ether, a 
group installed by Sevillano et al. on the β-hydroxyl group of the Hajos-Parrish ketone in 
79% yield using trimethylsilyl triflate and triethylamine.199 Following these conditions, 
the 3/1 mixture of cis- and trans-carbinols 4.147 and 4.177 was treated with trimethylsilyl 
triflate (Scheme 4.41). A unique compound was isolated in 24% yield, which was 
identified as the 14- trimethylsilyl ether 4.198.  
 
Scheme 4.41. Trimethylsilyl-protection of the 14-hydroxyl group. 
Chapter 4. Studies towards novel withanolide analogues 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 96 - 
The order of addition of the reagents was crucial to the outcome of the reaction. The 
starting material decomposed rapidly when trimethylsilyl triflate was added before 
triethylamine. When trimethylsilyl chloride was used instead of the triflate only unreacted 
starting material was recovered. 
The relative stereochemistry of the C-13 and C-14 groups in the novel trimethylsilyl 
derivative 4.198 was firstly tentatively assigned as trans (such as in compound 4.199, 
Figure 4.13) by NMR spectroscopy on comparison with the chemical shifts of the angular 
methyl group at 1.05 ppm (in the 1H-NMR spectrum) and at 18.3 ppm (in the 13C-NMR 
spectrum), with those of the same group in the trans-carbinol 4.177, which were shown 
at 1.08 and 18.3 ppm, respectively, and dissimilar to the signals at 1.28 ppm and at 12.9 
ppm, respectively, of the cis-carbinol 4.147.  
 
Figure 4.13. Potential configurations of trimethylsilyl ethers. 
Nevertheless, nOe experiments showed a correlation between the C-13 methyl group and 
the C-14 silyl ether (such as in compounds 4.200 and 4.201, Figure 4.13) which would 
be improbable if the two groups were trans-related. nOe Correlations were also observed 
between these groups and either the H-8 or H-9 proton, whose signals were overlapping. 
A configuration such as in compound 4.200 was excluded by comparison with the 
analytical data of an analogous triethylsilyl ether, whose relative stereochemistry was 
unambiguously assigned as described below (see Section 4.3.3.6 and Table 4.8 for further 
details). A highly hindered structure such as 4.201 could be supported by the nOe 
analysis, although it was likely to be energetically disfavoured by reason of the 1,3-axial 
interactions between the bulky C-9 chain and the C-13 methyl group. NMR spectroscopy 
studies to fully elucidate the relative stereochemistry at the C-9, C-13 and C-14 centres 
were therefore inconclusive. 
To support the stereochemical studies, the release of the 14-hydroxyl group was 
attempted under diverse reaction conditions (Table 4.6) to enable comparison with the 
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carbinols 4.147 and 4.177 whose structures have been assigned unambiguously. 
However, on treatment with acids (entries 1 and 2) or fluoride (entry 3) only 
decomposition or starting material was obtained.  
 
Entry Conditions Outcome 
1 1 M aq HCl, dioxane, rt, 2h Decomposition  
2 THF/AcOH/H2O = 1/1/1 Sm 4.198 
3 TBAF (1.2 eq), CH2Cl2, 0 °C to rt, 1 h Decomposition 
 
Table 4.6. Attempted release of the hydroxyl group. Reactions carried out on 10-50 mg scale. 
Therefore, alternative protecting groups were considered. 
4.3.3.3. Towards the 14-triethylsilyl ether 
The introduction of a 14-triethylsilyl group was addressed next (Table 4.7).  
 
Entry Conditions Yield 
1 TESOTf (2.2 eq), Et3N (2.2 eq), 
CH2Cl2, 0 °C to rt, 30 min 
4.202 20%  
2 TESOTf (2.2 eq), Et3N (2.2 eq), 
CH2Cl2, 0 °C, 30 min 
4.202 7%, 4.203 14% 
3 TESOTf (1.2 eq), Et3N (1.2 eq), 
CH2Cl2, 0 °C, 1 h 
4.202 13%, 4.204 6%, 4.176 36%, 
4.148 11%, sm 4.147 23% 
 
Table 4.7: Protection of the 14β-hydroxyl group as its triethylsilyl ether.  
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Following the protocol used to prepare the trimethylsilyl ether 4.198, a mixture of 
carbinols 4.147 and 4.177 (in about 3/1 ratio) was treated with triethylamine and 
triethylsilyl triflate. The only compound isolated was the triethylslyl ether 4.202, which 
was obtained in 20% yield (entry 1), in accordance to the results seen in the case of the 
trimethylsilyl ether 4.198 described above. Efforts to increase the yield were carried out 
by screening temperatures, reaction times and equivalents of base and triethylsilyl triflate. 
Of particular relevance were the results of the cyclisation attempted at 0 °C. In fact, after 
30 minutes reaction time the formation of the triethylsilyl derivative 4.202 was minimal 
(entry 2), and the major product isolated was compound 4.203 with the substituents at C-
10, i.e. the bulky chain and the triethylsilyl ether, in the axial and equatorial positions, 
respectively. However, when less equivalents of reagents were used and the reaction was 
stirred for a longer time (entry 3), a number of compounds were formed, including the 
silyl ether 4.202, the isomeric bridged compound 4.204, dienone 4.176 and triketone 
4.148, whilst only cis-carbinol 4.147 was recovered. 
The complex mixture of compounds obtained reflects the high reactivity of carbinols 
4.147 and 4.177 (Scheme 4.42). 
Scheme 4.42. Potential reactivity of carbinols 4.147 and 4.177. 
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Indeed, under acidic conditions a retro-aldol ring-opening reaction to triketone 4.148 and 
its tautomers 4.205 and 4.206 could occur. In turn, enol 4.206 might undergo a further 
ring-closure reaction by nucleophilic attack of C-16 to the C-10 ketone followed by 
silylation, thus resulting in the isolation of bicyclic products 4.203 and 4.204. Silylation 
of the C-14 hydroxyl group of carbinols 4.147 and/or 4.177 to silyl ether 4.207 could also 
take place. However, it might be followed by elimination to diketone 4.174 and further 
intramolecular cyclo-alkylation to form dienone 4.176 after dehydration of intermediate 
alcohol 4.197 which was not isolated. Moreover, carbinols 4.147 and/or 4.177 might also 
directly undergo a similar sequence of elimination and cyclisation reactions, thus giving 
dienone 4.176 which was isolated as the major compound. 
The silyl ethers 4.202, 4.203 and 4.204 are novel, and the connectivity of the atoms was 
fully assigned by means of 1D- and 2D-NMR spectroscopy. With regard to the  
14-triethylsilyl ether 4.202, the assignment of relative stereochemistry at C-9, C-13 and 
C-14 was controversial, as it was seen in the case of the trimethylsilyl ether 4.198. The 
chemical shifts of the diagnostic angular methyl group at 1.09 and 18.3 ppm, in the proton 
and carbon NMR, respectively, would suggest a trans-connectivity (as represented in 
compound 4.208, Figure 4.14) by comparison with the signals shown for the trans-
carbinol 4.147.  
 
Figure 4.14. Possible structures of isomeric 14-silyl ethers. 
However, nOe experiments acquired by irradiation of the angular methyl group showed 
a clear correlation with the triethylsilyl group and vice versa, thus suggesting the two 
groups having the same orientation with respect to the molecular plane (such as in isomers 
4.209 and 4.210). Silyl ether 4.209 was unambiguously described later as the product 
obtained from a different reaction (see Section 4.3.3.6 and Table 4.8 for further details), 
so 4.202 could not be identified as stereoisomer 4.209. Moreover, correlations were seen 
between the aromatic protons, the methoxy group and the overlapping H-8 or H-9. Again, 
in light of the nOe experiments, silyl ether 4.202 could be tentatively assigned as the 
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sterically hindered and unfavoured compound 4.210. However, additional experiments to 
confirm this hypothesis would be required.  
With regard to the bridged silyl ethers 4.203 and 4.204, the position of the substituents at 
C-10 was assigned on the basis of the chemical shifts of the C-15 axial and equatorial 
protons, which were seen at 2.94 and 2.45 ppm, respectively, in compound 4.203, and 
overlapped at 2.45 ppm in compound 4.204, in agreement with the literature models 
described by Hajos and Parrish and with the chemical shift values of bridged ketol 4.182 
(see Schemes 4.31 and 4.32).195  
4.3.3.4. Towards the 14-tert-butyldimethylsilyl ether  
The formation of the more stable and bulkier 14β-tert-butyldimethylsilyl ether was also 
attempted in the presence of tert-butyldimethylsilyl triflate (Scheme 4.43), but it resulted 
again in a complex mixture of compounds. Amongst those, bis-silyl ether 4.211 and  
17-silyl enol ether 4.212 were isolated in 6% and 9% yield, respectively, with traces of 
unidentified products, and they were fully characterised by means of 1D- and 2D-NMR 
spectroscopy. The formation of isomeric silyl ethers 4.213 and 4.214 was also detected 
by LC-MS and NMR spectroscopy, but they could not be fully characterised.  
Scheme 4.43. Towards 14-tert-butyldimethylsilyl steroids. aDetected as the major compound of a complex 
mixture of products. 
Treatment of carbinols 4.147 and 4.177 with tert-butyldimethylsilyl chloride in the 
presence of triethylamine or imidazole gave instead solely recovered starting material. 
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4.3.3.5. Towards the 14-acetate 
Considering the difficulties in the formation of 14-silyl ethers, the formation of a  
14-acetate was also addresssed, which is known to be easy cleaved under acidic or basic 
conditions, but is stable enough for the Friedel-Crafts cyclisation.  
The acetylation was attempted first in the presence of acetic anhydride in pyridine, but it 
failed, and it gave just unreacted starting material. However, when acidic conditions were 
used175 a single compound identified as the acetyl derivative 4.215 was obtained in 48% 
yield, along with dienone 4.176 and a mixture of unidentified by-products (Scheme 4.44).  
 
Scheme 4.44. Acetylation of the 14-hydroxyl group. 
Acetate 4.215 is novel and it was fully characterised. In the proton NMR spectrum a 
singlet at 2.01 ppm and an apparent doublet at 3.46 ppm were assigned to the acetyl group 
and the proton at C-8, respectively. The signals of the angular methyl group were found 
at 1.28, and 14.2 ppm in the 1H- and 13C-NMR, respectively. This was in agreement with 
the values of the same group in the cis-carbinol 4.147, which were observed at 1.29 and 
12.9 ppm. The relative β-configuration of C-8, C-13 and C-14 were confirmed by nOe 
experiments, which showed correlations between the aforementioned groups irradiated at 
3.46 ppm, 1.28 ppm and 2.01 ppm, respectively (Figure 4.15). 
 
Figure 4.15. nOe Correlations on acetate 4.215. 
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4.3.3.6. Intramolecular cyclo-alkylation of the 14-triethylsilyl ether 4.202 
Although the stereochemistry of 14-triethylsilyl ether 4.202 was unclear, its 
intramolecular cyclo-alkylation with Lewis acid was attempted (Table 4.8).  
 
Entry Conditions Outcome 
1 (i-PrO)3TiCl (1 eq), CH2Cl2, rt, 10 h Sm 4.202 
2 (i-PrO)3TiCl (1 eq), toluene, rt to 80 °C, 4 h Decomposition 
3 AlCl3 (1 eq), CH2Cl2, 0 °C to rt, 10 h 4.174 (not isolated),  
4.176 46%, 4.209 7% 
4 AlMe3 (1 eq), CH2Cl2, rt to 40 °C, 10 h Sm 4.202 
5 AlMe3 (1 eq), toluene, 40 °C, 18 h Sm 4.202 and decomposition 
 
Table 4.8. Attempted cyclisation of triethylsilyl ether 4.202. 
As described above (see Scheme 4.40), it was noticed that the first step in the formation 
of the tetracyclic steroidal framework is the formation of enedione 4.174, followed by 
cyclisation and dehydration to the dienone 4.176. It might be possible, under acidic 
conditions and in the presence of a protected 14-hydroxyl group, to induce cyclisation 
with no elimination. The medium stength acid chlorotitanium triisopropoxide was tried 
first (entry 1). However, under mild conditions only unreacted starting material was 
recovered, whereas changing the solvent and increasing the temperature up to 80 °C gave 
just decomposition of the starting material (entry 2). 
The cyclisation using stoichiometric amounts of aluminium trichloride was tried next, 
and the outcome of the reaction was carefully monitored by LC-MS. It was seen that the 
formation of diketone 4.174 occurred first, even at low temperature, and it was followed 
by the formation of dienone 4.176 which was the major compound isolated (entry 3). 
Interestingly, a novel compound was isolated and it was clearly identified as the cis-
triethylsilyl derivative 4.209, which could have arisen from a sequence of desilylation-
retro-aldol ring-opening of the starting material 4.202 to enol 4.205, followed by aldol 
ring-closure and further silylation (Scheme 4.45).  
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Scheme 4.45. Potential sequence leading to silyl ether 4.209. 
In a last attempt the milder trimethylaluminium was used (entries 4 and 5, Table 4.8). 
The reactions were again unsuccessful, and therefore this strategy was abandoned. 
Silyl ether 4.209 is novel and it was fully characterised. The relative stereochemistry of 
the proton at C-8, of the methyl group at C-13 and of the silyl ether at C-14 was assigned 
by 1D- and 2D-NMR spectroscopy and confirmed by nOe experiments. The signals of 
the angular C-18 methyl were of particular relevance, and they were found at 1.29 and 
14.3 ppm in the proton and carbon NMR spectra, respectively. These values are in 
accordance with those of the same methyl group in the cis-carbinol 4.147 and in the cis-
acetate 4.215 which were shown at 1.28 and 1.29 ppm in the proton NMR spectrum, 
respectively, and at 12.9 ppm and 16.1 ppm in the carbon NMR spectrum, respectively. 
4.3.3.7. Intramolecular cyclo-alkylation of the 14-acetate 4.215  
Finally, attention was focussed on the cyclisation of acetate 4.215 to give either 
compounds 4.216 or 4.217 (Table 4.9). p-Toluenesulfonic acid was chosen as a Brønsted 
acid (entry 1),193 and aluminium trichloride as a Lewis acid (entry 2). However, both 
attempts failed to produce 4.216 or 4.217 and mainly dienone 4.176 was isolated (in 
agreement with the results of Daniewski, see Scheme 4.37),193 along with some 
decomposition of the starting material. 
 
Entry Conditions Outcome 
1 PTSA (1 eq), Ac2O, rt, 1 h 4.176 7% and decomposition 
2 AlCl3 (1 eq), CH2Cl2, 0 °C rt, 5 min 4.176 75% 
 
Table 4.9. Intended Friedel-Crafts cycloalkylation of acetate 4.215. 
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Hence, the strategy first planned towards the synthesis of the target 14β-withanolide F 
2.5 was reconsidered. 
4.3.4. Towards the reintroduction of the 14β-hydroxyl group on dienone 4.176 
Given the apparent challenge of performing the cyclisation while retaining the  
14-hydroxyl group and taking advantage of the easy formation of the dienone 4.176, the 
reintroduction of the 14β-alcohol to give compound 4.146 after the formation of the 
steroidal framework was addressed next (Scheme 4.46). 
 
Scheme 4.46. Towards the reintroduction of the 14β-hydroxyl group. 
4.3.4.1. Synthesis of dienone 4.176 
Attention was focused first on increasing the yield of dienone 4.176 and shortening the 
full procedure by one step. During the attempted cycloalkylation of diketocarbinols 4.147 
and 4.177, dienone 4.176 was obtained as a by-product in yields up to 90% depending on 
the acid used. However, Wang et al. reported a synthesis of the same dienone occurring 
in 65% yield, by heating triketone 4.148 at reflux in benzene containing p-toluenesulfonic 
acid.179 Indeed, under these conditions dienone 4.176 was isolated in 62% yield (Scheme 
4.47). The two other products formed were the unsaturated ketones 4.218 and 4.174, in 
6% and 11% yield, respectively. 
 
Scheme 4.47. Towards the cyclisation of triketone 4.148 to dienone 4.176. 
Both the enantionerically pure192 and enantiomerically enriched (81% ee)200 forms of 
compound 4.218 are known in the literature. The spectroscopic data of racemic 4.218 
(proton and carbon NMR and IR spectra) were consistent with the published data.192, 200  
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Several more conditions were screened to improve the yield of steroid 4.176, including 
the isomerization of enone 4.218 under basic conditions, but they proved to be 
unsuccessful. 
4.3.4.2. Attempted cycloaddition to a 14-hydroxyl steroid 
Kirsch et al. developed a method to introduce a steroidal 14β-hydroxyl group by means 
of a [4+2]-cycloaddition reaction between diene 4.219 and benzyl nitrosoformate, which 
was generated in situ by oxidation of benzyl N-hydroxycarbamate 4.220 with 
tetrabutylammonium iodide (Scheme 4.48). The mixture of isomeric adducts 4.221 and 
4.222 was completely converted into the 14β-hydroxyl derivative 4.223 upon reflux in 
methanol. Palladium-catalysed hydrogenation led finally to carbinol 4.224 in 87% yield 
based on 4.219.201 
 
Scheme 4.48. Kirsch’s stereoselective synthesis of 14β-hydroxysteroids.201 
To follow Kirsch’s procedure, we tried to convert dienone 4.176 into the known enol 
acetate 4.225, which was prepared in 47% yield by Hughes and Smith in 1966 by heating 
at reflux dienone 4.176 in isopropenyl acetate 4.123 containing catalytic amounts of  
p-toluenesulfonic acid for 15 h.202 The authors suggested the flask to be left open and 
protected from the light with aluminium foil during the reaction time. In our hands, the 
reaction turned quickly dark coloured and it resulted in just decomposition  
(Scheme 4.49). 
 
Scheme 4.49. Attempted acetylation of steroid 4.176. 
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More attempts to make enol acetate 4.225 were tried. However, unsuccessful results were 
obtained when camphorsulfonic acid was used instead of p-toluenesulfonic acid, and 
when isopropenyl acetate was replaced by acetic anhydride in the presence of catalytic 
amounts of N,N-dimethylaminopyridine. The combination of acetic anhydride and 
catalytic amounts of p-toluenesulfonic acid gave instead unreacted starting material. 
Therefore, an alternative route was again considered. 
4.3.4.3. Attempted C-14,C-15-epoxidation 
Attention was turned to the selective epoxidation of the C-14,C-15 double bond which 
could lead to the desired 14β-hydroxyl group after reductive ring-opening. Although no 
literature precedent has been reported starting from dienone 4.176, the stereoselective 
route established by Bull and Floor leading to 14β-diol 4.228 in two steps from alcohol 
4.226 via epoxide 4.227 seemed attractive (Scheme 4.50).203 
 
Scheme 4.50: Bull and Floor’s stereoselective ring D elaboration.203 
The preparation of 4.229 was first attempted using the conditions of Bull and Floor 
(Scheme 4.51).203 However, no reaction was observed on treatment of dienone 4.176 with  
m-chloroperbenzoic acid at 0 °C, whereas the starting material decomposed when the 
oxidant was added at room temperature.  
 
Scheme 4.51. Attempted epoxidation on ring D.  
The formation of the epoxide was also attempted on treatment with N-bromosuccinimide 
and sodium methoxide, but in the presence of the brominating agent the starting material 
decomposed quickly.  
Homo-allylic alcohol 4.230 could be imagined as a suitable substrate for the selective  
C-14,C-15-epoxidation using titanium isopropoxide as a transition metal catalyst and tert-
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butyl hydroperoxide as oxidising agent (Scheme 4.52).204, 205 Reduction of dienone 4.176 
with sodium borohydride206 proceeded smoothly, and resulted in a single compound 
identified as the known 17β-homo-allylic alcohol 4.230.207, 208 However, the following 
epoxidation to obtain compound 4.231 failed and gave again just a complex mixture of 
products which were not isolated. 
 
Scheme 4.52: Attempted epoxidation or ring D in the presence of titanium isopropoxide and tert-butyl 
hydroperoxide. 
4.3.4.4. Attempted selective reduction of ring B 
It was proposed that interruption of the conjugation between rings A-D in dienone 4.176 
by selective reduction of the C-8,C-9 double bond would give compound 4.232, whose 
ring D, with the remaining C-14,C-15 double bond, should be easier to elaborate to 
reintroduce the 14β-hydroxyl group and give ketoalcohol 4.146 (Scheme 4.53).  
 
Scheme 4.53. Intended selective reduction of the benzylic double bond towards the ring D elaboration 
Catalytic hydrogenation was tried first (Table 4.10). Although this reaction is known to 
proceed via a syn mechanism (thus forming an undesired cis-junction between rings C 
and D), it was seen a feasible method to address the selective reduction of the styrene 
double bond in the presence of palladium as metal catalyst. Ethyl acetate was chosen as 
the solvent, in order to decrease the reaction rate and hopefully favour the reduction of 
the styrene against the less substituted alkene. However, enone 4.234 was the only 
compound isolated (entry 1).  
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Entry Conditions Outcome 
1 H2, Pd(C), AcOEt, 30 min 4.234 25%
 
2 Et3SiH (1 eq), H2, 10% Pd(C),benzene, 0 °C rt, 18 h 4.234 56% 
 
Table 4.10. Catalytic hydrogenation of steroid 4.176. 
Enone 4.234 is a known compound,209, 210 which was also synthesised according to the 
procedure of Corey and co-workers via a catalytic hydrogenation of dienone 4.176 in 
benzene in the presence of triethylsilane (entry 2).209 These results emphasised the 
challenge to achieve the internal reduction in a selective manner. 
Next, the reduction of the aromatic steroid 4.176 under Birch conditions was tried. Firstly, 
the 17-keto group of 4.176 was protected as acetal 4.235 in high yield in the presence of 
ethylene glycol, trimethyl orthoformate and catalytic amounts p-toluenesulfonic acid 
(Scheme 4.54).211 Acetal 4.235 is a known compound but no NMR spectra are  
provided,212 therefore it was fully characterised.  
 
Scheme 4.54: Preparation of acetal 4.235.  
Compound 4.235 was afterwards treated with an excess of metallic sodium in liquid 
ammonia and tetrahydrofuran (Scheme 4.55). However, compound 4.236 was not seen, 
but the major product isolated was phenol 4.237, with rings C and D fused in a cis-fashion. 
 
Scheme 4.55: Towards the Birch reduction of diene 4.235.  
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Phenol 4.237 is novel and it was fully characterised. The stereochemistry at C-14 was 
assigned by nOe experiments (which showed a clear correlation between this proton and 
the angular C-18 methyl group), and it was confirmed by comparison with the analytical 
data of the same compound prepared as shown below (Scheme 4.56). 
Ring D of the cis-fused dienone 4.218 was exhaustively reduced with sodium borohydride 
to obtain the 17α-hydroxyl compound 4.238,213 which is a known compound, but no 
analytical data are available (Scheme 4.56). The stereochemistry at C-17 was assigned 
by NMR spectroscopy on the basis of the chemical shift of the C-17 proton seen at 3.89 
ppm, in accordance with literature examples,207 and different from the chemical shift of 
the same atom in the 17β-alcohol 4.230 which was found at 4.05 ppm. Further oxidation 
of the 17-alcohol by means of Dess-Martin periodinane 4.239 resulted in the known cis-
enone 4.240,210, 214 in which the relative stereochemistry between C-13 and C-14 was also 
confirmed by nOe experiments. Demethylation of the aromatic methoxy group in the 
presence of boron tribromide gave the known phenol 4.241215 in good yield. Finally, 
acetal protection of the C-17 ketone gave compound 4.237 in 56% yield, whose analytical 
data were in agreement with those of the same compound prepared by Birch reduction of 
acetal 4.235 as described in Scheme 4.55. 
Scheme 4.56. Synthesis of rings C and D cis-fused steroid 4.219. 
It was noteworthy that reduction of steroidal ring D in the presence of a C-17 ketone 
produced compound 4.234 with a trans-junction between ring C and D (Table 4.10). By 
contrast, when the ketone was protected as its acetal, a cis-junction was obtained, such as 
in compound 4.237 (Schemes 4.55). Likewise, sodium borohydride reduction of dienone 
4.176 furnished compound 4.230 with a 17β-hydroxyl group (Schemes 4.52). On the 
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other hand, the same reduction performed on the conjugated ketone 4.218 produced the 
isomeric 17α-hydroxyl steroid 4.238. (Schemes 4.56). 
A screening of different solvent systems for the Birch reduction resulted in complex 
mixtures of products whose structures were not resolved, but none of them was compound 
4.242. However, using a mixture of tetrahydrofuran and t-butanol as solvents,175 the 
isomeric dienedione 4.243216 was isolated in a low yield (Scheme 4.57).  
 
Scheme 4.57: Birch reduction of the steroidal framework. 
Steroid 4.243 has been prepared in 27% yield by Re and co-workers in 1966 on treatment 
of acetal 4.235 with lithium metal in liquid ammonia, using tetrahydrofuran and diethyl 
ether as solvents, ethanol as proton source, and a mixture of acetic acid and 1 M 
hydrochloric acid for the following hydrolysis.217 No 1H- and 13C-NMR data were 
available, therefore compound 4.243 was fully characterised. 
It was proposed that a chemoselective epoxidation of the unconjugated C-8,C-14 double 
bond followed by epoxide ring-opening might allow the reintroduction of the  
14β-hydroxyl group. Unfortunately, attempts to scale up the reaction failed giving just a 
complex mixture of products none of them having the mass spectrum required for 
compound 4.243. 
Disappointingly, the strategy was abandoned. 
4.4. SUMMARY AND FUTURE WORK 
The formidable challenge of synthesising the unnatural C-14 epimer of withanolide F 2.5 
when starting from cheap commercially available materials was unsuccessful (Scheme 
4.58). In spite of that, three of the four key intermediates have been effectively 
synthesised on the basis of literature procedures, which were modified to achieve a better 
yield and/or reproducibility.  
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Scheme 4.58. Planned strategy to 14β-withanolide F 2.5. 
The first key intermediate, vinyl ketone 4.150 was obtained in 6 steps and 33% overall 
yield following the procedure developed by Wang et al.179 Glycolic esters 4.163 and 
4.164, keto alcohol 4.160 and acetate 4.161 were novel, and have been completely 
characterised (Figure 4.16). 
 
Figure 4.16. Novel intermediates isolated in the earlier steps of the target total synthesis. 
The synthesis of the second key intermediate was improved, and triketone 4.148 was 
obtained in 90% yield after a one day reaction, against the published 80% yield after a 5 
day reaction time.179, 190 
The asymmetric amino-acid catalysed cylisation of triketone 4.148 to diketo carbinol 
4.147 was disappointing using (S)-proline 4.168. However, when the cyclisation was 
performed via an intramolecular aldol condensation, a mixture of diastereoisomers 4.147 
and 4.177 in approximatively 3/1 ratio was obtained in 74% yield. The structures of 
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compounds 4.147 and 4.177 were elucidated by 1D- and 2D-NMR spectroscopy after 
separation of an analytical sample by HPLC (Figure 4.17). 
 
Figure 4.17. Epimeric 14-hydroxy steroids. 
Unfortunately, the further cyclisation to complete the steroidal framework led first to the 
elimination of the 14-hydroxyl group to enone 4.174, followed by ring B-closure and 
further dehydration to dienone 4.176 (Scheme 4.59). 
 
Scheme 4.59. Outcome of the intramolecular Friedel-Crafts cycloalkylation of the unprotected carbinols 
4.174 and 4.177. 
Protection of the hydroxyl groups of the mixture of 14β- and 14α-isomers 4.147 and 4.177 
proved difficult and additional bicyclic compounds arising from sequences of retro-aldol  
ring-opening and aldol-ring closing reactions were also isolated and fully characterised 
(Figure 4.18). 
 
Figure 4.18. Structures of novel bicyclic systems.  
Since dienone 4.176 was the major side-product obtained, attempts to reintroduce the  
14β-hydroxyl group on 4.176 were also carried out, but they were unsuccessful and led 
to several by-products. 
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In future work, the total synthesis of 14β-withanolide F 2.5 could be investigated starting 
from the commercially available dehydroepiandrosterone 4.244 (Schemes 4.60-4.62). 
Modification of ring A could be carried out by adapting the procedures of Ikekawa and 
co-workers167 and Medrano and Grieco172 which have been used in the synthesis of 
withanolide D (see Scheme 4.7) and E (see Scheme 4.13), respectively (Scheme 4.60).  
 
Scheme 4.60. Towards the 1-oxo-2,5-diene system starting from dehydroepiandrosterone 4.244. 
On dehydroepiandrosterone 4.244, the reintroduction of the 14β-hydroxyl group could be 
addressed following the procedure of Kirsch et al.201 as used in the stereoselective 
synthesis of 14β-hydroxysteroids (see Scheme 4.48, Scheme 4.61). 
 
Scheme 4.61. Towards the reintroduction of the 14β-hydroxyl group in dehydroepiandrosterone 4.244.  
Finally, on dehydroepiandrsosterone 4.243 the lactonic side-chain containing the 17β- 
and 20β-hydroxyl groups could be installed following the procedure of Medrano and 
Grieco172 which has been used in the synthesis of withanolide E (see Scheme 4.13, 
Scheme 4.62). 
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Scheme 4.62. Towards the installation of the lactonic side-chain in dehydroepiandrosterone 4.244. 
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CHAPTER 5.  
ELABORATION OF COAGULIN L 2.1 
5.1. INTRODUCTION TO COAGULIN L 2.1 
5.1.1. Structural features 
Coagulin L 2.1 is a withanolide first identified by Atta-Ur-Rahman et al. in 1998 during 
studies on the constituents of Withania coagulans Dunal, a plant endemic of South Asia 
which was named after the evidence of its milk coagulating properties. The authors 
reported that 30 mg of coagulin L 2.1 (1.02 x 10-5%) were isolated from 25 Kg of dried 
plant material. Its structure was elucidated by spectroscopic and spectrometric techniques, 
and by comparison with related compounds.218 
As with other withanolides, coagulin L 2.1 is characterised by a hyperoxygenated 
steroidal framework and a side-chain containing a δ-lactone (Figure 5.1). In addition, its 
3β-hydroxyl group is ether-linked to a molecule of glucose. The aglycone of coagulin L 
2.1, 3β-hydroxy-2,3,-dihydro-withanolide F 5.1, is a compound which was first isolated 
by Velde et al. and described as a potential intermediate in the biosynthesis of the 
withanolides.158 
 
Figure 5.1. Structures of coagulin L 2.1 and its aglycone 5.1. 
5.1.2. Biological activities 
In 2008 Maurya et al. investigated the constituents of Withania coagulans to seek 
compounds with antihyperglycemic activity, after earlier evidence of the cholesterol-
lowering properties of the aqueous extracts of this plant when administrated to diabetic 
rats.219 Amongst a number of withanolides isolated, coagulin L 2.1 was found to have the 
highest antihyperglicemic activity in promoting glucose tolerance by 29.8% in 
normoglycemic and by 23.3% in streptozotocin-induced diabetic rats (at a dose of 100 
mg/kg body weight, compared with the value of 26.4% and 23.3 % of the standard drug 
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metformine), and in decreasing by 22.7% the postprandial blood glucose level in type 2 
diabetes model mice (at a dose of 50 mg/kg body weight, compared with the value of 
18.6% of the standard drug metformine). A remarkable antidyslipidemic activity similar 
to fenofibrate was also observed.219, 220 
Recently Beg et al. reported the antiadipogenetic properties of coagulin L 2.1.221 It is 
known that adipogenesis is modulated by the Wnt/β-catenin signalling pathway, whose 
activation in mesenchymal stem cells and 3T3-L1 pre-adipocyte cell lines prevents their 
differentiation into adipocytes.222 Interestingly, it was shown that treatment of 3T3-L1 
cells with coagulin L 2.1 remarkably inhibited the degradation of β-catenin and enhanced 
the expression of Wnt3a (a Wnt ligand) and its co-receptor LRP, with blockage of 
adipogenesis as the effects, thus, giving light to the potential applications of coagulin L 
2.1 as treatment for metabolic syndrome and obesity.221 
5.2. PROJECT AIM: TOWARDS THE ELABORATION OF COAGULIN L 2.1 
Obesity and metabolic dysfunctions such as insulin resistance and type 2 diabetes are high 
risk factors of mortality, and coagulin L 2.1 has been shown to be a potential novel 
therapeutic to target these diseases.221 Moreover, the study of Beg et al.221 showed a clear 
correlation between coagulin L 2.1 and Wnt signalling, one of the three most studied 
embryonic signalling pathways. However, to the best of our knowledge, no studies of the 
biological effect of coagulin L 2.1 on the Hh/Gli pathway have been published. 
AnalytiCon Discovery has reliable access to a large amount of plant material. 
Investigation of the chemical constituents of the powdered leaves of Withania coagulans 
and Withania adpressa resulted in the isolation of a substantial amount of coagulin L 2.1. 
Around 5 g of this natural product were isolated from 5 kg of plant material, along with 
withanolide F 2.2, which was obtained in a considerably lower yield (2.1/2.2 = 50/1 ratio) 
(Figures 5.2 and 5.3 ). 
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Figure 5.2. AnalytiCon’s methodology for isolation of natural products.  
The only structural differences between coagulin L 2.1 and withanolide F 2.2 can be 
found in ring A, where the elimination of glucose at C-3 from compound 2.1 followed by 
elimination of the resulting alcohol produces the C-2,C-3-unsaturation found in 
compound 2.2 (Figure 5.3).  
 
Figure 5.3. Structures of coagulin L 2.1 and withanolide F 2.2. 
Therefore, we considered that the deglycosylation of an original sample of coagulin L 2.1 
would give withanolide 5.1 (Scheme 5.1), the right-hand side of which could be 
elaborated such as in 2.6 to provide additional analogues of withanolide F 2.2 for a 
structure-activity relationship study on the Hh/Gli signalling pathway, as well as 
potentially novel antihyperglycemic and antiobesity remedies. 
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Scheme 5.1. Intended modifications of withanolide rings A and B. W, X, Y, Z = H, C, O, S, N, halogen. 
5.3. RESULTS AND DISCUSSION 
5.3.1. Recent literature elaboration of rings A and B of withanolides 
In spite of the apparent fragility of the lactone ring, modifications of the withanolide 
framework after installation of the cyclic oxygenated side-chain have been widely 
reported, especially on withaferin A 4.1,160 and, recently on withanolide A 4.49.162  
With regards to withaferin A 4.1, the most recent elaborations of the left-hand side have 
been reported by Joshi et al.,160 who converted the 5β,6β-epoxide in ring B into the  
5β-alcohol 5.2 by means of polymethylhydrosiloxane and a catalytic amount of iodine, 
and into the 5α,6α-thiirane 5.3 using cyanuric chloride 5.4 and ammonium thiocyanate 
(Scheme 5.2). The butyl-aminoalcohols 5.5 and 5.6, and benzyl-aminoalcohol 5.7 were 
also prepared by treatment of compound 4.1 with the appropriate amines and water. In all 
these cases the lactone ring remained untouched. 
 
Scheme 5.2. Modification of the epoxide of withaferin A 4.1 by Joshi et al.160 
Similar observations were also noted during the elaboration of withanolide A 4.49 by 
Gademann and co-workers,162 who showed that only the ring A could be functionalised 
in spite of the presence of an epoxyalcohol in ring B and of the tetrasubstituted 
unsaturated lactone in the side-chain (Schemes 5.3 and 5.4).  
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In fact, the C,2-C,3 double bond was exclusively epoxidised to compound 5.8 when 
withaferin A 4.49 was treated with tert-butylhydroperoxide and tetrabutylammonium 
fluoride (Scheme 5.3). Moreover, the C-2,C-3 epoxide was solely converted into the 
1α,3α-diol 5.9 via an organoselenium-mediated reduction (followed by treatment with 
sodium borohydride to reduce the C-1 ketone), and into the 3α-allylic alcohol 5.10 via a 
Wharton carbonyl transposition. The ring A of compound 5.10 was also selectively 
reduced to compound 5.11 via catalytic hydrogenation in the presence of Crabtree’s 
catalyst, and transformed into the 3β-hydroxyl derivative 5.13 by a Mitsunobu reaction 
of 3α-alcohol 5.10 with p-nitrobenzoic acid 5.12, diethylazodicarboxylate and 
triphenylphosphine followed by basic hydrolysis. 
 
Scheme 5.3. Gademann’s functionalisation of withanolide A 4.49.162 
The C-2,C-3 double bond and the C-1 ketone of withanolide A 4.49 could be also 
smoothly reduced to compounds 5.14 and 5.15. However, further functionalization at  
C-1 proved to be trickier, and only oximes 5.16-5.19 were prepared (Scheme 5.4).162 
 
Scheme 5.4. Gademann’s functionalisation of C-1 of withanolide A 4.49.162 
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It is interesting to note that also in the case of coagulin L 2.1, apart from its enzymatic 
deglycosylation, only the preparation of oxime 5.20 has been reported. It was prepared 
by heating compound 2.1 at reflux in the presence hydroxylamine hydrochloride (Scheme 
5.5). The yield and additonal details of the reaction were not given.220 
 
Scheme 5.5. Derivatisation of coagulin L 2.1 by Maurya et al.
220
 
Inspired by these results, we believed that also the elaboration of rings A and B of 
coagulin L 2.1 could be selectively achieved, and that the two additional hydroxyl groups 
at C-14 and C-17 (compared with withaferin A 4.1 and withanolide A 4.49) should not 
pose particular problems.  
5.3.2. Towards withanolide F 2.2. 
To further functionalise the left-hand side of coagulin L 2.1 there was the need to 
introduce a reactive functionality, for example, in ring A (Scheme 5.6). Thus, we 
expected that conversion of coagulin L 2.1 into withanolide F 2.2 would provide an  
α,β-unsaturated ketone, which could be envisaged as a building block to introduce a 
variety of functionalities at C-3 by means of Michael additions of diverse nucleophiles. 
 
Scheme 5.6. Intended conjugated additions to withanolide F 2.2. Nu = general carbon, sulfur, or nitrogen 
nucleophile. 
Therefore, the deglycosylation of compound 2.1 followed by acetylation of the secondary 
alcohol in 5.1 and subsequent elimination of acetate 5.22 to obtain the unsaturated system 
2.2 was first explored (Scheme 5.7). 
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Scheme 5.7. Towards withanolide F 2.2 from coagulin L 2.1. 
5.3.2.1. Deglycosylation of coagulin L 2.1 
The enzymatic deglycosylation of coagulin L 2.1 was previously reported by Maurya and  
co-workers using the spores of Aspergillus ochraceous (the yield was not given).220  
However, an extensive screening of reaction conditions performed at AnalytiCon 
Discovery established that the most reliable way to carry out this deglycosylation was by 
using the enzyme β-glucosidase from Aspergillus niger. The optimised procedure 
involved adding a solution of coagulin L 2.1 and β-glucosidase to a buffered solution of 
sodium acetate at pH 4, and incubation of the resulting mixture at 37 °C for one day. 
Under these conditions 3β-alcohol 5.1 was obtained in 61% yield (entry 1, Table 5.1). 
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Entry Conditions Outcome 
1 2.1 (500 mg), enzyme, H2O/MeOH = 1/1  
(1100 mL), 37 °C, 1 d 
5.1 61%a 
2 2.1 (200 mg), enzyme, H2O/MeOH = 1/1 (440 mL), 
37 °C, 18 h 
5.1 43%b 
3 2.1 (50 mg), enzyme, H2O/MeOH = 1/1 (110 mL), 
37 °C, 18 h 
5.1 50%c 
4 2.1 (20 mg), enzyme, H2O/MeOH = 1/1 (44 mL), 
37 °C, 18 h 
5.1 100%c 
5 10% aq HCl, dioxane/H2O, rt to 40 °C, 3 h Mainly 2.2
d  
6 10% aq HCl, dioxane/H2O, reflux, 10 min Decomposition
d 
7 1 M methanolic HCl, reflux, 4 h Decompositiond 
8 1 M aq LiOH, THF/H2O, rt 18 h Decomposition
d 
9 0.1 M aq KOH, dioxane, rt 1 h Mainly 2.2d 
10 DBU (1 + 1.2 eq), rt to 60 °C, 1 d  Mainly 5.23d 
 
Table 5.1. Deglycosylation of coagulin L 2.1. Reactions in entries 5-10 were carried out in 5-20 mg scale. 
aReaction carried out in incubator at AnalytiCon Discovery. bReaction carried out in incubator at the 
University of York. cReaction carried out in an oil bath at the University of York. dAs detected by NMR 
spectroscopy and ESI-MS of the crude material.  
This deglycosylation proved to be sensitive to the amount of starting material used, and 
gave alcohol 5.1 in yields ranging between 43 and 100% starting from 200, 50 and 20 mg 
of coagulin L 2.1, respectively (entries 2-4). However, despite the variable yields, the 
amount of compound 5.1 isolated enabled us to carry out subsequent transformations.  
The deglycosylation was also attempted under acidic (entries 5-7) and basic (entries 8-
10) conditions. However, only decomposition or a mixture of products including 
withanolide F 2.2 and its isomer 5.23 were detected.  
5.3.2.2. Acetylation of 3β-hydroxy-coagulin L 5.1  
The acetylation of 3β-hydroxy-coagulin L 5.1 proceeded smoothly following the 
procedure of Vande Velde et al.158 who used acetic anhydride in pyridine, and gave  
3β-acetyl-coagulin L 5.22 in quantitative yield (Scheme 5.8). 
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Scheme 5.8. Synthesis of 3β-acetyl withanolide 5.22. 
5.3.2.3. Elimination of acetate  
The next step was the elimination of acetate from compound 5.22 to form the enone in 
ring A of withanolide F 2.2 (Table 5.2). The reaction was first attempted using an aqueous 
solution of KOH in dioxane,158 conditions which led to the isolation of withanolide F 2.2 
in 61% yield (entry 1).  
 
Entry Conditions Outcome 
1 1 M aq KOH (2.5 eq), dioxane, rt, 15 min 2.2 61%a 
2 DBU (1 eq), CH2Cl2, rt, 30 min Sm 5.22 25%, 2.2 75%  
3 DBU (1 eq), CH2Cl2, rt, 40 min Starting material 5.22 25%,  
2.2 58%, 5.23 17% 
4 DBU (1.5 eq), CH2Cl2, rt, 20 min 5.23 50% 
5 DBU (1.5 eq), CH2Cl2, 0 °C, 2 h Sm 5.22 41%, 2.2 59%  
6 DBU (1.5 eq), CH2Cl2, 0 °C, 3 h 2.2 75%, 5.23 25% 
Table 5.2. Elimination of acetate 5.22. Reactions were carried out on a 5-50 mg scale. aReaction 
and purification performed at AnalytiCon Discovery. 
We also carried out the elimination in the presence of the non-nucleophilic hindered base 
1,8-diazabicyclo[5.4.0]undec-7-ene (entries 2-6). At room temperature, it was found that 
stoichiometric amounts of base gave withanolide F 2.2 in good yield along with unreacted 
starting material 5.22 (entry 2). When the reaction time was longer (entry 3) withanolide 
F 2.2 was formed along with the isomeric compound 5.23.158 A slight excess of base led 
mainly to compound 5.23 (entry 4). Similar results were seen when the reaction was 
carried out at 0 °C. A two hour reaction gave withanolide F 2.2 in 59% yield with 41% 
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of unreacted starting material (entry 5). By stirring the reaction mixture for a longer time 
the starting material was completely consumed, but again the isomeric compound 5.23 
was obtained as well as withanolide F 2.2 (entry 6). 
It is important to note that the products 2.2, 5.23 and the starting material 5.22 have 
similar Rf values thus preventing their further separation (the course of the reactions had 
to be followed by NMR spectroscopy).  
5.3.3. Michael addition of thiophenol 5.24 to withanolide F 2.2 
We began the derivatisation of the ring A of withanolide F 2.2 by investigating the use of 
thiophenol 5.24 as a nucleophile (Table 5.3). Since the preparation of the starting material 
2.2 proved difficult, a direct replacement of the sugar moiety of coagulin L 2.1 with 
thiophenol 5.24 was attempted first. However, when coagulin L 2.1 was treated with 
thiophenol and potassium hydroxide in pyridine (entry 1), a clean thiophenyl-derivative 
5.25 could not be isolated, even when the reaction was carried out in the presence of 
stoichiometric amounts of N,N-dimethylaminopiridine (entry 2). The Michael additions 
attempted in the presence of triethylamine (entry 3), or 1,5-diazabicyclo(4.3.0)non-5-ene 
in methanol (entry 4) were also unsuccessful.70 
 
Entry Conditions Outcome 
1 5.24 (10 eq), 0.1 M aq KOH (10 eq), py, rt to 60 °C, 7 h Traces of 5.25  
2 5.24 (5 eq), DMAP (1 eq), py, rt, 18 h Decomposition 
3 5.24 (1 eq), Et3N (3 eq), MeOH, rt, 3 h Decomposition 
4 5.24 (5 eq), DBN (1.5 eq), MeOH, rt to 60 °C, 7 h Decomposition 
Table 5.3. Attempted synthesis of thiophenyl ether 5.25 from coagulin L 2.2. Rections were carried out 
on 5-20 mg of starting material. aDetected by NMR spectroscopy analysis of the crude material. 
The addition of thiophenol 5.24 was next tried on the crude withanolide F 2.2 
contaminated by acetate 5.22 (1/3, 11 mg) (Scheme 5.9). The formation of the thiophenyl 
ether 5.25 was detected by NMR spectroscopy and HRMS, however, the small scale and 
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the difficulties faced during the attempted purification process did not allow the isolation 
of a sufficient amount of material for its full characterisation (Scheme 5.9).  
 
Scheme 5.9. Attempted synthesis of thiophenyl ether 5.25. 
Additional attempts to achieve achieve an adequate amount of pure phenylthioether 5.25 
proved unsuccessful. 
5.3.4. C-3 Esterification 
Driven by the easy acetylation of the 3β-hydroxyl group of withanolide 5.1, we wanted 
to check the feasibility of introducing other carboxylate esters on C-3. The benzoic ester 
was investigated first (Table 5.4).  
 
Entry Conditions Outcome 
1 Benzoic acid (1.2 eq), T3P (2 eq), DIPEA, CHCl3,  
rt to 40 °C, 18 h 
Sm 5.1 
2 Benzoic acid (1.5 eq), T3P (1.3 eq), py, rt, 18 h Sm 5.1 
3 Benzoic acid (1.5 eq), T3P (2 eq), py, 40 °C, 18 h Sm 5.1, 2.2a 
4 Benzoic anhydride (10 eq), py, rt to 40 °C, 24 h 5.26 49% 
5 Benzoyl chloride (10 eq), py, rt, 18 h 5.26 98% 
Table 5.4. The formation of benzoic ester 5.26. Reactions were carried out on a 5-50 mg 
scale. aDetected by NMR spectroscopy of the unpurified material.  
Early efforts were carried out by using benzoic acid and propylphosphonic anhydride 
(T3P) as a coupling agent (entries 1-3). However, only unreacted starting material or a 
mixture of by-products including traces of 2.2 were detected by NMR spectroscopy of 
the crude material. Benzoic anhydride was tried next, following the protocol that, in the 
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acetylation (see Scheme 5.8), was successful. Indeed, by treating compound 5.1 with 
benzoic anhydride in pyridine, benzoic ester 5.26 was obtained in good yield (entry 4) 
which increased to 98% by replacing benzoic anhydride with benzoyl chloride (entry 5).  
This strategy proved successful and reproducible, and led to the synsthesis of the 
(E)-cinnamic ester 5.28 in 89% yield on treatment of alcohol 5.1 with (E)-cinnamoyl 
chloride 5.27 in pyridine at room temperature (Scheme 5.10). 
 
Scheme 5.10. Synthesis of (E)-cinnamic ester 5.28 
5.3.5. Attempted C-3 oxidation 
The oxidation of C-3 to obtain the novel dienone 5.29 was attempted on 3β-hydroxy 
withanolide 5.1 (Scheme 5.11). However, when withanolide 5.1 was treated with Dess-
Martin periodinane 4.239, the starting material decomposed quickly, and no traces of the 
desired product were detected by analytical techniques. Similar results were seen when 
withanolide 5.1 was subjected to stoichiometric amounts of Jones reagent. This oxidation 
approach was therefore abandoned. 
 
Scheme 5.11. Attempted oxidation of 3β-alcohol 5.1. 
5.3.6. Attempted epoxidation of ring B 
Finally, the epoxidation of ring B was also attempted on acetate 5.22 in the presence of 
m-chloroperbenzoic acid and sodium hydrogen carbonate (Scheme 5.12). After one day 
of stirring at room temperature the starting material was consumed completely and  
LC-MS showed a peak corresponding to the mass of the intended compound. Two 
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consecutive purifications by flash column chromatography on silica gel were attempted 
using different solvent systems to isolate compound 5.30. Unfortunately only 
decomposition was observed.  
 
Scheme 5.12. Attempted epoxidation of acetate 5.21. 
5.4. SUMMARY AND FUTURE WORK 
The glycoside withanolide coagulin L 2.1 was successfully deglycosylated on a small 
scale using the enzyme β-glucosidase from Aspergillus niger, following a procedure 
which was optimised at AnalytiCon Discovery. 
The resulting 3β-hydroxy coagulin L 5.1 was converted in two steps, via acetate 5.22, 
into the lead compound withanolide F 2.2 in satisfactory yield, although it was mainly 
isolated as a mixture with its isomer isowithanolide F 5.23 (Scheme 5.13). Since 
withanolide F 2.2 is extracted in minimal amounts from plant material compared to 
coagulin L 2.1 (which is instead present in gram amounts), a feasible way to obtain larger 
quantities of this natural product from coagulin L 2.1 has been provided. 
Scheme 5.13. Synthesis of withanolide F 2.2 from coagulin L 2.1. 
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In addition to the known acetate 5.22,160 the preparation of the novel benzoate 5.26 and 
(E)-cinnamate 5.28 from 3β-hydroxy coagulin L 5.1 were also carried out in good yields 
(Figure 5.4). However, other transformations also proved difficult. 
 
Figure 5.4. Structure of benzoate 5.26 and (E)-cinnamate 5.28 
In future work, conditions for the selective conversion of coagulin L 2.1 into withanolide 
F 2.2 will be developed, allowing the Michael additions to be explored under more 
controlled conditions.  
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CHAPTER 6. EXPERIMENTAL  
6.1. GENERAL DIRECTIONS 
Reactions were monitored by Thin Layer Chromatography (TLC) and/or LC-MS (Liquid 
Chromatography-Mass Spectrometry). TLC was performed using pre-coated aluminium 
foil TLC-sheet Xtra SIL G/UV254 (MACHERAY-NAGEL), layer 0.20 mm, silica gel 60 
with fluorescent indicator UV254, and on Merck silica gel 60F254. Visualisation was 
carried out using UV light at 254 nm and basic aqueous potassium permanganate or 
ethanolic p-anisaldehyde as stains. Chemical reactions were carried out with magnetic 
stirring. All air and moisture sensitive reactions were performed in flame-dried glassware 
and under a nitrogen or argon atmosphere. Water refers to distilled water. 
Reagents were purchased form commercial sources and used without any further 
purification except for: 
 Pyridine, purchased anhydrous from commercial sources. 
 Tetrahydrofuran, either purchased anhydrous from commercial sources or 
distilled from sodium-benzophenone ketyl immediately before use. 
 Dichloromethane, either purchased anhydrous from commercial sources or 
obtained from an Innovative Technology Inc. PureSolv® solvent purification 
system. 
Flash column chromatography was performed on a Biotage Isolera Four with a UV-VIS 
detector, using Fluka silica gel 60 (SiO2) or using slurry packed Fluka silica gel, 35-70 
µm, 60 Å, with the specific eluent. Petroleum ether (PE) is the fraction with the boiling 
point range 40-60 °C.  
Melting points (m.p.) were determined using a Gallenkamp apparatus and are 
uncorrected.  
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AVANCE 
spectrometer or on a Jeol ECX400 spectrometer operating at 400 MHz for 1H and at 100 
MHz for 13C or at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts (δ) are quoted 
in parts per million (ppm) from tetramethylsilane calibrated to the residual nondeuterated 
solvent peak as internal standard.223 Coupling constants (J) are quoted in Hertz. Structural 
assignment was verified by two dimensional NMR (HSQC, HMBC, COSY) and nOe 
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where necessary. When required, deuterated chloroform was dried over oven-dried 
MgSO4, stirred with K2CO3, filtered and stored over 4 Å molecular sieves.  
High resolution mass spectra were obtained by the University of York Mass Spectrometry 
Service using electrospray ionisation (ESI) on a Bruker Daltonics, Micro-Tof 
spectrometer.  
LC-MS spectra were recorded at AnalytiCon Discovery GmbH using API165, API150, 
API365, AB Sciex (UV, ELSD and DAD detectors), gradient A: 5mM ammonium 
formate + 0.1% formic acid, B: methanol/acetonitrile = 1/1 + ammonium monohydrogen 
carbonate.  
CHN elemental analyses were obtained by the University of York CHN Service using an 
Exeter Analytical CE440 Elemental Anayser.  
Optical Rotations were measured on a JASCO DIP-370 polarimeter using a sodium lamp 
and a 2 mL cell with 1 dm path length or a 1 mL cell with 10 mm path length. Data are 
reported as follows: [α]DT (c in g/100 mL, solvent). 
Infrared spectra were recorded on a ThermoNicolet IR-100 spectrometer with NaCl plates 
as a thin film dispersed from a CH2Cl2 solution, or a PerkinElmer UATR spectrometer. 
The naming of compounds conforms to IUPAC rules. The numbering on the structures 
do not always conform the IUPAC nomenclature but refers to the historic numbering of 
this class of compounds, and/or for purpose of characterisation. 
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6.2. CHAPTER 3: EXPERIMENTAL DETAILS 
(3β)-20-Oxopregn-5-en-3-yl 4-methylbenzenesulfonate 3.59 
 
Synthesis of tosylate 3.59 using p-TsCl in py81 
p-TsCl (2.00 g, 10.5 mmol) was dissolved in py (6 mL) and pregnenolone 3.56 (1.00 g, 
3.16 mmol) was added in one portion. The reaction mixture was stirred at rt for 18 h and 
afterwards poured into an ice-bath cooled H2O (20 mL). The solid obtained was collected 
by filtration and air dried to yield tosylate 3.59 (1.40 g, 94%) as white needles.  
Ref. LNB0145-067 
Rf: 0.29 (PE/AcOEt = 9/1); m.p.: 139-140 °C (acetone/H2O) [lit. 139-140 °C 
(acetone/H2O)];
82 [α]D24: +12 (c 1.16, CHCl3) [lit. +9 (c 68.55, CHCl3)];82 1H-NMR (500 
MHz, CDCl3), δ: 7.78 (2H, d, J = 8.1 Hz, H-2a, H-6a), 7.32 (2H, d, J = 8.1 Hz, H-3a,  
H-5a), 5.30-5.27 (1H, m, H-6), 4.36-4.27 (1H, m, H-3), 2.5 (1H, “t”, J = 8.8 Hz, H-17), 
2.45-2.38 (1H, m, H-4), 2.43 (3H, s, 3H-7a), 2.29-2.23 (1H, m, H-4), 2.18-2.11 (1H, m, 
H-16), 2.09 (3H, s, 3H-21), 2.04-2.99 (1H, m, H-12), 1.99-1.92 (1H, m,  
H-7), 1.85-1.77 (2H, m, H-1, H-2), 1.73-1.36 (8H, m, H-2, H-7, H-8, 2H-11, H-12, H-15, 
H-16), 1.25-1.15 (1H, m, H-15), 1.15-1.07 (1H, m, H-14), 1.06-0.98 (1H, m, H-1),  
0.97-0.88 (1H, m, H-9), 0.95 (3H, s, 3H-19), 0.59 (3H, s, 3H-18); 13C-NMR (125 MHz, 
CDCl3), δ: 209.5 (C, C-20), 144.5 (C, C-4a), 138.9 (C, C-5), 134.8 (C, C-1a), 129.9 (2CH, 
C-3a, C-5a), 127.7 (2CH, C-2a, C-6a), 123.3 (CH, C-6), 82.3 (CH, C-3), 63.7 (CH,  
C-17), 56.9 (CH, C-14), 49.8 (CH, C-9), 44.0 (C, C-13), 38.9 (CH2, C-4), 38.8 (CH2,  
C-12), 37.0 (CH2, C-1), 36.4 (C, C-10), 31.8 (CH, C-7 + CH2, C-8), 31.6 (CH3, C-21), 
28.7 (CH2, C-2), 24.5 (CH2, C-15), 22.9 (CH2, C-16), 21.7 (CH3, C-7a), 21.1 (CH2,  
C-11), 19.2 (CH3, C-19), 13.3 (CH3, C-18); IR (neat): 2944, 2898, 2849, 1702, 1360, 
1188, 1175, 937 cm-1; HRMS (ESI): calculated for C28H38NaO4S [MNa
+] requires 
493.2388, found 493.2368 (3.1 ppm error). Data in accordance with those reported in the 
literature.82, 84 
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Synthesis of tosylate 3.59 using p-TsCl and DMAP in py84 
p-TsCl (4.65 g, 24.5 mmol) and DMAP (5.97 mg, 0.05 mmol) were added to a solution 
of pregnenolone 3.56 (1.55 g, 4.89 mmol) in dry py (30 mL). The reaction mixture was 
stirred at rt overnight before being poured into ice-bath cooled H2O (75 mL). A white 
precipitate was formed, which was filtered, dissolved in CH2Cl2 (150 mL) and washed 
with H2O (3 x 150 ml). The organic layer was separated, dried over MgSO4, filtered, 
evaporated under reduced pressure and dried in vacuo to give tosylate 3.59 (2.11 g, 92%) 
as white needles. Ref. LNB0161-139 
Synthesis of tosylate 3.59 using p-TsCl, Et3N and DMAP in CH2Cl2
86 
Pregnenolone 3.56 (500 mg, 1.58 mmol) was dissolved in CH2Cl2 (8 mL), and Et3N (660 
µL, 4.75 mmol), DMAP (192 mg, 1.58 mmol) and p-TsCl (603 mg, 3.16 mmol) were 
added. The reaction mixture was stirred at rt overnight. The mixture was diluted with 
CH2Cl2 (40 mL) and H2O (40 mL). The organic layer was separated, washed with 
NaHCO3 (3 x 40 mL), H2O (40 mL) and brine (40 mL), dried over MgSO4, filtered and 
evaporated under reduced pressure. Recrystallisation of the crude product from acetone 
and water gave tosylate 3.59 (630 mg, 85%) as white needles. The mother liquor was 
evaporated under reduced pressure and the residual aqueous layer was extracted with 
CH2Cl2 (250 mL). The organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash column chromatography (SiO2, 
PE/AcOEt = 9/1 to 4/1) to afford tosylate 3.59 (107 mg, 14%) as a white solid. The two 
batches were collected together to give tosylate 3.59 (737 mg, 99%) as a white solid.  
Ref. LNB0162-090 
(3α, 5α, 6β)-6-Hydroxy-3,5-cyclopregnan-20-one 3.61 
Isolation of cyclosteroid 3.61 by-product of the synthesis of tosyl pregnenolone 3.59 
 
Pregnenolone 3.56 (2.05 g, 6.48 mmol) was dissolved in py (60 mL) and p-TsCl (6.16 g, 
32.4 mmol) and DMAP (79.1 mg, 0.65 mmol) were added. The reaction mixture was 
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stirred at rt overnight. H2O (120 mL) was added and the mixture was allowed to crystallise 
at rt. The precipitate was collected by filtration, dissolved in CH2Cl2 (100 mL) and 
washed with H2O (3 x 50 mL). The organic layer was dried over MgSO4, filtered and 
evaporated under reduced pressure to afford tosylate 3.59 (1.96 g, 64%) as a white solid. 
The aqueous filtrate was then extracted with CH2Cl2 (3 x 50 mL). Combined organic 
layers were dried over MgSO4, filtered and evaporated under reduced pressure. The 
residue was purified by flash column chromatography (SiO2, PE/AcOEt = 4/1) to afford 
cyclosteroid 3.61 (148 mg, 7%) as a white solid. Ref. LNB0161-098 
Rf: 0.28 (PE/AcOEt = 4/1); m.p.: 180-182 °C (hexane/AcOEt) [lit. 182 °C 
(hexane/AcOEt)];83 [α]D24: +105 (c 0.34, CHCl3) [lit. +107.4 (c 2.4, CHCl3)];83 1H-NMR 
(500 MHz, CDCl3), δ: 3.26-3.23 (1H, m, H-6), 2.51 (1H, “t”, J = 9.0 Hz, H-17), 2.20-
2.12 (1H, m, H-16), 2.09 (3H, s, 3H-21), 2.01 (1H, dd, J = 8.1, 2.7 Hz, H-12), 1.89-1.80 
(2H, m, H-7, H-8,), 1.78-1.48 (6H, m, H-1, 2H-2, H-11, H-15, H-16), 1.44-1.36 (2H, m, 
H-11, H-12), 1.33-1.22 (1H, m, H-15), 1.22-1.12 (2H, m, H-7, H-14), 1.09-1.04 (1H, m, 
H-3), 1.03 (3H, s, 3H-19), 0.91-0.81 (2H, m, H-1, H-9), 0.65 (3H, s, 3H-18), 0.51 (1H, 
“t”, J = 4.3 Hz, H-4), 0.28 (1H, dd, J = 8.1, 4.9 Hz, H-4); 13C-NMR (125 MHz, CDCl3), 
δ: 209.7 (C, C-20), 73.6 (CH, C-6), 63.9 (CH, C-17), 56.8 (CH, C-14), 47.7 (CH, C-9), 
44.4 (C, C-13), 43.0 (C, C-10), 39.3 (CH2, C-12), 38.9 (C, C-5), 37.2 (CH2, C-7), 33.3 
(CH2, C-1), 31.6 (CH2, C-21), 30.0 (CH, C-8), 25.1 (CH2, C-2), 24.5 (CH2, C-15), 24.3 
(CH, C-3), 23.0 (CH2, C-16), 22.8 (CH2, C-11), 20.3 (CH3, C-19), 13.6 (CH3, C-18), 11.7 
(CH2, C-4); IR (neat): 3517, 2928, 2913, 2859, 1693, 1015 cm
-1; HRMS (ESI): calculated 
for C21H32NaO2 [MNa
+] requires 339.2295, found 339.2286 (2.3 ppm error). Data are 
consistent with those reported in the literature except for the 1H-NMR assignments of  
H-3 and H-4.83, 85 
Synthesis of cyclosteroid 3.61 from tosylate 3.5983 
 
Tosylate 3.59 (107 mg, 0.23 mmol) was dissolved in a mixture of acetone/H2O (5/1, 12 
mL) and treated with AcOK (134 mg, 1.37 mmol). The mixture was stirred at reflux for 
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1 d. The acetone was evaporated under reduced pressure and the residue was then diluted 
with H2O (10 mL) and extracted with AcOEt (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, PE/AcOEt = 4/1) to afford cyclosteroid 
3.61 (43.0 mg, 59%) as a white solid. Ref. LNB0162-092 
(3β)-3-Methoxypregn-5-en-20-one 3.60 and (3β)-3-methoxy-17α-pregnen-5-en-20-
one 3.7392  
Synthesis of 3β-methoxy-pregnenolones 3.60 and 3.73 via rearrangement of tosylate 
3.5982, 84 
 
Tosylate 3.59 (2.11 g, 4.49 mmol) was suspended in MeOH (50 mL) and stirred at reflux 
for 4 h. After cooling down to rt, the methanol was evaporated under reduced pressure. 
The residue was dissolved in AcOEt (100 mL) and washed with H2O (3 x 80 mL). The 
organic layer was dried over MgSO4, filtered and evaporated under reduced pressure to 
afford the diastereomeric mixture of methyl ethers 3.60/3.73 (81/19, 1.50 g, 99%) as a 
white solid. Recrystallisation from methanol gave methyl ether 3.60 (842 mg, 57%) as 
white needles. Evaporation of the filtrate gave a mixture of 3.60/3.73 (3/2, 658 mg) as a 
yellow solid. Ref. LNB0161-141  
Characterisation of 3.60: Rf: 0.33 (PE/AcOEt = 9/1); m.p.: 124 °C (MeOH) [lit. 123-124 
°C (methanol/H2O)];
82 [α]D24: +16 (c 1, CHCl3) [lit. +18 (c 31.8, CHCl3)];82 1H-NMR 
(500 MHz, CDCl3), δ: 5.36-5.31 (1H, m, H-6), 3.34 (3H, s, 3H-1a), 3.09-3.00 (1H, m,  
H-3), 2.51 (1H, “t”, J = 8.9 Hz, H-17), 2.38 (1H, ddd, J = 13.1, 4.5, 2.2 Hz, H-4),  
2.23-2.09 (2H, m, H-4, H-16), 2.11 (3H, s, 3H-21), 2.06-1.95 (2H, m, H-7, H-12), 1.91 
(1H, “dt”, J = 12.6, 3.0 Hz, H-2), 1.86 (1H, “dt”, J = 13.1, 3.3 Hz, H-1), 1.72-1.59 (m, 
3H, H-16, H-15, H-11), 1.59-1.51 (1H, m, H-7), 1.51-1.36 (4H, m, H-2, H-8, H-11, H-
12), 1.28-1.17 (1H, m, H-15), 1.17-1.09 (1H, m, H-14), 1.08-1.01 (1H, m, H-1),  
1.00-0.93 (1H, m, H-9), 0.98 (3H, s, 3H-19), 0.62 (3H, s, 3H-18); 13C-NMR (125 MHz, 
CDCl3), δ: 209.6 (C, C-20), 141.0 (C, C-5), 121.4 (CH, C-6), 80.4 (CH, C-3), 63.8 (CH, 
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C-17), 57.1 (CH, C-14), 55.7 (CH3, C-1a), 50.2 (CH, C-9), 44.1 (C, C-13), 39.0 (CH2,  
C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, C-10), 32.0 (CH, C-8), 31.9 (CH2,  
C-7), 31.6 (CH3, C-21), 28.1 (CH2, C-2), 24.6 (CH2, C-15), 22.9 (CH2, C-16), 21.2 (CH2, 
C-11), 19.5 (CH3, C-19), 13.3 (CH3, C-18); 1H-NMR (500 MHz, C6D6), δ: 5.36-5.32 (1H, 
m, H-6), 3.22 (3H, s, 3H-1a), 3.05 (1H, “tt”, J = 11.1, 4.5 Hz, H-3), 2.55-2.47 (1H, m,  
H-4), 2.38-2.28 (2H, m, H-16, H-4), 2.12 (1H, “t”, J = 8.9 Hz, H-17), 1.97-1.90 (1H, m, 
H-2), 1.90-1.79 (2H, m, H-7, H-12), 1.82 (3H, s, 3H-21), 1.71 (1H, “dt”, J = 13.3, 3.5 Hz, 
H-1), 1.57-1.71 (5H, m, H-2, H-7, H-11, H-15, H-16), 1.36-1.23 (2H, m, H-8, H-11), 
1.15-0.93 (3H, m, H-1, H-12, H-15,), 0.93-0.80 (2H, m, H-9, H-14), 0.89 (3H, s, 3H-19), 
0.57 (3H, s, 3H-18); 13C-NMR (125 MHz, C6D6), δ: 206.8 (C, C-20), 141.2 (C, C-5), 
121.5 (CH, C-6), 80.6 (CH, C-3), 63.8 (CH, C-17), 57.0 (CH, C-14), 55.5 (CH3, C-1a), 
50.5 (CH, C-9), 43.8 (C, C-13), 39.4 (CH2, C-4), 39.0 (CH2, C-12), 37.6 (CH2, C-1), 37.2 
(C, C-10), 32.2 (CH2, C-7), 31.9 (CH, C-8), 31.2 (CH3, C-21), 28.6 (CH2, C-2), 24.7 
(CH2, C-15), 23.2 (CH2, C-16), 21.4 (CH2, C-11), 19.5 (CH3, C-19), 13.3 (CH3, C-18); 
1H-NMR (400 MHz, CD2Cl2), δ: 5.38-5.33 (1H, m, H-6), 3.30 (3H, s, 3H-1a), 3.02 (1H, 
“tt”, J = 11.2, 4.4 Hz, H-3), 2.52 (1H, “t”, J = 9.0 Hz, H-17), 2.41-2.32 (1H, m, H-4), 
2.18-1.95 (4H, m, H-4, H-7, H-12, H-16), 2.08 (3H, s, 3H-21), 1.94-1.83 (2H, m, H-1, H-
2), 1.71-1.31 (8H, m, H-2, H-7, H-8, 2H-11, H-12, H-15, H-16,), 1.28-1.10 (2H, m,  
H-14, H-15), 1.10-0.98 (2H, m, H-1, H-9), 0.99 (3H, m, 3H-19), 2.06 (3H, s, 3H-18);  
13C-NMR (100 MHz, CD2Cl2), δ: 209.3 (C, C-20), 141.4 (C, C-5), 121.5 (CH, C-6), 80.6 
(CH, C-3), 63.9 (CH, C-17), 57.2 (CH, C-14), 55.7 (CH3, C-1a), 50.5 (CH, C-9), 44.2 (C, 
C-13), 39.2 (CH2, C-12), 39.1 (CH2, C-4), 37.6 (CH2, C-1), 37.3 (C, C-10), 32.2 (CH,  
C-8), 32.2 (CH2, C-7), 31.7 (CH3, C-21), 28.4 (CH2, C-2), 24.8 (CH2, C-15), 23.1 (CH2, 
C-16), 21.5 (CH2, C-11), 19.6 (CH3, C-19), 13.3 (CH3, C-18); IR (neat): 2968, 2947, 
2847, 1698, 1351, 1189, 1094, 945, 593 cm-1; HRMS (ESI): calculated for C22H34NaO2 
[MNa+] requires 353.2451, found 353.2435 (4.6 ppm error). Data are consistent with 
those reported in the literature.82, 84 
Characterisation of 3.73 within the diastereoisomeric mixture 3.60/3.73 in approximately 
47/53 ratio (only signals of the 17α-isomer 3.73 are reported): Rf: 0.31 (PE/AcOEt = 
9/1); 1H-NMR (500 MHz, CDCl3), δ: 5.36-5.30 (1H, m, H-6), 3.33 (3H, s, 3H-1a),  
3.09-2.98 (1H, m, H-3), 2.79 (1H, dd, J = 8.3, 2.4 Hz, H-17), 2.40-2.33 (1H, m, H-4), 
2.20-2.08 (1H, m, H-4), 2.10 (3H, s, 3H-21), 2.06-1.94 (12H, m, H-1, 2H-2, 2H-7, H-8, 
2H-11, H-12, H-15, 2H-16), 1.28-1.08 (3H, m, H-12, H-14, H-15), 1.08-0.84 (2H, m,  
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H-1, H-9), 0.97 (3H, s, 3H-19), 0.91 (3H, s, 3H-18); 13C-NMR (125 MHz, CDCl3), δ: 
212.8 (C, C-20), 140.6 (C, C-5), 121.7 (CH, C-6), 80.3 (CH, C-3), 61.4 (CH, C-17), 55.7 
(CH3, C-1a), 50.7 (CH, C-14), 49.7 (CH, C-9), 45.6 (C, C-13), 38.8 (CH2, C-4), 37.3 
(CH2, C-1), 37.0 (C, C-10), 35.2 (CH2, C-12), 32.9 (CH3, C-21), 32.2 (CH2, C-7), 31.2 
(CH, C-8), 28.1 (CH2, C-2), 26.1 (CH2, C-15), 24.5 (CH2, C-16), 21.1 (CH2, C-11), 20.8 
(CH3, C-18), 19.4 (CH3, C-19); HRMS (ESI): calculated for C22H34NaO2 [MNa
+] 
requires 353.2451, found 353.2451 (0.5 ppm error). 
Synthesis of 3β-methoxypregenolone 3.60 from pregnenolone 3.56 
 
Preparation of silver(I) oxide224 
A solution of AgNO3 (850 mg, 5.00 mmol) in H2O (1.5 mL) was added to a solution of 
NaOH (200 mg, 5.00 mmol) in H2O (6 mL) under manual stirring. The brown precipitate 
formed was filtered, washed with H2O and dried to give Ag2O (540 mg, 48%) as a brown 
solid. LNB0162-093  
Methylation of pregnenolone 3.56 with methyl iodide and silver(I) oxide94 
Pregnenolone 3.56 (275 mg, 0.87 mmol) was added to a suspension of freshly prepared 
Ag2O (303 mg, 1.31 mmol) and activated 4 Å molecular sieves in a mixture of Et2O (15 
mL) and THF (6 mL). MeI (1.08 mL, 17.4 mmol) was added and the reaction mixture 
was stirred at 40 °C for 2 d. After cooling down to rt, the reaction mixture was diluted 
with AcOEt (10 mL) and filtered through a pad of Celite®. The filtrate was evaporated 
under reduced pressure. Purification of the residue by flash column chromatography 
(SiO2, PE/AcOEt = 4/1) afforded methyl ether 3.60 (200 mg, 70%) as a white solid.  
Ref. LNB0145-074 
Methylation of pregnenolone 3.56 with methyl iodide and sodium hydride95 
Pregnenolone 3.56 (2.00 g, 6.33 mmol) was dissolved in dry THF (60 mL) and cooled to 
0 °C. NaH (60% dispersion in mineral oil, 304 mg, 7.60 mmol) was added, and the 
mixture was stirred at 0 °C for 30 min. The ice bath was removed, MeI (1.97 mL, 31.7 
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mmol) was added and the reaction mixture was stirred at rt overnight. The reaction was 
re-cooled to 0 °C, quenched with H2O (200 mL) and extracted with AcOEt (3 x 50 mL). 
The combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude was purified by flash column chromatography (SiO2, 
PE/AcOEt = 4/1) to afford methyl ether 3.60 (1.59 g, 80%) as a white solid.  
Ref. LNB0161-146 
1-[(3S,8S,9S,10R,13S,14S,17S)-3-Methoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13, 
14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propan-1-one 3.76 
Isolation of ethyl-steroid 3.76 as by-product of the synthesis of 3β-methoxypregnenolone 
3.60 
 
NaH (60% dispersion in mineral oil, 198 mg, 4.95 mmol) was suspended in THF (30 mL) 
and cooled to 0 °C. Pregnenolone 3.56 (1.04 g, 3.30 mmol) was added as a solid and the 
mixture was stirred at 0 °C for 20 min. MeI (1.03 mL, 16.5 mmol) was added, the ice bath 
was removed, and the reaction mixture stirred at rt for three d. The reaction was quenched 
with H2O (30 mL) and extracted with AcOEt (3 x 30 mL). The combined organic layers 
were dried over MgSO4, filtered and evaporated under reduced pressure. The crude was 
purified by flash column chromatography (SiO2, PE/AcOEt = 9/1 to 4/1) to afford methyl 
ether 3.60 (691 mg, 63%) as a single diastereoisomer and white solid. Also isolated was 
ethyl ketone 3.76 (54.0 mg, 5%) as a white solid. Ref. LNB0145-073 
Characterisation of ethyl ketone 3.76: Rf: 0.40 (PE/AcOEt = 95/5); m.p.: 104-106 °C [lit. 
118-119 °C (PE)];96 [α]D24: +10 (c 0.34, CHCl3) [lit. +17 (c 0.4, Et2O)];96 1H-NMR (500 
MHz, CDCl3), δ: 5.36-5.30 (1H, m, H-6), 3.33 (3H, s, 3H-1a), 3.04 (1H, “tt”, J = 11.2, 
4.5 Hz, H-3), 2.50 (1H, “t”, J = 8.9 Hz, H-17), 2.41-2.31 (3H, m, H-4, 2H-21), 2.21-2.09 
(2H, m, H-4, H-16), 2.03-1.94 (2H, m, H-7, H-12), 1.90 (1H, “dt”, J = 12.6, 3.0 Hz,  
H-2), 1.85 (1H, “dt”, J = 13.1, 3.3 Hz, H-1), 1.72-1.35 (8H, m, H-2, H-7, H-8, 2H-11,  
H-12, H-15, H-16), 1.27-1.17 (1H, m, H-15), 1.16-1.08 (1H, m, H-14), 1.07-0.91 (2H, m, 
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H-1, H-9), 1.01 (3H, t, J = 7.2 Hz, 3H-22), 0.97 (3H, s, 3H-19), 0.59 (3H, s, 3H-18);  
13C-NMR (125 MHz, CDCl3), δ: 212.1 (C, C-20), 141.0 (C, C-5), 121.4 (CH, C-6), 80.4 
(CH, C-3), 62.8 (CH, C-17), 57.1 (CH, C-14), 55.7 (CH3, C-1a), 50.2 (CH, C-9), 44.2 (C, 
C-13), 39.0 (CH2, C-12), 38.7 (CH2, C-4), 37.4 (CH2, C-21), 37.3 (CH2, C-1), 37.0 (CH, 
C-10), 32.0 (CH, C-8), 31.9 (CH2, C-7), 28.1 (CH2, C-2), 24.7 (CH2, C-15), 23.2 (CH2, 
C-16), 21.2 (CH2, C-11), 19.5 (CH3, C-19), 13.5 (CH3, C-18), 7.9 (CH3, C-22); IR (neat): 
2968, 2937, 2859, 1706, 1452, 1380, 1102, 1011, 800 cm-1; HRMS (ESI): calculated for 
C23H37O2 [MH
+] requires 345.2788, found 345.2782 (1.6 ppm error), calculated for 
C23H36NaO2 [MNa
+] requires, 367.2608 found 367.2589 (4.5 ppm error). Data are 
consistent with those reported in the literature.96 
(3α, 5α, 6β)-6-Methoxy-3,5-cyclopregnan-20-one 3.7582, 97 
 
A solution of tosylate 3.59 (146 mg, 0.311 mmol) and potassium acetate (152 mg, 1.55 
mmol) in methanol (35 mL) was stirred at reflux overnight. The mixture was cooled down 
to rt and then H2O (20 mL) was added. The methanol was evaporated under reduced 
pressure and the aqueous phase was extracted with AcOEt (3 x 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated under reduced pressure. 
The crude material was purified by flash column chromatography (SiO2, PE/AcOEt = 9/1, 
1% Et3N) to afford the title compound 3.75 (81.0 mg, 79%) as a white solid.  
Ref. LNB0161-034 
Rf: 0.47 (PE/AcOEt = 9/1, 1% Et3N); m.p.: 124-125 °C (MeOH) [lit. 124-125 °C 
(Et2O)];
82 [α]D24: +137.9 (c 1.12, CHCl3) [lit. +132 (c 3.18, CHCl3)];82 1H-NMR (500 
MHz, CDCl3), δ: 3.29 (3H, s, 3H-1a), 2.75 (1H, “t”, J = 2.7 Hz, H-6), 2.51 (1H, “t”,  
J = 9 Hz, H-17), 2.20-2.11 (1H, m, H-16), 2.09 (3H, s, 3H-21), 2.00 (1H, dd, J = 8.2, 2.8 
Hz, H-12), 1.87 (1H, “dt”, J = 13.4, 2.9 Hz, H-7), 1.79-1.57 (4H, m, H-2, H-8, H-15,  
H-16), 1.55-1.45 (3H, m, H-1, H-2, H-11), 1.45-1.35 (2H, m, H-11, H-12), 1.30-1.20 (1H, 
m, H-15), 1.20-1.12 (1H, m, H-14), 1.12-1.04 (1H, m, H-7), 1.00 (3H, s, 3H-19),  
0.91-0.80 (3H, m, H-1, H-3, H-9), 0.67-0.61 (1H, m, H-4), 0.64 (3H, s, H-18), 0.42 (1H, 
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dd, J = 8.2, 5.1 Hz, H-4); 13C-NMR (125 MHz, CDCl3), δ: 209.6 (C, C-20), 82.3 (CH, 
C-6), 64.0 (CH, C-17), 56.8 (CH, C-14), 56.7 (CH3, C-1a), 48.1 (CH, C-9), 44.5 (C,  
C-13), 43.5 (C, C-10), 39.4 (CH2, C-12), 35.5 (C, C-5), 35.2 (CH2, C-7), 33.5 (CH2,  
C-1), 31.6 (CH3, C-21), 30.6 (CH2, C-8), 25.0 (CH2, C-2), 24.5 (CH2, C-15), 23.0 (CH2, 
C-16), 22.86 (CH2, C-11), 21.5 (CH, C-3), 19.4 (CH3, C-19), 13.7 (CH3, C-18), 13.2 
(CH2, C-4); 1H-NMR (500 MHz, C6D6), δ: 3.19 (3H, s, 3H-1a), 2.58 (1H, “t”, J = 2.6 Hz, 
H-6), 2.41-2.31 (1H, m, H-16), 2.20-2.13 (1H, m, H-17), 1.92-1.85 (2H, m, H-7, H-8), 
1.85-1.72 (2H, m, H-2, H-12,), 1.81 (3H, s, 3H-21), 1.61-1.43 (4H, m, H-1, H-2, H-7,  
H-15), 1.39-1.27 (2H, m, 2H-11), 1.23-1.13 (1H, m, H-15), 1.15 (3H, s, 3H-19), 1.09 (1H, 
“td”, J = 12.1, 5.1 Hz, H-12), 0.97-0.71 (5H, m, H-1, H-3, H-7, H-9, H-14,), 0.63 (3H, s, 
3H-18), 0.63-0.59 (1H, m, H-4), 0.40 (1H, dd, J = 7.8, 5.1 Hz, H-4); 13C-NMR (125 
MHz, C6D6), δ: 206.8 (C, C-20), 82.3 (CH, C-6), 63.9 (CH, C-17), 56.8 (CH, C-14), 56.6 
(CH3, C-1a), 48.4 (CH, C-9), 44.2 (C, C-13), 43.7 (C, C-10), 39.6 (CH2, C-12), 35.7 (C, 
C-5), 35.5 (CH2, C-7), 33.8 (CH2, C-1), 31.1 (CH3, C-21), 30.8 (CH, C-8), 25.4 (CH2, C-
2), 24.7 (CH2, C-15), 23.3 (CH2, C-16), 23.2 (CH2, C-11), 21.7 (CH, C-3), 19.7 (CH3, C-
19), 13.6 (CH3, C-18), 13.5 (CH2, C-4); IR (neat): 2933, 1702, 1094, 1020 cm
-1; HRMS 
(ESI): calculated for C22H34NaO2 [MNa
+] requires, 353.2451, found 353.2439 (3.0 ppm 
error). Data in accordance to those reported in the literature.82, 97 
(1R)-1-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-1-(1,3-thiazol-2-yl)ethanol 3.79 and 
1-[(3b,17b)-3-methoxyandrost-5-en-17-yl]-1-(1,3-thiazol-2-yl)ethanol 3.80 
 
Thiazole 3.78 (54.0 µL, 0.76 mmol) was dissolved in THF (500 µL), cooled to -30 °C, 
and n-BuLi (2.5 M solution in hexane, 303 µL, 0.76 mmol) added dropwise. The reaction 
mixture was stirred for 30 min (during which time the temperature of the cooling bath 
reached -20 °C), before a solution of 3β-methoxy-pregnenolone 3.60 (100 mg, 0.32 
mmol) in THF (1 mL) was added. The reaction mixture was stirred for 10 min at -20 °C, 
and then brought to rt and stirred for a further 2 h. The reaction was quenched with H2O 
(20 mL) and extracted with AcOEt (3 x 20 mL). The combined organic layers were 
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washed with brine (20 mL), dried over MgSO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (SiO2, PE/AcOEt = 
4/1) to afford the diasteromeric mixture of thiazolyl-steroids 3.79/3.80 (9/1, 105 mg, 
84%) as white solids. Recrystallisation from methanol gave thiazolyl steroid 3.79 (64.0 
mg, 48%) as white needles. Evaporation of the filtrate under reduced pressure gave a 
mixture of 3.79/3.80 (77/23, 35.0 mg) as a white solid. Ref. LNB0162-099 
Characterisation of 3.79: Rf: 0.14 (PE/AcOEt = 9/1); m.p.: 190-193 °C (MeOH);  
[α]D24 = -42 (c 0.40, CHCl3); 1H-NMR (500 MHz, CDCl3), δ: 7.65 (1H, d, J = 3.2 Hz, H-
2b), 7.22 (1H, d, J = 3.2 Hz, H-3b), 5.35-5.31 (1H, m, H-6), 3.34 (3H, s, 3H-1a), 3.12 
(1H, brs, OH), 3.09-3.01 (1H, m, H-3), 2.41-2.34 (1H, m, H-4), 2.19-2.07 (2H, m, H-4, 
H-12), 2.04 (1H, “t”, J = 9.8 Hz, H-17), 1.99-1.88 (2H, m, H-4, H-7), 1.85 (1H, “dt”, J = 
13.3, 3.1 Hz, H-1), 1.82-1.73 (1H, m, H-16), 1.70 (3H, s, 3H-21), 1.60-1.22 (8H, m, H-2, 
H-7, H-8, 2H-11, H-12, H-15, H-16), 1.18-0.97 (3H, m, H-1, H-14, H-15,), 0.99 (3H, s, 
3H-19), 0.97-0.89 (1H, m, H-9), 0.86 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 
180.6 (C, C-1b), 141.8 (CH, C-2b), 141.0 (C, C-5), 121.5 (CH, C-6), 118.9 (CH, C-3b), 
80.4 (CH, C-3), 77.8 (C, C-20), 60.4 (CH, C-17), 56.8 (CH, C-14), 55.7 (CH3, C-1a), 50.2 
(CH, C-9), 43.3 (C, C-13), 40.0 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, 
C-10), 31.9 (CH2, C-7), 31.4 (CH, C-8), 30.0 (CH3, C-21), 28.1 (CH2, C-2), 23.8 (CH2, 
C-15), 22.9 (CH2, C-16), 21.0 (CH2, C-11), 19.5 (CH3, C-19), 13.4 (CH3, C-18);  
IR (neat): 3500, 2927, 1441, 1097 cm-1; HRMS (ESI): calculated for C25H37NNaO2S 
[MNa+] requires 438.2437, found 438.2403 (8.0 ppm error); calculated for C25H38NO2S 
[MH+] requires 416.2618, found 416.2586 (7.3 ppm error); 
Characterisation of 3.80 within the diastereomeric mixture 3.79/3.80 = 77/23 (only 
relevant signals of isomer 3.80 are reported): Rf: 0.14 (PE/AcOEt  = 9/1); 1H-NMR (500 
MHz, CDCl3), δ: 7.69 (1H, d, J = 3.2 Hz, H-2b), 7.25 (1H, d, J = 3.2 Hz, H-3b),  
5.36-5.30 (1H, m, H-6), 3.32 (3H, s, 3H-1a), 3.12-2.97 (2H, m, H-3, OH), 2.38-2.32 (1H, 
m, H-4), 1.58 (3H, s, 3H-21), 0.91 (3H, s, 3H-19), 0.84 (3H, s, 3H-18); 13C-NMR (500 
MHz, CDCl3), δ: 179.4 (C, C-1b), 141.8 (CH, C-2b), 141.0 (C, C-5), 121.5 (CH, C-6), 
118.8 (CH, C-3b), 80.4 (CH, C-3), 77.8 (C, C-20), 60.5 (CH, C-17), 56.7 (CH, C-14), 
55.7 (CH3, C-1a), 50.1 (CH, C-9), 42.8 (C, C-13), 38.8 (CH2, C-4), 37.9 (CH2, C-12), 
37.2 (CH2, C-1), 36.9 (C, C-10), 31.9 (CH2, C-7), 31.6 (CH3, C-21), 31.4 (CH, C-8), 28.1 
(CH2, C-2), 22.8 (2CH2, C-15, C-16), 20.9 (CH2, C-11), 19.4 (CH3, C-19), 13.1 (CH2,  
C-18); IR (neat): 2923, 2853, 1097 cm-1; HRMS (ESI): calculated for C25H37NNaO2S 
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[MNa+] requires 438.2437, found 438.2414 (5.4 ppm error); calculated for C25H38NO2S 
[MH+] requires 416.2618, found 416.2592 (6.2 ppm error). 
1-[(3β,17α)-3-Methoxyandrost-5-en-17-yl]-1-(1,3-thiazol-2-yl)ethanol 3.88 
 
Thiazole 3.78 (38.0 µl, 0.54 mmol) was dissolved in THF (1 mL) and cooled to -40 °C, 
then n-BuLi (1.6 M in hexane, 339 µL, 0.54 mmol) was added. The mixture was stirred 
at -40 °C for 30 min, before a solution of diastereisomeric steroids 3.60/3.73 (42/58 ratio, 
163 mg, 0.35 mmol) in THF (1 mL) was added. The reaction was allowed to reach rt and 
stirred for 3 h before being quenched with H2O (5 mL) and extracted with AcOEt (3 x 5 
mL). The combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash column chromatography (SiO2, 
PE/AcOEt = 9/1 to 7/3) to afford the mixture of thiazolyl-steroids 3.79/3.88 (37/63, 122 
mg, 60%) as a white solid. Ref. LNB0161-001 
Characterisation of 3.88 as major isomer of the diastereomeric mixture 3.79/3.88 = 37/63 
(only relevant signals of isomer 3.88 are reported): Rf: 0.10 (PE/AcOEt = 9/1);  
1H-NMR (500 MHz, CDCl3), δ: 7.64 (1H, d, J = 3.2 Hz, H-2b), 7.25 (1H, d, J = 3.2 Hz, 
H-3b), 5.34-5.29 (1H, m, H-6), 3.33 (3H, s, 3H-1a), 3.07-3.00 (1H, m, H-3), 2.40-2.33 
(1H, m, H-4), 2.32-2.25 (1H, brs, H-17), 1.68 (3H, s, 3H-21), 0.96 (3H, s, 3H-19),  
0.86 (3H, s, 3H-18); 13C-NMR (125 MHz, CDCl3), δ: 180.7 (C, C-1b), 141.3 (CH,  
C-2b), 140.8 (C, C-5), 121.6 (CH, C-6), 119.2 (CH, C-3b), 80.4 (CH, C-3), 77.8 (C,  
C-20), 59.2 (CH, C-17), 55.6 (CH, C-1a), 53.3 (CH, C-14), 49.7 (CH, C-9), 44.6 (C,  
C-13), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, C-10), 35.2 (CH2, C-12), 32.4 (2C, 
CH2, C-7, CH, C-8), 30.0 (CH3,C-21), 28.1 (CH2, C-2), 26.2 (CH2, C-15), 25.9 (CH2,  
C-16), 22.5 (CH3, C-18), 21.4 (CH2, C-11), 19.4 (CH3, C-19); IR (liquid film): 3318, 
2889, 1430, 1081 cm-1; HRMS (ESI): calculated for C25H38NO2S [MH
+] requires 
416.2618, found 416.2600 (4.8 ppm error). 
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(1R)-1-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-1-(pyridin-2-yl)ethanol 3.94 and  
1-[(3b,17b)-3-methoxyandrost-5-en-17-yl]-1-(pyridin-2-yl)ethanol 3.95108 
 
2-Bromopyridine 3.93 (64.0 µL, 0.67 mmol) was dissolved in THF (1 mL) and cooled to 
-78 °C, then n-BuLi (2.5 M solution in hexane, 303 µL, 0.76 mmol) was added. The 
mixture was stirred at -78 °C for 10 min, and then at 0 °C before a solution of steroid 3.60 
(100 mg, 0.30 mmol) in THF (1 mL) was added. The reaction mixture was stirred at rt 
for 3.5 h, before being quenched with H2O (20 mL) and extracted with AcOEt (3 x 10 
mL). The combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash column chromatography (SiO2, 
hexane/AcOEt = 9/1) to afford a mixture of 3.94/3.95 (9/1, 80.0 mg, 68%) as a white 
solid. Recrystallisation from MeOH and CH2Cl2 gave compound 3.94 (65.0 mg, 53%) as 
white needles, Evaporation of the filtrate under reduced pressure gave a mixture of 
3.94/3.95 (2/3 ratio, 35.0 mg) as a white solid. Ref. LNB0162-104 
Characterisation of isomer 3.94: Rf: 0.24 (PE/AcOEt = 9/1); m.p.: 223-225 °C 
(CH2Cl2/MeOH); [α]D24: -90 (c 0.49, CHCl3); 1H-NMR (400 MHz, CDCl3), δ: 8.46 (1H, 
d, J = 4.4 Hz, H-5b), 7.68 (1H, “td”, J = 7.7, 1.5 Hz, H-3b), 7.33 (1H, d, J = 8.1 Hz,  
H-2b), 7.16 (1H, dd, J = 6.6, 5.1 Hz, H-4b), 5.53 (1H, s, OH), 5.37-5.31 (1H, m, H-6), 
3.35 (3H, s, 3H-1a), 3.13-3.00 (1H, m, H-3), 2.43-2.34 (1H, m, H-4), 2.23 (1H, “dt”, J = 
12.1, 3.3 Hz, H-12), 2.29-2.10 (1H, m, H-4), 2.19-1.84 (3H, m, H-1, H-2, H-7), 1.82-1.75 
(1H, “t”, J = 9.8 Hz, H-17), 1.67-1.27 (8H, m, H-2, H-7, H-8, 2H-11, H-12, H-15, H-16), 
1.59 (3H, s, 3H-21), 1.17-0.88 (4H, m, H-1, H-9, H-14, H-15), 1.02 (3H, s, 3H-19), 0.95 
(3H, s, 3H-18), 0.88-0.76 (1H, m, H-16); 13C-NMR (100 MHz, CDCl3), δ: 166.2 (C,  
C-1b), 146.7 (CH, C-5b), 141.1 (C, C-5), 137.1 (CH, C-3b), 121.6 (2CH, C-6, C-4b), 
119.5 (CH, C-2b), 80.5 (CH, C-3), 75.1 (C, C-20), 60.5 (CH, C-17), 57.2 (CH, C-14), 
55.8 (CH3, C-1a), 50.4 (CH, C-9), 43.5 (C, C-13), 40.5 (CH2, C-12), 38.8 (CH2, C-4), 
37.4 (CH2, C-1), 37.1 (C, C-10), 32.0 (CH2, C-7), 31.5 (CH, C-8), 28.9 (CH3, C-21), 28.2 
(CH2, C-2), 23.9 (CH2, C-15), 22.6 (CH2, C-16), 21.2 (CH2, C-11), 19.5 (CH3, C-19), 
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13.4 (CH3, C-18); IR (liquid film): 3329, 2891, 2324, 1366, 1341, 1082 cm
-1; HRMS 
(ESI): calculated for C27H40NO2 [MH
+] requires 410.3054, found 410.3054 (4.6 ppm 
error); Elemental Analysis: calculated for C27H39NO2 requires C 79.17, H 9.60, N 3.42 
found C 78.82, H 9.54, N 3.42. 
Characterisation of isomer 3.95 within the diastereomeric mixture 3.94/3.95 = 2/3 (only 
relevant signals of isomer 3.95 are reported): Rf: 0.24 (PE/AcOEt = 9/1); 1H-NMR (400 
MHz, CDCl3), δ: 8.48 (1H, d, J = 4.9 Hz, H-5b), 7.69-7.62 (1H, m, H-3b), 7.36-7.32 (1H, 
m, H-2b), 7.21-7.16 (1H, m, H-4b), 3.31 (3H, s, 3H-1a), 1.45 (3H, s, 3H-21), 0.87 (3H, 
s, 3H-19), 0.73 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 165.2 (C, C-1b), 146.6 
(CH, C-5b), 140.9 (C, C-5), 136.5 (CH, C-3b), 121.9 (2CH, C-6, C-4b), 120.7 (CH,  
C-2b), 80.4 (CH, C-3), 74.9 (C, C-20), 60.6 (CH, C-17), 56.9 (CH, C-14), 55.7 (CH3, C-
1a), 50.2 (CH, C-9), 42.6 (C, C-13), 38.8 (CH2, C-4), 38.7 (CH2, C-12), 37.2 (CH2, C-1), 
36.9 (C, C-10), 31.9 (CH2, C-7), 31.3 (CH, C-8), 30.4 (CH3, C-21), 28.1 (CH2, C-2), 23.8 
(CH2, C-15), 23.1 (CH2, C-16), 20.8 (CH2, C-11), 19.4 (CH3, C-19), 13.3 (CH3, C-18); 
IR (neat): 3350, 2925, 2324, 1096 cm-1; HRMS (ESI): calculated for C27H40NO2 [MH
+] 
requires 410.3030, found 410.3026 (1.5 ppm error). 
(1R)-1-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-1-(thiophen-2-yl)ethanol 3.100  
 
Thiophene 3.99 (19.0 µL, 0.24 mmol) and TMEDA (36.0 µL, 0.24 mmol) were dissolved 
in THF (0.5 mL) and cooled to 0 °C. n-BuLi (1.6 M solution in hexane, 150 µL, 0.24 
mmol) was added and the reaction mixture was stirred for 10 min at 0 °C, it was then 
allowed to warm to rt and stirred for a further 50 min. The solution of 2-lithiothiophene 
was re-cooled again to 0 °C, and a solution of ketone 3.60 (72 mg, 0.22 mmol) in THF (1 
mL) was added. The reaction mixture was stirred at rt for 3 h, before being quenched with 
H2O (5 mL) and extracted with AcOEt (3 x 5 mL). The combined organic layers were 
dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, PE/AcOEt = 9/1) followed by 
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recrystallisation in methanol to afford diastereomerically pure thiophenyl-steroid 3.100 
(46.0 mg, 51%) as a white solid. Ref. LNB0145-112 
Rf: 0.40 (PE/AcOEt = 9/1); m.p.: 190-192 °C (MeOH); [α]D24: -67 (c 0.40, CH2Cl2);  
1H-NMR (400 MHz, CD2Cl2), δ: 7.13 (1H, dd, J = 5.0, 1.1 Hz, H-4b), 6.92 (1H, dd,  
J = 5.0, 3.6 Hz, H-3b), 6.84 (1H, dd, J = 3.6, 1.1 Hz, H-2b), 5.37-5.30 (1H, m, H-6), 3.30 
(3H, s, 3H-1a), 3.06-2.96 (1H, m, H-3), 2.39-2.21 (1H, m, H-4), 2.16-2.06 (1H, m, H-4), 
2.05-1.81 (5H, m, H-1, H-2, H-7, H-12, H-17), 1.80-1.69 (1H, m, H-16), 1.68 (3H, s,  
H-21), 1.62-1.22 (8H, m, H-2, H-7, H-8, 2H-11, H-12, H-15, H-16), 1.19-0.89 (4H, m, 
H-1, H-9, H-14, H-15), 1.00 (3H, s, 3H-19), 0.86 (3H, s, 3H-18); 13C-NMR (100 MHz, 
CD2Cl2), δ: 156.6 (C, C-1b), 141.5 (C, C-5), 126. 9 (CH, C-3b), 123.2 (CH, C-4b), 121.8 
(CH, C-2b), 121.6 (CH, C-6), 80.7 (CH, C-3), 76.6 (C, C-20), 61.9 (CH, C-17), 57.3 (CH, 
C-14), 55.7 (CH3, C-1a), 50.5 (CH, C-9), 43.3 (C, C-13), 40.1 (CH2, C-12), 39.1 (CH2, 
C-4), 37.6 (CH2, C-1), 37.2 (C, C-10), 32.2 (CH2, C-7), 31.7 (CH, C-8), 31.4 (CH3,  
C-21), 28.4 (CH2, C-2), 23.9 (CH2, C-15), 23.6 (CH2, C-16), 21.3 (CH2, C-11), 19.5 (CH3, 
C-19), 13.4 (CH3, C-18); IR (neat): 3454, 2932, 2902, 2861, 1096 cm
-1; HRMS (ESI): 
calculated for C26H38NaO2S [MNa
+] requires, 437.2485, found 437.2470 (2.6 ppm error).  
 (3β,17β)-17-[1-(Furan-2-yl)ethenyl]-3-methoxyandrost-5-ene 3.112116 
 
Furan 3.110 (65 µL, 0.90 mmol) was dissolved in THF (0.5 mL) and cooled to -10 °C.  
n-BuLi (1.6 M in hexane, 563 µL, 0.90 mmol) was added and the reaction mixture was 
stirred at -10 °C for 30 min before addition of a solution of steroid 3.60 (147 mg, 0.45 
mmol) in THF (2 mL). The reaction mixture was stirred at -10 °C for 20 min, and then at 
rt for a further 2 h. The reaction was cooled to 0 °C, quenched with sat aq NH4Cl (15 mL) 
and extracted with AcOEt (3 x 5 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated under reduced pressure. The residue was purified by flash 
column chromatography (SiO2, PE/AcOEt = 9/1) to afford compound 3.112 (56.0 mg, 
33%) as a white foam. LNB0145-059 
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Rf: 0.38 (hexane/AcOEt = 9/1); [α]D24: -51 (c 0.37, CHCl3); 1H-NMR (400 MHz, C6D6), 
δ: 7.09 (1H, d, J = 1.6 Hz, H-4b), 6.25 (1H, d, J = 3.2 Hz, H-2b), 6.15 (1H, dd, J = 3.2, 
1.6 Hz, H-3b), 5.92 (1H, brs, H-21b), 5.42-5.37 (1H, m, H-6), 5.07 (1H, brs, H-21a), 3.22 
(3H, s, 3H-1a), 3.12-3.01 (1H, m, H-3), 2.62 (1H, “t”, J = 9.6 Hz, H-17), 2.54 (1H, ddd,  
J = 13.1, 4.6, 2.1 Hz, H-4), 2.41-2.29 (1H, m, H-4), 2.01-1.87 (2H, m, H-2, H-7),  
1.86-1.72 (2H, m, 2H-16), 1.72-1.64 (1H, m, H-1), 1.63-1.31 (6H, m, H-2, H-7, H-8,  
H-11, H-12, H-15), 1.31-1.18 (1H, m, H-11), 1.17-0.86 (5H, m, H-1, H-9, H-12, H-14, 
H-15), 0.89 (3H, s, 3H-19), 0.62 (3H, s, 3H-18); 13C-NMR (100 MHz, C6D6), δ = 156.9 
(C, C-1b), 141.7 (CH, C-4b), 141.4 (C, C-5), 137.6 (C, C-20), 121.6 (CH, C-6), 111.2 
(CH, C-3b), 110.6 (CH2, C-21), 106.6 (CH, C-2b), 80.6 (CH, C-3), 57.0 (CH, C-14), 55.4 
(CH3, C-1a), 52.4 (CH, C-17), 50.9 (CH, C-9), 43.4 (C, C-13), 39.5 (CH2, C-4), 39.0 
(CH2, C-12), 37.6 (CH2, C-1), 37.3 (C, C-10), 32.8 (CH, C-8), 32.3 (CH2, C-7), 28.6 
(CH2, C-2), 26.6 (CH2, C-16), 24.5 (CH2, C-15), 21.5 (CH2, C-11), 19.5 (CH3, C-19), 
13.0 (CH3, C-18); IR (thin film): 3337, 2892, 1246, 1081, 728 cm
-1; HRMS (ESI): 
calculated for C26H37O2 [MH
+] requires 381.2788, found 381.2793 (-0.9 ppm error).  
(1R)-1-(Furan-2-yl)-1-[(3β,17β)-3-methoxyandrost-5-en-17-yl]ethanol 3.111  
 
Furan 3.110 (162 µL, 2.24 mmol) and TMEDA (401 µL, 2.73 mmol) were dissolved in 
THF (0.2 mL) and the resulting solution was cooled to -50 °C. n-BuLi (1.6 M solution in 
THF, 1.47 mL, 2.35 mmol) was added and the reaction mixture was stirred at -50 °C for 
40 min. A solution of steroid 3.60 (368 mg, 1.12 mmol) in THF (2 mL) was added, and 
the reaction mixture was stirred between -50 and -30 °C for 30 min, before being 
quenched with H2O (10 mL) and extracted with AcOEt (3 x 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated under reduced pressure. 
The residue was purified by flash column chromatography (SiO2, PE/AcOEt = 9/1, 1% 
Et3N) to afford the title compound 3.111 (364 mg, 84%) as a white solid.  
Ref. LNB0161-038 
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Rf: 0.30 (PE/AcOEt = 9/1, 1% Et3N); m.p.: 152 °C (MeOH); [α]D24: -57 (c 0.82, CH2Cl2); 
1H-NMR (400 MHz, C6D6), δ: 7.08 (1H, brs, H-4b), 6.11 (1H, dd, J = 3.0, 1.6 Hz, H-3b), 
6.06 (1H, d, J = 3.0 Hz, H-2b), 5.39-5.34 (1H, m, H-6), 3.22 (3H, s, 3H-1a), 3.11-2.99 
(1H, m, H-3), 2.57-2.49 (1H, m, H-4), 2.41-2.30 (1H, m, H-4), 1.98-1.77 (5H, m, H-2,  
H-7, H-12, H-16, H-17), 1.71 (1H, “dt”, J = 13.2, 3.3 Hz, H-1), 1.60-1.28 (7H, m, H-2,  
H-7, H-8, 2H-11, H-15, H-16), 1.54 (3H, s, 3H-21), 1.18-0.82 (5H, m, H-1, H-9, H-12, 
H-14, H-15), 0.93 (3H, s, 3H-19), 0.78 (3H, s, 3H-18); 13C-NMR (100 MHz, C6D6), δ: 
162.1 (C, C-1b), 141.2 (C, C-5), 140.7 (CH, C-4b), 121.7 (CH, C-6), 110.4 (CH, C-3b), 
104.0 (CH, C-2b), 80.6 (CH, C-3), 73.9 (C, C-20), 59.5 (CH, C-17), 57.0 (CH, C-14), 
55.4 (CH3, C-1a), 50.6 (CH, C-9), 42.8 (C, C-13), 39.7 (CH2, C-12), 39.4 (CH2, C-4), 
37.6 (CH2, C-1), 37.2 (C, C-10), 32.2 (CH2, C-7), 31.7 (CH, C-8), 28.6 (CH2, C-2), 27.6 
(CH3, C-21), 24.0 (CH2, C-15), 23.4 (CH2, C-16), 21.3 (CH2, C-11), 19.5 (CH3, C-19), 
13.2 (CH3, C-18); IR (thin film): 3378, 2889, 2856, 2806, 1347, 1138, 1081, 995 cm
-1; 
HRMS (ESI): calculated for C26H38NaO3 [MNa
+] requires 421.2713, found 421.2699 
(3.3 ppm error). 
5-Hydroxy-6-[(3β,17β)-3-methoxyandrost-5-en-17-yl]-6-methyl-5,6-dihydro-2H-
pyran-2-one 3.123121 
 
A solution of furyl steroid 3.111 (630 mg, 1.58 mmol) in a mixture of THF/H2O (4/1 
ratio, 12.5 mL) was cooled to 0 °C. NBS (281 mg, 1.58 mmol) was added portionwise 
(the yellow colour of the reaction mixture faded before addition of a second portion of 
NBS), while the temperature was carefully maintained at 0 °C. After the addition of the 
last portion of NBS the reaction was stirred for a further 10 min at 0 °C and diluted with 
AcOEt (20 mL). The organic phase was washed successively with aq 10% KI (20 mL), 
sat aq Na2S2O4 (20 mL) and H2O (20 mL), dried over MgSO4, filtered and evaporated 
under reduced pressure. The residue was purified by flash column chromatography (SiO2, 
PE/AcOEt = 4/1) to afford compound 3.123 as a mixture of diastereomers (at C-1b) (3/2, 
510 mg, 78%) as a white solid. Ref. LNB0161-152 
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Rf: 0.14 (PE/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3, evident signals of the minor 
isomer starred), δ: 6.88-6.79 (1H, m, H-2b), 6.05 (0.67H, d, J = 10.5 Hz, H-3b), 6.00 
(0.33H, d, J = 10.2* Hz, H-3b*), 5.70 (1H, brs, H-1b), 5.37-5.31 (1H, m, H-6), 3.35 (3H, 
s, 3H-1a), 3.19 (1H, m, OH), 3.11-3.00 (1H, m, H-3), 2.42-2.33 (1H, m, H-4), 2.20-1.77 
(8H, m, H-1, H-2, H-4, H-7, H-12, 2H-16, H-17), 1.64-1.35 (6H, m, H-2, H-7, H-8,  
2H-11, H-15), 1.59 (3H, s, H-21), 1.34-1.18 (2H, m, H-12, H-15), 1.17-0.95 (2H, m,  
H-1, H-14), 0.99 (3H, s, 3H-19), 0.96-0.86 (1H, m, H-9), 0.82 (0.99H, s, 3H-18*); 0.80 
(2.01H, s, 3H-18); 13C-NMR (100 MHz, CDCl3, evident signals of the minor isomer 
starred), δ: 119.4 (C, C-4b), 199.0 (C, C-4b*), 146.7 (CH, C-2b*), 143.5 (CH, C-2b), 
141.0 (C, C-5), 140.9 (CH, C-5*), 127.7 (CH, C-3b*), 126.8 (CH, C-3b), 121.7 (CH, C-
6*), 121.6 (CH, C-6), 87.7 (CH, C-1b*), 87.5 (CH, C-1b), 84.0 (C, C-20), 83.7 (C, C-
20*), 80.5 (2CH, C-3, C-3*), 56.8 (CH, C-17), 56.6 (CH, C-14*), 56.5 (CH, C-14), 55.8 
(CH, C-17*), 55.7 (2CH3, C-1a, C-1a*), 50.3 (2CH, C-9, C-9*), 42.9 (C, C-13), 42.8 (C, 
C-13*), 40.2 (CH2, C-12*), 40.1 (CH2, C-12), 38.8 (2CH2, C-4, C-4*), 37.3 (2CH2, C-1, 
C-1*), 37.1 (2C, C-10, C-10*), 31.9 (2CH2, C-7, C-7*), 31.5 (2CH, C-8, C-8*), 28.1 
(2CH2, C-2, C-2*), 26.9 (2CH3, C-21, C-21*), 24.0 (2CH2, C-15, C-15*), 22.6 (CH2,  
C-16), 22.2 (CH2, C-16*), 21.0 (2CH2, C-11, C-11*), 19.5 (2CH3, C-19, C-19*), 13.8 
(CH3, C-18), 13.7 (CH3, C-18*); IR (neat): 3366, 2934, 1685, 1368, 1099, 1025, 944, 496 
cm-1; HRMS (ESI): calculated for C26H38NaO4 [MNa
+] requires 437.2662, found 
437.2655 (1.4 ppm error). 
6-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-6-methyl-2H-pyran-2,5(6H)-dione 
3.124128 
 
Lactol 3.123 (451 mg, 1.09 mmol) was dissolved in CH2Cl2 (10 mL), NMO (446 mg, 3.82 
mmol) was added and the mixture was stirred at rt for 10 min. TPAP (38.0 mg, 0.11 
mmol) was added and the reaction mixture was stirred at rt for 2 h, before being diluted 
with CH2Cl2 (20 mL) and filtered through a pad of Celite
®. The filtrate was evaporated 
under reduced pressure and the residue was purified by flash column chromatography 
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(SiO2, PE/AcOEt = 9/1) to afford lactone 3.124 (240 mg, 53%) as a white solid.  
Ref. LNB0161-160 
Rf: 0.28 (hexane/AcOEt = 4/1); m.p.: 240-250 °C (decomposition); [α]D24: -43 (c 0.46, 
CHCl3); 1H-NMR (400 MHz, CDCl3), δ = 6.87 (1H, d, J = 10.1 Hz, H-2b), 6.67 (1H, d, 
J = 10.1 Hz, H-3b), 5.36-5.31 (1H, m, H-6), 3.35 (3H, s, 3H-1a), 2.42-2.34 (1H, m, H-4), 
2.20-2.09 (1H, m, H-4), 2.07-1.80 (5H, m, H-1, H-2, H-7, H-12, H-17), 1.70-1.29 (9H, 
m, H-2, H-7, H-8, 2H-11, H-12, H-15, 2H-16), 1.64 (3H, s, 3H-21), 1.25-1.12 (1H, m, H-
15), 1.09-0.96 (2H, m, H-1, H-14), 1.00 (3H, s, 3H-19), 0.96-0.89 (1H, m, H-9), 0.87 (3H, 
s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 196.3 (C, C-4b), 160.8 (C, C-1b), 141.1 (C, 
C-5), 137.7 (CH, C-3b), 135.3 (CH, C-2b), 121.3 (CH, C-6), 92.4 (C, C-20), 80.4 (CH, 
C-3), 58.4 (CH, C-17), 56.3 (CH, C-14), 55.8 (CH3, C-1a), 50.1 (CH, C-9), 43.3 (C, C-
13), 39.8 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, C-10), 31.8 (CH2, C-
7), 31.4 (CH, C-8), 28.1 (CH2, C-2), 25.6 (CH3, C-21), 23.8 (CH2, C-15), 23.0 (CH2, C-
16), 21.0 (CH2, C-11), 19.5 (CH3, C-19), 13.8 (CH3, C-18); IR (neat): 2971, 2948, 1685, 
1721, 1683, 1301, 1101, 867 cm-1; HRMS (ESI): calculated for C26H36NaO4 [MNa
+] 
requires 435.2506, found 435.2511 (-0.8 ppm error). 
2-Furanmethyl tert-butyldimethylsilylchloride 3.130129 
 
Furfuryl alcohol 3.129 (1.00 g, 10.2 mmol) was dissolved in DMF (20 mL) and imidazole 
(1.66 mg, 24.4 mmol) and TBSCl (3.68 mg, 20.4 mmol) were added. The resulting 
mixture was stirred at rt for 2 h, then diluted with Et2O (120 mL) and washed with  
ice-cold H2O (3 x 50 mL). The organic layer was dried over MgSO4, filter and evaporated 
under reduced pressure. The residue was purified by flash column chromatography (SiO2, 
PE/AcOEt = 95/5) to afford ether 3.130 (2.16 g, 100%) as a yellow oil.  
Ref. LNB0161-011 
Rf: 0.35 (PE/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.37 (1H, d, J = 1.4 Hz, H-
1), 6.32 (1H, dd, J = 1.4, 2.9 Hz, H-2), 6.23 (1H, d, J = 2.9 Hz, H-3), 4.64 (2H, s, H-5), 
0.90 (9H, s, 3H-9, 3H-10, 3H-111), 0.08 (6H, s, 3H-6, 3H-7). NMR data in accordance 
with those reported in the literature.129 
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(1R)-1-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-1-(5-{[(2,3,3-trimethylbutan-2-
yl)oxy]methyl furan-2-yl)ethanol 3.131 
 
A solution of silyl ether 3.130 (720 mg, 3.39 mmol) and TMEDA (420 µL, 3.39 mmol) 
in THF (3 mL) was cooled to 0 °C and n-BuLi (1.6 M in hexane, 2.23 mL, 3.56 mmol) 
was added. The reaction mixture was stirred at 0 °C for 40 min and then a solution of  
3β-methoxy-pregnenolone 3.60 (560 mg, 1.70 mmol) in THF (2 mL) was added. The 
reaction mixture was stirred for a further 5 min at 0 °C, and then at rt for 18 h. The reaction 
was quenched with H2O (10 mL) and extracted with AcOEt (3 x 10 mL). Combined 
organic layers were dried over MgSO4, filtered and evaporated under reduced pressure. 
The residue was purified by flash column chromatography (SiO2, PE/AcOEt = 9/1) to 
afford furfuryl-steroid 3.131 (688 mg, 75%) as a yellow gum. Ref. LNB0161-058 
Rf: 0.11 (PE/AcOEt = 9/1); [α]D24: -32 (c 0.98, CHCl3); 1H-NMR (400 MHz, C6D6), δ: 
6.04 (2H, brs, H-2b, H-3b), 5.39-5.34 (1H, m, H-6), 4.51 (2H, s, 2H-5b), 3.21 (3H, s, 3H-
1a), 3.10-3.00 (1H, m, H-3), 2.57-2.48 (1H, m, H-4), 2.40-2.30 (1H, m, H-4), 2.00-1.79 
(5H, m, H-2, H-7, H-12, H-16, H-17), 1.77-1.68 (1H, m, H-1), 1.62-1.34 (7H, m, H-2,  
H-7, H-8, 2H-11, H-15, H-16), 1.57 (3H, s, 3H-21), 1.24-0.75 (5H, m, H-1, H-9, H-12, 
H-14, H-15), 0.98 (9H, s, 3H-9b, 3H-10b, 3H-11b), 0.94 (3H, s, 3H-19), 0.81 (3H, s,  
3H-18), 0.09 (6H, s, 3H-6b, 3H-7b); 13C-NMR (100 MHz, C6D6), δ: 161.7 (C, C-1b), 
153.0 (C, C-4b), 141.2 (C, C-5), 121.7 (CH, C-6), 108.2 (CH, C-3b), 104.6 (CH, C-2b), 
80.6 (CH, C-3), 73.8 (C, C-20), 59.5 (CH, C-17), 58.4 (CH2, C-5b), 57.1 (CH, C-14), 
55.4 (CH3, C-1a), 50.6 (CH, C-9), 42.8 (C, C-13), 39.7 (CH2, C-12), 39.4 (CH2, C-4), 
37.6 (CH2, C-1), 37.2 (C, C-10), 32.2 (CH2, C-7), 31.7 (CH, C-8), 28.6 (CH2, C-2), 27.6 
(CH3, C-21), 26.1 (3CH3, C-9b, C-10b, C-11b), 24.0 (CH2, C-15), 23.4 (CH2, C-16), 21.3 
(CH2, C-11), 19.5 (CH3, C-19), 18.5 (C, C-8b), 13.4 (CH3, C-18), -5.0 (2CH3, C-6b,  
C-7b); IR (neat): 3453, 2932, 1074, 835, 777, 497 cm-1; HRMS (ESI): calculated for 
C33H54NaO4Si [MNa
+] requires 565.3684, found 565.3674 (1.8 ppm error). 
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(3β,17β)-17-{1-[5-({[t-Butyl(dimethyl)silyl]methyl)furan-2-yl]ethenyl-3-
methoxyandrost-5-ene 3.133 
 
Alcohol 3.131 (50.0 mg, 0.09 mmol) was dissolved in a mixture of Ac2O/py (1/3, 1 mL) 
and stirred at rt for 2 h. The solvents were evaporated under reduced pressure and the 
residue purified by flash column chromatography (SiO2, PE/AcOEt = 10/0 to 9/1), which 
afforded alkene 3.133 (4.00 mg, 8%) as a yellow gum. Ref. LNB0161-050 
Rf: 0.48 (hexane/AcOEt = 9/1); [α]D24: -40 (c 1, CHCl3); 1H-NMR (400 MHz, C6D6), δ: 
6.22 (1H, d, J = 3.2 Hz, H-2b), 6.14 (1H, d, J = 3.2 Hz, H-3b), 5.94 (1H, brs, H-21b), 
5.42-5.37 (1H, m, H-6), 5.07 (1H, brs, H-21a), 4.52 (2H, s, 2H-5b), 3.22 (3H, s, 3H-1a), 
3.12-3.01 (1H, m, H-3), 2.62 (1H, “t”, J = 9.7 Hz, H-17), 2.54 (1H, ddd, J = 13.1, 4.5, 2.1 
Hz, H-4), 2.41-2.30 (1H, m, H-4), 2.02-1.65 (5H, H-1, H-2, H-7, 2H-16), 1.64-0.86 (12H, 
m, H-1, H-2, H-7, H-8, H-9, 2H-11, 2H-12, H-14, 2H-15, H-16), 0.97 (9H, s, 3H-9b, 3H-
10b, 3H-11b), 0.90 (3H, s, 3H-19), 0.63 (3H, s, 3H-18), 0.09 (3H, s, 3H-6b or 3H-7b), 
0.08 (3H, s, 3H-6b or 3H-7b); 13C-NMR (100 MHz, C6D6), δ: 156.3 (C, C-1b), 154.0 (C, 
C-4b), 141.4 (C, C-5), 137.6 (C, C-20), 121.6 (CH, C-6), 110.3 (CH2, C-21), 108.9 (CH, 
C-3b), 107.3 (CH, C-2b), 80.6 (CH, C-3), 58.5 (CH2, C-5b), 57.0 (CH, C-14), 55.4 (CH3, 
C-1a), 52.2 (CH, C-17), 50.9 (CH, C-9), 43.4 (C, C-10), 39.5 (CH2, C-4), 39.1 (CH2, C-
12), 37.6 (CH2, C-1), 37.3 (C, C-10), 32.9 (CH, C-8), 32.3 (CH2, C-7), 28.6 (CH2, C-2), 
26.6 (CH2, C-16), 26.1 (3CH3, C-9b, C-10b, C-11b), 24.5 (CH2, C-15), 21.5 (CH2, C-11), 
19.5 (CH3, C-19), 18.6 (C, C-8b), 13.1 (CH3, C-13), -5.0 (2CH3, C-6b, C-7b); IR (neat): 
2935, 2953, 1463, 1252, 1092, 775, 740 cm-1; HRMS (ESI): calculated for C33H53O3Si 
[M+] requires 525.3758, found 525.3751 (2.6 ppm error), calculated for C33H52NaO3Si 
[MNa+] requires 547.3578, found 547.3573 (4.9 ppm error). 
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(1R)-1-(1-Benzofuran-2-yl)-1-[(3β,17β)-3-methoxyandrost-5-en-17-yl]ethanol 3.135 
 
Benzofuran 3.134 (92.0 µL, 0.83 mmol) was dissolved in THF (1 mL) and cooled to  
-30 °C. n-BuLi (1.6 M in hexane, 520 µL, 0.83 mmol) was added and the reaction mixture 
was allowed to warm to -10 °C over 30 min. A solution of 3β-methoxy-pregnenolone 
3.60 (100 mg, 0.33 mmol) in THF (1.5 mL) was added, and the mixture was allowed to 
reach rt and stirred for 4 h. The reaction was re-cooled to 0 °C, quenched with sat aq 
NH4Cl (10 mL) and extracted with AcOEt (3 x 6 mL). The combined organic layers were 
dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, PE/AcOEt = 4/1) to afford benzofuranyl 
steroid 3.135 (83 mg, 56%) as a white solid. Ref. LNB0145-079 
Rf: 0.30 (PE/AcOEt = 4/1); m.p.: 187-189 °C (MeOH/CH2Cl2); [α]D24: -37 (c 1, CHCl3); 
1H-NMR (400 MHz, C6D6), δ: 7.44 (1H, d, J = 7.1 Hz, H-4b), 7.40 (1H, d, J = 8.1 Hz, 
H-7b), 7.14-7.09 (2H, m, H-5b, H-6b), 6.41 (1H, s, H-2b), 5.39-5.31 (1H, m, H-6), 3.22 
(3H, s, 3H-1a), 3.12-2.99 (1H, m, H-3), 2.58-2.48 (1H, m, H-4), 2.40-2.30 (1H, m, H-4), 
2.04-1.79 (5H, m, H-2, H-7, H-12, H-16, H-17), 1.69 (1H, “dt”, J = 13.2, 3.3 Hz, H-1), 
1.62-1.27 (7H, m, H-2, H-7, H-8, 2H-11, H-15, H-16), 1.60 (3H, s, 3H-21), 1.23-1.12 
(1H, m, H-12), 1.09-0.80 (4H, m, H-1, H-9, H-14, H-15), 0.92 (3H, s, 3H-9), 0.82 (3H, s, 
3H-18); 13C-NMR (100 MHz, C6D6), δ: 165.1 (C, C-1b), 155.2 (C, C-8b), 141.2 (C,  
C-5), 129.1 (C, C-3b), 124 (C, C-6b), 123.1 (CH, C-5b), 121.6 (CH, C-6), 121.2 (CH, 
C4b), 111.4 (CH, C-7b), 100.9 (CH, C-2b), 80.6 (CH, C-3), 74.1 (C, C-20), 58.5 (CH,  
C-17), 57.0 (CH, C-14), 55.4 (CH3, C-1a), 50.6 (CH, C-9), 42.9 (C, C-13), 39.9, (CH2, 
C-12), 39.4 (CH2, C-4), 37.6 (CH2, C-1), 37.2 (C, C-10), 32.2 (CH2, C-7), 31.7 (CH,  
C-8), 28.6 (CH2, C-2), 27.8 (CH3, C-21), 24.0 (CH2, C-15), 23.3 (CH2, C-16), 21.2 (CH2, 
C-11), 19.5 (CH3, C-19), 13.4 (CH3, C-18); IR (thin film): 3371, 2873, 1431, 1078 cm
-1; 
HRMS (ESI): calculated for C30H40NaO3 [MNa
+] requires 471.2870, found 471.2892  
(-4.8 ppm error). 
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(1R)-1-(1-Benzothiophen-2-yl)-1-[(3β,17β)-3-methoxyandrost-5-en-17-yl]ethanol 
3.137 
 
A solution of benzothiophene 3.136 (87.0 µL, 0.74 mmol) in THF (2 mL) was cooled to 
-30 °C, then n-BuLi (1.6 M in hexane, 463 µL, 0.74 mmol) was added. The cooling bath 
was removed and the reaction mixture was stirred at rt for 2.5 h before adding a solution 
of 3β-methoxy-pregnenolone 3.60 (98.0 mg, 0.30 mmol) in THF (1 mL). The reaction 
was stirred at rt for 3 h, re-cooled to 0 °C, quenched with H2O (10 mL) and extracted with 
AcOEt (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, PE/AcOEt = 95/5 to 4/1) followed by recrystallisation from 
methanol to afford benzothiophenyl steroid 3.137 (65.0 mg, 47%) as a white solid.  
Ref. LNB0145-104 
Rf: 0.30 (PE/AcOEt = 4/1); m.p.: 194-196 °C (MeOH); [α]D24: -70 (c 0.61, CHCl3);  
1H-NMR (400 MHz, CDCl3), δ: 7.78 (1H, d, J = 7.9 Hz, H-7b), 7.68 (1H, d, J = 7.7 Hz, 
H-4b), 7.35-7.23 (2H, m, H-5b, H-6b) 7.10 (1H, s, H-2b), 5.37-5.32 (1H, m, H-6), 3.36 
(3H, s, 3H-1a), 3.12-3.02 (1H, m, H-3), 2.44-2.36 (1H, m, H-4), 2.20-2.06 (2H, m, H-4, 
H-12), 2.02-1.77 (5H, m, H-1, H-2, H-7, H-16, H-17), 1.76 (3H, s, 3H-21), 1.63-1.29 (8H, 
m, H-2, H-7, H-8, 2H-11, H-12, H-15, H-16), 1.21-0.89 (4H, m, H-1, H-9, H-14, H-15), 
1.01 (3H, s, 3H-19), 0.92 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 156.7 (C,  
C-1b), 141.0 (C, C-3b), 130.1 (C, C-5), 139.1 (C, C-8b), 124.2 (CH, C-5b), 123.7 (CH, 
C-6b), 123.3 (CH, C-4b), 122.3 (CH, C-7b), 121.6 (CH, C-6), 117.9 (CH, C-2b), 80.3 
(CH, C-3), 76.6 (C, C-20), 61.1 (CH, C-17), 57.0 (CH, C-14), 55.8 (CH3, C-1a), 50.2 
(CH, C-9), 43.2 (C, C-13), 40.0 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, 
C-10), 31.9 (CH2, C-7), 31.4 (CH, C-8), 31.2 (CH3, C-21), 28.1 (CH2, C-2), 23.7 (CH2, 
C-15), 23.3 (CH2, C-16), 21.0 (CH2, C-11), 19.5 (CH3, C-19), 13.5 (CH3, C-18); IR (thin 
film): 3361, 2887, 1411, 1343, 1074 cm-1; HRMS (ESI): calculated for C30H40NaO2S 
[MNa+] requires 487.2641, found 487.2657 (-3.2 ppm error). 
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(1R)-1-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-1-(1-methyl-1H-indol-2-yl)ethanol 
3.139 
 
N-Methyl indole 3.138 (37.0 µL, 0.30 mmol) was dissolved in THF (1 mL) and n-BuLi 
(1.6 M in hexane, 0.27 mL, 0.30 mmol) was added. The mixture was heated at reflux for 
4 h, cooled to rt and a solution of 3β-methoxy-pregnenolone 3.60 (90.0 mg, 0.27 mmol) 
in THF (1 mL) added. The reaction mixture was stirred at rt overnight, quenched with 
H2O (3 mL) and extracted with AcOEt (3 x 4 mL). The combined organic layers were 
dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, PE/AcOEt = 9/1 to 4/1) followed by 
recrystallisation from methanol to afford benzothiophenyl steroid 3.139 (16.0 mg, 12%) 
as a white solid. Ref. LNB0145-125 
Rf: 0.20 (PE/AcOEt = 4/1); m.p. = 182-184 °C (MeOH); [α]D24: -50 (c 0.21, CHCl3);  
1H-NMR (400 MHz, C6D6), δ: 7.30 (1H, d, J = 7.3 Hz, H-4b), 7.33-7.22 (2H, m, H-5b, 
H-6b), 7.19 (1H, d, J = 8.1 Hz, H-7b), 6.33 (1H, s, H-2b), 5.39-5.32 (1H, m, H-6), 3.68 
(3H, s, 3H-9b), 3.19 (3H, s, 3H-1a), 3.08-2.95 (1H, m, H-3), 2.55-2.46 (1H, m, H-4), 
2.38-2.27 (1H, m, H-4), 2.18-2.10 (1H, m, H-17), 1.96-1.73 (4H, m, H-2, H-7, 2H-16), 
1.62-1.27 (5H, m, H-1, H-2, H-7, H-8, H-15), 1.56 (3H, s, 3H-21), 1.10-0.61 (8H, m,  
H-1, H-9, 2H-11, 2H-12, H-14, H-15), 0.83 (3H, s, 3H-19), 0.71 (3H, s, 3H-18);  
13C-NMR (100 MHz, C6D6), δ: 145.4 (C, C-1b), 141.4 (C, C-5), 139.0 (C, C-8b), 127.6 
(C, C-3b), 121.9 (CH, C-6b), 121.5 (CH, C-6), 120.9 (CH, C-4b), 120.1 (CH, C-5b), 109.5 
(C, C-7b), 100.2 (C, C-2b), 80.6 (CH, C-3), 74.1 (C, C-20), 58.6 (CH, C-17), 57.3 (CH, 
C-14), 55.4 (CH3, C-1a), 50.7 (CH, C-9), 42.5 (C, C-13), 39.4 (CH2, C-4), 37.7 (CH2,  
C-12), 37.5 (CH2, C-1), 37.1 (C, C-10), 32.3 (CH3, C-9b), 32.2 (CH2, C-7), 31.8 (CH, C-
8), 28.5 (CH2, C-2), 27.0 (CH3, C-21), 23.9 (CH2, C-15), 23.4 (CH2, C-16), 20.9 (CH2,  
C-11), 19.4 (CH3, C-19), 13.3 (CH3, C-18); IR (thin film): 3376, 2889, 1411, 1354, 1080, 
742 cm-1; HRMS (ESI): calculated for C31H43NNaO2 [MNa
+] requires 484.3186, found 
484.3182 (0.6 ppm error). 
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(1R)-1-[(3α,5α,6β,17β)-6-Methoxy-3,5-cycloandrostan-17-yl]-1-(1,3-thiazol-2-
yl)ethanol 3.140 
 
Thiazole 3.78 (54.0 µL, 0.76 mml) was dissolved in THF (1 mL), cooled to -30 °C, and 
n-BuLi (2.5 M in hexane, 303 µL, 0.76 mmol) was added. The reaction mixture was 
stirred at -30 °C for 30 min and then a solution of i-steroid 3.75 (100 mg, 0.30 mmol) in 
THF (1 mL) was added. The cold bath was removed and the reaction mixture was stirred 
at rt for 3.5 h, quenched with H2O (10 mL), and extracted with AcOEt (3 x 10 mL). The 
combined organic layers were washed with brine (20 mL), dried over MgSO4, filtered 
and evaporated under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, hexane/AcOEt = 9/1 to 4/1) to afford the title compound 3.140 
(73.0 mg, 58%) as a white solid. Ref. LNB0162-105 
Rf: 0.15 (hexane/AcOEt  = 9/1); m.p.: 55-57 °C; [α]D24: +15 (c 1, CHCl3); 1H-NMR (500 
MHz, CDCl3), δ: 7.65 (1H, d, J = 3.3 Hz, H-2b), 7.21 (1H, d, J = 3.3 Hz, H-3b), 3.30 (3H, 
s, 3H-1a), 3.12 (1H, brs, OH), 2.75 (1H, “t”, J = 2.5 Hz, H-6), 2.10-2.02 (2H, m, H-12,  
H-17), 1.90-1.84 (1H, m, H-7), 1.80-1.67 (3H, m, H-2, H-8,H-16), 1.69 (3H, s, 3H-21), 
1.62-0.97 (10H, m, H-1, H-2, H-7, 2H-11, H-12, H-14, 2H-15, H-16), 1.01 (3H, s, 3H-
19), 0.92-0.75 (3H, m, H-1, H-3, H-9), 0.89 (3H, s, 3H-18), 0.63 (1H, “t”, J = 4.4 Hz, H-
4), 0.41 (1H, dd, J = 8.0, 5.0 Hz, H-4); 13C-NMR (125 MHz, CDCl3), δ: 180.9 (C, C-1b), 
141.8 (CH, C-2b), 118.8 (CH, C-3b), 82.4 (CH, C-6), 77.8 (C, C-20), 60.5 (CH, C-17), 
56.7 (CH, C-14), 56.5 (CH3, C-1a), 48.7 (CH, C-9), 43.7 (C, C-13), 43.5 (C, C-10), 40.4 
(CH2, C-12), 35.3 (C, C-5), 35.0 (CH2, C-7), 33.4 (CH2, C-1), 31.0 (CH, C-8), 29.9 (CH3, 
C-21), 25.1 (CH2, C-2), 23.7 (CH2, C-15), 22.9 (CH2, C-16), 22.7 (CH2, C-11), 21.6 (CH, 
C-3), 19.4 (CH3, C-19), 13.8 (CH3, C-18), 13.2 (CH2, C-4); IR (neat): 3339, 2928, 2865, 
1099, 735 cm-1; HRMS (ESI): calculated for C25H37NNaO2S [MNa
+] requires 438.2437, 
found 438.2432 (0.7 ppm error). 
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(1R)-1-(Furan-2-yl)-1-[(3α,5α,6β,17β)-6-methoxy-3,5-cycloandrostan-17-yl]ethanol 
3.141 
 
A solution of furan 3.110 (44.0 µL, 0.61 mmol) in THF (1 mL) was cooled to -50 °C and 
TMEDA (113 µL, 0.76 mmol) and n-BuLi (2.5 M in hexane, 254 µL, 0.64 mmol) were 
added. The reaction mixture was stirred for 40 min and then a solution of i-steroid 3.75 
(100 mg, 0.30 mmol) in THF (1 mL) was added. The reaction mixture was stirred for 3.5 
h during which time the temperature reached rt. The reaction was quenched with H2O (10 
mL), and extracted with AcOEt (3 x 10 mL). The combined organic layers were dried 
over MgSO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (SiO2, PE/AcOEt = 9/1 to 4/1) to afford the title 
compound 3.141 (54.0 mg, 45%) as a yellow gum. Ref. LNB0162-106 
Rf: 0.24 (hexane/AcOEt  = 4/1, 1% Et3N); [α]D24: + 35 (c 0.35, CHCl3); 1H-NMR (400 
MHz, C6D6), δ: 7.08 (1H, d, J = 0.7 Hz, H-4b), 6.10 (1H, dd, J = 3.1, 0.7 Hz, H-3b), 6.06 
(1H, d, J = 3.1 Hz, H-2b), 3.19 (3H, s, 3H-1a), 2.61-2.58 (1H, m, H-6), 2.01-1.70 (6H, m, 
H-2, H-7, H-8, H-12, H-16, H-17), 1.64-1.27 (6H, m, H-1, H-2, 2H-11, H-15, H-16), 1.53 
(3H, s, 3H-21), 1.25-1.03 (2H, m, H-12, H-15), 1.18 (3H, s, 3H-19), 1.01-0.70 (5H, m, 
H-1, H-3, H-7, H-9, H-14), 0.83 (3H, s, 3H-18), 0.61 (1H, “t”, J = 4.4 Hz, H-4), 0.39 (1H, 
dd, J = 7.9, 5.1 Hz, H-4); 13C-NMR (100 MHz, C6D6), δ: 162.0 (C, C-1b), 140.7 (CH,  
C-4b), 110.4 (CH, C-3b), 104.0 (CH, C-2b), 82.4 (CH, C-6), 73.9 (C, C-20), 59.6 (CH, 
C-17), 56.7 (CH, C-14), 56.6 (CH3, C-1a), 48.4 (CH, C-9), 43.7 (C, C-13), 43.2 (C,  
C-10), 40.1 (CH2, C-12), 35.7 (C, C-5), 35.4 (CH2, C-7), 33.7 (CH2, C-1), 30.3 (CH3,  
C-21), 27.4 (CH, C-8), 25.4 (CH2, C-2), 24.0 (CH2, C-15), 23.4 (CH2, C-16), 23.0 (CH2, 
C-11), 21.5 (CH, C-3), 19.7 (CH3, C-19), 13.6 (CH2, C-4), 13.5 (CH3, C-18); IR (neat): 
3465, 2935, 2971, 1096 cm-1; HRMS (ESI): calculated for C26H38NaO3 [MNa
+] requires 
421.2713, found 421.2719 (-1.2 ppm error). 
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(3β)-3-Methoxychola-5,23-dien-20-ol 3.164138 
 
Methyl ether 3.60 (83.0 mg, 0.25 mmol) was dissolved in THF (1 mL), cooled to 0 °C 
and allylmagnesium bromide 3.163 (1 M solution in Et2O, 503 µL, 0.50 mmol) added. 
The reaction mixture was stirred at 0 °C for 5 min, then at rt for 4 h. The reaction was 
quenched with H2O (10 mL) and the resulting mixture was diluted with AcOEt (20 mL) 
and filtered through a pad of Celite®. The organic layer was isolated and the aqueous 
phase was extracted with AcOEt (3 x 5 mL). The combined organic layers were dried 
over MgSO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (SiO2, PE/AcOEt = 9/1) to afford the title compound 
3.161 (67.0 mg, 72%) as a white solid. Ref. LNB0161-080 
Rf: 0.46 (hexane/AcOEt = 4/1); m.p.: 103-105 °C (methanol); [α]D24: -62 (c 0.27, CHCl3); 
1H-NMR (400 MHz, CDCl3), δ: 5.89-5.73 (1H, m, H-2b), 5.35 (1H, m, H-6), 5.14-5.02 
(2H, m, 2H-3b), 3.34 (3H, s, 3H-1a), 3.11-2.99 (1H, m, H-3), 2.42-2.33 (1H, m, H-4), 
2.23-2.04 (4H, m, H-4, H-12, 2H-1b), 2.02-1.34 (12H, m, H-1, 2H-2, 2H-7, H-8, 2H-11, 
H-15, 2H-16, H-17), 1.32-1.09 (2H, m, H-12, H-15), 1.28 (3H, s, H-21), 1.08-0.82 (3H, 
m, H-1, H-9, H-14), 0.99 (3H, s, H-19), 0.86 (3H, s, H-18); 13C-NMR (100 MHz, CDCl3), 
δ: 141.0 (C, C-5), 134.5 (CH, C-2b), 121.6 (CH, C-6), 118.3 (CH2, C-3b), 80.4 (CH, 
C-3), 74.7 (C, C-20), 58.0 (CH, C-17), 56.9 (CH, C-14), 55.7 (CH3, C-1a), 50.2 (CH,  
C-9), 48.3 (CH2, C-1b), 42.8 (C, C-13), 40.2 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, 
C-1), 37.0 (C, C-10), 31.9 (CH2, C-7), 31.4 (CH, C-8), 28.1 (CH2, C-2), 26.7 (CH3,  
C-21), 23.9 (CH2, C-15), 22.4 (CH2, C-16), 21.0 (CH2, C-11), 19.5 (CH3, C-19), 13.7 
(CH3, C-18); IR (neat): 3486, 2973, 2931, 2901, 2871, 2841, 1458, 1434, 1374, 1102, 
909 cm-1; HRMS (ESI): calculated for C25H40NaO2 [MNa
+] requires 395.2921, found 
395.2930 (-2.5 ppm error). 
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(3β)-3-Methoxychola-5,23-dien-20-yl prop-2-enoate 3.166138 
 
Alcohol 3.164 (474 mg, 1.27 mmol) was dissolved in THF (6 mL) and Et3N (442 µL, 
3.18 mmol), acryloyl chloride 3.165 (205 µL, 2.55 mmol) and DMAP (1.55 mg, 0.013 
mmol) were added. The resulting suspension was stirred at 40 °C for 48 h, cooled to rt 
and quenched with H2O (30 mL). The organic compounds were extracted with AcOEt  
(3 x 40 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, PE/AcOEt = 95/5 to 9/1) to afford ester 3.166 (176 mg, 33%) as 
a colourless gum. Ref. LNB0161-155 
Rf: 0.63 (hexane/AcOEt = 4/1); [α]24D: -61° (c 0.26, CHCl3); 1H-NMR (400 MHz, 
CDCl3), δ: 6.28 (1H, dd, J = 17.3, 1.4 Hz, H-6bb), 6.02 (1H, dd, J = 17.3, 10.4 Hz, H-
5b), 5.80-5.67 (1H, m, H-2b), 5.72 (1H, dd, J = 10.4, 1.4 Hz, H-6ba), 5.35 (1H, m, H-6),  
5.14-5.00 (2H, m, 2H-3b), 3.34 (3H, s, 3H-1a), 3.14 (1H, dd, J = 13.5, 6.4 Hz, H-1b), 
3.10-3.00 (1H, m, H-3), 2.42-2.28 (2H, m, H-4, H-1b), 2.20-2.09 (1H, m, H-4), 2.07-1.80 
(5H, m, H-1, H-2, H-7, H-12, H-16), 1.79-1.66 (1H, m, H-17), 1.64 (3H, s, H-21),  
1.57-1.09 (9H, m, H-2, H-7, H-8, 2H-11, H-12, 2H-15, H-16), 1.09-0.80 (3H, m, H-1,  
H-9, H-14), 0.99 (3H, s, 3H-19), 0.84 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 
165.5 (C, C-4b), 141.0 (C, C-5), 134.0 (CH, C-2b), 130.7 (CH, C-5b), 129.4 (CH2, C-6b), 
121.6 (CH, C-6), 118.0 (CH2, C-3b), 87.2 (C, C-20), 80.4 (CH, C-3), 57.0 (CH, C-17), 
56.7 (CH, C-14), 55.7 (CH3, C-1a), 50.1 (CH, C-9), 43.1 (CH2, C-1b), 42.7 (C, C-13), 
40.0 (CH2 C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, C-10), 31.9 (CH2, C-7), 31.5 
(CH, C-8), 28.1 (CH2, C-2), 23.9 (CH2, C-15), 23.7 (CH3, C-21), 22.5 (CH2, C-16), 21.0 
(CH2, C-11), 19.5 (CH3, C-19), 14.1 (CH3, C-18); IR (neat): 2937, 2901, 2853, 1720, 
1398, 1205, 1102, 806 cm-1; HRMS (ESI): calculated for C28H42NaO3 [MNa
+] requires 
449.3026, found 449.3036 (-2.1 ppm error). 
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6-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-6-methyl-5,6-dihydro-2H-pyran-2-one 
3.168 
 
Diene 3.166 (10.0 mg, 0.02 mmol) was dissolved in CH2Cl2 (2 mL) and the 2
nd generation 
Hoveyda-Grubbs catalyst 3.167 (1.50 mg, 0.002 mmol) was added. The reaction mixture 
was stirred at rt overnight, diluted with CH2Cl2 (20 mL) and filtered through a pad of 
Celite®. The filtrate was evaporated under reduced pressure, and the residue was purified 
by flash column chromatography (SiO2, PE/AcOEt = 4/1) to afford 3.168 (9.00 mg, 98%) 
as a white solid. Ref. LNB0161-078 
Rf: 0.16 (hexane/AcOEt = 8/2); m.p.: 177-179 °C; [α]D24: -54 (c 0.44, CHCl3); 
1H-NMR (400 MHz, CDCl3), δ: 6.71 (1H, ddd, J = 9.7, 5.9, 2.4 Hz, H-2b), 6.00 (1H, dd, 
J = 9.7, 1.8 Hz, H-3b), 5.38-5.31 (1H, m, H-6), 3.35 (3H, s, 3H-1a), 3.10-2.99 (1H, m, H-
3), 2.75-2.65 (1H, m, H-1b), 2.43-2.33 (1H, m, H-4), 2.22-2.06 (3H, m, H-4, H-12, H-
1b), 2.05-1.72 (5H, m, H-1, H-2, H-7, 2H-16), 1.71-1.33 (7H, m, H-2, H-7, H-8, 2H-11, 
H-15, H-17), 1.51 (3H, s, 3H-21), 1.30-1.11 (2H, m, H-12, H-15), 1.10-0.82 (3H, m,  
H-1, H-9, H-14), 1.00 (3H, s, 3H-19), 0.91 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), 
δ: 163.9 (C, C-4b), 143.7 (CH, C-2b), 141.1 (C, C-5), 121.5 (CH, C-6), 120.9 (CH, C-
3b), 84.9 (C, C-20), 80.4 (CH, C-3), 59.1 (CH, C-17), 57.1 (CH, C-14), 55.8 (CH3, C-1a), 
50.2 (CH, C-9), 43.0 (C, C-13), 40.2 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 
(C, C-10), 34.5 (CH2, C-1b), 31.9 (CH2, C-7), 31.4 (CH, C-8), 28.1 (CH2, C-2), 24.8 
(CH3, C-21), 23.8 (CH2, C-15), 23.5 (CH2, C-16), 21.0 (CH2, C-11), 19.5 (CH3, C-19), 
13.7 (CH3, C-18); IR (neat): 2974, 2929, 2828, 1721, 1381, 1136, 1102 cm
-1; HRMS 
(ESI): calculated for C26H38NaO3 [MNa
+] requires 421.2713, found 421.2709 (1.8 ppm 
error). 
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(3β)-3-Methoxy-23-methylidenechol-5-en-20-ol 3.170 
 
Methyl ether 3.60 (700 mg, 2.12 mmol) was dissolved in THF (20 mL) and cooled to  
-78 °C. 2-Methylallylmagnesium chloride 3.169 (0.5 M solution in THF, 6.36 mL, 3.18 
mmol) was added and the reaction mixture was stirred for 2 h during which time the 
temperature reached -30 °C. Due to the presence of residual starting material, the reaction 
was re-cooled to -78 °C and a further portion of 2-methylallylmagnesium bromide (0.5 
M solution in THF, 2.12 mL, 1.06 mmol) was added. The reaction mixture was stirred 
for a further 2 h during which time the temperature reached -30 °C, quenched with H2O 
(20 mL) and extracted with AcOEt (3 x 20 mL). The combined organic layers were dried 
over MgSO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (SiO2, PE/AcOEt = 95/5) to afford 3.170 (610 mg, 75%) 
as a white solid. Ref. LNB0161-143 
Rf: 0.38 (hexane/AcOEt = 4/1); m.p.: 124 °C (MeOH); [α]D24: -50 (c 0.1, CHCl3);  
1H-NMR (400 MHz, CDCl3), δ: 5.33 (1H, m, H-6), 4.88 (1H, brs, H-3b), 4.69 (1H, brs, 
H-3b), 3.33 (3H, s, H-1a), 3.08-2.98 (1H, m, H-3), 2.40-2.32 (1H, m, H-4), 2.22 (1H, d, 
J = 13.5 Hz, H-1b), 2.18-2.06 (2H, m, H-4, H-12), 2.05 (1H, d, J = 13.5 Hz, H-1b), 2.00-
1.33 (12H, m, H-1, 2H-2, 2H-7, H-8, 2H-11, H-15, 2H-16, H-17), 1.80 (3H, s, H-4b), 
1.31-1.09 (2H, m, H-12, H-15), 1.26 (3H, s, H-21), 1.05-0.78 (3H, m, H-1, H-9, H-14), 
0.98 (3H, s, H-19), 0.84 (3H, s, H-18) 13C-NMR (100 MHz, CDCl3), δ: 142.9 (C, C-2b), 
140.9 (C, C-5), 121.6 (CH, C-6), 114.9 (CH2, C-3b), 80.4 (CH, C-3), 74.9 (C, C-20), 59.4 
(CH, C-17), 57.0 (CH, C-14), 55.5 (CH3, C-1a), 50.9 (CH2, C-1b), 50.2 (CH, C-9), 42.9 
(C, C-13), 40.3 (CH2, C-12), 38.7 (CH2, C-4), 37.2 (CH2, C-1), 36.9 (C, C-10), 31.9 (CH2, 
C-7), 31.4 (CH, C-8), 28.1 (CH2, C-2), 26.8 (CH3, C-21), 25.3 (CH3, C-4b), 23.9 (CH2, 
C-15), 22.7 (CH2, C-16), 21.0 (CH2, C-11), 19.4 (CH3, C-19), 13.5 (CH3, C-18); IR 
(neat): 3492, 2931, 2895, 2865, 1368, 1090, 902, 885, 734 cm-1; HRMS (ESI): calculated 
for C26H42NaO2 [MNa
+] requires 409.3077, found 409.3081 (-0.9 ppm error); Elemental 
Analysis: calculated for C26H42O2 requires C 80.77, H 10.95, found C 80.86, H 11.05. 
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(3β)-3-Methoxy-23-methylidenechol-5-en-20-yl 2-methylprop-2-enoate 3.172 
 
Alcohol 3.170 (90.0 mg, 0.23 mmol) was dissolved in CH2Cl2 (2 mL) and Et3N (130 µL, 
0.93 mmol), 2-methylacryloyl chloride 3.171 (68.0 µL, 0.70 mmol) and DMAP (0.28 mg, 
0.002 mmol) were added. The reaction mixture was stirred at 40 °C for 18 h, cooled to rt 
and quenched with H2O (10 mL). The organic layer was isolated, diluted with CH2Cl2 (5 
mL) and then washed with sat aq NaHCO3 (3 x 5 mL), dried over MgSO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, PE/AcOEt = 95/5) to afford the title compound 3.172 (13.0 mg, 
12%) as a colourless gum. Ref. LNB0161-109 
Rf: 0.65 (hexane/AcOEt = 4/1); [α]D24: -54 (c 0.13, CHCl3); 1H-NMR (400 MHz, CDCl3), 
δ: 6.00 (1H, brs, H-7b), 5.48 (1H, brs, H-7b), 5.38-5.32 (1H, m, H-6), 4.85 (1H, brs,  
H-3b), 4.78 (1H, brs, H-3b), 3.35 (3H, s, 3H-1a), 3.11-3.00 (2H, m, H-3, H-1b),  
2.42-2.33 (2H, m, H-4, H-1b), 2.20-2.10 (1H, m, H-4), 2.09-1.58 (8H, m, H-1, H-2, H-7, 
H-12, H-15, 2H-16, H-17), 1.90 (3H, s, H-8b), 1.79 (3H, s, H-4b), 1.67 (3H, s, H-21), 
1.57-1.38 (5H, m, H-2, H-7, H-8, 2H-11), 1.28-1.11 (2H, m, H-12, H-15), 1.08-0.96 (2H, 
m, H-1, H-14), 0.99 (3H, s, 3H-19), 0.96-0.81 (1H, m, H-9), 0.85 (3H, s, 3H-18);  
13C-NMR (100 MHz, CDCl3), δ: 166.8 (C, C-5b), 142.2 (C, C-2b), 141.03 (C, C-5), 138.4 
(C, C-6b), 124.6 (CH2, C-7b), 121.6 (CH, C-6), 115.5 (CH2, C-3b), 88.0 (C, C-20), 80.4 
(CH, C-3), 56.9 (CH, C-17), 56.7 (CH, C-14), 55.8 (CH3, C-1a), 50.1 (CH, C-9), 46.0 
(CH2, C-1b), 42.8 (C, C-13), 39.8 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 
(C, C-10), 31.9 (CH2, C-7), 31.5 (CH, C-8), 28.1 (CH2, C-2), 24.7 (CH3, C-21 or C-4b), 
24.5 (CH3, C-21 or C-4b), 23.9 (CH2, C-15), 23.1 (CH2, C-16), 21.0 (CH2, C-11), 19.5 
(CH3, C-19), 18.8 (CH3, C-8b), 14.2 (CH3, C-18); IR (neat): 2933, 2829, 1710, 1171, 
1144, 1101 cm-1; HRMS (ESI): calculated for C30H46NaO3 [MNa
+] requires 477.3339, 
found 477.3332 (1.3 ppm error). 
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6-[(3β,17β)-3-Methoxyandrost-5-en-17-yl]-3,4,6-trimethyl-5,6-dihydro-2H-pyran-
2-one 3.173 
 
Diene 3.172 (58.0 mg, 0.13 mmol) was dissolved in toluene (10 mL) and 2nd generation 
Hoveyda-Grubbs catalyst 3.167 (8.00 mg, 0.01 mmol) was added. The reaction mixture 
was stirred at 120 °C for 24 h. At that time TLC still showed the presence of unreacted 
starting material, so another portion of catalyst (40 mg, 0.06 mmol) was added and the 
mixture was stirred at 120 °C for further 18 h. After cooling to rt, the mixture was diluted 
with CH2Cl2 (10 mL) and filtered through a pad of Celite
®. The filtrate was evaporated 
under reduced pressure and the residue was purified by flash column chromatography 
(SiO2, PE/AcOEt = 9/1 to 4/1) and then recrystallisation from methanol to afford lactone 
3.173 (13.0 mg, 24%) as a colourless solid. Ref. LNB0161-162 
Rf: 0.18 (hexane/AcOEt = 4/1); m.p.: 168-170 °C (methanol) [α]D24: -65 (c 0.15, CHCl3); 
1H-NMR (400 MHz, CDCl3), δ: 5.38-5.32 (1H, m, H-6), 3.35 (3H, s, 3H-1a), 3.11-2.99 
(1H, m, H-3), 2.71 (1H, d, J = 17.8 Hz, H-1b), 2.43-2.33 (1H, m, H-4), 2.22-2.05 (2H, m, 
H-4, H-12), 2.05-1.69 (6H, m, H-1, H-2, H-7, 2H-16, H-1b), 1.88 (6H, s, 3H-5b, 3H-6b), 
1.69-1.36 (7H, m, H-2, H-7, H-8, 2H-11, H-15, H-17), 1.44 (3H, s, 3H-21), 1.31-1.09 
(2H, m, H-12, H-15), 1.08-0.96 (2H, m, H-1, H-14), 1.00 (3H, s, H-19), 0.95-0.80 (1H, 
m, H-9), 0.90 (3H, s, H-18); 13C-NMR (100 MHz, CDCl3), δ: 165.9 (C, C-4b), 146.5 (C, 
C-2b), 141.1 (C, C-5), 121.5 (CH, C-6), 121.4 (C, C-3b), 82.6 (C, C-20), 80.4 (CH, C-3), 
59.0 (CH, C-17), 57.1 (CH, C-14), 55.8 (CH3, C-1a), 50.2 (CH, C-9), 43.0 (C, C-13), 41.1 
(CH2, C-1b), 40.2 (CH2, C-12), 38.8 (CH2, C-4), 37.3 (CH2, C-1), 37.0 (C, C-10), 31.9 
(CH2, C-7), 31.4 (CH, C-8), 28.1 (CH2, C-2), 24.6 (CH3, C-21), 23.8 (CH2, C-15), 23.4 
(CH2, C-16), 21.0 (CH2, C-11), 20.8 (CH3, C-6b), 19.5 (CH3, C-19), 13.7 (CH3, C-18), 
12.5 (CH3, C-5b); IR (neat): 2925, 2850, 1704, 1463, 1381, 1102 cm
-1; HRMS (ESI): 
calculated for C28H42NaO3 [MNa
+] requires 449.3026, found 449.3034 (-1.3 ppm error).  
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6.3. CHAPTER 4: EXPERIMENTAL DETAILS 
Ethyl 6-(3-methoxyphenyl)-3-oxohexanoate 4.157 
 
γ-Alkylation by means of NaH and n-BuLi179 
NaH (60% dispersion in mineral oil, 210 mg, 5.25 mmol) was suspended in dry THF (25 
mL) and cooled at 0 °C, then ethyl acetoacetate 4.152 (570 µL, 4.51 mmol) was added. 
The reaction mixture was stirred at 0 °C for 10 min, then n-BuLi (2.5 M in hexanes, 1.80 
mL, 4.51 mmol) was added. The reaction mixture was stirred for a further 15 min in the 
ice-cold bath, then 3-methoxyphenethyl bromide 4.151 (0.30 mL, 1.90 mmol) was added. 
The reaction mixture was stirred at 0 °C for 15 min, then allowed to reach rt and stirred 
for another 30 min. The suspension was brought to pH 6 with 1 M aq HCl added under 
vigorous stirring, diluted with H2O (50 mL) and extracted with AcOEt (3 x 150 mL). The 
combined organic layers were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 25 
g SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to give ester 4.157 as a colourless oil  
(450 mg, 90%). Ref. LNB0083-007 
Rf: 0.29 (heptane/AcOEt = 4/1); 1H-NMR (500 MHz, CDCl3), δ: 7.19 (1H, “t”, J = 7.2 
Hz, H-1), 6.80-6.68 (3H, m, H-2, H-4, H-6), 4.18 (2H, q, J = 7.2 Hz, 2H-13), 3.78 (3H, 
s, 3H, 1a), 3.40 (2H, s, 2H-11), 2.61 (2H, t, J = 7.4 Hz, 2H-7), 2.54 (2H, t, J = 7.4 Hz, 
2H-9), 1.26 (2H, quint, J = 7.4 Hz, 2H-8), 1.26 (3H, t, J = 7.2 Hz, 3H-14); 13C-NMR 
(125 MHz, CDCl3), δ: 202.7 (C, C-10), 167.3 (C, C-12), 159.7 (C, C-3), 143.1 (C, C-5), 
129.4 (CH, C-1), 120.9 (CH, C-6), 114.2 (CH, C-4), 111.4 (CH, C-2), 61.4 (CH2, C-13), 
55.2 (CH3, C-1a), 49.4 (CH2, C-11), 42.1 (CH3, C-9), 34.9 (CH3, C-7), 24.8 (CH3, C-8), 
14.1 (CH3, C-14); IR (neat): 2939, 1742, 1717, 1259, 1150, 1038 cm
-1; HRMS (ESI): 
calculated for C15H20NaO4 [MNa
+] requires 287.1254, found 287.1240 (4.9 ppm error). 
Data are consistent with those reported in the literature.179 
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γ-Alkylation by means of LDA  
n-BuLi (2.5 M in hexanes, 5.76 mL, 14.4 mmol) was added dropwise to a solution of 
DIPA (2.03 mL, 14.4 mmol) in dry THF (20 mL) cooled to -78 °C and stirred under 
nitrogen atmosphere. The resulting yellow solution was allowed to reach -40 °C over 20 
min, whereupon it was added to a solution of ethyl acetoacetate 4.149 (850 µL, 6.75 
mmol) in dry THF (20 mL) previously cooled to 0 °C. The mixture turned dark red 
coloured. The cooling bath was removed and the reaction mixture was stirred at rt for 1 
h. Finally, a solution of 3-methoxyphenethyl bromide 4.148 (0.96 g, 4.47 mmol) in dry 
THF (10 mL) was added dropwise. The reaction mixture was stirred at rt overnight before 
being brought to pH 6 with 1M aq HCl, diluted with H2O (100 mL) and extracted with 
AcOEt (3 x 150 mL). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP 50 g SiO2 cartridge, heptane/AcOEt = 10/0 to 7/3) to 
give ester 4.153 as a colourless oil (710 mg, 60%). Ref. LNB0083-126 
Ethyl {2-[3-(3-methoxyphenyl)propyl]-1,3-dioxolan-2-yl}acetate 4.158179 
 
Ethylene glycol (3.44 mL, 61.7 mmol) and PTSA (23.5 mg, 0.12 mmol) were added to a 
solution of ketoester 4.157 (3.26 g, 12.3 mmol) in benzene (150 mL). The reaction 
mixture was heated to 90 °C and stirred overnight with a Dean-Stark water separator 
attached. After cooling to rt, the reaction mixture was quenched with a solution of 
NaHCO3 (10.4 mg, 0.12 mmol) in H2O (2 mL). Benzene was evaporated under reduced 
pressure. The residue was dissolved in AcOEt (200 ml) and washed with sat aq NaHCO3 
(3 x 150 mL). The organic layer was separated, dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP 100 g SiO2 cartridge, toluene/AcOEt = 10/0 to 9/1) to 
give the acetal 4.158 (2.86 g, 75%) as a colourless oil. Ref. LNB0083-143 
Rf: 0.24 (heptane/AcOEt = 4/1); 1H-NMR (500 MHz, CDCl3), δ: 7.16 (1H, “t”, J = 7.6 
Hz, H-1), 6.76 (1H, d, J = 7.6 Hz, H-6), 6.73-6.66 (2H, m, H-2, H-4), 4.11 (2H, q, J = 7.2 
Hz, 2H-13), 4.00-3.88 (4H, m, 2H-15, 2H-16), 3.76 (3H, s, 3H-1a), 2.62 (2H, s, 2H-11), 
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2.59 (2H, t, J = 7.9 Hz, 2H-7), 1.89-1.82 (2H, m, 2H-9), 1.77-1.68 (2H, m, 2H-8), 1.21 
(3H, t, J = 7.2 Hz, 3H-14); 13C-NMR (125 MHz, CDCl3), δ: 169.4 (C, C-12), 159.6 (C, 
C-3), 143.9 (C, C-5), 129.2 (CH, C-1), 120.8 (CH, C-6), 114.1 (CH, C-4), 111.0 (CH,  
C-2), 109.2 (C, C-10), 65.1 (2CH2, C-15, C-16), 60.4 (CH2, C-13), 55.0 (CH3, C-1a), 42.7 
(CH2, C-11), 37.3 (CH2, C-9), 35.9 (CH2, C-7), 25.2 (CH2, C-8), 14.1 (CH3, C-14);  
IR (neat): 2953, 1728, 1259, 1157, 1038 cm-1; HRMS (ESI): calculated for C17H24NaO5 
[MNa+] requires 331.1516, found 331.1502 (3.8 ppm error). Data are consistent with 
those reported in the literature.179  
2-Hydroxyethyl 6-(3-methoxyphenyl)-3-oxohexanoate 4.163 
 
Ethylene glycol (11.1 mL, 0.20 mol) and PTSA (75.8 mg, 0.40 mmol) were added to a 
solution of ketoester 4.157 (10.5 g, 39.9 mmol) in benzene (250 mL). The reaction 
mixture was heated at reflux for 3 d, with a Dean-Stark apparatus in place. The mixture 
was quenched with sat aq NaHCO3 (100 mL), then benzene was evaporated and the 
aqueous layer was extracted with AcOEt (3 x 100 mL). Combined organic layers were 
washed with brine (250 mL), dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 100 
g silica cartridge, heptane/AcOEt = 10/0 to 8/2, then CH2Cl2/MeOH = 9/1, 1% AcOEt) 
to yield glycolic ester 4.163 (5.39 g, 48%) as a yellow oil along with recovered starting 
material 4.157 (3.63 g). Ref. LNB0103-078 
Rf: 0.31 (hexane/AcOEt = 5/5); 1H-NMR (500 MHz, CDCl3), δ: 7.8 (1H, “t”, J = 7.8 Hz, 
H-1), 6.80-6.68 (3H, m, H-2, H-4, H-6), 4.33-4.21 (2H, m, 2H-13), 3.87-3.77 (5H, m, 
2H-14, 3H-1a), 3.45 (2H, s, 2H-11), 2.61 (2H, t, J = 7.4 Hz, 2H-7), 2.54 (2H, t, J = 7.4 
Hz, 2H-9), 1.94 (2H, quint, J = 7.4 Hz, 2H-8); 13C-NMR (125 MHz, CDCl3), δ: 203.2 
(C, C-10), 167.3 (C, C-12), 159.8 (C, C-3), 142.9 (C, C-5), 129.5 (CH, C-1), 121.0 (CH,  
C-6), 114.4 (CH, C-4), 111.4 (CH, C-2), 66.8 (CH2, C-13), 60.9 (CH2, C-14), 55.3 (CH3, 
C-1a), 49.4 (CH2, C-11), 42.3 (CH2, C-9), 34.9 (CH2, C-7), 24.8 (CH2, C-8); IR (neat): 
3481, 2943, 1738, 1710, 1259, 1147, 1038 cm-1; HRMS (ESI): calculated for C15H20NaO5 
[MNa+] requires 303.1203, found 303.1193 (3.1 ppm error). 
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2-{2-[3-(3-Methoxyphenyl)propyl]-1,3-dioxolan-2-yl}ethanol 4.159 
 
A solution of ethyl ester 4.158 (116 mg, 0.38 mmol) in dry THF (4 mL) was added to a 
suspension of LiAlH4 (15.0 mg, 0.38 mmol) in dry THF (4 mL) cooled to 0 °C. The  
ice-bath was removed and the mixture was stirred at rt for 1 h. Excess LiAlH4 was 
decomposed with ice-cold water (10 mL). The mixture was then brought to pH 4 with 1M 
aq. HCl and extracted with AcOEt (3 x 10 mL). Combined organic layers were dried over 
Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by 
flash column chromatography (Biotage SNAP 10 g SiO2 cartridge, heptane/AcOEt = 10/0 
to 5/5) to obtain alcohol 4.159 (89.0 mg, 88%) as a colourless oil. Ref. LNB0083-009 
Rf: 0.17 (heptane/AcOEt = 5/5); 1H-NMR (500 MHz, CDCl3), δ: 7.22-7.15 (1H, m, H-
1), 6.77 (1H, d, J = 7.1 Hz, H-6), 6.75-6.70 (2H, m, H-2, H-4), 4.03-3.90 (4H, m, 2H-13, 
2H-14), 3.80 (3H, s, 3H-1a), 3.75-3.70 (2H, m, 2H-12), 2.64-2.56 (2H, m, 2H-7), 2.40 
(1H, brs, OH), 1.91 (2H, t, J = 5.6 Hz, 2H-11), 1.74-1.65 (4H, m, 2H-8, 2H-9); 13C-NMR 
(125 MHz, CDCl3), δ: 159.7 (C, C-3), 143.8 (C, C-5), 129.4 (CH, C-1), 120.1 (CH, C-6), 
114.3 (CH, C-4), 112.2 (CH, C-2), 111.2 (C, C-10), 64.9 (2CH2, C-13, C-14), 58.9 (CH2, 
C-12), 55.2 (CH3, C-1a), 38.3 (CH2, C-11), 36.7 (CH2, C-9), 36.0 (CH2, C-7), 25.5 (CH2, 
C-8); IR (neat): 3471, 2946, 1251, 1153, 1038 cm-1; HRMS (ESI): calculated for 
C15H22NaO4 [MNa
+] requires 289.1410, found 289.1401 (3.3 ppm error). Data are 
consistent with those reported in the literature.179 
2-Hydroxyethyl {2-[3-(3-methoxyphenyl)propyl]-1,3-dioxolan-2-yl}acetate 4.164 
 
Ethylene glycol (3.07 mL, 55.2 mmol) and CSA (42.6 mg, 0.18 mmol) were added to a 
solution of ketoester 4.163 (5.15 g, 18.4 mmol) in benzene (150 mL). The reaction 
mixture was heated at 95 °C and stirred for 3 h with a Dean-Stark apparatus in place. Due 
to the presence of residual starting material, a further amount of ethylene glycol (1.5 mL, 
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27.6 mmol) and CSA (21.0 mg, 0.09 mmol) were added and reaction mixture was heated 
at reflux for 1 h. After cooling to rt, the reaction was quenched with sat aq NaHCO3 (10 
mL). Benzene was evaporated and the residue was diluted with AcOEt (150 mL) and 
washed with sat aq NaHCO3 (2 x 150 ml) and brine (150 mL). The organic phase was 
dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (Biotage SNAP 100 g SiO2, heptane/AcOEt = 
4/1 to 5/5) to yield an inseparable mixture of acetal 4.164 and starting material 4.163 
(about 1/1, 4.02 g). The crude product was dissolved in benzene (120 mL) and ethylene 
glycol (1.11 mL, 19.8 mmol) and CSA (15.3 mg, 0.066 mmol) were added. The reaction 
mixture was stirred at reflux for 3 d, and a further amount of ethylene glycol (1.11 mL, 
19.8 mmol) and CSA (15.3 mg, 0.07 mmol) were added. The reaction mixture was stirred 
at reflux for an additional 1 d, before being worked up as described above. Purification 
of the crude material (Biotage SNAP 100 g SiO2, CH2Cl2/MeOH = 9/1 + 1% AcOEt) 
gave acetal 4.164 (4.17 g, 69%) as a yellow oil. Ref. LNB0103-089 
Rf: 0.33 (hexane/AcOEt = 5/5); 1H-NMR (500 MHz, CDCl3), δ: 7.22-7.15 (1H, m, H-1), 
6.78 (1H, d, J = 7.6 Hz, H-6), 6.75-6.69 (2H, m, H-2, H-4), 4.25-4.20 (2H, m, 2H-13),  
4.03-3.91 (4H, m, 2H-15, 2H-16), 3.84-3.73 (5H, m, 2H-14, 3H-1a), 2.69 (2H, s, 2H-11), 
2.60 (2H, t, J = 7.6 Hz, 2H-7), 1.90-1.82 (2H, m, 2H-9), 1.79-1.69 (2H, m, 2H-8); 13C-
NMR (125 MHz, CDCl3), δ: 169.8 (C, C-12), 159.7 (C, C-3), 143.9 (C, C-5), 129.4 (CH, 
C-1), 121.0 (CH, C-6), 114.3 (CH, C-4), 111.2 (CH, C-2), 109.4 (C, C-10), 66.2 (CH2, 
C-13), 65.3 (2CH2, C-15, C-16), 61.1 (CH2, C-14), 55.3 (CH3, C-1a), 43.0 (CH2, C-11), 
37.5 (CH2, C-9), 35.9 (CH2, C-7), 25.3 (CH2, C-8); IR (neat): 3471, 2946, 1735, 1262, 
1145, 1038 cm-1; HRMS (ESI): calculated for C17H24NaO6 [MNa
+] requires 347.1465, 
found 347.1472 (2.3 ppm error).  
Convertion of glycolic ester 4.164 into alcohol 4.159 
 
LiAlH4 (494 mg, 13.0 mmol) was added portionwise to a solution of glycolic ester 4.164 
(4.17 g, 13.0 mmol) in THF (150 mL) cooled to 0 °C. The ice-bath was removed and the 
mixture was stirred at rt for 3 h. Excess LiAlH4 was decomposed with ice-cold water  
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(200 mL). The mixture was brought to pH 5 with 1M aq HCl and extracted with AcOEt  
(3 x 100 mL). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The title compound 4.155 was obtained as a 
colourless oil (3.09 g, 90%) without any further purification. Ref. LNB0103-102 
1-Chloro-6-(3-methoxyphenyl)hexan-3-one 4.165179 
 
A solution of alcohol 4.159 (158 mg, 0.59 mmol) in acetone (20 mL) was cooled to  
0 °C and acidified with 12 M aq HCl (891 µL, 10.7 mmol) added dropwise. The reaction 
mixture was stirred at 0 °C for 10 min, and at rt for a further 4 h. The reaction mixture 
was quenched with H2O (20 mL) and the organic compounds were extracted with CH2Cl2 
(3 x 20 mL). The combined organic layers were washed with sat aq NaHCO3 (3 x 20 ml), 
dried over MgSO4, filtered and evaporated under reduced pressure to give chloride 4.165 
(140 mg, 99%) as a colourless oil. Ref. LNB0162-107 
Rf: 0.34 (heptane/AcOEt = 4/1); 1H-NMR (500 MHz, CDCl3), δ: 7.20 (1H, “t”, J = 7.9 
Hz, H-1), 6.77-6.72 (3H, m, H-2, H-4, H-6), 3.80 (3H, s, 3H-1a), 3.73 (2H, t, J = 6.6 Hz, 
2H-12), 2.84 (2H, t, J = 6.6 Hz, 2H-11), 2.61 (2H, t, J = 7.4 Hz, 2H-7), 2.45 (2H, t,  
J = 7.4 Hz, 2H-9), 1.93 (2H, quint, J = 7.4 Hz, 2H-8); 13C-NMR (125 MHz, CDCl3), δ: 
207.3 (C, C-10), 159.9 (C, C-3), 143.2 (C, C-5), 129.5 (CH, C-1), 121.0 (CH, C-6), 114.4 
(CH, C-4), 111.5 (CH, C-2), 55.3 (CH3, C-1a), 45.2 (CH2, C-11), 42.5 (CH2, C-9), 38.4 
(CH2, C-12), 35.1 (CH2, C-7), 24.9 (CH2, C-8); IR (neat): 2925, 1710, 1255, 1154 cm
-1; 
HRMS (ESI): calculated for C13H17
35ClNaO2 [MNa
+] requires 263.0809, found 263.0804 
(2.4 ppm error). 
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1-Hydroxy-6-(3-methoxyphenyl)hexan-3-one 4.160 
 
A solution of acetal 4.159 (2.90 g, 11.0 mmol) in acetone (50 mL) was treated with 1 M 
aq HCl (5.50 mL, 5.50 mmol). The reaction mixture was stirred at rt for 2 h, then the 
acetone was evaporated. The residue was diluted with AcOEt (200 mL) and washed with 
sat aq NaHCO3 (3 x 200 mL). The organic layer was separated, dried over Na2SO4, 
filtered and evaporated under reduced pressure. The crude oil was purified by flash 
column chromatography (Biotage SNAP 50 g SiO2 cartridge, heptane/AcOEt = 10/0 to 
5/5) to give ketoalcohol 4.160 (2.30 g, 94%) as a colourless oil. Ref. LNB0103-048 
Rf: 0.17 (heptane/AcOEt = 5/5); 1H-NMR (500 MHz, CDCl3), δ: 7.20 (1H, “t”, J = 7.8 
Hz, H-1), 6.78-6.69 (3H, m, H-2, H-4, H-6), 3.82 (2H, t, J = 7.5 Hz, 2H-12), 3.80 (3H, s, 
3H-1a), 2.66-2.57 (4H, m, 2H-11, 2H-7), 2.45 (2H, t, J = 7.4 Hz, 2H-9), 1.92 (2H, quint, 
J = 7.4 Hz, 2H-8); 13C-NMR (125 MHz, CDCl3), δ: 211.5 (C, C-10), 159.7 (C, C-3), 
143.2 (C, C-5), 129.5 (CH, C-1), 120.9 (CH, C-6), 114.4 (CH, C-4), 111.4 (CH, C-2), 
58.0 (CH2, C-12), 55.3 (CH3, C-1a), 44.5 (CH2, C-11), 42.5 (CH2, C-9), 35.1 (CH2, C-7), 
24.9 (CH2, C-8); IR (neat): 3471, 2932, 1710, 1580, 1255, 1150, 1038 cm
-1; HRMS 
(ESI): calculated for C13H18NaO3 [MNa
+] requires 245.1148, found 245.1143 (1.9 ppm 
error). 
6-(3-Methoxyphenyl)-3-oxohexyl acetate 4.161 
 
A solution of alcohol 4.160 (33.0 mg, 0.15 mmol), Ac2O (70.0 µL, 0.74 mmol) and Et3N 
(45.0 µL, 0.33 mmol) in CH2Cl2 (2 mL) was stirred at rt overnight. The reaction mixture 
was diluted with CH2Cl2 (1 mL) and washed with sat aq NH4Cl (2 x 3 mL). The combined 
organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. 
The residue was purified by flash column chromatography (Biotage SNAP 10 g silica 
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cartridge, heptane/AcOEt = 10/0 to 4/1) to give acetate 4.161 (24.0 mg, 61%) as a 
colourless oil. Ref. LNB0083-020 
Rf: 0.17 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.20 (1H, “t”, J = 7.6 
Hz, H-1), 6.76-6.71 (3H, m, H-2, H-4, H-6), 4.31 (2H, t, J = 6.2 Hz, 2H-12), 3.79 (3H, s, 
3H-1a), 2.70 (2H, t, J = 6.2 Hz, 2H-11), 2.60 (2H, t, J = 7.5 Hz, H-7), 2.44 (2H, t, J = 7.5 
Hz, H-9), 2.01 (3H, s, 3H-14), 1.92 (2H, quint, J = 7.5 Hz, H-8); 13C-NMR (100 MHz, 
CDCl3), δ: 207.7 (C, C-10), 170.8 (C, C-13), 159.8 (C, C-3), 143.0 (C, C-5), 129.3 (CH, 
C-1), 120.8 (CH, C-6), 114.2 (CH, C-4), 111.2 (CH, C-2), 59.8 (CH2, C-12), 55.1 (CH3, 
C-1a), 42.2 (CH2, C-9), 41.3 (CH2, C-11), 34.9 (CH2, C-7), 24.8 (CH2, C-8), 20.2 (CH3, 
C-14); IR (neat): 2935, 1734, 1714, 1238, 1150, 1038 cm-1; HRMS (ESI): calculated for 
C15H20NaO4 [MNa
+] requires 287.1254, found 287.1241 (4.8 ppm error). 
6-(3-Methoxyphenyl)hex-1-en-3-one 4.150 
Synthesis of vinyl ketone 4.150 from acetate 4.161 
 
DBU (34.0 µL, 0.23 mmol) was added to a solution of acetate 4.161 (20.0 mg, 0.08 mmol) 
in toluene (4 mL). The reaction mixture was stirred at rt for 2 h. Toluene was evaporated 
and the residue was diluted with CH2Cl2 (20 mL) and washed with sat aq NH4Cl (3x 8 
mL). The organic layer was dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 10 
g SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to give vinyl ketone 4.150 (15.0 mg, 98%) 
as a colourless oil. Ref. LNB0083-034 
Rf: 0.39 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.20 (1H, “t”, J = 8.1 
Hz, H-1), 6.78-6.73 (3H, m, H-2, H-4, H-6), 6.34 (1H, dd, J = 17.1, 10.6 Hz, H-11), 6.18 
(1H, d, J = 17.1 Hz, H-12a), 5.81 (1H, d, J = 10.6 Hz, H-12b), 3.80 (3H, s, C-1a), 2.65-
2.58 (4H, m, 2H-7, 2H-9), 1.96 (2H, quint, J = 7.6 Hz, 2H-8); 13C-NMR (100 MHz, 
CDCl3), δ: 200.5 (C, C-10), 159.6 (C, C-3), 143.2 (C, C-5), 136.4 (CH, C-11), 129.3 (CH, 
C-1), 127.9 (CH2, C-12), 120.8 (CH, C-6), 114.1 (CH, C-4), 111.2 (CH, C-2), 55.4 (CH3, 
C-1a), 38.6 (CH2, C-9), 35.0 (CH2, C-7), 25.1 (CH2, C-8); IR (neat): 2932, 1699, 1679, 
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1580, 1259, 1147, 1038 cm-1;  HRMS (ESI): calculated for C13H16NaO2 [MNa
+] requires 
227.1043, found 227.1038 (1.7 ppm error). Data are consistent with those reported in the 
literature.179 
Synthesis of vinyl ketone 4.165 from chloride 4.150 
 
DBU (71.0 µL, 0.48 mmol) was added to a solution of chloride 4.165 (38.0 mg, 0.16 
mmol) in toluene (10 mL). The reaction mixture was stirred at rt for 2 h. The mixture was 
diluted with CH2Cl2 (10 mL) and washed with sat aq NH4Cl (3 x 5 mL). The organic 
layer was dried over Na2SO4, filtered and evaporated under reduced pressure. The residue 
was purified by flash column chromatography (Biotage SNAP 10 g SiO2 cartridge, 
heptane/AcOEt = 10/0 to 4/1) to afford vinyl ether 4.150 (17.0 mg, 54%) as a colourless 
oil. Ref. LNB0083-036 
2-(6-(3-Methoxyphenyl)-3-oxohexyl)-2-methylcyclopentane-1,3-dione 4.148 
 
Acid-catalysed Michael addition178 
Vinyl ketone 4.150 (220 mg, 1.10 mmol) was added to a solution of 2-methylcyclpentane-
1,3-dione 4.149 (145 mg, 1.30 mmol) in a mixture of glacial AcOH (6 mL) and H2O (1 
mL). The reaction mixture was heated to 80 °C and stirred overnight. After cooling to rt, 
the mixture was diluted with H2O (10 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (SiO2, 
heptane/AcOEt = 3/2) to give triketone 4.148 (148 mg, 43%) as a yellow oil. Ref. 
LNB0083-062. 
Rf: 0.33 (heptane/AcOEt = 5/5); 1H-NMR (400 MHz, CDCl3), δ: 7.19 (1H, “t”, J = 7.9 
Hz, H-1), 6.77-6.58 (3H, m, H-2, H-4, H-6), 3.79 (3H, s, 3H-1a), 2.90-2.70 (4H, m,  
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2H-15, 2H-16), 2.56 (2H, t, J = 7.6 Hz, 2H-7), 2.42-2.32 (4H, m, 2H-11, 2H-9),  
1.90-1.80 (4H, m, 2H-12, 2H-8), 1.09 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 
215.9 (2C, C-14, C-17), 209.9 (C, C-10), 159.8 (C, C-3), 143.2 (C, C-5), 129.5 (CH,  
C-1), 121.0 (CH, C-6), 114.3 (CH, C-4), 111.4 (CH, C-2), 55.3 (2C, C, C-13, CH3, C-1a), 
42.1 (CH2, C-9), 36.6 (CH2, C-11), 35.1 (CH2, C-7), 34.8 (2CH2, C-15, C-16), 28.0 (CH2, 
C-12), 25.0 (CH2, C-8), 19.3 (CH3, C-18); IR (neat): 2932, 1710, 1266, 1150, 1038 cm
-
1; HRMS (ESI): calculated for C19H24NaO4 [MNa
+] requires 339.1567, found 339.1537 
(8.4 ppm error). Data are consistent with those reported in the literature.179  
Base-catalysed Michael addition 
Et3N (1.30 mL, 9.28 mmol) was added to a suspension of 2-methylcyclpentane-1,3-dione 
4.149 (0.97 g, 8.70 mmol) in THF (20 mL). The reaction mixture was stirred at rt until 
complete dissolution, then a solution of vinyl ketone 4.150 (600 mg, 2.90 mmol) in THF 
(10 mL) was added. The reaction mixture was heated to 40 °C and stirred for 1 d. After 
cooling to rt, the mixture was diluted with AcOEt (100 mL) and washed with H2O (3 x 
100 mL). The combined aqueous layers were further extracted with AcOEt (2 x 200 mL). 
The combined organic layers were dried over Na2SO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash column chromatography (Biotage 
SNAP 50 g SiO2 cartridge, heptane/AcOEt = 10/0 to 3/2) to yield triketone 4.148 (828 
mg, 90%) as a yellow oil. Ref. LNB0083-144 
(14β)-14-Hydroxy-1-methoxy-9,10-secoestra-1(10),2,4-triene-9,17-dione 4.147 and 
14-hydroxy-1-methoxy-9,10-secoestra-1(10),2,4-triene-9,17-dione 4.177 
 
DBU (365 µL, 2.45 mmol) was added to a solution of triketone 4.148 (2.58 g, 8.16 mmol) 
in THF (40 mL). The reaction mixture was heated to 40 °C and stirred for 6 d under a 
nitrogen atmosphere. After cooling to rt, the reaction mixture was diluted with AcOEt 
(200 mL) and washed with H2O (3 x 200 mL). The combined aqueous layers were further 
extracted with AcOEt (2 x 150 mL). The combined organic layers were dried over 
Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by 
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flash column chromatography (Biotage SNAP 100 g SiO2 cartridge, heptane/AcOEt = 1/4 
to 2/3) to yield a diastereomeric mixture of 4.147 and 4.177 (about 3/1, 1.92 g, 74%) as a 
white solid. Ref. LNB0083-152 
Characterisation of alcohol 4.147: Rf: 0.33 (heptane/AcOEt = 5/5); m.p.: 128-130 °C 
(lit. m.p. of racemic 4.147: 132-135.5 °C, m.p. of optically active 4.147: 136-137 °C);193  
1H-NMR (400 MHz, CDCl3), δ: 7.21 (1H, “t”, J = 7.6 Hz, H-1), 6.80 (1H, d, J = 7.3 Hz, 
H-6), 6.78-6.72 (2H, m, H-2, H-4), 3.80 (3H, s, 3H-1a), 2.92-2.83 (1H, m, H-7),  
2.61-2.48 (2H, m, H-9, H-11), 2.48-2.33 (4H, m, H-7, H-11, 2H-16), 2.22-2.11 (1H, m, 
H-8), 1.91-1.51 (5H, m, H-8, 2H-12, 2H-15), 1.28 (3H, s, 3H-18); 13C-NMR (100 MHz, 
CDCl3), δ: 218.1 (C, C-17), 208.3 (C, C-10), 159.9 (C, C-3), 143.7 (C, C-5), 129.6 (CH, 
C-1), 120.9 (CH, C-6), 114.3 (CH, C-4), 111.5 (CH, C-2), 85.0 (C, C-14), 56.3 (CH,  
C-9), 55.3 (CH3, C-1a), 53.7 (C, C-13), 37.4 (CH2, C-11), 34.9 (CH2, C-7), 32.9 (CH2,  
C-16), 30.5 (CH2, C-12), 28.7 (CH2, C-15), 24.0 (CH2, C-8), 12.9 (CH3, C-18); IR (neat): 
3478, 2929, 1742, 1714, 1259 cm-1; HRMS (ESI): calculated for C19H24NaO4 [MNa
+] 
requires 339.1567, found 339.1592 (1.1 ppm error). 
Characterisation of alcohol 4.177: Rf: 0.30 (heptane/AcOEt = 5/5); m.p.: 82-84 °C;  
1H-NMR (400 MHz, CDCl3), δ: 7.21 (1H, “t”, J = 7.6 Hz, H-1), 6.77-6.67 (3H, m, H-2, 
H-4, H-6), 3.79 (3H, s, 3H-1a), 2.84-2.74 (1H, m, H-7), 2.54-2.44 (1H, m, H-16),  
2.42-2.12 (6H, m, H-7, H-8, H-9, 2H-11, H-12), 2.09-1.83 (3H, m, 2H-15, H-16),  
1.83-1.72 (1H, m, H-8), 1.71-1.62 (1H, m, H-12), 1.08 (3H, s, 3H-18); 13C-NMR (100 
MHz, CDCl3), δ: 217.4 (C, C-17), 210.5 (C, C-10), 159.9 (C, C-3), 143.1 (C, C-5), 129.7 
(CH, C-1), 121.6 (CH, C-6), 114.5 (CH, C-4), 111.6 (CH, C-2), 84.9 (C, C-14), 55.4 
(CH3, C-1a), 54.9 (CH, C-9) 53.7 (C, C-13), 37.8 (CH2, C-11), 34.4 (CH2, C-7), 33.8 
(CH2, C-16), 31.5 (CH2, C-15), 29.8 (CH2, C-12), 25.4 (CH2, C-8), 18.3 (CH3, C-18); 
IR (neat): 3468, 2922, 1742, 1711, 1259 cm-1; HRMS (ESI): calculated for C19H24NaO4 
[MNa+] requires 339.1568, found 339.1592 (0.5 ppm error). 
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2-Hydroxy-2-[3-(3-methoxyphenyl)propyl]-5-methylbicyclo[3.2.1]octane-6,8-dione 
4.182 
 
DBU (91.0 µL, 0.61 mmol) and (S)-proline 4.168 (70.0 mg, 0.61 mmol) were added to a 
solution of triketone 4.148 (193 mg, 0.61 mmol) in dry THF (10 mL) and the resulting 
mixture was stirred at rt overnight. The reaction was quenched with H2O (10 mL) and the 
organic compounds were extracted with AcOEt (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, hexane/AcOEt = 4/1 to 7/3) to give 
compound 4.182 (20.0 mg, 11%) as a yellow oil. Ref. LNB0162-110 
Rf: 0.23 (hexane/AcOEt = 7/3); 1H-NMR (400 MHz, CDCl3), δ: 7.19 (1H, “t”, J = 7.8 
Hz, H-1), 6.78-6.68 (3H, m, H-2, H-4, H-6), 3.79 (3H, s, H-1a), 2.79 (1H, d, J = 6.6 Hz, 
H-16), 2.66-2.49 (3H, m, 2H-7, H-15), 2.42-2.31 (1H, m, H-15), 2.14-2.06 (1H, m, H-
12), 1.89-1.66 (7H, m, 2H-8, 2H-9, 2H-11, H-12), 1.06 (3H, s, H-18); 13C-NMR (100 
MHz, CDCl3), δ: 214.1 (C, C-17), 211.2 (C, C-14), 159.8 (C, C-3), 143.3 (C, C-5), 129.5 
(CH, C-1), 128.8 (CH, C-6), 114.4 (CH, C-4), 111.3 (CH, C-2), 82.6 (C, C-10), 58.8 (C, 
C-13), 55.5 (CH, C-16), 55.3 (CH3, C-1a), 42.3 (CH2, C-15), 40.0 (CH2, C-9), 38.5 (CH2, 
C-12), 35.9 (CH2, C-7), 31.0 (CH2, C-11), 24.3 (CH2, C-8), 11.9 (CH3, C-18); IR (neat): 
3460, 2936, 1770, 1724 cm-1; HRMS (ESI): calculated for C19H24NaO4 [MNa
+] requires 
339.1567, found 339.1555 (3.0 ppm error). In spite of the presence of (S)-proline 4.168 
in the reaction mixture, compound 4.182 was assumed to be racemic (see Table 4.4 and 
Scheme 4.31). 
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Conversion of bicycle 4.182 into carbinols 4.147 and 4.177 
 
DBU (12.0 µL, 0.08 mmol) was added to a solution of bicycle 4.182 (102 mg, 0.32 mmol) 
in THF (1 mL), and the reaction mixture was stirred at 40 °C for 3 d. Due to the presence 
of residual starting material, a further amount of DBU (12.0 µL, 0.08 mmol) was added 
and the temperature was gradually increased to 70 °C during 2 d. The reaction mixture 
was diluted with AcOEt (10 mL) and washed with H2O (3 x 20 mL). The combined 
organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. 
The residue was purified by flash column chromatography (Biotage SNAP SiO2 cartridge, 
heptane/Et2O = 1/1) to yield a diastereomeric mixture of 4.147 and 4.177 (about 4/1, 40.0 
mg, 40%) as a white solid. Ref. LNB0083-102 
1-Methoxy-9,10-secoestra-1(10),2,4,8(14)-tetraene-9,17-dione 4.174 
 
A diastereomeric mixture of carbinols 4.147 and 4.177 (about 3/1, 51.0 mg, 0.16 mmol) 
in CH2Cl2 (1 mL) was cooled to 0 °C and (i-PrO)3TiCl (1 M in hexane, 160 µl, 0.16 
mmol) was added slowly. The reaction mixture was allowed to reach rt and stirred 
overnight. The reaction was quenched with sat aq NaHCO3 (5 mL) and extracted with 
CH2Cl2 (3 x 5 mL). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP, silica cartridge, heptane/AcOEt = 4/1 to 3/2) to give the 
title diketone 4.174 (24.0 mg, 50%) as a yellow oil. Ref. LNB0103-015  
Rf: 0.37 (heptane/AcOEt = 5/5); 1H-NMR (400 MHz, CDCl3), δ: 7.16 (1H, “t”, J = 7.9 
Hz, H-1), 6.74-6.70 (1H, m, H-2), 6.68 (1H, d, J = 7.9 Hz, H-6), 6.64 (1H, brs, H-4), 3.77 
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(3H, s, 3H-1a), 2.72-2.65 (2H, m, 2H-7), 2.60-2.43 (6H, m, 2H-8, 2H-11, H-15, H-16), 
2.27-2.15 (1H, m, H-15), 2.09-1.98 (2H, m, H-12, H-16), 1.79 (1H, “td”, J = 13.6, 5.8 
Hz, H-12), 1.19 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 217.6 (C, C-17), 197.6 
(C, C-10), 164.4 (C, C-14), 159.3 (C, C-3), 143.3 (C, C-5), 132.7 (C, C-9) 129.9 (CH,  
C-1), 121.6 (CH, C-6), 115.1 (CH, C-4), 111.1 (CH, C-2), 55.1 (CH3, C-1a), 49.0 (C,  
C-13), 35.7 (CH2, C-16), 34.8 (CH2, C-7), 33.2 (CH2, C-11), 29.0 (CH2, C-12), 27.6 (CH2, 
C-8), 24.5 (CH2, C-15), 21.2 (CH3, C-18); HRMS (ESI): calculated for C19H22NaO3 
[MNa+] requires 321.1461, found 321.1447 (3.7 ppm error). Data are consistent with 
those reported in the literature.179 
3-Methoxyestra-1(10),2,4,8,14-pentaen-17-one 4.176 
 
BF3
.OEt2 (15.0 µL, 0.16 mmol) was added dropwise to a solution of of carbinols 4.147 
and 4.177 (about 3/1, 50.0 mg, 0.16 mmol) in CH2Cl2 (1 mL) and the reaction mixture 
was stirred at rt for 2 h. The reaction was quenched with H2O (5 mL). The organic layer 
was separated, and the aqueous phase was extracted with CH2Cl2 (2 x 5 ml). The 
combined organic layers were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 10 
g SiO2 cartridge, heptane/AcOEt = 10/0 to 9/1) to yield title compound 4.176 (40.0 mg, 
90%) as a white solid. Ref. LNB0083-149 
Rf: 0.48 (hexane/AcOEt = 4/1); m.p.: 111-113 °C (MeOH) [lit. 111-113 °C];179 
1H-NMR (400 MHz, CDCl3), δ: 7.26-7.24 (1H, m, H-1), 6.78-6.69 (2H, H-2, H-4), 5.86 
(1H, brs, H-15), 3.81 (3H, s, 3H-1a), 3.31 (1H, dd, J = 23.3, 3.0 Hz, H-16), 2.95 (1H, dd, 
J = 23.3, 3.0 Hz, H-16), 2.82-2.77 (2H, m, 2H-6), 2.65-2.57 (3H, m, H-7, 2H-11),  
2.35-2.27 (1H, m, H-7), 2.06-2.01 (1H, m, H-12), 1.63-1.55 (1H, m, H-12), 1.14 (3H, s, 
H-18);  13C-NMR (100 MHz, CDCl3), δ: 220.3 (C, C-17), 158.8 (C, C-3), 147.0 (C,  
C-14), 138.3 (C, C-5), 129.9 (C, C-9), 128.7 (C, C-10), 125.1 (C, C-8), 124.6 (CH, C-1), 
114.4 (CH, C-15), 113.8 (CH, C-4), 111.3 (CH, C-2), 55.6 (CH3, C-1a), 49.3 (C, C-13), 
42.3 (CH2, C-16), 28.6 (CH2, C-6), 27.4 (CH2, C-12), 23.1 (CH2, C-11), 22.9 (CH2, C-7), 
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20.8 (CH3, C-18); HRMS (ESI): calculated for C19H20NaO2 [MNa
+] requires 303.1356, 
found 303.1358 (0.5 ppm error). Data are consistent with those reported in the 
literature.179 
1-Methoxy-14-[(trimethylsilyl)oxy]-9,10-secoestra-1(10),2,4-triene-9,17-dione 4.198 
 
Et3N (106 µL, 0.76 mmol) was added to a solution of carbinols 4.174 and 4.175 (about 
3/1, 200 mg, 0.63 mmol) in dry CH2Cl2 (5 mL) under a nitrogen atmosphere. The mixture 
was cooled to 0 °C and TMSOTf (137 µL, 0.76 mmol) was added dropwise. Aftet 10 min, 
the ice bath was removed, and the reaction mixture was stirred at rt for an additional 1 h. 
The reaction was quenched with H2O (5 mL). The organic layer was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were 
dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (Biotage SNAP 10 g silica cartidge, 
heptane/AcOEt = 10/0 to 4/1) to afford the title compound 4.198 (58.0 mg, 24%) as a 
colourless oil. Ref. LNB0103-054 
Rf: 0.29 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.19 (1H, “t”, J = 7.9 
Hz, H-1), 6.76-6.66 (3H, m, H-2, H-4, H-6), 3.87 (3H, s, 3H-1a), 2.78-2.69 (1H, m,  
H-7), 2.48-2.28 (3H, m, H-7, H-11, H-16), 2.25-2.13 (3H, m, H-8, H-9, H-11), 2.06-1.90 
(4H, m, H-12, 2H-15, H-16), 1.85-1.74 (1H, m, H-8), 1.67-1.55 (1H, m, H-12), 1.05 (3H, 
s, 3H-18), 0.12 (9H, s, 3H-19, 3H-20, 3H-21); 13C-NMR (100 MHz, CDCl3), δ: 217.5 
(C, C-17), 210.4 (C, C-10), 159.9 (C, C-3), 143.2 (C, C-5), 129.6 (CH, C-1), 120.9 (CH, 
C-6), 114.4 (CH, C-4), 111.5 (CH, C-2), 87.6 (C, C-14), 56.3 (CH, C-9), 55.3 (CH3,  
C-1a), 54.5 (C, C-13), 36.6 (CH2, C-11), 34.2 (CH2, C-7), 33.8 (CH2, C-16), 31.0 (CH2, 
C-15), 29.3 (CH2, C-12), 26.9 (CH2, C-8), 18.3 (CH3, C-18), 2.48 (3CH3, C-19, C-20,  
C-21); IR (neat): 2953, 1742, 1717, 1252, cm-1; HRMS (ESI): calculated for 
C22H32NaO4Si [MNa
+] requires 411.1962, found 411.1955 (0.7 ppm error). 
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1-Methoxy-14-[(triethylsilyl)oxy]-9,10-secoestra-1(10),2,4-triene-9,17-dione 4.202 
 
Et3N (194 µL, 1.39 mmol) was added to a solution of carbinols 4.147 and 4.177 (about 
3/1, 200 mg, 0.63 mmol) in dry CH2Cl2 (5 mL) stirred under an argon atmosphere. The 
reaction mixture was cooled at 0 °C, then TESOTf (314 µL, 1.39 mmol) was added 
dropwise. The reaction mixture was stirred at 0 °C for 10 min. The ice-bath was removed 
and the mixture was stirred at rt for a further 30 min before quenching with H2O (5 mL). 
The organic layer was separated and the aqueous phase was extracted with CH2Cl2 (2 x 
10 mL). Combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue oil was purified by flash column chromatography 
(Biotage SNAP 25 g SiO2 cartridge, heptane/AcOEt= 10/0 to 4/1) to obtain the title 
compound 4.202 (54.0 mg, 20%) as a colorless oil. Ref. LNB0103-055 
Rf: 0.31 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.19 (1H, “t”, J = 7.9 
Hz, H-1), 6.76-6.66 (3H, m, H-2, H-4, H-6), 3.87 (3H, s, 3H-1a), 2.78-2.69 (1H, m,  
H-7), 2.48-2.28 (3H, m, H-7, H-11, H-16), 2.25-2.13 (3H, m, H-8, H-9, H-11), 2.06-1.90 
(4H, m, H-12, 2H-15, H-16), 1.85-1.74 (1H, m, H-8), 1.67-1.55 (1H, m, H-12), 1.09 (3H, 
s, 3H-18), 0.92 (9H, t, J = 7.8 Hz, 3H-19, 3H-20, 3H-21), 0.58 (6H, q, J = 7.8 Hz, 2H-22, 
2H-23, 2H-24); 13C-NMR (100 MHz, CDCl3), δ: 217.6 (C, C-17), 210.5 (C, C-10), 159.9 
(C, C-3), 143.1 (C, C-5), 129.6 (CH, C-1), 121.0 (CH, C-6), 114.4 (CH, C-4), 111.6 (CH, 
C-2), 87.0 (C, C-14), 56.9 (CH, C-9), 55.3 (CH3, C-1a), 54.7 (C, C-13), 36.3 (CH2,  
C-11), 34.2 (CH2, C-7), 33.7 (CH2, C-16), 31.7 (CH2, C-15), 29.5 (CH2, C-12), 27.1 (CH2, 
C-8), 17.9 (CH3, C-18), 7.3 (3CH3, C-22, C-23, C-24), 6.9 (3CH2, C-19, C-20, C-21); IR 
(neat): 2957, 1742, 1721, 1259, 741 cm-1; HRMS (ESI): calculated for C25H38NaO4Si 
[MNa+] requires 453.2432, found 453.2422 (2.4 ppm error). 
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2-[3-(3-Methoxyphenyl)propyl]-5-methyl-2-[(triethylsilyl)oxy]bicyclo[3.2.1]octane-
6,8-dione 4.194 
 
Carbinols 4.147 and 4.177 (about 3/1, 214 mg, 0.68 mmol) were dissolved in CH2Cl2  
(6 mL) under an argon atmosphere, and Et3N (207 µL, 1.49 mmol) was added. The 
reaction mixture was cooled at 0 °C, then TESOTf (336 µL, 1.49 mmol) was added 
slowly. The reaction mixture was maintained at 0 °C for 30 min then H2O (10 mL) was 
added. After warming up to rt, the aqueous layer was separated and the organic phase was 
washed with H2O (3 x 15 mL), dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatoghaphy (Biotage SNAP 25 
g SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to afford the bridged silylether 4.203 (40.0 
mg, 14%), and the isomer 4.202 (20.0 mg, 7%) as clear oils. Ref. LNB0103-087 
Rf: 0.66 (hexane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.23-7.17 (1H, m, H-1), 
6.78 (1H, d, J = 7.6 Hz, H-6), 6.76-6.71 (2H, m, H-2, H-4), 3.81 (3H, s, 3H-1a), 3.02-
2.87 (2H, m, H-15ax, H-16), 2.69-2.48 (3H, m, 2H-7, H-15eq), 2.03-1.88 (1H, m, H-8), 
1.81-1.41 (7H, m, H-8, 2H-9, 2H-11, 2H-12), 1.04 (3H, s, 3H-18), 0.92 (9H, t, J = 7.9 
Hz, 3H-22, 3H-23, 3H-24), 0.63-0.48 (6H, m, 2H-19, 2H-20, 2H-21); 13C-NMR (100 
MHz, CDCl3), δ: 213.1 (C, C-17), 211.7 (C, C-14), 159.8 (C, C-3), 147.3 (C, C-5), 129.4 
(CH, C-1), 121.0 (CH, C-6), 114.3 (CH, C-4), 111.4 (CH, C-2), 81.6 (C, C-10), 58.8 (C, 
C-13), 56.1 (CH, C-16), 55.3 (CH3, C-1a), 41.4 (CH2, C-15), 38.5 (CH2, C-9), 36.2 (CH2, 
C-7), 36.0 (CH2, C-12), 33.7 (CH2, C-11), 24.7 (CH2, C-8), 11.7 (CH3, C-18), 7.26 (3CH3, 
C-22, C-23, C-24), 6.76 (3CH2, C-19, C-20, C-21); IR (neat): 2953, 2876, 1742, 1727, 
1223, 729, 693 cm-1; HRMS (ESI): calculated for C25H38NaO4Si [MNa
+] requires 
453.2425, found 453.2422 (1.9 ppm error). 
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2-[3-(3-Methoxyphenyl)propyl]-5-methyl-2-[(triethylsilyl)oxy]bicyclo[3.2.1]octane-
6,8-dione 4.204 
 
Et3N (498 µL, 3.58 mmol) and TESOTf (808 µL, 3.58 mmol) were added to a solution 
of carbinols 4.147 and 4.177 (about 3/1, 942 mg, 2.98 mmol) in dry CH2Cl2 (10 mL) 
cooled at 0 °C and stirred under an argon atmosphere. The reaction mixture was stirred 
at 0 °C for 1 h, then it was quenched with H2O (5 mL) and diluted with CH2Cl2 (10 mL). 
The organic layer was separated and the aqueous phase was extracted with CH2Cl2 (3 x 
10 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
product was purified by flash column chromatoghaphy (Biotage SNAP 25 g SiO2 
cartridge, heptane/AcOEt = 10/0 to 3/2) to afford silylether 4.202 (168 mg, 13%) as a 
clear oil, the bridged silylether 4.204 (8.00 mg, 6%) as a clear oil, dienone 4.176 (342 
mg, 36%) as a white solid , triketone 4.148 (100 mg, 11%) as a clear oil and recovered  
cis-carbinol 4.174 (214 mg) as a white solid. Ref. LNB0103-084 
Rf: 0.55 (hexane/AcOEt = 4 /1); 1H-NMR (400 MHz, CDCl3), δ: 7.21 (1H, “t”, J = 7.2 
Hz, H-1), 6.78-6.68 (3H, m, H-2, H-4, H-6), 3.80 (3H, s, 3H-1a), 2.86 (1H, d, J = 6.7 Hz, 
H-16), 2.62-2.53 (2H, m, 2H-7), 2.49-2.42 (2H, m, 2H-15), 2.02 (1H, td, J = 12.7, 6.4 Hz, 
H-12), 1.82-1.52 (7H, m, 2H-8, 2H-9, 2H-11), 1.04 (3H, s, 3H-18), 0.94 (9H, t, J = 7.9 
Hz. 3H-22, 3H-23, 3H-24), 0.66-0.55 (6H, m, 2H-19, 2H-20, 2H-21); 13C-NMR (100 
MHz, CDCl3), δ: 212.4 (C, C-17), 211.8 (C, C-14), 159.9 (C, C-3), 147.4 (C, C-5), 129.6 
(CH, C-1), 120.9 (CH, C-6), 114.4 (CH, C-4), 111.3 (CH, C-2), 85.3 (C, C-10), 58.4 (C, 
C-13), 55.6 (CH, C-16), 55.3 (CH3, C-1a), 42.4 (CH2, C-15), 39.9 (CH2, C-9), 38.0 (CH2, 
C-12), 36.2 (CH2, C-7), 32.2 (CH2, C-11), 25.0 (CH2, C-8), 12.1 (CH3, C-18), 7.29 (3CH3, 
C-22, C-23, C-24), 6.77 (3CH2, C-19, C-20, C-21); IR (neat): 2953, 2884, 1742, 1772, 
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1732, 1255, 1008, 741 cm-1; HRMS (ESI): calculated for C25H38NaO4Si [MNa
+] requires 
453.2432, found 453.2427 (1.2 ppm error). 
(14ξ)-14,17-bis{[tert-Butyl(dimethyl)silyl]oxy}-1-methoxy-9,10-secoestra-
1(10),2,4,16-tetraen-9-one 4.211 and (14ξ)-17-{[tert-butyl(dimethyl)silyl]oxy}-14-
hydroxy-1-methoxy-9,10-secoestra-1(10),2,4,16-tetraen-9-one 4.212 
Lutidine (26.0 µL, 0.23 mmol) and TBSOTf (44.0 µL, 0.19 mmol) were added 
subsequently to a solution of alcohols 4.147 and 4.177 (about 3/1, 61.0 mg, 0.19 mmol) 
dissolved in CH2Cl2 (800 µL) under an argon atmosphere. The reaction mixture was 
stirred at rt overnight, quenched with H2O (10 mL) and extracted with CH2Cl2 (3 x 10 
The combined organic layers were dried over Na2SO4, filtered and evaporated under 
reduced pressure. The residue was purified by repeated flash column chromatography 
(Biotage SNAP 10 g SiO2 cartridge, heptane/AcOEt = 10/0 to 7/3, then Biotage SNAP 
10 g SiO2 cartridge, heptane/AcOEt = 3/2) to give TBS ethers 4.211 (6.00 mg, 6% 
contaminated by unidentified by-products) and 4.212 (7.00 mg, 9% contaminated by 
unidentified by-products) as white solids. Ref. LNB0103-097 
Characterisation of bis-silylether 4.211: Rf: 0.76 (heptane/AcOEt = 3/2); 1H-NMR (400 
MHz, CDCl3), δ: 7.15-7.08 (1H, m, H-1), 6.75-6.63 (3H, m, H-4, H-6, H-2), 4.21 (1H, 
brs, H-16), 3.73 (3H, s, 3H-1a), 2.82-2.72 (1H, m, H-7), 2.50 (1H, d, J = 9.8 Hz, H-9), 
2.38-2.10 (6H, m, H-7, H-8, 2H-11, 2H-15), 2.87-1.79 (1H, m, H-12), 1.70-1.53 (2H, m, 
H-8, H-12), 0.96 (3H, s, 3H-18), 0.86 (9H, s, 3H-22, 3H-23, 3H-24), 0.77 (9H, s, 3H-28, 
3H-29, 3H-30), 0.09 (3H, s, 3H-19 or 3H-20), 0.07 (3H, s, 3H-25 or 3H-26), 0.07 (3H, s, 
3H-19 or 3H-20), 0.01 (3H, s, 3H-25 or 3H-26); 13C-NMR (100 MHz, CDCl3), δ: 212.7 
(C, C-10), 159.7 (C, C-3), 159.0 (C, C-17), 144.1 (C, C-5), 129.3 (CH, C-1), 121.6 (CH, 
C-6), 114.4 (CH, C-4), 111.2 (CH, C-2), 95.0 (CH, C-16), 87.0 (C, C-14), 55.4 (CH3, C-
1a), 55.3 (CH, C-9), 50.6 (C, C-13), 39.2 (CH2, C-15), 36.2 (CH2, C-11), 35.3 (CH2, C-
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7), 30.4 (CH2, C-12), 26.4 (CH2, C-8), 26.3 (3CH3, C-28, C-29, C-30), 25.6 (3CH3,  
C-22, C-23, C-24), 21.0 (CH3, C-18), 18.8 (C, C-27), 18.3 (C, C-21), -1.6 (CH3, C-19 or 
C-20), -1.7 (CH3, C-19 or C-20), -4.7 (CH3, C-25 or C-26), -4.8 (CH3, C-25 or C-26); 
HRMS (ESI): calculated for C31H52NaO4Si2 [MNa
+] requires 567.3296, found 567.3293 
(-0.5 ppm error); IR spectrum could not be recorded because compound 4.211 
decomposed. 
Characterisation of mono-silylether 4.212: Rf: 0.35 (heptane/AcOEt = 3/2); 1H-NMR 
(400 MHz, CDCl3), δ: 7.25-7.19 (1H, m, H-1), 6.83 (1H, d, J = 7.9 Hz, H-6), 114.4 (1H, 
brs, H-4), 111.7 (1H, d, J = 7.9 Hz, H-2), 4.35 (1H, brs, H-16), 3.80 (3H, s, 3H-1a),  
2.85-2.74 (1H, m, H-7), 2.58 (1H, d, J = 8.5 Hz, H-9), 2.50-2.41 (1H, m, H-7), 2.37-2.25 
(2H, m, H-11, H-15), 2.22-2.02 (3H, m, H-8, H-11, H-15), 1.92-1.79 (2H, m, H-12,  
H-8), 1.79-1.70 (1H, m, H-12), 1.14 (3H, s, 3H-18), 0.92 (9H, s, 3H-22, 3H-23, 3H-24), 
0.16 (3H, s, 3H-19 or 3H-20), 0.14 (3H, s, 3H-19 or 3H-20); 13C-NMR (100 MHz, 
CDCl3), δ: 210.5 (C, C-10), 159.7 (C, C-3), 156.2 (C, C-17), 144.5 (C, C-5), 129.9 (CH, 
C-1), 121.3 (CH, C-6), 114.4 (CH, C-4), 111.7 (CH, C-2), 96.6 (CH, C-16), 82.2 (CH,  
C-14), 55.4 (CH3, C-1a), 56.5 (CH, C-9), 51.9 (C, C-13), 39.1 (CH2, C-15), 37.1 (CH2, 
C-11), 35.2 (CH2, C-7), 30.3 (CH2, C-12), 25.8 (3CH3, C-22, C-23, C-24), 25.2 (CH2,  
-8), 18.5 (CH3, C-18), 18.3 (C, C-21), -5.0 (CH3, C-19 or C-20); HRMS (ESI): calculated 
for C25H38NaO4Si [MNa
+] requires 453.2432, found 453.2435 (-0.4 ppm error); IR 
spectrum could not be recorded because compound 4.212 decomposed. 
(14β)-1-Methoxy-9,17-dioxo-9,10-secoestra-1(10),2,4-trien-14-yl acetate 4.215 
 
A solution of PTSA (5.77 mg, 0.03 mmol) in Ac2O (113 µL) was added to a solution of 
carbinols 4.147 and 4.177 (about 3/1, 96.0 mg, 0.30 mmol) in Ac2O (560 µL). The 
reaction mixture was stirred at rt under a nitrogen atmosphere atmosphere for 1 d. The 
reaction was quenched with H2O (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 25 
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g SiO2, heptane/AcOEt = 10/0 to 5/5) to give title compound 4.215 (52.0 mg, 48%) as a 
colourless oil and dienone 4.176 (9.00 mg, 11%) as a white solid. Ref. LNB0103-012 
Rf: 0.35 (heptane/AcOEt = 5/5); 1H-NMR (400 MHz, CDCl3), δ: 7.21 (1H, “t”, J = 7.6 
Hz, H-1), 6.80 (1H, d, J = 7.6 Hz, H-6), 6.77-6.73 (2H, m, H-2, H-4); 3.81 (3H, s,  
3H-1a), 3.48 (1H, d, J = 9.8 Hz, H-9), 2.86-2.75 (1H, m, H-7), 2.62-2.50 (2H, m,  
H-11, H-16), 2.47-2.38 (1H, m, H-7), 2.38-2.28 (2H, m, H-11, H-16), 2.25-2.10 (2H, m, 
H-8, H-15), 2.01 (3H, s, 3H-20), 1.96-1.88 (1H, m, H-15), 1.88-1.79 (1H, m, H-12),  
1.73-1.57 (2H, m, H-8, H-12), 1.25 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 
216.0 (C, C-17), 208.2 (C, C-10), 170.5 (C, C-9), 159.4 (C, C-3), 143.1 (C, C-5), 129.5 
(CH, C-1), 121.0 (CH, C-6), 114.5 (CH, C-4), 111.3 (CH, C-2), 94.9 (C, C-14), 54.0 (CH, 
C-9), 55.3 (CH3, C-1a), 53.8 (C, C-13), 37.2 (CH2, C-11), 34.7 (CH2, C-7), 33.8 (CH2,  
C-16), 31.2 (CH2, C-12), 28.5 (CH2, C-15), 25.2 (CH2, C-8), 16.1 (CH3, C-18), 21.9 (CH3, 
C-20); IR (neat): 2936, 1738, 1714, 1245, 1021 cm-1; HRMS (ESI): calculated for 
C21H26NaO5 [MNa
+] requires 381.1672, found 381.1682 (2.5 ppm error).  
(14β)-1-Methoxy-14-[(triethylsilyl)oxy]-9,10-secoestra-1(10),2,4-triene-9,17-dione 
4.209 
 
Triethylsilyl ether 4.202 (200 mg, 0.47 mmol) was dissolved in CH2Cl2 (6 mL) and the 
solution was cooled to 0 °C. AlCl3 (62.0 mg, 0.47 mmol) was added portionwise and the 
reaction mixture was stirred at 0 °C for 2 h and at rt overnight. The reaction was quenched 
with H2O (10 mL). The organic layer was separated and the aqueous phase was extracted 
with CH2Cl2 (3 x 3 ml). The combined organic layers were dried over Na2SO4, filtered 
and evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP 25 g SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to 
yield dienone 4.176 (60.0 mg, 46%) as a white solid and isomeric triethylsilyl ether 4.209 
(15.0 mg, 7%) as a yellow gum. Ref. LNB0103-086 
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Rf: 0.40 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.22 (1H, “t”, J = 7.9 
Hz, H-1), 6.81 (1H, d, J = 7.9 Hz, H-6), 6.79-6.73 (2H, m, H-2, H-4), 3.81 (3H, s, 3H-
1a), 2.82 (1H, “dt”, J = 12.2, 4.3 Hz, H-7), 2.65 (1H, d, J = 11.0 Hz, H-9), 2.56 (1H, td, 
J = 13.7, 6.1 Hz, H-11), 2.47-2.27 (4H, m, H-7, H-11, 2H-16), 2.15-1.98 (1H, m,  
H-8), 1.94-1.83 (1H, m, H-15), 1.79-1.69 (2H, m, H-8, H-15), 1.68-1.60 (1H, m, H-12), 
1.57-1.46 (1H, m, H-12), 1.29 (3H, s, 3H-18), 0.91 (9H, t, J = 7.9 Hz, 3H-22, 3H-23,  
3H-24), 0.64-0.53 (6H, m, 2H-19, 2H-20, 2H-21); 13C-NMR (100 MHz, CDCl3), δ: 218.7 
(C, C-17), 209.0 (C, C-10), 159.9 (C, C-3), 143.9 (C, C-5), 129.5 (CH, C-1), 120.9 (CH, 
C-6), 114.1 (CH, C-4), 111.6 (CH, C-2), 89.0 (C, C-14), 57.3 (CH, C-9), 55.3 (2C, C,  
C-13, CH3, C-1a,), 37.4 (CH2, C-11), 35.2 (CH2, C-7), 33.2 (CH2, C-16), 30.3 (CH2, C-
12), 28.9 (CH2, C-15), 25.4 (CH2, C-8), 14.1 (CH3, C-18), 7.3 (3CH3, C-22, C-23,  
C-24), 7.0 (3CH2, C-19, C-20, C-21); IR (neat): 2963, 1745, 1721, 1714, 1073, 741  
cm-1; HRMS (ESI): calculated for C25H38NaO4Si [MNa
+] requires 453.2432, found 
453.2429 (0.7 ppm error). 
(14β)-3-Methoxyestra-1,3,5(10),8,15-pentaen-17-one 4.218179 
 
A solution of triketone 4.148 (1.00 g, 3.16 mmol) in benzene (150 mL) containing PTSA 
(301 mg, 1.58 mmol) was heated at 95 °C for 30 min with a Dean-stark water separator 
attached. The reaction mixture was allowed to reach rt and quenched with sat aq NaHCO3 
(30 mL). Benzene was evaporated under reduced pressure and the residual aqueous layer 
was extracted with CH2Cl2 (3 x 30 ml). The combined organic layers were washed with 
H2O (40 ml), dried over Na2SO4, filtered and evaporated under reduced pressure. The 
residue was purified by flash column chromatography (Biotage SNAP 25 g SiO2 
cartridge, heptane/AcOEt = 10/0 to 3/2) to yield dienone 4.176 (547 mg, 62%) as a white 
solid, dienone 4.218 (55.0 mg, 6% yield) as pink solid and enedione 4.174 (108 mg, 11%) 
as a yellow oil. Ref. LNB0103-120 
Rf: 0.44 (heptane/AcOEt = 4/1); m.p.: 120-123 °C [lit. 133-135 °C, enatiomerically pure 
4.202 isolated as a white solid];192 1H-NMR (400 MHz, CDCl3), δ: 7.64 (1H, dd, J = 5.5, 
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2.4 Hz, H-15), 7.08 (1H, d, J = 8.5 Hz, H-1), 6.75-6.68 (2H, m, H-2, H-4), 6.15-6.10 (1H, 
m, H-16), 3.80 (3H, s, 3H-1a), 3.15 (1H, brs, H-14), 2.90-2.79 (1H, m, H-6), 2.78-2.70 
(1H, m, H-6), 2.49-2.37 (2H, m, H-7, H-11), 2.30-2.20 (1H, m, H-7), 2.18-2.08 (1H, m, 
H-11), 1.98-1.87 (1H, m, H-12), 1.64-1.54 (1H, m, H-12), 1.20 (3H, s, 3H-18); 13C-NMR 
(100 MHz, CDCl3), δ: 214.5 (C, C-17), 162.7 (CH, C-15), 158.4 (CH, C-3), 136.8 (C, C-
5), 130.7 (CH, C-16), 129.7 (C, C-9), 128.8 (C, C-8), 128.5 (C, C-10), 123.5 (CH, C-1), 
113.7 (CH, C-4), 111.1 (CH, C-2), 55.6 (CH, C-14), 55.4 (CH3, C-1a), 47.0 (C, C-13), 
31.7 (CH2, C-12), 28.8 (CH2, C-6), 27.6 (CH2, C-7), 22.6 (CH2, C-11), 22.4 (CH3, C-13); 
IR (neat): 2925, 2830, 1703, 1252 cm-1; HRMS (ESI): calculated for C19H20NaO2 
[MNa+] requires 303.1356, found 303.1343 (4.0 ppm error). Data are consistent with 
those reported in the literature for the enantiopure 13(S),14(R)-compound.192  
(17β)-3-Methoxyestra-1,3,5(10),8,14-pentaen-17-ol 4.230206 
 
NaBH4 (7.50 mg, 0.20 mmol) was added to a suspension of dienone 4.176 (22.0 mg, 0.08 
mmol) in EtOH (1.5 mL) cooled at 0 °C. The reaction mixture was stirred at 0 °C for 5 
min, then brought to rt and stirred for a further 30 min. The mixture was re-cooled to 0 
°C and it was quenched with AcOH (7.00 µL). The solvents were evaporated under 
reduced pressure and the residue was purified by flash column chromatography (Biotage 
SNAP 10 g SiO2 cartridge, heptane/AcOEt = 7/30) to give alcohol 4.230 (20.0 mg, 90%) 
as a white solid. Ref. LNB0145-005 
Rf: 0.40 (heptane/AcOEt = 7/3); m.p.: 110-112 °C (MeOH) [lit. 110-111 °C 
(MeOH/H2O)];
208 1H-NMR (400 MHz, CDCl3), δ: 7.24 (1H, d, J = 8.1 Hz, H-1),  
6.77-6.70 (2H, m, H-2, H-4), 5.50 (1H, brs, H-15), 4.09 (1H, “t”, J = 8.3 Hz, H-17), 3.81 
(3H, s, 3H-1a), 2.76 (2H, dd, J = 9.1, 6.6 Hz, 2H-6), 2.71-2.56 (3H, m, H-16, 2H-11), 
2.56-2.47 (1H, m, H-7), 2.46-2.39 (1H, m, H-16), 2.29-2.19 (1H, m, H-7), 2.05 (1H, dd, 
J = 12.6, 4.0 Hz, H-12), 1.52 (1H, “dt”, J = 12.1, 6.8 Hz, H-12), 0.97 (3H, s, 3H-18);  
13C-NMR (100 MHz, CDCl3), δ: 158.5 (C, C-3), 147.3 (C, C-14), 138.2 (C, C-5), 129.4 
(C, C-9), 129.3 (C, C-10), 126.0 (C, C-8), 124.1 (CH, C-1), 116.8 (CH, C-15), 113.6 (CH, 
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C-4), 111.2 (CH, C-2), 82.4 (CH, C-17), 55.4 (CH3, C-1a), 45.2 (C, C-13), 38.5 (CH2,  
C-16), 34.0 (CH2, C-12), 28.7 (CH2, C-6), 23.8 (CH2, C-11), 23.1 (CH2, C-7), 14.9 (CH2, 
C-18); IR (neat): 3383, 2921, 2834, 1605, 1497 cm-1; HRMS (ESI): calculated for 
C19H22NaO2 [MNa
+] requires 305.1512, found 305.1510 (1.0 ppm error). Data are 
consistent with those reported in the literature.207, 208 
3-Methoxyestra-1,3,5(10),8-tetraen-17-one 4.234 
 
Catalytic hydrogenation without triethylsylane 
Dienone 4.176 (20.0 mg, 0.07 mmol) was dissolved in AcOEt (3.2 mL) and 10% Pd(C) 
(5.00 mg) was added. The flask was evacuated and recharged with H2 three times. The 
reaction mixture was then stirred at rt under a H2 atmosphere for 30 min. The catalyst was 
filtered off through a pad of Celite® and the filtrate was evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 4 g 
SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to obtain ketone 4.234 (5.00 mg, 25%) as a 
white solid. Ref. LNB0103-118 
Rf: 0.51 (hexane/AcOEt = 4/1); m.p.: 118-120 °C (MeOH) [lit. 120-123 °C 
(MeOH/Et2O=3/1)];
210 1H-NMR (400 MHz, CDCl3), δ: 7.14 (1H, d, J = 7.1 Hz, H-1), 
6.75-6.70 (2H, m, H-2, H-4), 3.80 (3H, s, 3H-1a), 2.85-2.65 (3H, m, 2H-6, H-14), 2.62-
2.52 (3H, m, 2H-11, H-16), 2.34-2.09 (4H, m, 2H-7, H-15, H-16), 2.07-2.00 (1H, m, H-
12), 1.82-1.60 (2H, m, H-12, H-15), 0.90 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), 
δ: 219.9 (C, C-17), 158.2 (C, C-3), 137.3 (C, C-5), 130.7 (C, C-8), 128.8 (C, C-10), 126.6 
(C, C-9), 123.2 (CH, C-1), 113.8 (CH, C-4), 110.9 (CH, C-2), 55.4 (CH3, C-1a), 47.8 (C, 
C-13), 47.4 (CH, C-14), 36.7 (CH2, C-16), 29.0 (CH2, C-12), 28.7 (CH2, C-6), 24.5 (CH2, 
C-7), 23.9 (CH2, C-11), 21.3 (CH3, C-18); IR (neat): 2932, 1737, 1499, 1253 cm
-1; 
HRMS (ESI): calculated for C19H22NaO2 [MNa
+] requires 305.1512, found 305.1511 (-
4.4 ppm error). Data are consistent with those reported in the literature except for the 13C-
NMR assignment of C-8 and C-10.210 
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Catalytic hydrogenation in the presence of triethylsylane209 
A solution of dienone 4.176 (30.0 mg, 0.11 mmol) in benzene (3 mL) was cooled to  
0 °C and 10% Pd/C (4.50 mg) and Et3SiH (341 µL, 2.14 mmol) were subsequently added. 
The reaction mixture stirred was maintained at 0 °C, and the flask was evacuated and 
recharged with H2 three times. The mixture was allowed to slowly reach rt and stirred 
under a H2 atmosphere overnight. Solids were filtrated through a pad of Celite
®, and the 
filtrate was evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP 4 g SiO2 cartridge, heptane/AcOEt = 9/1) to obtain 
ketone 4.234 (17.0 mg, 56%) as a white solid. Ref. LNB0103-146 
(13S)-3-Methoxy-13-methyl-6,7,11,12,13,16-
hexahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolane] 4.235 
 
A mixture of dienone 4.176 (312 mg, 1.11 mmol), ethylene glycol (151 µL, 2.79 mmol), 
trimethyl ortoformate (243 mL, 2.23 mmol) and PTSA (2.1 mg, 0.001 mmol) was genlty 
warmed to 30 °C and stirred overnight. The mixture was cooled to rt and diluted with 
AcOEt (15 mL). The organic layer was washed with sat aq NaHCO3 (3 x 10 mL), dried 
over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (Biotage SNAP 25 g silica cartridge, heptane/AcOEt = 
10/0 to 4/1) to afford the protected diene 4.235 (327 mg, 91%) as a white foam. Ref. 
LNB0103-129 
Rf: 0.38 (heptane/AcOEt = 4/1); m.p.: 91-95 °C (MeOH) (lit. 94-97.5 °C);212 1H-NMR 
(400 MHz, CDCl3), δ: 7.26-7.23 (1H, brs, H-1), 6.76-6.69 (2H, m, H-2, H-4), 5.62 (1H, 
brs, H-15), 4.04-3.93 (4H, m, 2H-19, 2H-20), 3.81 (3H, s, 3H-1a), 2.84 (1H, d, J = 17.2 
Hz, H-16), 2.78-2.71 (2H, m, 2H-6), 2.64-2.48 (4H, m, H-7, 2H-11, H-16), 2.29-2.16 
(1H, m, H-7), 2.10-2.00 (1H, m, H-12), 1.61-1.53 (1H, m, H-12), 1.06 (3H, s, 3H-18); 
13C-NMR (100 MHz, CDCl3), δ: 159.3 (C, C-3), 147.2 (C, C-14), 138.3 (C, C-5), 129.8 
(C, C-9), 129.0 (C, C-10), 125.8 (C, C-8), 123.8 (CH, C-1), 116.1 (CH, C-15), 113.4 (CH, 
C-4), 111.4 (CH, C-2), 54.7 (CH3, C-1a), 48.2 (C, C-13), 41.0 (CH2, C-16), 28.6 (CH2, 
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C-6), 26.7 (CH2, C-12), 23.3 (CH2, C-11), 22.7 (CH2, C-7), 18.0 (CH3, C-18); IR (neat): 
2928, 1549, 1493, 1243 cm-1; HRMS (ESI): calculated for C21H24NaO3 [MNa
+] requires 
347.1618, found 347.1625 (-4.4 ppm error). 
(13S,14R)-13-Methyl-6,7,11,12,13,14,15,16-
octahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-ol 4.237 
 
In a three necked round flask cooled to -40 °C liq NH3 (15 mL) was trapped. Metallic 
sodium (360 mg, 15.7 mmol) was cut in small pieces and slowly added. After 30 min 
diene 4.235 (127 mg, 0.39 mmol) was dissolved in THF (2 mL) and added dropwise to 
the solution of sodium in ammonia. After 1 h of stirring at -40 °C, MeOH (2.4 mL) was 
added until the blue colour faded. NH3 was evaporated under a stream of Ar and the 
reaction mixture was slowly allowed to reach rt. H2O (10 mL) was added and the organic 
compounds were extracted with AcOEt (3 x 5 mL). The combined organic layers were 
washed with brine (2 x 10 mL), dried over Na2SO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage SNAP 10 
g SiO2 cartridge, heptane/AcOEt = 4/1) to afford phenol 4.237 (58.5 mg, 48%) as a white 
foam. Ref. LNB0103-138 
Rf: 0.30 (heptane/AcOEt = 4/1); 1H-NMR (400 MHz, CDCl3), δ: 7.08 (1H, d, J = 8.4 Hz, 
H-1), 6.65 (1H, dd, J = 8.4, 2.1 Hz, H-2), 6.61 (1H, brs, H-4), 4.01-3.91 (4H, m, 2H-19, 
2H-20), 2.73-2.65 (2H, m, 2H-6), 2.39-2.31 (2H, m, 2H-11), 2.24-2.03 (5H, m, 2H-7,  
H-14, H-15, H-16), 1.89-1.81 (1H, m, H-16), 1.73-1.68 (1H, m, H-12), 1.65-1.55 (1H, m, 
H-12), 1.55-1.46 (1H, m, H-15), 0.90 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 
153.9 (C, C-3), 138.1 (C, C-5), 134.5 (C, C-8), 129.7 (C, C-10), 123.9 (C, C-9), 123.4 
(CH, C-1), 120.4 (C, C-17), 114.9 (CH, C-4), 111.3 (CH, C-2), 65.6 (CH2, C-19 or  
C-20), 64.5 (CH2, C-19 or C-20), 47.7 (CH, C-14), 44.5 (C, C-13), 33.1 (CH2, C-16), 29.1 
(CH2, C-6), 28.7 (CH2, C-7), 27.7 (CH2, C-15), 27.3 (CH2, C-12), 22.6 (CH2, C-11), 16.4 
(CH3, C-18); IR (neat): 3361, 2936, 1610, 1493 cm
-1; HRMS (ESI): calculated for 
C20H24NaO3 [MNa
+] requires 335.1618, found 335.1627 (-3.5 ppm error).  
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(14β,17α)-3-Methoxyestra-1,3,5(10),8-tetraen-17-ol 4.238 
 
NaBH4 (35.5 mg, 0.96 mmol) was added to a solution of dienone 4.218 (67.0 mg, 0.24 
mmol) in methanol (15 mL) cooled to 0 °C. The reaction mixture was stirred at 0 °C for 
5 min, then brought to rt and stirred for 3 h. The reaction mixture was re-cooled to 0 °C 
before being quenched with H2O (30 mL). The pH was brought to 5 with 1 M aq HCl and 
the organic compounds were extracted with AcOEt (3 x 20 mL). The combined organic 
layers were washed with sat aq NaHCO3 (20 mL), H2O (20 mL) and brine (20 mL), dried 
over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (SiO2, heptane/AcOEt = 7/3) to give alcohol 4.238 (65.0 
mg, 95%) as a white solid. Ref. LNB0162-114 
Rf: 0.33 (heptane/AcOEt = 7/3); m.p.: 131-133 °C (hexane) [lit. 131-133 °C 
(cyclohexane)];213 1H-NMR (400 MHz, CDCl3), δ: 7.15 (1H, t, J = 8.8 Hz, H-1),  
6.75-6.67 (2H, m, H-2, H-4), 3.89 (1H, t, J = 8.8 Hz, H-17), 3.80 (3H, s, 3H-1a), 2.77-
2.68 (2H, m, 2H-6), 2.43-2.34 (2H, m, 2H-11), 2.23-1.99 (4H, m, 2H-7, H-15, H-16), 
1.95 (1H, t, J = 8.7 Hz, H-14), 1.77-1.64 (1H, m, H-16), 1.59-1.48 (3H, m, 2H-12, H-15), 
1.01 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 157.9 (C, C-3), 137.2 (C, C-5), 
134.4 (C, C-8), 129.5 (C, C-10), 124.3 (C, C-9), 123.0 (CH, C-1), 113.6 (CH, C-4), 111.0 
(CH, C-2), 82.4 (CH, C-17), 55.4 (CH3, C-1a), 48.1 (CH, C-14), 41.8 (C, C-13), 30.6 
(CH2, C-16), 29.1 (CH2, C-6), 28.1 (CH2, C-7), 27.7 (CH2, C-15), 23.2 (CH2, C-12), 22.4 
(CH2, C-11), 22.1 (CH3, C-18); IR (neat): 3381, 2933, 2876, 1610, 1497, 1249 cm
-1; 
HRMS (ESI): calculated for C19H24NaO2 [MNa
+] requires 307.1669, found 307.1665 
(2.4 ppm error).  
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(14β)-3-Methoxyestra-1,3,5(10),8-tetraen-17-one 4.240 
 
A solution of alcohol 4.238 (13.0 mg, 0.05 mmol) in CH2Cl2 (500 µL) was added to a 
suspension of Dess-Martin periodinane 4.239 (38.8 mg, 0.09 mmol) in CH2Cl2 (0.5 mL). 
The reaction mixture was stirred at rt for 3 h, then diluted with CH2Cl2 (15 mL) and 5% 
aq NaOH was added until the suspension turned into a solution. The organic layer was 
separated, washed with H2O (2 x 5 mL) and brine (5 mL), dried over Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage SNAP 4 g SiO2 cartridge, heptane/AcOEt = 10/0 to 4/1) to give 
ketone 4.240 (6.00 mg, 46%) as a withe solid. Ref. LNB0103-148 
Rf: 0.42 (heptane/AcOEt = 4/1); m.p.: 90-92 °C (MeOH) [lit. 88-90 °C (Et2O/hexane)];
210 
1H-NMR (400 MHz, CDCl3), δ: 7.14 (1H, d, J = 8.1 Hz, H-1), 6.78-6.70 (2H, m, H-2,  
H-4), 3.80 (3H, s, 3H-1a), 2.83-2.75 (2H, m, 2H-6), 2.44 (1H, t, J = 7.8 Hz, H-14),  
2.39-2.25 (6H, m, H-7, 2H-11, H-15, 2H-16), 2.23-2.11 (1H, m, H-7), 1.89-1.75 (2H, m, 
H-12, H-15), 1.56-1.47 (1H, m, H-12), 1.08 (3H, s, 3H-18); 13C-NMR (100 MHz, 
CDCl3), δ: 223.5 (C, C-17), 158.3 (C, C-3), 137.2 (C, C-5), 131.9 (C, C-8), 129.2 (C,  
C-10), 126.6 (C, C-9), 123.2 (CH, C-1), 113.6 (CH, C-4), 111.1 (CH, C-2), 55.4 (CH3, 
C-1a), 48.8 (CH, C-14), 47.2 (C, C-13), 36.9 (CH2, C-16), 28.9 (CH2, C-6), 27.6 (CH2, 
C-7), 27.2 (CH2, C-12), 25.6 (CH2, C-15), 22.1 (CH3, C-11), 20.8 (CH3, C-18); IR (neat): 
2923, 1736, 1499, 1250 cm-1; HRMS (ESI): calculated for C19H22NaO2 [MNa
+] requires 
305.1512, found 305.1513 (-0.7 ppm error). Data are consistent with those reported in the 
literature, except for the NMR spectroscopy assignment of the chemical shifts of H-11, 
H-15, C-8 and C-10.210 
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(14β)-3-Hydroxyestra-1,3,5(10),8-tetraen-17-one 4.241 
 
Boron tribromide (1 M sol in CH2Cl2, 312 µL, 0.31 mmol) was added to a solution of 
ketone 4.240 (44.0 mg, 0.16 mmol) in CH2Cl2 (5 mL) cooled to -78 °C and stirred under 
an argon atmosphere. The cold bath was removed, and the reaction mixture was stirred at 
rt for 2 h. The reaction was cooled to 0 °C and it was quenched with H2O (20 mL). After 
dilution with CH2Cl2 (20 mL), the aqueous layer was separated and the organic phase was 
washed with H2O (3 x 20 mL), dried over MgSO4, filtered and evaporated under reduced 
pressure. The residue was purified by flash column cromathography (SiO2, 
hexane/AcOEt = 7/3) to give phenol 4.241 (38.0 mg, 91%) as a white solid. 
Ref. LNB0162-117 
Rf: 0.23 (hexane/AcOEt = 4/1); m.p.: 230-235 °C (MeOH) [lit. 202-204 °C (MeOH)];215 
1H-NMR (400 MHz, CDCl3), δ: 7.06 (1H, d, J = 8.4 Hz, H-1), 6.78-6.61 (2H, m, H-2,  
H-4), 2.80-2.66 (2H, m, 2H-6), 2.47-2.40 (1H, t, J = 6.9 Hz, H-14), 2.39-2.23 (6H, m, H-
7, 2H-11, H-15, 2H-16), 2.19-2.07 (1H, m, H-7), 1.86-1.73 (2H, m, H-12, H-15), 1.60 
(1H, brs, OH), 1.54-1.44 (1H, m, H-12), 1.08 (3H, s, 3H-18); 13C-NMR (100 MHz, 
CDCl3), δ: 223.6 (C, C-17), 154.1 (C, C-3), 137.5 (C, C-5), 131.9 (C, C-8), 129.4 (C,  
C-10), 126.5 (C, C-9), 123.2 (CH, C-1), 114.6 (CH, C-4), 111.8 (CH, C-2), 48.7 (CH,  
C-14), 47.3 (C, C-13), 36.9 (CH2, C-16), 28.8 (CH2, C-6), 27.5 (CH2, C-7), 27.0 (CH2, 
C-12), 25.5 (CH2, C-15), 22.1 (CH2, C-11), 20.7 (CH3, C-18); IR (neat): 3377, 2933, 
1724, 1501 cm-1; HRMS (ESI): calculated for C18H20NaO2 [MNa
+] requires 291.1356, 
found 291.1343 (-4.4 ppm error). 
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Protection of ketone 4.241 as acetal 4.237: 
 
A mixture of ketone 4.241 (13.0 mg, 0.05 mmol), ethylene glycol (6.80 µL, 0.12 mmol), 
trimethyl orthoformate (10.7 µL, 0.10 mmol) and PTSA (0.09 mg, 0.015 mmol) was 
stirred at 30 °C until dissolution, and at rt overnight. The mixture was diluted with AcOEt 
(15 mL) and washed H2O (3 x 6 mL), dried over Na2SO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash column chromatography (SiO2, 
heptane/AcOEt = 10/0 to 4/1) to afford the protected phenol 4.237 (8.50 mg, 56%) as a 
white foam. Ref. LNB0162-118 
(9α,10β)-Estra-4,8(14)-diene-3,17-dione 4.243175 
 
Liquid NH3 (30 mL) was trapped in a dried three necked round flask cooled to -40 °C. 
Metallic sodium (558 mg, 24.3 mmol) was cut in small pieces and carefully added. The 
solution turned dark blue, and it was stirred at -40 °C for 30 min before addition of a 
solution of pentaene 4.235 (157 mg, 0.49 mmol) in THF/t-BuOH (3/1, 4 mL). The 
reaction was stirred at -40 °C for a further 2 h before being quenched with MeOH (20 
mL). NH3 was left to evaporate under a stream of argon. NH4Cl (1.30 g) was then added 
and the mixture was stirred for 20 min at rt. The residue was dilute with H2O (20 mL) and 
extracted with AcOEt (3 x 20 mL). The combined organic layers were washed with brine 
(10 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
product was dissolved in MeOH (15 mL) and 3 M aq HCl (1.5 mL) was added. The 
mixture was stirred at rt for 3 h, then the pH was brought to 8 with sat aq NaHCO3. 
Organic compounds were extracted with CH2Cl2 (3 x 50 mL), dried over Na2SO4, filtered 
and evaporated under reduced pressure. The residue was purified by flash column 
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chromatography (Biotage SNAP 25 g SiO2 cartridge, heptane/AcOEt = 7/3) to give 
ketone 4.243 (44.0 mg, 34%) as a white solid. Ref. LNB0145-027 
Rf: 0.23 (heptane/AcOEt = 7/3); m.p.: 126-128 °C [lit. 127-131 °C (EtOH)];216 1H-NMR 
(400 MHz, CDCl3), δ: 5.86 (1H, brs, H-4), 2.78-2.68 (2H, m, H-7, H-15), 2.64-2.50 (3H, 
m, H-6, H-15, H-16), 2.47-2.40 (1H, m, H-2), 2.32-2.14 (5H, m, H-1, H-2, H-6, H-16), 
2.10-1.79 (4H, m, H-7, H-9, H-10, H-11, H-12), 1.71-1.62 (1H, m, H-1), 1.45-1.38 (1H, 
m, H-11), 1.30-1.21 (1H, m, H-12), 1.12 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), 
δ: 220.9 (C, C-17), 119.7 (C, C-3), 165.3 (C, C-5), 135.3 (C, C-14), 129.9 (C, C-8), 124.8 
(CH, C-4), 47.8 (C, C-13), 45.4 (CH, C-10), 43.5 (CH, C-9), 36.5 (CH2, C-2), 36.2 (CH2, 
C-16), 35.6 (CH2, C-6), 28.9 (CH2, C-7), 28.7 (CH2, C-12), 26.8 (CH2, C-1), 25.0 (CH2, 
C-11), 23.2 (CH2, C-15), 22.6 (CH3, C-18); IR (neat): 2929, 2856, 1736, 1671 cm
-1; 
HRMS (ESI): calculated for C18H22NaO2 [MNa
+] requires 293.1512, found 293.1505 
(2.1 ppm error).   
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6.4. CHAPTER 5: EXPERIMENTAL DETAILS 
3β-Hydroxy-2,3-dihydrowithanolide F 5.1 
 
Preparation of 100 mM AcONa buffer (pH = 4) 
Sodium acetate trihydrate (19.0 g, 0.14 mol) was dissolved in H2O (1.12 L) and the pH 
of the resulting solution was brought to 4 with 1 M aq HCl. H2O was then added to reach 
a total volume of 1.4 L. Ref. LNB0145-044 
Enzymatic deglycosylation of coagulin L 2.1 carried out at AnalytiCon Discovery 
A solution of coagulin L 2.1 (500 mg, 0.77 mmol) in 50% aqueous EtOH (100 mL) and 
a solution of β-glucosidase from Aspergillus niger (100 mg, 75 U) in H2O (100 mL) were 
added to a buffered solution of 100 mM AcONa (900 mL) prepared as above. The mixture 
was incubated at 37 °C and with shaking for 1 d. The aqueous mixture was divided into 
three portions of 300 mL, and each portion was extracted with AcOEt (2 x 200 mL). The 
combined organic layers were dried over Na2SO4, filtered and evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (Biotage 
SNAP 25 g SiO2 cartridge, CH2Cl2/MeOH = 95/5) to give the title compound 5.1 (232 
mg, 61%) as a white solid. Ref. LNB0145-001 
Rf: 0.16 (CH2Cl2/MeOH = 95/5); m.p.: 261-263 °C (MeOH/H2O) [lit. 260-261 °C 
(MeOH/acetone)];158 [α]D24: +61 (c 0.11, CHCl3) [lit. +61 (c 0.2, CHCl3)];158 1H-NMR 
(400 MHz, DMSO-d6), δ: 6.70 (1H, brs, OH), 5.76 (1H, brs, OH), 5.57 (1H, brs, H-6), 
5.13 (1H, brs, OH), 4.73-4.59 (2H, m, H-22, OH), 3.58 (1H, brs, H-3), 2.61-2.54 (1H, m, 
H-2), 2.47-2.33 (6H, m, H-2, 2H-4, H-16, 2H-23), 2.21-2.13 (1H, m, H-12), 2.09-2.01 
(2H, m, H-7, H-9), 1.89 (3H, s, 3H-28), 1.78-1.70 (2H, m, H-7, H-8), 1.75 (3H, s, 3H-
27), 1.61-1.50 (3H, m, H-11, H-15, H-16), 1.43-1.32 (2H, m, H-11, H-15), 1.25 (3H, s,  
3H-21), 1.20 (3H, s, 3H-19), 1.18-1.12 (1H, m, H-12), 0.99 (3H, s, 3H-18); 13C-NMR 
(100 MHz, DMSO-d6), δ: 210.9 (C, C-1), 166.1 (C, C-26), 150.9 (C, C-24), 135.5 (C,  
C-5), 125.1 (CH, C-6), 120.1 (C, C-25), 87.4 (C, C-17), 81.3 (C, C-14), 80.9 (CH, C-22), 
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78.2 (C, C-20), 67.9 (CH, C-3), 53.9 (C, C-13), 52.1 (C, C-10), 48.0 (CH2, C-2), 40.9 
(CH2, C-4), 35.8 (CH2, C-16), 35.4 (CH, C-8), 34.9 (CH2, C-23), 34.3 (CH, C-9), 31.9 
(CH2, C-15), 29.9 (CH2, C-12), 25.4 (CH2, C-7), 21.7 (CH2, C-11), 20.3 (2CH3, C-18,  
C-28), 19.2 (CH3, C-21), 18.5 (CH3, C-19), 12.2 (CH3, C-27); IR (neat): 3360, 2969, 
2926, 2849, 1686, 1679, 1381, 1321, 1135, 1095, 1020 cm-1; HRMS (ESI): calculated 
for C28H40NaO7 [MNa
+] requires 511.2666, found 511.2681 (-2.8 ppm error).  
Enzymatic deglycosylation of coagulin L 2.1 carried out at The University of York 
A solution of coagulin L 2.1 (20.0 mg, 0.03 mmol) in 50% aq EtOH (4 mL) and a solution 
of β-glucosidase from Aspergillus niger (36.0 mg, 31.0 U) in H2O (4 mL) were added to 
a buffered solution of 100 mM AcONa (36 mL) prepared as above. The reaction mixture 
was maintained in an oil bath at 37 °C overnight. The mixture was extracted with AcOEt 
(3 x 20 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated under reduced pressure. The crude was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH = 95/5 to 9/1) to give the title compound 5.1 (15.2 
mg, 100%) as a white solid. Ref. LNB0162-040 
3β-Acetyl-2,3-dihydrowithanolide F 5.22 
 
Alcohol 5.1 (20.0 mg, 0.04 mmol) was dissolved in a mixture of py/AcO2 (2/1, 15 µL) 
and the reaction mixture was stirred at rt overnight. Sat aq NaHCO3 (1 mL) was added 
and the mixture was vigourously stirred for 10 min. The mixture was extracted with 
AcOEt (3 x 500 µL). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH = 95/5) to give acetate 5.22 (22.0 mg, 100%) as a 
white solid. Ref. LNB0162-016 
Rf: 0.33 (CH2Cl2/MeOH = 95/5); m.p.: 156-158 °C (AcOEt/heptane) [lit. 154-155 °C 
(AcOEt)]158 [α]D24: +38 (c 3.10, CHCl3) [lit. +33 (c 0.15, CHCl3)];158 1H-NMR (400 
MHz, CDCl3), δ: 5.67 (1H, brs, H-6), 5.03 (1H, “dt”, J = 14.1, 6.9 Hz, H-3), 4.88 (1H, 
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dd, J = 9.6, 6.9 Hz, H-22), 2.80 (1H, dd, J = 13.5, 6.6 Hz, H-2), 2.74-2.65 (2H, m, H-4,  
H-16), 2.55-2.46 (2H, m, 2H-23), 2.45-2.24 (4H, m, H-2, H-4, H-7, H-12), 2.14-2.04 (1H, 
m, H-9), 2.02 (3H, s, 3H-21), 1.94-1.85 (2H, m, H-7, H-8), 1.93 (3H, s, 3H-28), 1.87 (3H, 
s, 3H-27), 1.79-1.52 (4H, m, 2H-11, 2H-15), 1.49-1.40 (1H, m, H-16), 1.42 (3H, s, 3H-
21), 1.35-1.26 (1H, m, H-12), 1.23 (3H, s, 3H-19), 1.11 (3H, s, 3H-18); 13C-NMR (100 
MHz, CDCl3), δ: 211.9 (C, C-1), 170.4 (C, C-1a), 166.1 (C, C-26), 150.7 (C, C-24), 134.7 
(C, C-5), 125.4 (CH, C-6), 121.6 (C, C-25), 88.0 (C, C-17), 81.9 (C, C-14), 79.9 (CH,  
C-22), 79.2 (C, C-20), 70.2 (CH, C-3), 54.8 (C, C-13), 53.0 (C, C-10), 43.6 (CH2, C-2), 
38.1 (CH2, C-16), 37.1 (CH2, C-4), 36.0 (2CH, C-8, C-9), 34.3 (CH2, C-23), 32.4 (CH2, 
C-15), 30.0 (CH2, C-12), 26.0 (CH2, C-7), 22.0 (CH2, C-11), 21.3 (CH3, C-2a), 20.8 (CH3, 
C-28), 20.5 (CH3, C-18), 19.9 (CH3, C-21), 17.4 (CH3, C-19), 12.5 (CH3, C-27);  
IR (neat): 3358, 2972, 1711, 1686, 1235 cm-1; HRMS (ESI): calculated for C30H42NaO8 
[MNa+] requires 533.2772, found 533.2755 (2.5 ppm error). 13C-NMR values in 
accordance to those reported in the literature except for the assignment of signals for  
C-23, C-15 and C-12.158 
Withanolide F 2.2  
 
Acetate 5.22 (20.0 mg, 0.04 mmol) was suspended in dioxane (1 mL) and 1 M aq KOH 
(100 µL) was added. The reaction mixture was stirred at rt 15 min, diluted with AcOEt 
(5 mL) and washed with H2O (3 x 5 mL). The organic layer was dried over Na2SO4, 
filtered and evaporated under educed pressure. The residue was purified by consecutive 
flash column chromatography (Biotage SNAP 10 g SiO2 cartridge, CH2Cl2/MeOH = 95/5 
then Biotage SNAP 10 g SiO2 cartridge, heptane/AcOEt = 10/0 to 0/10) to give 
withanolide F 2.2 (11.0 mg, 62% yield) as a white powder. Ref. LNB0145-011 
Rf: 0.29 (CH2Cl2/MeOH = 95/5); m.p.: 189-193 (PE/AcOE) [lit. 191-192 °C (AcOEt)];
158 
1H-NMR (400 MHz, CDCl3), δ: 6.80-6.74 (1H, m, H-3), 5.85 (1H, dd, J = 10.0, 3.7 Hz, 
H-2), 5.62-5.56 (1H, m, H-6), 4.95-4.86 (1H, m, H-22), 3.25 (1H, d, J = 20.7 Hz, H-4), 
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2.81 (1H, dd, J = 20.7, 3.7 Hz, H-4), 2.75-2.63 (1H, m, H-16), 2.57-2.15 (6H, m, H-7,  
H-9, H-11, H-12, 2H-23), 1.95-1.76 (2H, m, H-7, H-8), 1.93 (3H, s, 3H-28), 1.87 (3H, s, 
3H-27), 1.74-1.52 (3H, m, H-11, 2H-15), 1.49-1.28 (2H, m, H-12, H-16), 1.41 (3H, s, 
3H-21), 1.22 (3H, s, 3H-19), 1.12 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 204.4 
(C, C-1), 166.1 (C, C-26), 150.7 (C, C-24), 145.3 (CH, C-3), 135.1 (C, C-5), 128.1 (CH, 
C-2), 125.4 (CH, C-6), 121.6 (C, C-25), 88.1 (C, C-17), 82.2 (C, C-14), 80.2 (CH, C-22), 
79.1 (C, C-20), 54.6 (C, C-13), 50.8 (C, C-10), 37.8 (CH2, C-16), 37.6 (CH, C-8), 35.8 
(CH, C-9), 34.3 (CH3, C-23), 33.4 (CH2, C-4), 32.6 (CH2, C-15), 30.5 (CH2, C-12), 25.8 
(CH2, C-7), 23.2 (CH2, C-11), 20.8 (CH3, C-28), 20.7 (CH3, C-18), 20.1 (CH3, C-21), 
18.9 (CH3, C-19), 12.7 (CH3, C-27); IR (neat): 3356, 2968, 2925, 1683, 1670, 1139  
cm-1; HRMS (ESI): calculated for C28H38NaO6 [MNa
+] requires 493.2561, found 
493.2553 (1.5 ppm error). Data are in accordance with those reported in the literature.158 
Isowithanolide F 5.23 
 
Acetate 5.22 (32.0 mg, 0.06 mmol) was dissolved in CH2Cl2 (600 µL) and DBU (13.5 
µL, 0.09 mmol) was added. The reaction mixture was stirred at rt for 20 min, then diluted 
with CH2Cl2 (4 mL) and washed with sat aq NH4Cl (3 x 4 mL). The organic layer was 
dried over MgSO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography (SiO2, PE/AcOEt = 3/7) to afford withanolide 
5.23 (13.9 mg, 50%) as an amorphous solid which could not be recrystallised.  
Ref. LNB0162-045 
Rf: 0.32 (CH2Cl2/MeOH = 95/5); 1H-NMR (400 MHz, CDCl3), δ: 6.03 (1H, d, J = 8.4 
Hz, H-4), 5.71-5.65 (1H, m, H-6), 5.62-5.58 (1H, m, H-3), 4.92 (1H, t, J = 4.9 Hz, H-22), 
3.26 (1H, d, J = 20.0 Hz, H-2), 2.79-2.66 (2H, m, H-2, H-16), 2.55-2.43 (4H, m, H-9, H-
12, 2H-23), 2.37-2.26 (1H, m, H-7), 2.05-1.84 (2H, m, H-7, H-8), 1.94 (3H, s, 3H-28), 
1.88 (3H, s, 3H-27), 1.78-1.20 (6H, m, 2H-11, H-12, 2H-15, H-16), 1.43 (3H, s, 3H-21), 
1.37 (3H, s, 3H-19), 1.12 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 210.7 (C, C-
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1), 166.1 (C, C-26), 150.7 (C, C-24), 140.5 (C, C-5), 129.6 (CH, C-4), 128.1 (CH, C-6), 
121.6 (C, C-25), 121.3 (C, C-3), 88.1 (C, C-17), 81.9 (C, C-14), 80.4 (CH, C-22), 79.1 
(C, C-20), 53.8 (C, C-13), 52.3 (C, C-10), 39.9 (CH2, C-2), 38.0 (CH2, C-16), 36.3 (CH, 
C-8), 34.3 (CH2, C-23), 34.1 (CH, C-9), 32.5 (CH2, C-15), 30.3 (CH2, C-12), 26.1 (CH2, 
C-7), 22.0 (CH2, C-11), 20.8 (CH3, C-28), 20.7 (CH3, C-18), 20.5 (CH3, C-19), 20.1 (CH3, 
C-21), 12.5 (CH3, C-27); IR (neat): 3341, 2925, 1712, 1689, 1137 cm
-1; HRMS (ESI): 
calculated for C28H38NaO6 [MNa
+] requires 493.2561, found 493.2539 (3.3 ppm error). 
Data are in accordance with those reported in the literature except for the assignment of 
the 13C-NMR values of C-8, C-9, C-12, C-15 and C-23.158 
3β-Benzoyl-2,3-dihydrowithanolide F 5.26 
 
Alcohol 5.1 (5.0 mg, 0.01 mmol) was dissolved in py (150 µL) and benzoyl chloride (12.0 
µL, 0.10 mmol) was added. The reaction mixture was stirred at rt overnight, then diluted 
with CH2Cl2 (2 mL) and washed with sat aq NaHCO3 (3 x 1 mL) and H2O (1 mL). The 
organic layer was dried over MgSO4, filtered and evaporated under reduced pressure. The 
residue was purified by preparative TLC (SiO2, CH2Cl2/MeOH = 95/5) to afford bezoyl 
derivative 5.26 (5.80 mg, 98%) as a white solid. Ref. LNB0162-033 
Rf: 0.30 (CH2Cl2/MeOH = 95/5); m.p.: 180 °C (MeOH, decomposition); [α]D24: +37.9 (c 
0.29, CHCl3); 1H-NMR (400 MHz, CDCl3), δ: 8.00 (2H, d, J = 7.1 Hz, H-3a, H-7a), 7.55 
(1H, “t”, J = 7.4 Hz, H-5a), 7.42 (2H, “t”, J = 7.7 Hz, H-4a, H-6a), 5.73 (1H, brs,  
H-6), 5.35-5.27 (1H, m, H-3), 4.90 (1H, dd, J = 10.3, 6.6 Hz, H-22), 2.94 (1H, dd, J = 
13.6, 6.7 Hz, H-2), 2.85 (1H, dd, J = 13.6, 7.3 Hz, H-4), 2.81-2.69 (1H, m, H-16), 2.62-
2.28 (6H, m, H-2, H-4, H-7, H-12, 2H-23), 2.16 (1H, “td”, J = 11.5, 6.0 Hz, H-9),  
1.98-1.84 (2H, m, H-7, H-8), 1.94 (3H, s, 3H-28), 1.88 (3H, s, 3H-27), 1.78-1.54 (4H, m, 
2H-11, 2H-15), 1.49-1.42 (1H, m, H-16), 1.43 (3H, s, 3H-21), 1.40-1.30 (1H, m, H-12), 
1.28 (3H, s, 3H-19), 1.13 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 211.7 (C, C-
1), 165.9 (C, C-26), 165.8 (C, C-1a), 150.7 (C, C-24), 134.7 (C, C-5), 133.2 (CH, C-5a), 
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130.2 (C, C-2a), 129.8 (2CH, C-3a, C-7a), 128.5 (2CH, C-4a, C-6a), 126.6 (CH, C-6), 
121.6 (C, C-25), 87.9 (C, C-17), 81.9 (C, C-14), 79.8 (CH, C-22), 79.2 (C, C-20), 70.8 
(CH, C-3), 54.8 (C, C-13), 53.1 (C, C-10), 43.7 (CH2, C-2), 38.1 (CH2, C-16), 37.1 (CH2, 
C-4), 36.0 (2CH, C-8, C-9), 34.3 (CH2, C-23), 32.4 (CH2, C-15), 30.0 (CH2, C-12), 26.0 
(CH2, C-7), 22.0 (CH2, C-11), 20.8 (CH3, C-28), 20.5 (CH3, C-18), 19.9 (CH3, C-21), 
17.4 (CH3, C-19), 12.5 (CH3, C-27); IR (neat): 3372, 2925, 1715, 1699, 1273 cm
-1; 
HRMS (ESI): calculated for C35H44NaO8 [MNa
+] requires 615.2928, found 615.2924 
(0.6 ppm error).  
3β-(E)-Cinnamoyl-2,3-dihydrowithanolide F 5.28 
 
(E)-Cinnamic acid (62.0 mg, 0.42 mmol) was dissolved in CH2Cl2 (10 mL) and oxalyl 
chloride (54.0 µL, 0.63 mmol) and a catalytic amounts of DMF (3.50 µL, 0.04 mmol) 
were subsequently added. The mixture was stirred at rt for 2 h, then the solvent and the 
excess oxalyl chloride were evaporated. The crude (E)-cinnamoyl chloride 5.27 was 
dissolved in CH2Cl2 (10 mL) and added dropwise to a solution of alcohol 5.1 (20.0 mg, 
0.04 mmol) in py (10 mL). The reaction mixture was stirred at rt for 3 h, then diluted with 
CH2Cl2 (20 mL) and washed with sat aq NaHCO3 (3 x 20 mL), H2O (20 mL) and brine 
(20 mL). The organic layer was separated, dried over MgSO4, filtered and eveporated 
under reduced pressure. The residue was purified by preparative TLC (SiO2, 
CH2Cl2/MeOH = 95/5) to give compound 5.28 contaminated by residual (E)-cinnamic 
acid. The crude 5.28 was diluted with AcOEt (30 mL) and washed with sat aq NaHCO3 
(3 x 20 mL). The organic layer was separated, dried over MgSO4, filtered and evaporated 
under reduced pressure to afford (E)-cinnamoyl derivative 5.28 (23.0 mg, 89%) as a white 
solid. Ref. LNB0162-135 
Rf: 0.29 (CH2Cl2/MeOH = 95/5); m.p.: 129-132 °C; [α]D24: + 31.7 (c 0.36, CHCl3);  
1H-NMR (400 MHz, CDCl3), δ: 7.66 (1H, d, J = 16.0 Hz, H-3a), 7.55-7.48 (2H, m, H-
5a, H-9a), 7.41-7.35 (3H, m, H-6a, H-7a, H-8a), 6.39 (1H, d, J = 16.0 Hz, H-2a), 5.71 
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(1H, brs, H-6), 5.18 (1H, “quint”, J = 7.0 Hz, H-3), 4.89 (1H, dd, J = 9.7, 6.6 Hz, H-22), 
2.89 (1H, dd, J = 13.7, 6.8 Hz, H-2), 2.82-2.69 (2H, m, H-4, H-16), 2.57-2.47 (3H, m,  
H-2, 2H-23), 2.44-2.24 (3H, m, H-4, H-7, H-12), 2.20-2.08 (1H, m, H-9), 1.98-1.85 (2H, 
m, H-7, H-8), 1.94 (3H, s, 3H-28), 1.88 (3H, s, 3H-27), 1.76-1.53 (4H, m, 2H-11, 2H-
15), 1.50-1.40 (1H, m, H-16), 1.43 (3H, s, 3H-21), 1.36-1.28 (1H, m, H-12), 1.27 (3H, s, 
3H-19), 1.12 (3H, s, 3H-18); 13C-NMR (100 MHz, CDCl3), δ: 211.8 (C, C-1), 166.2 (C, 
C-1a), 166.0 (C, C-26), 150.7 (C, C-24), 145.3 (CH, C-3a), 134.9 (C, C-5), 134.5 (C, C-
4a), 130.5 (CH, C-7a), 129.8 (2CH, C-5a, C-9a), 128.3 (2CH, C-4a, C-6a), 126.4 (CH, 
C-6), 121.6 (C, C-25), 118.1 (CH, C-2a), 88.0 (C, C-17), 81.9 (C, C-14), 79.8 (CH, C-
22), 79.2 (C, C-20), 70.3 (CH, C-3), 54.9 (C, C-13), 53.1 (C, C-10), 43.7 (CH2, C-2), 38.1 
(CH2, C-16), 37.2 (CH2, C-4), 36.1 (CH, C-8), 36.0 (CH, C-9), 34.4 (CH2, C-23), 32.4 
(CH2, C-15), 30.0 (CH2, C-12), 26.1 (CH2, C-7), 22.0 (CH2, C-11), 20.8 (CH3, C-28), 
20.6 (CH3, C-18), 20.0 (CH3, C-21), 17.4 (CH3, C-19), 12.5 (CH3, C-27); IR (neat): 3325, 
2920, 2952, 1715, 1635, 1162 cm-1; HRMS (ESI): calculated for C37H46NaO8 [MNa
+] 
requires 641.3085, found 641.3098 (-2.8 ppm error). 
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Appendix I. 1H-NMR signals of 20-keto steroids 
  
The NMR assignment of 3β-methoxy-pregnenolone 3.60 (recorded in CDCl3, C6D6 and 
CD2Cl2), tosylate 3.59 (recorded in CDCl3), and ethyl ketone 3.76 (recorded in CDCl3) 
found correspondence in the complete NMR assignment of pregnenolone 3.56 (recorded 
in CDCl3 and C6D6) by Szendi et al.,
225 with minor differences in the proton and carbon 
chemical shifts of the atom next to the hydroxyl, tosylate or methoxyl at C-3, and in the 
side-chain of ethyl ketone 3.76 The structural assignment of the 17α,3β-methoxy-
pregnenolone 3.73 (recorded in CDCl3) was carried out on the diastereomeric mixture 
3.60/3.73 in 47/53 ratio, and compared to the NMR signals of 17α-pregnenolone 3.77 
(recorded in CDCl3) as reported by Černý.226 Variations of chemical shifts were observed 
mainly for atoms in ring D. On the other hand, difference in the chemical shift of i-steroids 
3.61 and 3.75 (recorded in CDCl3 and in CDCl3 and C6D6, respectively) compared with 
3β-methoxy-pregnenolone 3.60 involved mainly atoms at rings A and B. The relevant 
signals are highlighted in Table I.1. and in the corresponding 13C-NMR Table II.1 
reported in Appendix II. 
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Atom 
3.56225 3.60 3.59 3.76 
CDCl3a C6D6a CDCl3b C6D6b CD2Cl2a CDCl3b CDCl3b 
1 1.84; 
1.08 
1.65; 
0.95 
1.86; 
1.04 
1.71; 
0.97 
1.85; 
1.04 
1.81; 
1.02 
1.85; 
1.02 
2 1.84; 
1.48 
1.71; 
1.30 
1.91; 
1.42 
1.93; 
1.52 
1.89; 
1.37 
1.80; 
1.70 
1.90; 
1.40 
3 3.54 3.40 3.05 3.05 3.02 4.31 3.04 
4 2.27; - 2.23; - 2.38; 
2.14 
2.51; 
2.33 
2.36; 
2.13 
2.41; 
2.26 
2.36; 
2.13 
5 - - - - - - - 
6 5.34 5.31 5.34 5.34 5.34 5.29 5.33 
7 1.97; 
1.57 
1.84; 
1.43 
1.99; 
1.55 
1.86; 
1.47 
1.98; 
1.57 
1.95; 
1.50 
1.98; 
1.54 
8 1.46 1.43 1.45 1.31 1.49 1.43 1.46 
9 0.98 0.82 0.97 0.87 0.97 0.93 0.96 
10 - - - - - - - 
11 1.62; 
1.47 
1.38; 
1.27 
1.60; 
1.45 
1.42; 
1.30 
1.62; 
1.44 
1.54; 
1.42 
1.53; 
1.44 
12 2.04; 
1.43 
1.81; 
1.08 
2.04; 
1.42 
1.84; 
1.12 
2.02; 
1.44 
2.01; 
1.40 
1.98; 
1.40 
13 - - - - - - - 
14 1.17 0.84 1.14 0.85 1.15 1.09 1.12 
15 1.68; 
1.23 
1.46; 
1.03 
1.64; 
1.13 
1.50; 
1.06 
1.63; 
1.17 
1.65; 
1.19 
1.65; 
1.21 
16 2.19; 
1.66 
2.33; 
1.47 
2.18; 
1.66 
2.34; 
1.50 
2.12; 
1.65 
2.15; 
1.63 
2.18; 
1.63 
17 2.55 2.09 2.52 2.12 2.52 2.50 2.50 
18 0.63 0.58 0.62 0.57 0.60 0.59 0.59 
19 1.00 0.86 0.98 0.89 0.99 0.95 0.97 
20 - - - - - - - 
21 2.11 1.80 2.11 1.82 2.08 2.09 2.36 
22 - - - - - - 1.01 
1a - - 3.34 3.22 3.30 - 3.33 
2a - - - - - 7.78 - 
3a - - - - - 7.32 - 
4a - - - - - - - 
5a - - - - - 7.32 - 
6a - - - - - 7.78 - 
7a - - - - - 2.43 - 
Continued on following page 
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Atom 
3.77226 3.73 3.61 3.75 
CDCl3a CDCl3b CDCl3b CDCl3b C6D6b 
1 1.82; 1.05 1.84; 1.01 1.54; 0.86 1.48; 0.84 1.45; 0.85 
2 1.80; 1.49 1.90; 1.40 1.72; 1.52 1.73; 1.50 1.76; 1.57 
3 3.52 3.04 1.06 0.87 0.81 
4 2.29; 2.22 2.36; 2.12 0.50; 0.28 0.61; 0.42 0.61; 0.40 
5 - - - - - 
6 5.34 5.33 3.24 2.75 2.58 
7 2.00; 1.63 1.97; 1.60 1.82; 1.16 1.87; 1.08 1.87; 0.93 
8 1.44 1.43 1.84 1.74 1.87 
9 0.92 0.90 0.87 0.84 0.75 
10 - - - - - 
11 1.58; 1.49 1.55; 1.48 1.51; 1.41 1.48; 1.39 1.36; 1.34 
12 1.77; 1.17 1.76; 1.17 2.01; 1.40 2.00; 1.39 1.81; 1.08 
13 - - - - - 
14 1.25 1.24 1.17 1.15 0.90 
15 1.80; 1.25 1.79; 1.23 1.67; 1.26 1.67; 1.24 1.56; 1.18 
16 1.92; 1.73 1.90; 1.71 2.15; 1.61 2.15, 1.61 2.36; 1.54 
17 2.81 2.79 2.51 2.51 2.16 
18 0.93 0.91 0.65 0.64 0.63 
19 1.00 0.97 1.03 1.00 1.15 
20 - - - - - 
21 2.13 2.10 2.09 2.09 1.81 
1a - 3.33 - 3.29 3.19 
 
Table I.1. 1H-NMR signals of 3β-methoxy-pregnenolone 3.60, tosyl pregnenolone 3.59, ethyl ketone 3.76, 
17α,3β–methoxy-pregnenolone 3.73, cyclo-hydroxy-steroid 3.61 and cyclo-methoxy-steroid 3.75 
compared to pregnenolone 3.56225 and 17α-pregnenolone 3.77.226 aSpectrum recorded at 400 MHz. 
bSpectrum recorded at 500 MHz. Relevant signals highlighted. 
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Appendix II. 13C-NMR signals of 20 keto-steroids 
 
Atom 
3.56225 3.60 3.59 3.76 
CDCl3a C6D6a CDCl3b C6D6b CD2Cl2a CDCl3b CDCl3b 
1 37.3 37.4 37.3 37.6 37.6 37.0 37.3 
2 31.7 32.1 28.1 28.6 28.4 28.7 28.1 
3 71.7 71.6 80.4 80.6 80.6 82.3 80.4 
4 42.3 42.9 38.8 39.4 39.1 38.9 38.7 
5 140.9 141.4 141.0 141.2 141.4 138.9 141.0 
6 121.4 121.3 121.4 121.5 121.5 123.3 121.4 
7 31.8 32.2 31.9 32.2 32.2 31.8 31.9 
8 31.9 32.1 32.0 32.1 32.2 31.8 32.0 
9 50.1 50.5 50.2 50.5 50.5 49.8 50.2 
10 36.6 36.8 37.0 37.2 37.3 36.4 37.0 
11 21.1 21.4 21.2 21.4 21.5 21.1 21.2 
12 38.9 39.0 39.0 39.0 39.2 38.8 39.0 
13 44.0 43.8 44.1 43.8 44.2 44.0 44.2 
14 57.0 57.0 57.1 57.0 57.2 56.9 57.1 
15 24.5 24.7 24.6 24.7 24.8 24.5 24.7 
16 22.9 23.3 22.9 23.2 23.1 22.9 23.2 
17 63.8 63.7 63.8 63.6 63.9 63.7 62.8 
18 13.2 13.3 13.3 13.3 13.3 13.3 13.5 
19 19.4 19.5 19.5 19.5 19.6 19.2 19.5 
20 209.4 206.6 209.6 206.8 209.3 209.5 212.1 
21 31.5 31.1 31.6 31.2 31.7 31.6 37.4 
22 - - - - - - 7.9 
1a - - 55.7 55.5 55.7 134.8 55.7 
2a - - - - - 127.7 - 
3a - - - - - 129.9 - 
4a - - - - - 144.5 - 
5a - - - - - 129.9 - 
6a - - - - - 127.7 - 
7a - - - - - 21.7 - 
Continued on following page 
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Atom 
3.77226 3.73 3.61 3.75 
CDCl3a CDCl3b CDCl3b CDCl3b C6D6b 
1 37.2 37.3 33.3 33.5 33.8 
2 31.6 28.1 25.1 25.0 25.4 
3 71.6 80.3 24.3 21.5 21.7 
4 42.2 38.8 11.7 13.2 13.5 
5 140.4 140.6 38.9 35.3 35.7 
6 121.6 121.7 73.6 82.3 82.3 
7 31.9 32.2 37.2 35.2 35.5 
8 32.0 32.1 30.0 30.6 30.8 
9 50.5 49.7 47.7 48.1 48.4 
10 36.4 37.0 43.0 43.5 43.7 
11 21.0 21.1 22.8 22.9 23.2 
12 35.1 35.2 39.3 39.4 39.6 
13 45.5 45.6 44.4 44.5 44.2 
14 49.5 50.7 56.8 56.8 56.8 
15 26.0 26.1 24.5 24.5 24.7 
16 24.3 24.5 23.0 23.0 23.3 
17 61.3 61.4 63.9 64.0 63.9 
18 20.6 20.8 13.6 13.7 13.6 
19 19.3 19.4 20.3 19.4 19.7 
20 212.8 212.8 209.7 209.6 206.8 
21 32.8 32.9 31.6 31.6 31.1 
22 - - - - - 
1a - 55.7 - 56.7 56.6 
2a - - - - - 
3a - - - - - 
4a - - - - - 
5a - - - - - 
6a - - - - - 
7a - - - - - 
 
Table II.1. 13C-NMR signals of 3β-methoxy-pregnenolone 3.60, tosyl pregnenolone 3.59, ethyl ketone 
3.76, 17α,3β-methoxy-pregnenolone 3.73, cyclo-hydroxy-steroid 3.61 and cyclo-methoxy-steroid 3.75 
compared to pregnenolone 3.56225 and 17α-pregnenolone 3.77.227 aSpectrum recorded at 100 MHz. 
bSpectrum recorded at 125 MHz. 
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Appendix III. 1H- and 13C-NMR spectra of 20-keto steroids 
 
 
 
Figure III.1.  1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of 3β-methoxy-pregnenolone 3.60 
recorded in CDCl3. 
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Figure III.2. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of 3β-methoxy-pregnenolone 3.60 
recorded in C6D6. 
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Figure III.3. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra of 3β-methoxy-pregnenolone 3.60 
recorded in CH2Cl2 
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Figure III.4. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of tosylate 3.59 recorded in CDCl3 
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Figure III.5. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of ethyl-steroid 3.76 recorded in 
CDCl3. 
Appendices 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
- 210 - 
 
 
 
 
Figure III.6. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of the diastereomeric mixture of 
3.60/3.73 in approximately 47/53 ratio recorded in CDCl3. 
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Figure III.7. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of cyclo-alcohol 3.61 recorded in 
CDCl3. 
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Figure III.8. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of cyclo-ester 3.75 recorded in CDCl3. 
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Figure III.9. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of cyclo-ester 3.75 recorded in C6D6. 
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Appendix IV. 1H-NMR signals of diastereomeric thiazole-steroids 
 
Atom 
3.60 3.79 3.80 3.88 3.73 
CDCl3 CDCl3 CDCl3 CDCl3 CDCl3 
1 1.86; 1.04 1.85; 1.03 na na 1.84; 1.01 
2 1.91; 1.42 1.91; 1.40 na na 1.90; 1.40 
3 3.05 3.05 3.03 3.05 3.04 
4 2.38; 2.14 2.37; 2.14 2.35; na 2.36; na 2.36; 2.12 
5 - - - - - 
6 5.34 5.34 5.31 5.31 5.33 
7 1.99; 1.55 1.94; 1.49 na na 1.97; 1.60 
8 1.45 1.45 na na 1.43 
9 0.97 0.93 na 0.89 0.90 
10 - - na - - 
11 1.60; 1.45 1.52; 1.47 na na 1.55; 1.48 
12 2.04; 1.42 2.09; 1.35 na na 1.76; 1.17 
13 - - - - - 
14 1.14 1.07 na 1.17 1.24 
15 1.64; 1.13 1.55; 1.16 na na 1.79; 1.23 
16 2.18; 1.66 1.77; 1.26 na na 1.90; 1.71 
17 2.52 2.04 na 2.27 2.79 
18 0.62 0.86 0.84 0.86 0.91 
19 0.98 0.99 0.91 0.96 0.97 
20 - - - - - 
21 2.11 1.70 1.58 1.68 2.10 
1a 3.34 3.34 3.32 3.33 3.33 
1b - - - - - 
2b - 7.65 7.69 7.64 - 
3b - 7.22 7.24 7.25 - 
 
Table IV.1. 1H-NMR signals of 20(R)-thiazolyl-steroid 3.79, 20(S)-thiazolyl-steroid 3.80 and 17α-20(R)-
thiazolyl-steroid 3.88 compared to 3β-methoxy-pregenenolone 3.60 and 17α,3β-methoxy-pregnenolone 
3.73. The structure of compound 3.80 and compound 3.88 were elucidated in diastereomeric mixtures of 
3.79/3.80 and 3.79/3.88 in approximately 77/23 and 37/63 ratio, respectively. Relevant signals highlighted. 
na = Not assigned 
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Appendix V. 13C-NMR signals of diastereomeric thiazole-steroids. 
 
Atom 
3.60 3.79 3.80 3.88 3.73 
CDCl3b CDCl3b CDCl3b CDCl3b CDCl3b 
1 37.3 37.3 37.2 37.3 37.3 
2 28.1 28.1 28.1 28.1 28.1 
3 80.4 80.4 80.4 80.4 80.3 
4 38.8 38.8 38.8 38.8 38.8 
5 141.0 141.0 141.0 140.8 140.6 
6 121.4 121.5 121.5 121.6 121.7 
7 31.9 31.9 31.9 32.4 32.2 
8 32.0 31.4 31.6 32.4 32.9 
9 50.2 50.2 50.1 49.7 49.7 
10 37.0 37.0 36.9 37.0 37.0 
11 21.2 21.0 20.9 21.4 21.1 
12 39.0 40.0 37.9 35.2 35.2 
13 44.1 43.3 42.8 44.6 45.6 
14 57.1 56.8 56.7 53.3 50.7 
15 24.6 23.8 22.9 26.2 26.1 
16 22.9 22.9 22.9 25.9 24.5 
17 63.8 60.4 60.5 59.2 61.4 
18 13.3 13.4 13.1 22.5 20.8 
19 19.5 19.5 19.4 19.4 19.4 
20 209.6 77.8 77.8 77.8 212.8 
21 31.6 30.0 31.6 30.0 31.6 
1a 55.7 55.7 55.7 55.7 55.7 
1b - 180.6 179.4 180.7 - 
2b - 141.8 141.8 141.3 - 
3b - 118.9 118.8 119.2 - 
 
Table V.1. 13C-NMR signals of 20(R)-thiazolyl-steroid 3.79, 20(S)-thiazolyl-steroid 3.80 and  
17α-20(R)-thiazolyl-steroid 3.88 compared to 3β-methoxy-pregenenolone 3.60 and 17α,3β-methoxy-
pregnenolone 3.73. The structure of compound 3.80 and compound 3.88 were elucidated in diastereomeric 
mixtures of 3.79/3.80 and 3.79/3.88 in approximately 77/23 and 37/63 ratio, respectively. Relevant signals 
highlighted. 
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Appendix VI. 1H- and 13C-NMR spectra of diastereomeric thiazole-steroids. 
 
 
 
 
Figure VI.1. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of 20(R)-thiazolyl-steroid 3.79 
recorded in CDCl3. 
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Figure VI.2. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of the diastereomeric mixture of 
3.79/3.80 in approximately 77/23 ratio recorded in CDCl3. 
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Figure VI.3. 1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra of the diastereomeric mixture of 
3.79/3.88 in approximately 37/63 ratio recorded in CDCl3. 
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Appendix VII. Crystallographic data – Compound 3.60 (CCDC 1021885) 
Identification code   rjkt1303 
Empirical formula   C22H34O2 
Formula weight    330.49 
Temperature/K   110.0 
Crystal system   monoclinic 
Space group    P21 
a/Å     6.66855(17) 
b/Å     11.9626(3) 
c/Å     12.0329(3) 
α/     °90.00 
β/°     105.676(3) 
γ/°     90.00 
Volume/Å3    924.20(4) 
Z     2 
ρcalcmg/mm3    1.188 
m/mm-1    0.073 
F(000)     364.0 
Crystal size/mm3   0.274 × 0.0684 × 0.0545 
2Θ range for data collection  6.34 to 64.52° 
Index ranges    -9 ≤ h ≤ 10, -17 ≤ k ≤ 16, -17 ≤ l ≤ 17 
Reflections collected   8628 
Independent reflections  5515[R(int) = 0.0287] 
Data/restraints/parameters  5515/1/221 
Goodness-of-fit on F2   1.033 
Final R indexes [I>=2σ (I)]  R1 = 0.0474, wR2 = 0.1134 
Final R indexes [all data]  R1 = 0.0550, wR2 = 0.1185 
Largest diff. peak/hole / e Å-3  0.27/-0.23 
Flack parameter   0.6(10)  
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Appendix VIII. Crystallographic data – Compound 3.79 (dimer including 2.MeOH) 
(CCDC 1019833) 
Identification code:   rjkt1305 
Empirical formula   C51.5H80N2O5.5S2 
Formula weight    879.30 
Temperature/K   110.0 
Crystal system   monoclinic 
Space group    P21 
a/Å     12.2620(3) 
b/Å     11.8358(3) 
c/Å     16.5376(4) 
α/°     90.00 
β/°     97.549(2) 
γ/°     90.00 
Volume/Å3    2379.31(10) 
Z     2 
ρcalcmg/mm3    1.227 
m/mm-1    0.162 
F(000)     958.0 
Crystal size/mm3   0.195 × 0.1099 × 0.0557 
2Θ range for data collection  5.6 to 52.04° 
Index ranges    -15 ≤ h ≤ 15, -14 ≤ k ≤ 14, -19 ≤ l ≤ 20 
Reflections collected   10254 
Independent reflections  7181[R(int) = 0.0319] 
Data/restraints/parameters  7181/1/581 
Goodness-of-fit on F2   1.044 
Final R indexes [I>=2σ (I)]  R1 = 0.0449, wR2 = 0.0987 
Final R indexes [all data]  R1 = 0.0531, wR2 = 0.1056 
Largest diff. peak/hole / e Å-3  0.34/-0.29 
Flack parameter   -0.11(6) 
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Appendix IX. Crystallographic data – Compound 3.88 (CCDC 1019834) 
Identification code:   rjkt1216 
Empirical formula   C25H37NO2S 
Formula weight    415.62 
Temperature/K   109.90(14) 
Crystal system   orthorhombic 
Space group    P212121 
a/Å     7.29333(17) 
b/Å     9.5588(2) 
c/Å     32.2458(7) 
α/°     90.00 
β/°     90.00 
γ/°     90.00 
Volume/Å3    2248.03(9) 
Z     4 
ρcalcmg/mm3    1.228 
m/mm-1    0.165 
F(000)     904.0 
Crystal size/mm3   0.1443 × 0.1268 × 0.0636 
2Θ range for data collection  5.72 to 55.74° 
Index ranges    -5 ≤ h ≤ 9, -12 ≤ k ≤ 7, -19 ≤ l ≤ 42 
Reflections collected   6698 
Independent reflections  4868[R(int) = 0.0229] 
Data/restraints/parameters  4868/0/270 
Goodness-of-fit on F2   1.069 
Final R indexes [I>=2σ (I)]  R1 = 0.0401, wR2 = 0.0876 
Final R indexes [all data]  R1 = 0.0446, wR2 = 0.0899 
Largest diff. peak/hole / e Å-3  0.27/-0.22 
Flack parameter   -0.04(7) 
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Appendix X. Crystallographic data – Compound 3.94 (CCDC 1019835) 
Identification code:   rjkt1217a 
Empirical formula   C27H39NO2 
Formula weight    409.59 
Temperature/K   110.00(10) 
Crystal system   triclinic 
Space group    P1 
a/Å     6.1294(2) 
b/Å     6.1292(2) 
c/Å     15.9024(7) 
α/°     90.341(3) 
β/°     100.911(3) 
γ/°     106.244(3) 
Volume/Å3    563.95(4) 
Z     1 
ρcalcmg/mm3    1.206 
m/mm-1    0.074 
F(000)     224.0 
Crystal size/mm3   0.2187 × 0.1698 × 0.1409 
2Θ range for data collection  6.92 to 60.16° 
Index ranges    -8 ≤ h ≤ 8, -8 ≤ k ≤ 8, -22 ≤ l ≤ 22 
Reflections collected   9826 
Independent reflections  6370[R(int) = 0.0229] 
Data/restraints/parameters  6370/3/279 
Goodness-of-fit on F2   1.089 
Final R indexes [I>=2σ (I)]  R1 = 0.0380, wR2 = 0.0982 
Final R indexes [all data]  R1 = 0.0401, wR2 = 0.1004 
Largest diff. peak/hole / e Å-3  0.33/-0.21  
Flack parameter   -0.9(8)  
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Appendix XI. Crystallographic data – Compound 3.124 (CCDC 1019836) 
Identification code:   rjkt1314_twin1_hklf4 
Empirical formula   C26H36O4 
Formula weight    412.55 
Temperature/K   110.05(10) 
Crystal system   orthorhombic 
Space group    P212121 
a/Å     7.468(4) 
b/Å     10.075(6) 
c/Å     29.082(17) 
α/°     90.00 
β/°     90.000 
γ/°     90.000 
Volume/Å3    5188(2) 
Z     4 
ρcalcmg/mm3    1.252 
m/mm-1    0.083 
F(000)     896.6 
Crystal size/mm3   0.4066 × 0.2616 × 0.0229 
Radiation    MοKα (λ = 0.71070) 
2Θ range for data collection  6.12 to 50.7° 
Index ranges    -5 ≤ h ≤ 8, -5 ≤ k ≤ 12, -34 ≤ l ≤ 28 
Reflections collected   5177 
Independent reflections  3496[Rint = 0.0229, Rsigma = 0.1363] 
Data/restraints/parameters  3496/0/275 
Goodness-of-fit on F2   1.027 
Final R indexes [I>=2σ (I)]  R1 = 0.0874, wR2 = 0.1795 
Final R indexes [all data]  R1 = 0.1506, wR2 = 0.2016 
Largest diff. peak/hole / e Å-3  0.22/-0.27  
Flack parameter   2(4)  
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Appendix XII. Crystallographic data – Compound 3.168 (CCDC 1019837) 
Identification code   rjkt1313a 
Empirical formula   C26H38O3 
Formula weight   398.56 
Temperature/K   110.05(10) 
Crystal system   orthorhombic 
Space group    P212121 
a/Å     6.20811(17) 
b/Å     11.6297(3) 
c/Å     29.9007(7) 
α/°     90.00 
β/°     90.00 
γ/°     90.00 
Volume/Å3    2158.78(10) 
Z     4 
ρcalcmg/mm3    1.226 
m/mm-1    0.078 
F(000)     872.0 
Crystal size/mm3   0.1979 × 0.1378 × 0.0197 
Radiation    Mo Kα (λ = 0.7107) 
2Θ range for data collection  6.48 to 55.5° 
Index ranges    -7 ≤ h ≤ 8, -8 ≤ k ≤ 14, -39 ≤ l ≤ 24 
Reflections collected   5672 
Independent reflections  3690[R(int) = 0.0207] 
Data/restraints/parameters  3690/0/266 
Goodness-of-fit on F2   1.035 
Final R indexes [I>=2σ (I)]  R1 = 0.0437, wR2 = 0.0922 
Final R indexes [all data]  R1 = 0.0527, wR2 = 0.0974 
Largest diff. peak/hole / e Å-3  0.27/-0.21 
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ABBREVIATIONS 
Ac   Acetyl 
AD   Alzheimer’s disease 
aq   Aqueous 
brs   Broad singlet 
Bu   Butyl 
Bn   Benzyl 
c   Concentration 
°C   Grade(s) Celsius (Centigrade) 
CAN   Ceric ammonium nitrate 
Cat   Catalytic 
CCDC   Cambridge Crystallographic Data Centre 
CoA Coenzyme A 
Cos   Costal 
COSY   Correlation spectroscopy 
CSA   Camphorsulfonic acid 
CSCs   Cancer stem cells 
δ    Chemical shifts in ppm 
d   Day(s) 
DAD   Diode array detector 
DBN   1,5-Diazabicyclo[4.3.0]non-5-ene 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE   1,2-Dichloroethane 
dd   Doublet of doublets 
ddd   Doublet of doublets of doublets 
DDQ   2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD   Diethylazodicarboxylate 
DECA   N,N-Diethylcyclohexylamine 
DEPT   Distortionless enhancement by polarization transfer 
Dhh   Desert hedgehog 
DHP   3,4-Dihydro-2H-pyran 
DIPA   Diisopropylamine 
DIPEA  N,N-Diisopropylethylamine 
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Dll   Delta-like 
DMAP   4-Dimethylaminopyridine 
DME   1,2-Dimethoxyethane 
DMF   N,N-Dimethylformamide 
DMPU   N,N′-Dimethylpropylene urea 
DMSO   Dimethyl sulfoxide 
DOS   Diversity-oriented synthesis 
“dt”   Apparent doublet of triplets 
Dvl   Disheveled 
eq   Equivalents 
ELSD   Evaporative Light Scattering Detector 
ESC   Embryonic stem cells 
ESI   Electrospray ionisation 
Et   Ethyl 
Fused   Fu 
Fzd   Frizzled 
g   Gram(s) 
Gli   Glioma-associated oncogene homologue zinc finger protein 
h   Hour(s) 
Hh   Hedgehog 
HMBC  Heteronuclear Multiple Bond Correlation 
HMPA   Hexamethylphosphoramide 
HRMS   High resolution mass spectrometry 
HSD3B  3β-Hydroxysteroid dehydrogenase 
HSQC   Heteronuclear single quantum correlation 
HST   3β-Hydroxysteroid sulfotransferases 
HTC   High-throughput chemistry 
HTS   High-throughput screening 
Hz   Hertz 
IBX   2-Iodoxybenzoic acid 
i   Iso 
IC50   Inhibition of cellular proliferation by 50% 
Ihh   Indian hedgehog 
Ipc   Isopinocampheyl 
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iPS   Induced pluripotent stem 
iPSCs   Induced pluripotent stem cells 
IR   Infrared spectroscopy 
IUPAC  International Union of Pure and Applied Chemistry 
J   Coupling constant in Hz 
Jag   Jagged 
L   Liter(s) 
LC-MS  Liquid Chromatography – Mass Spectrometry 
LDA   Lithium diisopropylamide 
LiHMDS  Lithium bis(trimethylsilyl)amide 
LiICA   Lithium N-isopropylcyclohexylamide 
LXR   Liver X receptor 
M   Molar 
m   Multiplet 
m   Meta 
m-CPBA  m-Chloroperbenzoic acid 
Me   Methyl 
mg   Milligram(s) 
mL   Millilitre(s) 
MOM   Methoxymethyl 
m.p.   Melting point 
MPO   4-Methoxypyridine N-oxide 
MS   Mass spectrometry 
Ms   Mesyl 
MHz   MegaHertz 
µL   Microlitre(s) 
min   Minute(s) 
µM   Micromolar 
MPLC   Medium pressure liquid chromatography 
mRNA   Messenger ribonucleic acid 
MS   Molecular sieves 
n   Normal 
NBS   N-Bromosuccinimide 
NCS   N-Chlorosuccinimide 
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NAD+  Oxidised form of the coenzyme nicotinamide adenine dinucleotide 
NADPH Reduced form of the coenzyme icotinamide adenine dinucleotide 
phosphate 
nM   Nanomolar 
NMO   N-methylmorpholine N-oxide 
NMR   Nuclear magnetic resonance 
NP   Natural product 
nOe   Nuclear Overhauser effect 
Nu   Nucleophile 
p    Para 
PAPS   3’-Phosphoadenosine-5’-phosphosulfate 
PCC Pyridinium chlorochromate 
PD   Parkinson’s disease 
PDC   Pyridinium dichromate 
PE   Petroleum ether, fraction with the boiling point range 40-60 °C 
Ph   Phenyl 
PMHS   Polymethylhydrosiloxane 
PMP   para-Methoxyphenyl 
ppm   Parts per million 
pr   Propyl 
py   Pyridine 
Ptch   Patched 
PTSA   p-Toluenesulfonic acid 
q   Quartet 
quint   Quintet 
R   General alkyl group 
R   Rectus 
Rf   Retention factor 
rt   Room temperature 
S   Sinister 
s   Singlet 
SAR   Structure-activity relationship 
Sm   Starting material 
Smo   Smoothened 
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Shh   Sonic hedgehog 
ShhN   Shh/N-terminal peptide 
SMM   Small molecule microarrays 
Su(Fu)   Suppressor of Fused 
t   Tert 
“t”   Apparent triplet 
T3P   Propylphosphonic anhydride 
TBAF   Tetrabutylammonium fluoride 
TBAH   Tetrabutylammonium hydroxide 
TBAI   Tetrabutylammonium iodide 
TBHP   tert-Butyl hydroperoxide 
TBS   tert-Butyldimethylsilyl  
 “td”   Apparent triplet of doublets 
TEMPO  (2,2,6,6-Tetramethyl-piperidin-1-yl)oxy 
TES   Triethylsilyl 
Tf   Trifluoromethanesulfonate 
TFFA   Trifluoroacetic anhydride 
THF   Tetrahydrofuran 
TLC   Thin-layer chromatography 
TMEDA  N,N,N’,N’,-Tetramethylethylenediamine 
TMS   Trimethylsilyl 
TPAP   Tetrapropylammonium perruthenate 
TPP   Tetraphenylporphyrin 
Tr   Triphenylmethyl 
Ts   Tosyl, toluenesulfonyl 
TTIP   Titanium isopropoxide 
U   Enzyme activity 
UV   Ultraviolet 
UV-VIS  Ultraviolet-visible 
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